<%BANNER%>

Prodrug Strategies Aimed at Improving Topical Delivery of Drugs Using the N-Alkyl-N-Alkyloxycarbonylaminomethyl (NANAOCA...

xml version 1.0 encoding UTF-8
REPORT xmlns http:www.fcla.edudlsmddaitss xmlns:xsi http:www.w3.org2001XMLSchema-instance xsi:schemaLocation http:www.fcla.edudlsmddaitssdaitssReport.xsd
INGEST IEID E20101220_AAAAAE INGEST_TIME 2010-12-20T05:58:48Z PACKAGE UFE0015480_00001
AGREEMENT_INFO ACCOUNT UF PROJECT UFDC
FILES
FILE SIZE 27116 DFID F20101220_AAAEJO ORIGIN DEPOSITOR PATH majumdar_s_Page_130.QC.jpg GLOBAL false PRESERVATION BIT MESSAGE_DIGEST ALGORITHM MD5
77a141cc7a5e4c40dc677d629ba7a182
SHA-1
4faefbdc9e47f4a2dffd3a8760457b80d9360ea6
700 F20101220_AAAEKD majumdar_s_Page_003thm.jpg
901fce924e50a565cfcfaee0c9cec2f3
641fabd7f2ed0838043bbd949f736e420c62ad6a
39705 F20101220_AAAEJP majumdar_s_Page_034.pro
d2d5af800c17fe3066ef3196fd1d9dee
511a33fa13317e2019d90bc1adcef66e8025f814
2025 F20101220_AAAEKE majumdar_s_Page_116.txt
cabd6a2540a36f6c6972045bc43147a9
beae1442ad6c11c59497b5cb6fc0266cde36e84d
1524 F20101220_AAAEJQ majumdar_s_Page_119.txt
18a71608bc4f29f055946c54c58a68c8
e40cfaffb1dbb6d4d52b57e2a06dea8023de09df
6318 F20101220_AAAEKF majumdar_s_Page_003.jpg
8197ddc0d1fa4c2c4c1aff5c57b29e24
153dc643cefc8d539a545bdf56ba9397d1a7b80a
8053 F20101220_AAAEJR majumdar_s_Page_124thm.jpg
39b6760bce02cc0ee4c95c435514b722
578d1efa2e33be79fca2090f64d502bdff8daf80
33102 F20101220_AAAEKG majumdar_s_Page_084.pro
1856daff9c64ec7ee4b11b22eb3524b0
a8aaf12e7b58c5d31a6b7ff3d392e98a1beeda09
1053954 F20101220_AAAEKH majumdar_s_Page_150.tif
7ef8ee1b3de8bae5a4583e1f2c78d7d7
9d853e387dc7644af6489ee8824d8627ee897639
108122 F20101220_AAAEJS majumdar_s_Page_057.jpg
86497da4245b0cdf7c0a7f97aa4fd8eb
378869fe6be95c36b850045fb9c3cf77cf448a01
2399 F20101220_AAAEKI majumdar_s_Page_001thm.jpg
4b65e41cef8e11981eeceebf69c7c1dd
03fa096b3648fffdcad4c4c17a2c8c469dee527d
F20101220_AAAEJT majumdar_s_Page_128.tif
1f2cfb50797a863a133250bad21210e7
e5c46bee252e7762184b06e66ec09d087d4de75f
56232 F20101220_AAAEJU majumdar_s_Page_151.pro
d324949d393b7189f91c14e2d34fb315
d9f764a137762a8eb275d3a7d6ea79728a531cfb
87395 F20101220_AAAEKJ majumdar_s_Page_004.jp2
a212228926c9c08df749fff924df051e
a9f1fc6150ac6e826f9da704dbb04194131278a2
117126 F20101220_AAAEJV majumdar_s_Page_151.jpg
dd8138c4296d8f9209dd28fe471dc521
ef5c1ea6190d63cc3b878ebc6620f85a115662b6
48071 F20101220_AAAEKK majumdar_s_Page_048.pro
01619969cb98309f015fe894628ce1d7
c972d223f28de0c75c656b7e8d6061112baf1fa5
37679 F20101220_AAAEJW majumdar_s_Page_044.pro
f2ddb911c04f0e27ba6a604f8aaaa550
fe667c577da8a040b50b2c0900bb2edd48f799c3
9425 F20101220_AAAELA majumdar_s_Page_001.QC.jpg
5d5a49846596cf174625a84f6b82f5f0
a57a38ff29359e48efc1a55ff1f224d8206d5f92
5543 F20101220_AAAEKL majumdar_s_Page_022thm.jpg
9431a779b94626be81501860f290f1cb
85c1c5b39c952be26b43ee0a8c5d0cb9d5b60945
48997 F20101220_AAAEJX majumdar_s_Page_075.pro
cb338db1eaf48c25e7fe0f918530d4f9
987ce287c752010fe6033a45e21c235a4bd23bd9
2100 F20101220_AAAELB majumdar_s_Page_012.txt
0e612cab1a9722795f3ac05c40e64350
1a1c7bec330fb8a27b073f0d35d01f7f8f03171d
101934 F20101220_AAAEKM majumdar_s_Page_101.jpg
d7d787b9dc6e8aacf1bc4a29add1cf82
e76d61ccc27ffd0fbc2a3f99e20f2c4d1ef282cf
F20101220_AAAEJY majumdar_s_Page_063.tif
0f1b84266f8d393740b576050c46cae8
cf24b1cf13facf78f01156f2b51a6d9553e038f0
492 F20101220_AAAELC majumdar_s_Page_006.txt
46f65380543a5c3d051628a41fb2dac8
8c9aec5bd970397fa89a31f611a62e83e6593528
76984 F20101220_AAAEKN majumdar_s_Page_061.jpg
54ea322aa52f718f778057b86b5c009e
579b2e8c0093cd3df7d21e541b0db797a9a396a6
F20101220_AAAEJZ majumdar_s_Page_100.tif
f13c3ba9675abfb3ba54bc94979c8e0e
95b4c9702343ad214873aad7de11b354ba3d21a2
F20101220_AAAELD majumdar_s_Page_057.tif
96e1e86c81ccf0aa9db24088efd994ee
419f76cf768b96447b33750d77baf7dbdd3712ea
753668 F20101220_AAAEKO majumdar_s.pdf
9de3912b019b7675889adac6dbaa3776
3b10ad4c08daec0bb8f6469c14386a83741eadbb
98125 F20101220_AAAELE majumdar_s_Page_081.jp2
7b15e70c8fc4900beec316abb35d1577
d956a67794611ed2fe233ba183f14343217d11df
7750 F20101220_AAAEKP majumdar_s_Page_092thm.jpg
7c0a45ab8c3f189d044736fd691a7bb0
8c977df440d86a40902af87b0d067baf61e7dfa8
F20101220_AAAELF majumdar_s_Page_118.tif
d7fe35a390edaa410a1754a1f7a86c42
da1377c3652493eee5a6df430114543af468b3ac
21452 F20101220_AAAEKQ majumdar_s_Page_023.pro
3dc7372111a0b35cdb422d932248d996
b38ec365ef3477c47582ac4ab05ab06afbfe67a1
6447 F20101220_AAAELG majumdar_s_Page_061thm.jpg
6262f3f9097198b3ccc1f3d7a92aebee
f62595df746f569c470b9b58460d24989acdd7f5
F20101220_AAAEKR majumdar_s_Page_158.tif
fdc665e3180e7c2143758f4e5bb8f940
3e83a3e2efe652db2d6dc737398e8d8ae6cbf1b4
F20101220_AAAELH majumdar_s_Page_108.tif
19cc22a91ba08636fa81e40a59609ee4
585d7373271cf90480e97f7fea603dc20e3560bc
103632 F20101220_AAAEKS majumdar_s_Page_021.jp2
530e5765116a997c8733928a92890cc8
25f16fe74c548a5f0fc43be71805d1ecc463316d
33874 F20101220_AAAELI majumdar_s_Page_083.QC.jpg
7dea4ca90a001d91602293f4e5dd2b64
b565ceaee4ba15ff6af12e33b06ffdaa7fb05f6b
F20101220_AAAEKT majumdar_s_Page_072.tif
b03f394e4d38b88983c18bd70348cb36
93f49039958f7a245e142e4a474cc5b255a3da7d
115989 F20101220_AAAELJ majumdar_s_Page_018.jpg
b646e442353ab748884d9a9e82ca4af4
8c44f8f434b50e471303a8d005d2d0f636a6fdae
1579 F20101220_AAAEKU majumdar_s_Page_093.txt
e3051bebfeea4e2b578f57ccf60fdf59
a262d67b813329adfb663d1bd5d88af7ab823b85
34154 F20101220_AAAEKV majumdar_s_Page_075.QC.jpg
e48974ccce9c7277b71182f573eca2d3
4dbca237c2c015613938fb6d7e22bf58bedc2ab6
30292 F20101220_AAAELK majumdar_s_Page_128.QC.jpg
4a0161321b588309c4b836b6dfe32f9c
4c5d1c6000604c1bd99d9d9d3d8b41a53fa16d46
2561 F20101220_AAAEKW majumdar_s_Page_013.txt
99ed11f36dec253f91a8580cb2bb4b48
80ebfe84baa11633a17ed9c5e2eb22f4a8beab30
4243 F20101220_AAAELL majumdar_s_Page_062thm.jpg
5cffcab08ab65840502c5fc5f232c4b4
dbad8a03a8b2a788158b3f83dbe62ea5c7fb12dd
6591 F20101220_AAAEKX majumdar_s_Page_119thm.jpg
2cd6d3e7add189315d020ca5a8baf8e7
40edeeab537aef93ae768ce74b17c8ce468ef748
7615 F20101220_AAAEMA majumdar_s_Page_128thm.jpg
c4c709ca32471935c6ba5bc9bf12d62c
d449ec891770850de4988efebe3861524877b9e2
7743 F20101220_AAAELM majumdar_s_Page_039thm.jpg
5aa4ee2b77184e3731db061a7005e110
11b768e8c38e97999a5aebf7611d956076b081c4
1516 F20101220_AAAEKY majumdar_s_Page_123.txt
a744a607a7810a95976d16ee7df1c075
f09dd257fdf0f084ef8d9b58ce40803753354f90
48169 F20101220_AAAEMB majumdar_s_Page_021.pro
9f4bbfea6c43145c18edbd8aad7365e5
ad975ba05ab2c72f941fae1562cd4de4dc41243b
F20101220_AAAELN majumdar_s_Page_082.tif
7781f6f60f305355da15b89aac4643e4
faab209bf6cf10272981eadcc84449b75bbaa2f3
F20101220_AAAEKZ majumdar_s_Page_111.tif
22aab53f31b91c9a3a21ee1e2d03c350
9a62bedd32f8c456689a312df0200a8291beb8ed
33794 F20101220_AAAEMC majumdar_s_Page_032.pro
bf4a808d3515664f7702f4ae87765ec6
64319862e1d8df8b59f74bbcd0501bd1a6f87008
1936 F20101220_AAAELO majumdar_s_Page_029.txt
7aff15946e04dcf9a896fd0ef46a74da
9d3e7a6cdbc7ebeacb6a53d386ad726145f7bba9
17876 F20101220_AAAEMD majumdar_s_Page_042.QC.jpg
cccff9353c31360a9b99d41f5b5aa276
42da39d8a8a4342a64f1e2f20ebc3524343ebf63
33725 F20101220_AAAELP majumdar_s_Page_136.pro
53fd169200a4e7265823c1ded98811f8
08dcdb5a1cddda92485d99aea89d97a4294ee96c
27011 F20101220_AAAEME majumdar_s_Page_004.QC.jpg
97ac05bf4a09359e841fea3fd1db2c3a
a1d449439e4cffa644d026341322b498f646fe57
8423998 F20101220_AAAELQ majumdar_s_Page_022.tif
7f31a1af39206adfab03ab2d659a4421
9c988b6a3b4aa694f278ccb00626f02498f539f8
33127 F20101220_AAAEMF majumdar_s_Page_101.QC.jpg
5faf41c28a92777411bc58a599f4e82e
e915401924f4d78db20946b6d343682ba54b4e7d
1966 F20101220_AAAELR majumdar_s_Page_125.txt
9966d003ea25e64d5a2deb1c9b70bd0a
26fd03591a1bbadb8b7b0a0105ba8c2f765f4004
2034 F20101220_AAAEMG majumdar_s_Page_024.txt
059ed8810eb0b8b5d6d413a8a28d924b
2fad2e825f22322e97e7c439e64c6fcd61d7945d
F20101220_AAAELS majumdar_s_Page_132.tif
5d7d815ad0a2feb3b23ac9509feb75f4
9a315f6d2f66cd87f97df48df47618c41dc2044d
2070 F20101220_AAAEMH majumdar_s_Page_047.txt
3a2e4248935830d6fa2e63bc7457032b
c926b09c26bf89bfedeacdef5ccd9789e20c78b6
F20101220_AAAELT majumdar_s_Page_151.tif
efebacb5fccbe744afe7762f99ea18ae
ce546704afb855db4f8869d039151096f7cfd6d1
31743 F20101220_AAAEMI majumdar_s_Page_050.QC.jpg
c0e711ee809639026c53b311e60a740d
f915e4ae3ebf6d0ab0cd16a0f99032cbaea2d791
1898 F20101220_AAAELU majumdar_s_Page_083.txt
764ee305f5faed785429f23870f239c1
1a11ff7805537bb759a7d42dae3f6d63357d4ddd
2120 F20101220_AAAEMJ majumdar_s_Page_054.txt
9c620cb5711eeeb09dedac5055fdf52d
db4e78c9480e00f5a3313acf3cdda9eff62fb90d
F20101220_AAAELV majumdar_s_Page_122.tif
c9ca62e85f6bb7308f7c00efc10e5f4d
bc5f16b6997fdf38473cb3c732a4daa6d64e4eaf
1051975 F20101220_AAAEMK majumdar_s_Page_010.jp2
47313f0ada8688d953515ddc4c8fdbaa
de8179bc261b48ed96aaf89a55aab379c71336f4
99166 F20101220_AAAELW majumdar_s_Page_012.jpg
27e23b21b9cbfe2272c22608f7b56f8a
a39a5a30947807ec319398b6d142a7f9bc47093c
84153 F20101220_AAAELX majumdar_s_Page_034.jp2
bdf4ff4d4db8962b8e826b2889cf3d06
f0eb799c90496fbe3ef02a32e64da33305dfc576
25271604 F20101220_AAAENA majumdar_s_Page_007.tif
be2b1864012b6a729c2e1edd1e11c693
2f68a19cb16b3291afd99b5a44456d64f2e6a6f7
93929 F20101220_AAAEML majumdar_s_Page_040.jpg
7258e401dbfa3aa6ee623892f07200ab
f9a0df7575d2af6c65817ddbd372440638937539
7060 F20101220_AAAELY majumdar_s_Page_129thm.jpg
c5a87580719131156d6fd1fb93a97b2a
32913d0601a1fa52c9274663b526c45f327a6b04
7354 F20101220_AAAENB majumdar_s_Page_113thm.jpg
e5257ccb4b04c009938b229587088869
eda1a6692e97960d20fc5c7fb04d245a7303941e
83759 F20101220_AAAEMM majumdar_s_Page_044.jp2
6ab51b813059ba0b9c772a8ec3c70bf6
923b70f211ae6d26ff8b8cddd1a6dad58a0fc5a4
71358 F20101220_AAAELZ majumdar_s_Page_079.jpg
0bc1d93bc34344b0dc95a6898e6b063b
54e9d9ba029e03f738d71b4601c3d47db36b115e
1493 F20101220_AAAENC majumdar_s_Page_096.txt
25e6e1ea6d7f14483f29df58d7eee448
9472b7caf600c358fdb9e25ac9a62c04a8c9a764
70812 F20101220_AAAEMN majumdar_s_Page_035.jpg
3e73f0cd2edde03e4945ad4c34d8e2e1
00e304581cde2bd859df486a6a69ab5f577edd85
323249 F20101220_AAAEND majumdar_s_Page_078.jp2
32b6b10ea0d7090ce63abf23452b42a8
744c3ee89594a1b95d91691d4141f7bf7951188d
F20101220_AAAEMO majumdar_s_Page_091.tif
d897ae3b8be836e6252deb7e06e10c25
e42b28d42da1ac7ff7acb3fde341b0b5114891d2
89790 F20101220_AAAENE majumdar_s_Page_027.jp2
8845e937678b7063ae234c3c332ee821
2cdeece0e724708ae832441b35d2efb4afecdc73
8311 F20101220_AAAEMP majumdar_s_Page_066thm.jpg
1125ac7f6e458a709910a473379e6fa4
6215bd9367f0f84044b3c922ef1320896c544f99
46556 F20101220_AAAENF majumdar_s_Page_159.jpg
cacc75241f07eb81d3bb96c523e98997
0713e759deac449a2dc48231c086291be93b653e
51813 F20101220_AAAEMQ majumdar_s_Page_052.pro
3f801976e99cd72a2d8671f4405dddaf
e7f3104ff30cb2665d27bb373de639b2e53394ca
44755 F20101220_AAAENG majumdar_s_Page_111.pro
33f812231c28a38127f34d5f3c10eb60
33e2169155576d4d2d39e08f421d541b72bde324
F20101220_AAAEMR majumdar_s_Page_152.tif
dc45975bcff9012fea4453f82e63396b
56c61c76ec694f6619d3fb2bdf81a7be1effbd73
70568 F20101220_AAAENH majumdar_s_Page_060.jp2
da83e4981e3fd0f6194cda28c936741c
b7e7c5f56e5eb3fa945032269ccf2ecc8764cf7d
F20101220_AAAEMS majumdar_s_Page_139.tif
4bd472a1c5645b8ab592b0913c655a43
c15b967a2786f394ca8df91517dfac5e8ebf694e
107841 F20101220_AAAENI majumdar_s_Page_047.jpg
8985e63b3bde12b7a9845fb9da358a49
cd96f3d6bb255a138ecff62a84e1a3ea8e9c7b8b
8060 F20101220_AAAEMT majumdar_s_Page_037thm.jpg
770230339d26772a74edb69afa685b4a
ea17610c60eabdafb785efa8a5b95889cf41b4d5
14263 F20101220_AAAENJ majumdar_s_Page_058.QC.jpg
9ff009768d5416779fccbbb8d7cd9ba7
d4670b32aa1cf79cb80a5bb3a0be920422bb38cd
7576 F20101220_AAAEMU majumdar_s_Page_026thm.jpg
2de43d89c525a9a40bc5251dd9808ca8
848d8403e0677b228ff2d2be6b048f7ec60df652
74049 F20101220_AAAENK majumdar_s_Page_046.jp2
600413b39622da083e2208c5ca0e6301
6ee6bdf48f12a6cc78742ba9c978a7eadbad4af6
68544 F20101220_AAAEMV majumdar_s_Page_032.jp2
a6b1763877aaa674c0ccee0181142911
24852e6cc5706173ceef17b1e145782b002b6f86
7803 F20101220_AAAENL majumdar_s_Page_115thm.jpg
4881156c32132031395573463a11f069
1a72e2a6ce7b5b8eb8c6d31679962d5a7dc3f181
F20101220_AAAEMW majumdar_s_Page_095.tif
88f263e47f5516a1e6d814ac8fbd6532
da72f7cc7b3ab095de2f4544e2ba66b82a594e3b
84328 F20101220_AAAEOA majumdar_s_Page_027.jpg
c2292cb917606b1fad45b9cc36191a7b
eb7fc10d3ea6ab71936ee0359a31308eca163dc4
7626 F20101220_AAAEMX majumdar_s_Page_142thm.jpg
a18fdf18a081d2fe9aad0bb55902920e
1e6bb56b61efc1b3ab15c6f9f53b55493f3e6071
103043 F20101220_AAAEOB majumdar_s_Page_028.jpg
6537f9d08a4b0db6a8ea42c45e66e8e8
d7298ee1c1212f99ffd3441777c5470655d06803
F20101220_AAAENM majumdar_s_Page_156.tif
f93cf04ed4fadd5bb1c14569683b9b67
05d3582743ac147dff07576461939c78a0c8768e
8009 F20101220_AAAEMY majumdar_s_Page_094thm.jpg
e1e213412ebdb6a28563e9af26ac13b6
bc7422514aaf2f82bfabbf705814ac04fd353c72
78045 F20101220_AAAEOC majumdar_s_Page_031.jpg
9b833ba2edaf5d3a47014c7c383866ef
b520a1b545c205d867b6e750249d6c6255e068fe
185029 F20101220_AAAENN UFE0015480_00001.mets FULL
a062d35058746b9d58feba70c8a3434d
c48f1852376e4e10c9cd8a5aa0412ad8188d8325
2030 F20101220_AAAEMZ majumdar_s_Page_140.txt
70bd4b0c4780a5c754288f7dc3ebd7e8
11bbc1ec16fb832b4108967e4887a5d2e6baaabf
65455 F20101220_AAAEOD majumdar_s_Page_032.jpg
082b8d06424ed8d5de5d2458a79bff9e
f6e49ff19242ef1a8ceb15ad572ed474f657eee5
80664 F20101220_AAAEOE majumdar_s_Page_033.jpg
539867d0b067f3bdacc4735ed5f39a14
21d5193034cb4445d45c2804f2dbeb84c5067a55
95309 F20101220_AAAEOF majumdar_s_Page_037.jpg
d1593fa98172c228f190a2d318f52d96
342671cb90ecc0d2e4a6dfd36b60b875a1802515
31201 F20101220_AAAENQ majumdar_s_Page_001.jpg
d6c4e86e525df1948e90ed2042b189f1
0f8539d64cab80e7877ac679b0cc7aa90c4f4ae3
99693 F20101220_AAAEOG majumdar_s_Page_041.jpg
d590e46f87a45cfafccb11d3a86a6836
ff3c960b86e5dfa07fe509f9289db4cbac6f4063
83439 F20101220_AAAENR majumdar_s_Page_004.jpg
bb06a1aa939f9b4d555e346be4816a8f
9945fb1462490e149d88ea91863d6ac681f007a9
54647 F20101220_AAAEOH majumdar_s_Page_042.jpg
7604f3e98fb8b0f19057fc2e2a4f6404
5bea776ff74b88d5075dfd548290b2df1edfb697
28521 F20101220_AAAENS majumdar_s_Page_006.jpg
96b0f3da4567cf8fb9bb47118bf899c3
6fa7e2b6f1e62d647c267c9e81fc935d35923972
59307 F20101220_AAAEOI majumdar_s_Page_043.jpg
d9f71b9b4a4af009e53c1f7e486748ff
9e8f845f9b6553fd902072adb5f3d0a39490ed7a
110090 F20101220_AAAENT majumdar_s_Page_007.jpg
b7a124d71029add5c298ab33fe05c4b2
3ce11aae4d8310a699e93da5267ff65a998c6101
78951 F20101220_AAAEOJ majumdar_s_Page_044.jpg
9f835a0710b1398ec10e332624896232
9ccd84c9aece8d29a61e22930f6523973e86bf85
112421 F20101220_AAAENU majumdar_s_Page_010.jpg
72cecb9f319411cb87bca624b100e91c
8982a3dd6083dfd8bf3221402b060d802b548613
71299 F20101220_AAAEOK majumdar_s_Page_046.jpg
f13c1511963163191298e12e618eccbe
f529e32abe41a85d312d03d35fad9c31a4947bda
23001 F20101220_AAAENV majumdar_s_Page_014.jpg
9a0a7cc1be55a0b1f2f050b3cd318230
818f38d30aec8b5652f7da5ce6f6db24830d497d
106320 F20101220_AAAEOL majumdar_s_Page_051.jpg
9514eaa6bd95d2d2a52711fde68ff942
c7be4c9e9c495240ff96142075ae77212eedb073
86390 F20101220_AAAENW majumdar_s_Page_015.jpg
62bdc9092423fd7babe282279e642bdf
263bb592ab84bea85a080c1d017801af77aff9aa
105077 F20101220_AAAEOM majumdar_s_Page_052.jpg
8c89ba450741d68fab40535676fe2352
0edb897d8b8cdee2a683768b40fed8c68131e2be
104796 F20101220_AAAENX majumdar_s_Page_020.jpg
3e03b7478b992df0fcd7e24d8178706a
7cd66327f9f2906a70dd726ba41b8a6add099dcc
84988 F20101220_AAAEPA majumdar_s_Page_077.jpg
58807b0e66b5237793d30ebf5e780b14
d91f6bfa1949c1f9b3960ed1b075599787e80ae1
97103 F20101220_AAAENY majumdar_s_Page_021.jpg
48a5b858d27f1e8080b8818460dfd7b5
a2df7e7c2982d7b133880c3fd0a5a9c48d9c0903
34396 F20101220_AAAEPB majumdar_s_Page_080.jpg
5b705565428785105fd3a75c252a117d
221065f8febe41789eb5773a2568e38a466811fc
107826 F20101220_AAAEON majumdar_s_Page_053.jpg
fb8a2384cd0e3c773d30e2433cd09ce1
ca0f98572b06139dd9f7db6747465b95b553fadd
102418 F20101220_AAAENZ majumdar_s_Page_025.jpg
6dc7706eb8aab5dc250b2c738228717e
074a84496a87a69baf670587c67c02d7969915ac
94493 F20101220_AAAEPC majumdar_s_Page_081.jpg
345c6faf2b4b7e3703d37f0453720c32
6d092ad65e85ee0a951cddac96cb3229d04df865
88116 F20101220_AAAEOO majumdar_s_Page_055.jpg
607ee781a655270fec04a3c320562bcc
c08276da40c8b82dfbf1ca4a6fc8a083ce424a2f
57118 F20101220_AAAEPD majumdar_s_Page_082.jpg
e2f664ba681f8c46900225d376549f9b
3a6c25d3426228dde4f1888723c69be7d60f18ff
105431 F20101220_AAAEPE majumdar_s_Page_083.jpg
9dae09cc175d399898681f86d9ccf14f
f543fd369c5d11786d24ac273c2e59c5e36a0326
54907 F20101220_AAAEOP majumdar_s_Page_056.jpg
a6a1f2e3c59d24083478be3235c61859
951f64e3abc70deb55a0f1b525c28f87afcd562e
69495 F20101220_AAAEPF majumdar_s_Page_084.jpg
5e1dda81796827ea4b058138869b55a2
66f999e99e815b7487a95d0464df8ef0a42166e2
96270 F20101220_AAAEOQ majumdar_s_Page_059.jpg
377219ce4f9813a8cf17693bd048864c
24f5cad138fc99d2c21da4ec41108583bff9cdf9
88441 F20101220_AAAEPG majumdar_s_Page_085.jpg
32ad75f615f2606b7b9d3407d582c034
68a647c5fa3f1df0471b468230f96a09beb8d8f2
65169 F20101220_AAAEOR majumdar_s_Page_060.jpg
6bc705eb3b3bf36944d8040f514e7d5e
c880cee8e59df1b5c7fd94169f0c9139e3321663
88651 F20101220_AAAEPH majumdar_s_Page_086.jpg
82304c5b8d9660091c27338752cff402
7101a1a62f6189c0ebca16927359f5b6d6dce4db
45567 F20101220_AAAEOS majumdar_s_Page_062.jpg
b626b87664f8630ae8cd0983052e9419
c1c936677c575f37585faa2afaeb5c72b66a7be6
97039 F20101220_AAAEPI majumdar_s_Page_087.jpg
953049cf8aea0e98a252123d6695d21d
83148e94dfd97aa7a50636b303a36a758ad5fffb
36871 F20101220_AAAEOT majumdar_s_Page_063.jpg
baf14295d209434072bfb5a97bbdb9ff
f4e98fba1b76d94d96c096ad4c8439c5de73038a
72577 F20101220_AAAEPJ majumdar_s_Page_088.jpg
1b71c7609c5b7f9e5cd49ecbe9e3c592
03e52394fa852fb3884f68edeb2b4a356cf38b01
78029 F20101220_AAAEOU majumdar_s_Page_064.jpg
bfc4ce9e30d00d4975813877c8d8a59a
695968216fa6409da5f07c0d1356533329f18018
42378 F20101220_AAAEPK majumdar_s_Page_089.jpg
b86a588235fd30d4944ee222a89f91f3
c028a728eeef560a051c7109406545c7d584da31
95926 F20101220_AAAEOV majumdar_s_Page_066.jpg
a09420258512394b61c42464cbc0017f
cf94c1ed178d88501ff25c21f780032fb0fa7b30
94969 F20101220_AAAEPL majumdar_s_Page_090.jpg
c2bf0dc45b8645eacad447a69ccd551f
ced9224f548a2812a9211fb89ac416939317a37e
103679 F20101220_AAAEOW majumdar_s_Page_068.jpg
5b7b05f3c2d2b2b1ceecb6d4da2741be
e394927ab2221fd951fe97a01b4553b9ae67457a
66676 F20101220_AAAEQA majumdar_s_Page_122.jpg
ee3a6676f7019c651a0c449f2a83d8c3
d7bfbf3a1fecc98272caae4df773faeb214c9d87
95794 F20101220_AAAEPM majumdar_s_Page_092.jpg
4dbb1894055c00a1149ddc9ae2fdf2e4
a781493b5b2c65b711c5d8f894cff01252bb8fc3
90675 F20101220_AAAEOX majumdar_s_Page_070.jpg
345d081ca67b66128825a9ae7fa2f7aa
127bb1ed0475f3f1d385656f80542fdf8ee58cd5
76527 F20101220_AAAEQB majumdar_s_Page_123.jpg
45a51031190c0d607572107e7c628737
3c5638c77b8e01f62770e61d93f3e4eb8eac2cdb
93662 F20101220_AAAEPN majumdar_s_Page_095.jpg
7ae6d89cb01579ebb5e9da3834eb3cd0
0727ea2af90c068d73bedc5fb52ee8d15c791fc5
107316 F20101220_AAAEOY majumdar_s_Page_074.jpg
7548a1115300797f972c69d03ab6af3b
ef196176c873ea4aa9ceb7949090034127e6d37f
103144 F20101220_AAAEQC majumdar_s_Page_124.jpg
c0a0a37e90dcad51af553cf887abf27f
a5613575700bfff044088925956f38b5d257da6c
104518 F20101220_AAAEOZ majumdar_s_Page_075.jpg
ab30f7a73b2830c958f4f26864ba9f7c
a55f1e6f659259ead99cde30ed417ae9a9592efc
93280 F20101220_AAAEQD majumdar_s_Page_125.jpg
76141dafbf2329eeeb54568a57abaaa7
f3b3f3b467051342d2548ee328e15ec217cddca9
86912 F20101220_AAAEPO majumdar_s_Page_099.jpg
b99145bd870ef0139f0632b2d71dccce
9c8319a2c9365fea1874678fa60e63c81c28a778
94084 F20101220_AAAEQE majumdar_s_Page_126.jpg
702d6eb9a27776b7eeb7bb8ad82ee950
222ee4770a1cd24aee9d431c082bde5be26578d1
93894 F20101220_AAAEPP majumdar_s_Page_100.jpg
07737764ae2b4fc872df579e53ec4285
c203dec02dcafe3a15b9037bddaad1872ec85fb3
105012 F20101220_AAAEQF majumdar_s_Page_127.jpg
f23b1f0210280cc7aaa494e692bd9ea8
f87ea3d9f186124c08d16d785f958ff84f8fa41e
86641 F20101220_AAAEPQ majumdar_s_Page_102.jpg
827344185587fb2cd819277f3e390982
2bc218fc4bc7ba969ce0a09cd2997102322c4a82
78665 F20101220_AAAEQG majumdar_s_Page_130.jpg
866bcbf3fc8c42efa6a03fb3d49e353f
1f907e67649e69036a0da06be72dc68a2802cb6c
78283 F20101220_AAAEPR majumdar_s_Page_103.jpg
3955f12ab0e596209860f3f6e98abd12
d06eeb5a809f93224d34cf1c80f9623cd1db6a59
86419 F20101220_AAAEQH majumdar_s_Page_131.jpg
d9045edd360ac695c15f0aa928144bfc
17e46d417562dedffe817ff8bbc858c37236be2d
90545 F20101220_AAAEPS majumdar_s_Page_108.jpg
f19cd51792a85821b266891a77a06cb9
3bd54d95530e65452024af47e7fa1650391071fd
104863 F20101220_AAAEQI majumdar_s_Page_132.jpg
7dc04c7fb5408cc52d7dcae1a0de7922
527576b84dd27fdf5c244babb7ace891551c5814
76335 F20101220_AAAEPT majumdar_s_Page_109.jpg
03766986d46938ac73caba7817026613
c4079a422cf32ba13d0e4626c14ec677bb42e9eb
76859 F20101220_AAAEQJ majumdar_s_Page_135.jpg
1de0744414cf3fa6fac5099b3b37578c
cfa9ee838596576419cebc8d15004cdf3de964a3
85362 F20101220_AAAEPU majumdar_s_Page_110.jpg
d955deb24a2dd7d42439ce56b02199b0
8cacc9833ffa29730268a555f982ad61a13dd2ef
76717 F20101220_AAAEQK majumdar_s_Page_136.jpg
bbae9229d16c39e18142702d119cf3b2
249baa0aaf6dcf9f1797eb637bbcf7cfa67ef363
42688 F20101220_AAAEPV majumdar_s_Page_114.jpg
c82a883c5ca8b5e174942caf958663e1
57f7b189bbfaaf7b53573cc628a201e1ab9b20e3
75969 F20101220_AAAEQL majumdar_s_Page_137.jpg
8c2b9ebd17be1456c4d56a0a96d19051
42291e34530f334e9b1260fedc7ca58e05106df7
100393 F20101220_AAAEPW majumdar_s_Page_115.jpg
1c4e35774d4e505b0d40c941fe067a69
5ee22ade7eacb95b01919405aad0ddfb1901cb0e
88945 F20101220_AAAEQM majumdar_s_Page_138.jpg
a2228de4836f640f889e1dbc967e25a5
967d3ead3cd73378c81e26e3ba9e075bd5eaed9a
95327 F20101220_AAAEPX majumdar_s_Page_117.jpg
fedf7dfa2830e5632e1e8386565a2f22
5d43ed390aad81af1d95d84033101a44fce05b94
7377 F20101220_AAAERA majumdar_s_Page_003.jp2
9659248f3a1c819aa8231d4797dfe521
1653075b2b9b4e30c805fb1e6e9e1067f6a7ece8
94735 F20101220_AAAEQN majumdar_s_Page_139.jpg
9fd49d5d807debf4063639d21a3b4b67
6725ff375ceca0d0b6a998e0fa0997d6cc6e6d8b
83019 F20101220_AAAEPY majumdar_s_Page_119.jpg
c8367ad34ce3803d2a91ea99eb6a0a3c
880552a5ed8f12aba41e83a5ef5e4a916e3e4a22
104089 F20101220_AAAERB majumdar_s_Page_005.jp2
8ccf25b002c5bbda6385d06eb886f301
fd58767b77cbb088ebcf13ebcc6ae0cc6b69406a
90431 F20101220_AAAEQO majumdar_s_Page_140.jpg
71b8f60b4d0b64a2b590b4c3054db41e
cc95d167ecf71fd4c89d1e29e68259e592d3e854
82889 F20101220_AAAEPZ majumdar_s_Page_120.jpg
dcbdc5dd1cdee4d6b6df9c07818af3e6
bf11327794427c1d774349cfc5775b0c9b7cf410
29721 F20101220_AAAERC majumdar_s_Page_006.jp2
fda380ab1d2ba473d47627bb0929f36b
4a654e391c85e2340d8490e596fb9b0e6f431fa7
1051964 F20101220_AAAERD majumdar_s_Page_008.jp2
5c6b80cfca29b6409a9bb9e5f3521e49
8b2751813139c0f93ecf90c4186dff3b3d793cc8
81227 F20101220_AAAEQP majumdar_s_Page_141.jpg
5128f5ed5851b163a45cbb092fab56c0
84ee03ba6550dc7df8f0f9b7502c7efe153cfb05
1051942 F20101220_AAAERE majumdar_s_Page_011.jp2
cf7c599ac6958bafdf230d30ceda11ce
7ce59d4a91e7b5c0a1ab0629eb96a5e975aa0317
19497 F20101220_AAAEQQ majumdar_s_Page_144.jpg
0ac5acee34327fc0c48326d3e956a5f6
59d34f9457ba6c437bbc5b577a74547d9aadbf41
88387 F20101220_AAAERF majumdar_s_Page_017.jp2
c2f6642c09df4468cc3bc6b3b94aca35
5028ff6cdc4098edae48d76ba51fb6212b24735f
124690 F20101220_AAAEQR majumdar_s_Page_146.jpg
ad126abeb6223b7312ea4ab3b86948df
07ba8033ac0430024a8b82dd89ae46b399c9bf7c
114203 F20101220_AAAERG majumdar_s_Page_019.jp2
0c7628ef072e15f506df26103373f987
d2961ef62bc33f7410e5e2864286b909f7b07ac2
115891 F20101220_AAAEQS majumdar_s_Page_147.jpg
e9560177b7c8b07c5a637b1b63ad76dc
5e938a6362f46593ecd4e174fa71823ca17f0035
539403 F20101220_AAAERH majumdar_s_Page_022.jp2
9372891fb54cacdb65f1edef210b734e
8aa45c7bc66c23f15318d143e20836c8bb320276
137040 F20101220_AAAEQT majumdar_s_Page_148.jpg
255d54c7ffd7535bc3c602f524e7c517
ecafcc686762ba1bf33eb33a5971762f65a94ebc
66151 F20101220_AAAERI majumdar_s_Page_023.jp2
ad51fe3a024af8da5b13cd3375e7738d
1069d87523c60395d33ee7031886f434855c8f4c
128925 F20101220_AAAEQU majumdar_s_Page_149.jpg
fdf0edf2b998c234a5c89f582771fd25
bda6605cd81dd688b9e5ebe89d0674908758bd71
98755 F20101220_AAAERJ majumdar_s_Page_026.jp2
6f60565b59b3a9093787ee54d8b92ee2
d75de026349e479b7c20a0936fe36470c549f89c
127215 F20101220_AAAEQV majumdar_s_Page_152.jpg
013fddf35a8d5ccdd8f3b819b37feb62
9f0c22bbc58f35a72dbafb33ba4c755f204ac5a1
79716 F20101220_AAAERK majumdar_s_Page_031.jp2
c965dd9660d5ddecbcf7fd19a9902256
cd850df8ce30317472b6e4d84b7c6602a74e9c71
126403 F20101220_AAAEQW majumdar_s_Page_153.jpg
5d66087ddffe6ff37cdb5953def188f1
c1abccf9630537e7ebc0e768cfe88060178cc324
70844 F20101220_AAAERL majumdar_s_Page_036.jp2
b5fb2f12aedbf6fe8fc05e3391341920
4167413d10002d32cffe67c7f34a48204e400a87
42477 F20101220_AAAEQX majumdar_s_Page_158.jpg
a072937a2aa9c8cd8d36857853062ede
cc2500a655a552e9d70793b443044395f8c3475e
109729 F20101220_AAAESA majumdar_s_Page_074.jp2
b385d0e49b274ab588cc84c557331ec1
47f22b81c4bd6592f8c84a0eb2d1965f874053b6
96884 F20101220_AAAERM majumdar_s_Page_039.jp2
b846c2dc52990854521f805ed67ee113
769a04acaf7eb00441f8e0d918749236912de86c
28246 F20101220_AAAEQY majumdar_s_Page_001.jp2
0c27757b10c5c902e734b7762bfbb191
922897173709c2800493c3ddb3b99a1477a509e1
78026 F20101220_AAAESB majumdar_s_Page_076.jp2
fd501d57da45dc501173e89f86cededf
fda7750cfb504ab5f2ee5edcac2a1b54fb01e94f
100887 F20101220_AAAERN majumdar_s_Page_040.jp2
2588b31b2b02a4c3285f508b8dd10fd9
5be298b516ca8ce2d1c9a567bdd75843fa6c8ce6
5672 F20101220_AAAEQZ majumdar_s_Page_002.jp2
85619fde707ef786f7cba712a130af39
d35e4edeffbb5b5f6bfdc38c591cc632bec48cf7
82121 F20101220_AAAESC majumdar_s_Page_077.jp2
8cf75eabc2b654be0372997489a02a95
1a016d6f41880a99318d3be3bb0a791948de5e53
57768 F20101220_AAAERO majumdar_s_Page_042.jp2
ee49cd9b6c92cdb0e356e585916cd896
b83d3d2a92dfcea65054d6841b935ee3759f6509
110511 F20101220_AAAESD majumdar_s_Page_083.jp2
901994eb74ba75215dae48876897bf81
c26fd05029171f190481e1f19500f7ceae3b3cd0
101185 F20101220_AAAERP majumdar_s_Page_045.jp2
b82f71d547c7f5122b6197519c924bfb
16556d82f4a869d0f3f629bccaea8c9ba79f8759
72866 F20101220_AAAESE majumdar_s_Page_088.jp2
bac096480a9e6b32f62074ce15232b37
58f464f42b289c9cc0c8514e17b48ee434e66902
46159 F20101220_AAAESF majumdar_s_Page_089.jp2
8f57c771ad4f6c42654fbb41db22fee0
e314c76fc50e81773e9a07e5e417334a78555331
86847 F20101220_AAAERQ majumdar_s_Page_049.jp2
16c08f13d2ca5f3575d6f60fcbcebf1f
6273ef39a21cb27f8e2719ae611250464a2844f3
97318 F20101220_AAAESG majumdar_s_Page_090.jp2
ac73f1037f203225bf6dd24a50e54a96
be94c77976ee23fabe9897ae41e04b0d4c0e0e69
103469 F20101220_AAAERR majumdar_s_Page_054.jp2
02d141aa179affdfa18a33fb887303d8
0b892ddc38095042a42888ebb60f4af1b2258cab
90172 F20101220_AAAESH majumdar_s_Page_091.jp2
c76d99dc4a4309a58d5e208870a4e55f
ddec71efaea8abfb2a378d9e25096e4e2cfcf17c
56825 F20101220_AAAERS majumdar_s_Page_056.jp2
4fe3a51b1c9c08748d84d98bd74232f7
fb53bfa7f430456602805d0a5c9e32f81455efdc
80065 F20101220_AAAESI majumdar_s_Page_093.jp2
9c3980488cb60cc3f078ab9599d6f0dc
4d236fafe475788c7ad2a80d79407a0e2bf4c37d
46129 F20101220_AAAERT majumdar_s_Page_058.jp2
58d2771b3dd3886b944cc3a99f88b563
f8d560aba252e1ce3d7cfc901ad4b23f6df02685
103711 F20101220_AAAESJ majumdar_s_Page_094.jp2
cb14a81d653dc3e142742194e4e5dd59
729eb8a26b55bccb09b487e83fb82abb49571f74
99308 F20101220_AAAERU majumdar_s_Page_059.jp2
8069d7410e4d4a2b330e4ea6efc44f94
092a77fb48f1fa7f925cf517592dc88daeb3ad33
97811 F20101220_AAAESK majumdar_s_Page_095.jp2
a7e639c77a1a7640360d4666ca1d9485
be804890d85ce8d2d8204a466be828d38081a9f0
39429 F20101220_AAAERV majumdar_s_Page_062.jp2
5dd99a02bb6fd622b727d6d88509c014
f1d6930879d06b744b23edb1611fa9ab13917611
108040 F20101220_AAAESL majumdar_s_Page_097.jp2
b3ec936752c5a139877271303738ddbe
6dbceb7ce1e4abed7bc82225c3c759495bc54642
110253 F20101220_AAAERW majumdar_s_Page_065.jp2
b95bad969e054920789411106c37ed83
78849685a96e2bfdbbe3b755732df60eed4ece03
110362 F20101220_AAAETA majumdar_s_Page_127.jp2
d4e2ff1bf62d6ca9a8bc948403a9bf3b
9fdbe7eeb67726084393008c2e1ec1759db8c5dc
105530 F20101220_AAAESM majumdar_s_Page_098.jp2
284537674cfe695088529276c3c12130
2a92b943df8479e19da68f3ee8d1974782fda53c
106867 F20101220_AAAERX majumdar_s_Page_071.jp2
b59a1e70bdbfa2109f15093de2578b3a
beb42169c729ca7ff22016172f1da48f1c9fa5ba
86429 F20101220_AAAETB majumdar_s_Page_129.jp2
87850859a89bd6b354cede5a7671f0a6
4974f950758625783ce8549cf4bf61a7db90685f
107373 F20101220_AAAESN majumdar_s_Page_101.jp2
bf590c074f3d22ad318be6bd78aea778
5bedb201135bd319cae2db83a978ae0df28740c6
108039 F20101220_AAAERY majumdar_s_Page_072.jp2
f4363a1b8e38ccccda9bd7986817632e
63d08b73f70920cde6155df29cbc71aef8bb75b1
87321 F20101220_AAAETC majumdar_s_Page_131.jp2
c12b4cd670ff7c5e37a6674692b87899
5e1f676eb14759df11921b4f7dabf28e82ec65fb
85959 F20101220_AAAESO majumdar_s_Page_103.jp2
450cffb59185513d14f2b1517ff0d52c
16e22f34107cfe25d98e2b15a04c1436c41dbef7
111165 F20101220_AAAERZ majumdar_s_Page_073.jp2
a6b122e0a550d8047c60e2e111aea1c6
8f6bfaacd79ad970951f2c1730baca429872e80e
81276 F20101220_AAAETD majumdar_s_Page_133.jp2
5043b30d3bbacf0ae92d4d6de530cdf6
a7eccd68c1da003ace3c02382ccced9179736d23
79301 F20101220_AAAESP majumdar_s_Page_106.jp2
91b1953b0a646e7fdedea2f33a86a54c
01bdc70efe66b73d16e5e6047c80dd0831c76673
101001 F20101220_AAAETE majumdar_s_Page_134.jp2
b5b1b6e9bb967ff9e4b0c0207aac87ef
e4c6c5b96a3420cc368766b084c4b619c397d107
759526 F20101220_AAAESQ majumdar_s_Page_109.jp2
5c1f7edd746411c199b47ce9d02caf8b
9030939985b56cb21432c76436fe685876a0098a
74429 F20101220_AAAETF majumdar_s_Page_135.jp2
38a25e6210ec755e36b666dffd3d88e8
0f2a02f38fc9ca031917f1eb2f706aca42d0fe10
747349 F20101220_AAAETG majumdar_s_Page_136.jp2
ebc86e0bf270f23a4d8762cc0cda92b0
ba0a26d15a74aceff1487052c895291ebc00b007
82416 F20101220_AAAESR majumdar_s_Page_110.jp2
85ab69ea264beb6a6044a8ea8b2abd4e
2685b4fc1027b0e48415353c5f9fd7381c5f893c
78111 F20101220_AAAETH majumdar_s_Page_137.jp2
a72a0ad978aeb808778544949277cce8
2079858305fd16f1adf9d79d162517b183668049
99202 F20101220_AAAESS majumdar_s_Page_117.jp2
6cd5adb81f1e88cb2331d92e340ed57a
1c5f764e3f8d1cb224ed42e25ed7c4e3e550daab
F20101220_AAAETI majumdar_s_Page_138.jp2
ef6f5b87603d6e410b6c882a4762f888
ffa3d9e409c00e45db99fade68587d34f2f4df5a
86366 F20101220_AAAEST majumdar_s_Page_119.jp2
1fc2d4c82f476e1c2dd5e9864cca391a
5f16f033fba5527fa2fd4adda41c993ae4c6488b
98839 F20101220_AAAETJ majumdar_s_Page_139.jp2
d3bfa322d5286fe65cf9a54008a88452
28bebb9e2656fc1aa6ddebcab711c9ba943a7af5
108005 F20101220_AAAESU majumdar_s_Page_121.jp2
a18893a157521a8e54573a778b930a4b
f3b5b8e2ca2d6f89e70f662cfe2f5d2e5a437a41
824733 F20101220_AAAETK majumdar_s_Page_141.jp2
67f89121613ef606284a69075dacfe53
99dacc26c4ce1c03c8ddbb6148a1e916a063bb2d
66727 F20101220_AAAESV majumdar_s_Page_122.jp2
96cc6ab71dd78f7d9d2060132efb488f
a26e99b3ec87a304bc19a767ec155d74d090c7f8
127149 F20101220_AAAETL majumdar_s_Page_154.jp2
8d0d289310b42eeccee9447740b463cc
b248c8c37f7dd659d7061004948f562fb90b66e4
75714 F20101220_AAAESW majumdar_s_Page_123.jp2
9a8c1cc9867d285556db53b8e3044709
b4abf5ec2d2c4ca11b5db70b0ad6f00e4efed335
133311 F20101220_AAAETM majumdar_s_Page_155.jp2
31cd24d52c772dfd6faa05ad3a94e46a
cdade74b36de8d87795c8e0471559d19ccc76b13
102867 F20101220_AAAESX majumdar_s_Page_124.jp2
c2dc7f68ee897994b0f90279a35f3a7f
24ffef04cd2cb934e9172a2dbe6303a56f8767cf
F20101220_AAAEUA majumdar_s_Page_024.tif
f7bb112821f4f9e88b637b21f46ed789
30de0461fd36da8225c37aa57306b037cbb55f73
98472 F20101220_AAAESY majumdar_s_Page_125.jp2
421a0770e1cdef0a985b1c4f6b0d4773
4aa0a774abfc7f99f59d6a13f4d5ab3eb1f0dde7
F20101220_AAAEUB majumdar_s_Page_025.tif
f3d15fc63a5d45193221831ee6f6ed5b
9eaaee9f604bfb4cc485406f6203f35089aab77c
43130 F20101220_AAAETN majumdar_s_Page_158.jp2
b9175f0c52adf2a12a763ddeb1bcf3f3
048b1e6cbc4be9964b2a8669c874ca3643781b9e
99370 F20101220_AAAESZ majumdar_s_Page_126.jp2
5f08772082392d1a4252899efcec5e32
ced5fda7a8706a0375bdf6db803a1b37a7f7d1d7
49134 F20101220_AAADRA majumdar_s_Page_072.pro
53a05356dadae89fa04bb04af9bbcaa6
f8e900a80fa04e87f1f247fbb74d66f81111d0f0
F20101220_AAAEUC majumdar_s_Page_027.tif
da82b5a1994e5df8891d46a519cba3f4
02009456fe6ac00dba7186f534bdf05fe9bbd1a7
47900 F20101220_AAAETO majumdar_s_Page_159.jp2
9011579bf4bfd5f6323f1b141cea87d8
e90ec65744bfda64c94a964aa55489c30017b0dd
2469 F20101220_AAADRB majumdar_s_Page_157.txt
aac9ea2eb21d356723d0952547942ad3
a8bb3b5b106a91813adafdedc293b9b0bfff51c0
F20101220_AAAEUD majumdar_s_Page_028.tif
c8fe5f9d472d801f4eb1d536ed4426a0
99408ed3cfc677a95f60858ce362b4c8da27ef67
F20101220_AAAETP majumdar_s_Page_002.tif
9356435aef51bd125a1fae91ba54f0b9
f4236e6843fdf4dffe411b21908cce91fdc2251d
109122 F20101220_AAADRC majumdar_s_Page_075.jp2
6211bcfaaa9137fb2311210ed995baeb
5b3900d76c9e7cf0cd6b27b89431eb0bff22fd57
F20101220_AAAEUE majumdar_s_Page_030.tif
9f6b7f02dfa6517bac21839662957d12
40489f663d153bc89ab954f191af889e8bde0b65
F20101220_AAAETQ majumdar_s_Page_003.tif
89cb419a6d1cf727208c21a2d753cada
b742727aec67ec5bd213b33a7d8ea0003c6b974d
7985 F20101220_AAADRD majumdar_s_Page_081thm.jpg
dfe38e5e83685edc57fd2b349a0ccee9
518d822255dc1f0e85fefbcddc032a58fff931cc
F20101220_AAAEUF majumdar_s_Page_031.tif
2c7ffed80435c4ae4a26d094bfcdfac8
e8d3aefd3a09f620af9a52b43ee9f1776d62b998
F20101220_AAAETR majumdar_s_Page_006.tif
618c43e172a4f3b6e9674d8d4c17680e
942ebf9e938578f9e4b0de89fd8e93cbd419045e
1591 F20101220_AAAFAA majumdar_s_Page_032.txt
bfcc8e9cbd24ff1f38dac78eff2fb428
d3a6ef42ffee4c9aea76d0e39620cb1056bb40d3
37196 F20101220_AAADRE majumdar_s_Page_063.jp2
9a81e21a10e6670eb7e94f9332a7c613
2182306fd16a46e06803378c54d43377ca467bf3
F20101220_AAAEUG majumdar_s_Page_034.tif
b4506fa7d53a8f5b0d64413fd161aeb9
b0c86dedfbc5d3ae06f5b95124f37aa1f81cb32e
1834 F20101220_AAAFAB majumdar_s_Page_039.txt
ef0e0384a96fbc3484764c8815568e78
8fd0268058c63585909490ffcec914ccc522e47f
F20101220_AAADRF majumdar_s_Page_001.tif
7aa9b1bfcfb6cd83addccc696207e22b
3fd4c34c099cc6ce6780f0d66925e3d1b2094e95
F20101220_AAAEUH majumdar_s_Page_035.tif
a01ee1199aeb5701d20c3de4266ecc0b
e779ecbd06e1f3a0ed15c50877a1f434a4debb7c
F20101220_AAAETS majumdar_s_Page_009.tif
78c035d4f558a39e4804cbcc3021ed1e
63fe1203923676421a186c84c79433cb788487c2
698 F20101220_AAAFAC majumdar_s_Page_042.txt
45f66e06b44e57ac64e9dba43d92521c
93a0f109e584455e696a2c6c98b60615be36be20
1725 F20101220_AAADRG majumdar_s_Page_015.txt
ac305379bb58dc69b93ca6e6b9003318
888534ab7a8376e370577d41370d52894fe3d2ac
F20101220_AAAEUI majumdar_s_Page_038.tif
a2b81e4a2e0e77f3d8b32120aa256bd5
a5189dbb9d71e4f027f18bb7369cdf6405fe2d8b
F20101220_AAAETT majumdar_s_Page_010.tif
ebf80265c368c0bb0e0936c63f931896
08085297af07c11d7c09c633d1964faad28a9196
1826 F20101220_AAAFAD majumdar_s_Page_044.txt
cec7011247002d592719dbfc0e9a6824
7173765eadc2e4308a2e53d7e165825433d0dc9d
35825 F20101220_AAADRH majumdar_s_Page_035.pro
acbd0835bd3bedf80d0d2c0ef844ab9f
d7c3c5f263edbd988e692961f34bb22535d1e74d
F20101220_AAAEUJ majumdar_s_Page_039.tif
1d02ef31b4e41350ae6c2a8f3dcd21a0
106867b9aae2b08fd8a514e947f5c525f1b50fef
F20101220_AAAETU majumdar_s_Page_011.tif
7f387ce04459380259fbd91f0d39c2bf
f128e0dcaa1c46cbd60a958afeec530a03422b95
1908 F20101220_AAAFAE majumdar_s_Page_050.txt
3d9fd6d175476f5a207a0416403938c0
72c941cc938f01851f24dde3ce961418e8483905
101344 F20101220_AAADRI majumdar_s_Page_087.jp2
7b12ed4bb8cd60eb6ced2eea1a7af2c7
b37068b397b5d2a2eaa1ffd95456e3debdc4ea11
F20101220_AAAEUK majumdar_s_Page_040.tif
2c8fbc3b4869bf99cbb3bb9c68ed7962
bcfeaf59774c86ad86606dff18e9fb3f4f21e032
F20101220_AAAETV majumdar_s_Page_012.tif
59df1217d919de42c21ca18b9c05a2d0
a15668ce19217a5cbf7a73cc0b14eccbead88ee1
2092 F20101220_AAAFAF majumdar_s_Page_053.txt
d920c014e46a3e326cb6d619934627a0
a4514ddeba7d883daec409d5bdf2b46e70c59869
27185 F20101220_AAADRJ majumdar_s_Page_077.QC.jpg
4f422d4db011f6ce1507b5dc25a55dfa
09e89a44f85b6b9fc075c438cb0327d69cd48ce6
F20101220_AAAEUL majumdar_s_Page_041.tif
aeae8222e7082c1721030ea68277faa2
35fdd22e2caff17c88752fed9f0665bc291a8450
F20101220_AAAETW majumdar_s_Page_013.tif
a076971b5c0a429a03fbf79ce8b86c18
85564a22d3ebd6fce2c33b071e5658c6368f3efa
1857 F20101220_AAAFAG majumdar_s_Page_060.txt
c11b5a1e89cac903e53ea1b4665f375d
fd3809267446033117b6492d4b818b6106fcaae7
F20101220_AAAEVA majumdar_s_Page_092.tif
18706eb0c4ad1616fd34494fa64097e1
13ece19784a7f52cdb3649e872fa7edd47bb206d
115749 F20101220_AAADRK majumdar_s_Page_057.jp2
598dcd43c0d93b816b76010208886de1
3cda95a3351a796a9c685b348e2772790b2ad297
F20101220_AAAEUM majumdar_s_Page_046.tif
367001772e269eb490b4a1b95993c9e6
a495baab27e9a5952a4af040c2073725525f6340
F20101220_AAAETX majumdar_s_Page_014.tif
4dc14357f013310a523a12048c28f418
bad58cd6a1c7a3ccafdf7994500c74912ce543c7
1384 F20101220_AAAFAH majumdar_s_Page_061.txt
9f86b65efa87f0da923128a3baca2dd6
d967fa1dbac5d30a0c01d7c47ab2aa5ae928c162
F20101220_AAAEVB majumdar_s_Page_093.tif
d7febb717aa4df08080079586696581c
4166c81e4c7e260d12de2f6674af5293171c86af
7078 F20101220_AAADRL majumdar_s_Page_012thm.jpg
657b555d2fbdbfd191dba1095c08fa3d
94c61922c06391d40c2b7aa494ee2993f9aa961a
F20101220_AAAEUN majumdar_s_Page_047.tif
806d0ef6ee35c895afd89020ecff8290
a77ccd71c1f99fad6ba057b7dd2384595c945b9e
F20101220_AAAETY majumdar_s_Page_018.tif
9ab9014a96f88d2ae9c1855ed1771627
51070b4fd7b33e2b5d9d611c098e5c9214db9032
1923 F20101220_AAAFAI majumdar_s_Page_067.txt
c4a6a95eb091697abc8396e1f0126f95
a6c50111b90ff6391315c2079193803bd6807346
96605 F20101220_AAADSA majumdar_s_Page_107.jp2
5b566fb25e8f8bae89cde91cec07c50c
3798c7cf973989e90a7534022b44001bceee1186
F20101220_AAAEVC majumdar_s_Page_094.tif
bf15e739971de2cc420f7a11014f881a
763a6e44b8e62c29713951df952a28c49505e839
F20101220_AAADRM majumdar_s_Page_066.tif
59c634c3966db1d25f049d0948b4e85e
a4d5a5743d15c5731a6fa3437dc9b4fa17f4ac44
F20101220_AAAEUO majumdar_s_Page_050.tif
4942cc66fc28babaaed68bac614bd32d
095a6dd828adfc09791a345436d0e8c7ef29e43a
F20101220_AAAETZ majumdar_s_Page_023.tif
7212340c182b6491e7bd9e231ea231d2
6ed959fba4653a51dcbeefe3ed648dc596c9bba9
1904 F20101220_AAAFAJ majumdar_s_Page_068.txt
f5f556a122b6c395cc3260ad2994f803
d3e7070880537a506b06a4da03be2ef4a6b50213
25987 F20101220_AAADSB majumdar_s_Page_064.QC.jpg
9eeecc9f6cc11701ec76fa5125922569
7c3deb7b39484797cc9b6c849b0e668bdd00a92d
F20101220_AAAEVD majumdar_s_Page_097.tif
1befffab0bd09e75587bc56810555d8a
49deef5664dbf616b8d297bbd801fd46a66a78d7
87309 F20101220_AAADRN majumdar_s_Page_015.jp2
e9f48ac5035e2140d52866090adb744f
8cc0cbade0c88172fbb03ec4e946c05f028fa87e
F20101220_AAAEUP majumdar_s_Page_051.tif
89123f18e4a68a5e89fd01e1930ef547
5e96b111f0f99649f647fccb75c8acd4c0920380
1840 F20101220_AAAFAK majumdar_s_Page_069.txt
611ae92a9ab0580533c7b6b62db517b2
624b2b28d5c1b7e0393d600fe266fbc0be5f7e36
7535 F20101220_AAADSC majumdar_s_Page_134thm.jpg
12bd17f1d9ab1aa1a5eb84b63a45bd85
c15063aebddadb22cc0f881b9fee5832d1c1766f
F20101220_AAAEVE majumdar_s_Page_098.tif
b1d44c9844dae3d2a3459cc8a43fa348
4fb1b96c34223fe9730f118e460a0cc1b34fd6ec
5575 F20101220_AAADRO majumdar_s_Page_112thm.jpg
535db418636ce9395d9d68db65a46e2d
7bf1418b4f0e4c6751b67c3ac2378b086b42accb
F20101220_AAAEUQ majumdar_s_Page_056.tif
0bf10aa4024113e1b4fa88684ff7c7e8
506857717d955ba1409659e039d0784e6bed684f
3851 F20101220_AAADQZ majumdar_s_Page_058thm.jpg
2966c9aa96cf83b3e9dc0f47a7fd9fc3
1c516033b2431b287e4a59d2407b2afd843cfd41
1911 F20101220_AAAFAL majumdar_s_Page_071.txt
ed40ea39747af4b450e90cb4d05a6332
1c5f8d1b5f2fd66925b5fc175f15621738efa636
F20101220_AAAEVF majumdar_s_Page_099.tif
bb6931d82157e8eaa4263fb2e921acb2
1a52fa8e18cdfc239c3732cdba5d9e88c488161d
F20101220_AAADSD majumdar_s_Page_138.tif
3ed3f0973f3daf870cae1575838b1a69
f25217782d0d593c0a36426cb22b23c360c72562
6587 F20101220_AAADRP majumdar_s_Page_030thm.jpg
d6b04e235c2925d3419d5f2daf2263b7
f319b424b52540ff8fbe225039679714a7c65c33
F20101220_AAAEUR majumdar_s_Page_058.tif
0c0d1b3749a892e750e11e715496fa81
c47d220a8416cbd6f10e20b5826d207623bc6524
1793 F20101220_AAAFBA majumdar_s_Page_099.txt
441acc40da95f5e626bc57c8eeb9e612
77b0852a6775174ef4437715ff2dab8c9bdb42c3
1980 F20101220_AAAFAM majumdar_s_Page_074.txt
96261f5c3e6cab7bd06440aa32202991
6556214a1a83a7d5b720cf82e22a856ab4911d3d
F20101220_AAAEVG majumdar_s_Page_103.tif
b4e5118f4167ed5c0c874c5053deb1bd
9fcf7b149ab84bfe2034d7f0a7b495cc7a4630cd
1950 F20101220_AAADSE majumdar_s_Page_101.txt
adea5b0c2e5c5132f6fd1a2320adcb79
caf0e1bd192bc506eddcab0443ac99fc5c81ae04
32135 F20101220_AAADRQ majumdar_s_Page_057.QC.jpg
3e81899c62a0b7fee914e6d9f6a239d0
1a699ba7a6874c8ea802f850c0cb8d03b905cf90
F20101220_AAAEUS majumdar_s_Page_061.tif
9dd7a6267c3dc2ea3d00d339c145e94b
16ab531f830c534e10c337de2e213623f6035cbe
1762 F20101220_AAAFBB majumdar_s_Page_103.txt
9ec5c6f40b71729c8cf6bbf71af49822
e2ec33aa8e412cb35da1767e3806e720f520368c
1900 F20101220_AAAFAN majumdar_s_Page_076.txt
028901830079cc43c0515148edcee703
03c45a8685e0644d6774d2ccf3a9233e0e775ada
F20101220_AAAEVH majumdar_s_Page_104.tif
6887334e7f132dff4bf7d78caa018650
754ee1f9c8ee3e20bc498a82c7d6e86cd037b40c
6884 F20101220_AAADSF majumdar_s_Page_109thm.jpg
ca4e8cd96c9773b6de3635b3ceffe6e0
a5403f1afede075bd99e51b45d05a78f01ca46c1
1887 F20101220_AAAFBC majumdar_s_Page_104.txt
2e312126fe2a64f14566d5363fcd1ac9
2dae4090c453b0f84c1319f3bb7e01da2acdd5c6
494 F20101220_AAAFAO majumdar_s_Page_078.txt
7663700c044b3940a61ba0d2b411356b
8e9e21185c7d83943c7d798872bf77974cfb4b57
F20101220_AAAEVI majumdar_s_Page_105.tif
aadea963482c0212ab06378e0abce4a7
fdabf1ee7972268a825e5f7a2609e583d3619165
95742 F20101220_AAADSG majumdar_s_Page_045.jpg
5221c79493792a8a9c60b37ded868946
2f27bf9de1e4b408e0443729e40abf75ced522b9
F20101220_AAADRR majumdar_s_Page_020.tif
8484608375cca404b0d18f05cf13ad7a
7346111c4a067d41ce4e137f4f6ebef459ae5505
F20101220_AAAEUT majumdar_s_Page_065.tif
a77ecaf6f633f76408e8261f8396a3dd
8b9e14fe6ffdc3751eb1d61a85a45ffa724bae1b
1517 F20101220_AAAFBD majumdar_s_Page_105.txt
331fb29a442431a1a7bd1985e74bd252
dad7437157f284dc5f52951a271cd0761524af0e
1381 F20101220_AAAFAP majumdar_s_Page_079.txt
f28282fdbdc9d6ee36e713d932a9f38c
d21e8033205a66aaa05cf689ae9a72a3227553ef
F20101220_AAAEVJ majumdar_s_Page_112.tif
6f65f637fc0bc23d0315a529dbd14d16
6e36ce06b75dea10827ea49f402dbd33a9cf0253
55893 F20101220_AAADSH majumdar_s_Page_022.jpg
472105474d8addf5c46fe8866e1bdf8e
26042b579c8730873a9f8783b5c04cace9d7a2a6
93426 F20101220_AAADRS majumdar_s_Page_142.jpg
2ef267726190478ba27f91286a45fc54
0df09b127746933534bcc230b24ce5f1921dc535
F20101220_AAAEUU majumdar_s_Page_069.tif
58ecea51b4da17f42fcf5b8a288d34f3
93261062659e071f0b9ff9379bf37cfcc4b107d3
1748 F20101220_AAAFBE majumdar_s_Page_107.txt
e66fb553cd9cc67fb7dcf25fa64802f6
fda95daaad533338c794b4450a6fb3bf15137c38
712 F20101220_AAAFAQ majumdar_s_Page_080.txt
8bb14541e11f63da7c8cd62a245bfb64
302e4da76bfb8664de8edc89b2cf6bad2acd7f9e
F20101220_AAAEVK majumdar_s_Page_114.tif
2b5353bbb57f809065e02063f54f77dc
7817c74870533a75692b4632d17437a93582e2e4
844672 F20101220_AAADSI majumdar_s_Page_140.jp2
ed0814ca72941b231f74814b0db14322
25f97392cf348e51162dd43a6db599dc5e9c9699
61489 F20101220_AAADRT majumdar_s_Page_043.jp2
27ad6428fd848e8a32dde99ff3917f81
e4442495eb42497d6d4de1f810f9912bbbeb36be
F20101220_AAAEUV majumdar_s_Page_074.tif
c9584ce4b73b393e227d4b7e511299e8
820fc0c2fad8c73d5d2c30302aade3774085e105
1729 F20101220_AAAFBF majumdar_s_Page_108.txt
f4b825637c6a73ec5d266804ed3deb2a
978dea6eebe4e63176d0859e24bc8f423d4c9af6
1958 F20101220_AAAFAR majumdar_s_Page_081.txt
3529836a3d7ef4c26bc1a2e14cf7b77a
6f71e1f7d0a143244c1755e8cc038d15d2fca2c9
F20101220_AAAEVL majumdar_s_Page_116.tif
09466a2d1008906651a17d4597d17ca9
b7a12b5b5b3d668604e1ec6c24a60ff46d926845
F20101220_AAADSJ majumdar_s_Page_053.tif
075e374aac4134286a851166ae2d2d98
3c0b1277cf9cf0c29a1eb3f71ec8329a03aa1dc9
810849 F20101220_AAADRU majumdar_s_Page_113.jp2
e0cdcebca99634aba5b449117ce430f8
9ebd3f99bf58020e9a804df5d422d1d7ce8a1417
F20101220_AAAEUW majumdar_s_Page_076.tif
4a47b1d57b53ade91054d3475df685db
5cc482dc056f13abf9d4ef69894998a84c161fcb
1753 F20101220_AAAFBG majumdar_s_Page_109.txt
b97ad8d197358360b7f44b952ba4f1d7
413468737d63da24491dbb7bfe781272fa9a65fe
1635 F20101220_AAAFAS majumdar_s_Page_085.txt
289f064d3195ffbe7808b806b813da8b
2b9601c5a5bc18b05c574d28f43a5de12b082f91
F20101220_AAAEWA majumdar_s_Page_143.tif
8e852968c414607c4ab583bc0eb2b218
2ab2fedfad656573a273d073610921e7eeeefbcc
F20101220_AAAEVM majumdar_s_Page_117.tif
b6e6fed981f828158958f254ee153c6f
7fc51bec190dfc0a82da52e1f8b3686ba04f52a5
32451 F20101220_AAADSK majumdar_s_Page_126.QC.jpg
b13207d78c76f73ea3ce013613cdf0df
ee34bb8624da8ad6d7d45f1a7af7f243c2b50ee9
22477 F20101220_AAADRV majumdar_s_Page_112.pro
0aae9c4c2f1056998a903df6af137aa0
f253d2537b504b8d2014465dcf967e89b45e3bf1
F20101220_AAAEUX majumdar_s_Page_077.tif
779787d7ea80514bbf51fec490417d0b
199f2b9fad19e8a5948235dbd21cc7135dbbd301
1820 F20101220_AAAFBH majumdar_s_Page_110.txt
94ac3203b6e2c9c9f7e16b51b17e6459
b2844a99c0ab09f6fc66976a91f61bf3309026ad
1720 F20101220_AAAFAT majumdar_s_Page_086.txt
669441fbafa411a59c1658810fbc21e6
f6c97dafbcca2966dbf6e34a6103d8568e177032
F20101220_AAAEWB majumdar_s_Page_144.tif
45c27678976bb7d7caca049a89032d92
cecdb160240d89bcd4557b4a3479312f242b698a
F20101220_AAAEVN majumdar_s_Page_120.tif
25c4d870b78368ba44b58a3c8c753ca8
ca24aaf508dbfa438b713c6bab8c5f869c884bd1
F20101220_AAADSL majumdar_s_Page_132.txt
4ad0fb7587eb3744a84793f7f0b95eb7
c93a08e2d15f45e4ee2fa7d319995a86076dfc91
1326 F20101220_AAADRW majumdar_s_Page_046.txt
03e86cf239d28cc2a18e6e8651525c80
5451d092973a8dae1e9cf6e49937e1e373699869
F20101220_AAAEUY majumdar_s_Page_085.tif
1860527f3172a5bd108fe66c067a20de
558c676f3864421c8e467f7ae35460384dd314ed
781 F20101220_AAAFBI majumdar_s_Page_114.txt
145a2a2c2979efb264a54e05d9a9989a
28b30eccedf1046faf9213ab10329b7ae9a10404
1403 F20101220_AAAFAU majumdar_s_Page_088.txt
08c8d5a418f9b35498aa9ddf8a06c433
9f2db7f0d661e8bb850a58ed0a16bd1ae2f50694
F20101220_AAAEWC majumdar_s_Page_145.tif
9f0c656e10aebc100636994aec25a025
36bc5e1d1c942b5c7fe52a248f357aa5e2e5b759
F20101220_AAAEVO majumdar_s_Page_121.tif
62b76cf3026149c3d21cce53a9426800
1c2dc147d3f65a5dab4091f15ff924af03be39a9
2575 F20101220_AAADSM majumdar_s_Page_156.txt
e9646f05562bc79797030ad2d293b15e
8f6790dc1749188cfb1fa8e6affaf68205d2b594
F20101220_AAADRX majumdar_s_Page_008.tif
34fe7f3805f501f4553bc8a14a25a527
30a06766e0e2d042060d36789eef98fab10874f7
F20101220_AAAEUZ majumdar_s_Page_089.tif
753d6f7ecd9b4925850dd68898f4de56
704a641d579eae442604fbe1463388822e5dbd75
26823 F20101220_AAADTA majumdar_s_Page_110.QC.jpg
cfb29708462f2d40231df742e9e85fc5
2770f1d7eaa8161447fec60a40c5c89dfd00329c
1767 F20101220_AAAFBJ majumdar_s_Page_120.txt
9ac66f64116543bc4cca67fe6c6f82f5
9075c0604d21b970f0450e50939ea49384ea1363
905 F20101220_AAAFAV majumdar_s_Page_089.txt
53bcd8a9050c1b953933fd1098c79673
9818892fc19e50cc3048d92418e1e960573503ae
F20101220_AAAEWD majumdar_s_Page_147.tif
d24a2674ca11d707602442021fc70022
e73ea017a0e936fc6e572cab6137abdfcb30177f
F20101220_AAAEVP majumdar_s_Page_123.tif
9fbd6eb1b36373cfdc0cbeb3f3300173
e1699dae4809e6a08d3c9af98cbf4251101bb71a
28604 F20101220_AAADSN majumdar_s_Page_122.pro
325985f856a88d85fc2d17d18179d464
f7361b79cb80b32c497ec564c5f5a5633336f62b
15227 F20101220_AAADRY majumdar_s_Page_159.QC.jpg
8e2e9b85ed412e317d73b88ef6ed6d14
1e64ec4e47cdadac64562e3875895c9ff4fbd14b
31662 F20101220_AAADTB majumdar_s_Page_041.QC.jpg
643dda86c5f0a9251041d7f8d7ccc97d
b0fce03c9bacf506a762af218a06ceb36fafe7c4
1942 F20101220_AAAFBK majumdar_s_Page_121.txt
1d9fce77a7a79847338b433d4bd8b6fe
21c64cc45079cbe3a0b49048cf0e0b9e6d0db0f8
2053 F20101220_AAAFAW majumdar_s_Page_092.txt
1c246a6b0d3e16221573a57e5da7ec4f
628f21d80098a4e59b193c715f5d4f77d0d0c3a9
F20101220_AAAEWE majumdar_s_Page_148.tif
030b4e12e019adda8260fbdd8ba46b7d
8cedeb4ab3fcd8348f29281eac1513fa7b04ee2d
F20101220_AAAEVQ majumdar_s_Page_125.tif
0359468b83703df415a61147ba71f5e9
a3a00c5de2e97fb49ffa23deab3b55f2fc623003
31878 F20101220_AAADSO majumdar_s_Page_021.QC.jpg
54f47bab38db04b8c38776618f7910c8
84766657b1fce12dc8535d97cdea1536a8ddeb3c
34750 F20101220_AAADRZ majumdar_s_Page_132.QC.jpg
21b3fa5d2d8656d56d0f3e2404f4fb6c
323b94818204117db5f87ef3d706e028d987a9a5
2099 F20101220_AAADTC majumdar_s_Page_019.txt
5ab075f156f19bdbdc655f0f65f9aca2
549e8d909711be523e033a38baf819ad5b223267
1303 F20101220_AAAFBL majumdar_s_Page_122.txt
7503a75844c9b93a296ed5a7fb8945e1
bb46040dc2c817a878e35a196395c2be064cfef1
1883 F20101220_AAAFAX majumdar_s_Page_094.txt
ce9a00e4960be0ba52fb08417a4596fe
4620b5c9e311be0dccbf9d66a5a902b9f37c4969
F20101220_AAAEWF majumdar_s_Page_149.tif
428713afb97c4d87a0e248a5ae9fb3d7
23a3308e7031d1368d9e4577131bad73b9de20e0
F20101220_AAAEVR majumdar_s_Page_126.tif
294b2ae55567e37709936d5716c80756
de6446dc2d5e79bff521b6d75fca92aff87be60b
106939 F20101220_AAADSP majumdar_s_Page_073.jpg
c67d9360bcbe37aa3faf6e7aeba8b339
5bd10fd3278bdf9aa29fbf79ad8c6578754afee7
89482 F20101220_AAADTD majumdar_s_Page_118.jpg
2bcce4f0d03407bfe08c057dc9da1e67
acf2c723354dd8cd4ecc27a69a2545cd05dd71bf
2253 F20101220_AAAFCA majumdar_s_Page_147.txt
007baabbd35c7cdd2796b88740df52a3
732e49beb9175337ca5dd117f83bec83d723f821
2014 F20101220_AAAFBM majumdar_s_Page_126.txt
ec83f1da9717c5fa6f0a234a57735890
f6df1ca6d718d806a23228fe1226e96fbaf98cd0
1746 F20101220_AAAFAY majumdar_s_Page_095.txt
e8c1c3253f2850149f69892752e20e82
b47d635564ef29e0c3e3154ceca527342170e93f
F20101220_AAAEWG majumdar_s_Page_153.tif
d61e01210fae63cf57eac0b43089d096
922f455ad62718e6febdb98e8d54a887cd82588a
F20101220_AAAEVS majumdar_s_Page_127.tif
f0ff691a0d5697efbf56f54a6bbad32a
4b32fac2cf71e1d1b8ed6c35e0f556620db9c123
35317 F20101220_AAADSQ majumdar_s_Page_155.QC.jpg
daba4884a39cc849986ce68786fd866e
db12476fe17a167204fc1dcd715c9001288307a0
31305 F20101220_AAADTE majumdar_s_Page_037.QC.jpg
96b0204db0b41577190b13036ce074af
2aadce98dcb97e23b6204a438c39adf9b6c57f50
2474 F20101220_AAAFCB majumdar_s_Page_149.txt
a7062816406669706894f8d80f37726b
20dde7be6480fd3ed2a17136c3ee608769f9046e
2018 F20101220_AAAFBN majumdar_s_Page_127.txt
06a9dd75ff5ed432a28f6d2847237454
12a0be04d5e378ce6e0500a00169a09fdc753a3f
F20101220_AAAFAZ majumdar_s_Page_097.txt
6020de85839dadc11b9f27d43d4dc522
062b9deccaf2aa83ad3e84c411ca9e209ca624a8
F20101220_AAAEWH majumdar_s_Page_155.tif
2fbe5cc2d7ac9c1edee8ef7f6242826d
a21ab5b67ff1b9b7a05dee04691c0b57337731c3
F20101220_AAAEVT majumdar_s_Page_133.tif
56bbc236bf1eb4f5451ff802f761c500
452864ed7ee5b2bdf47cae094feccc972791919d
11010 F20101220_AAADSR majumdar_s_Page_080.pro
0b89f91e0f3a5cc071588cd2690fc0a2
7bbc72f523ccf08bf5117332a20ef1e9b58cc37c
30679 F20101220_AAADTF majumdar_s_Page_090.QC.jpg
10e336ebf7aafc828a49f6bfa385f845
11b8267b27751f031cfe056130e671486a1b45ca
2552 F20101220_AAAFCC majumdar_s_Page_150.txt
8e2ff25371dfad29ed1a0d937179158f
f438324fa50a4e00453720957fdbf2de72f260eb
1822 F20101220_AAAFBO majumdar_s_Page_128.txt
ae6849521ea1dc51d46202fd152bbedd
502e32147ec51b126d824cc283d85eff4fef48e0
F20101220_AAAEWI majumdar_s_Page_157.tif
91c69912955b83c9506534fde67ce013
65ab6275e2ee09c129ad0ae4f51fcae8ce4ac5cb
1758 F20101220_AAADTG majumdar_s_Page_034.txt
4c709567aaa6f67e0b26b6de4bb223c4
f5e4cb04fa15356941e29a0e4add01f73a5974b3
2287 F20101220_AAAFCD majumdar_s_Page_151.txt
6c623dad7b5c8f7cbff3bb610776df6b
2012ede509033915f19a2384020f736511a31a55
1751 F20101220_AAAFBP majumdar_s_Page_129.txt
a6929ec42db5f674a6540cc37b2bd3cc
8286415e474e0e326a0f72a7ec879e15a835efc8
F20101220_AAAEWJ majumdar_s_Page_159.tif
30cc1aaa38023299d28cc8ec3caace9e
422421f5499ee3fec328702369d7619ceb9710ae
F20101220_AAAEVU majumdar_s_Page_134.tif
5d489c78b657c299c31e3c47a33a1453
d32659c179ede7f475c29a2eb7a26e6ac764789c
48770 F20101220_AAADSS majumdar_s_Page_071.pro
426d2e80084f24b90487c637d9fa7227
5577ec25deee27c42de1805ec3a8322bb5315851
28600 F20101220_AAADTH majumdar_s_Page_133.QC.jpg
fa76ab82a46574117cecdb2d8f021b05
da602b890657206068b62fe6dda12c3bb08cf279
2622 F20101220_AAAFCE majumdar_s_Page_152.txt
87b708b107709295c04fbff2e7f11ef6
9317aa73a6de8a2b843e66ca148f10e7bacac19a
1483 F20101220_AAAFBQ majumdar_s_Page_130.txt
e7e0f3f347de62dfbd50ea63db379fde
3aafe624a261779f8d583e9c657aa3fba3ed7a42
1202 F20101220_AAAEWK majumdar_s_Page_002.pro
8c52b37651705e3168da93ebd61dccb7
0fc2efb65946297255de8586bce7c230c34a639a
F20101220_AAAEVV majumdar_s_Page_135.tif
89ac2e7de71c136aa89b5a9f16b0ecf3
f06bd36bfab0ab6b01e4f5606f99df3948eaaa19
122392 F20101220_AAADST majumdar_s_Page_154.jpg
60f9e250a6951f2c6cfb7a54fb17bd72
d78ac2115a3ec9e4104bb30ba76dbd0bc30edb42
110094 F20101220_AAADTI majumdar_s_Page_052.jp2
9ae8815c0038e9c93061ef1f40329f9f
5197f03fdd0f7c224e0e7dd7bb50816e50a530c1
2584 F20101220_AAAFCF majumdar_s_Page_153.txt
5d3533d5f22d8f889e4008c23cf64a18
55e035f715e1ea6cebe7c9da9c828c600c5789a3
1910 F20101220_AAAFBR majumdar_s_Page_133.txt
8c386e54a1a573b08e86054bcf13e8b5
ec2b82581bb741e814c9fdc01d089e74354a9a08
1926 F20101220_AAAEWL majumdar_s_Page_003.pro
832925052fbe5b717b5da67110ceb812
8a26779dc0a5ebd0b6e55756d6b452a4b1ee1abf
F20101220_AAAEVW majumdar_s_Page_137.tif
2559bdb1fe6becb6387c6ef87df75d75
129016f2c93586ef80150cc7cc4b664a1fa81782
83865 F20101220_AAADSU majumdar_s_Page_033.jp2
f39a7a4bc4918f536e558759e8cd5ed1
79e577576b375fd4014d5747e0a794cb86c32856
34404 F20101220_AAADTJ majumdar_s_Page_080.jp2
fe02b8c3197bee03a86571a3a8c7fc2a
303c103b5ea7342d77e53fd1d34c8bdb0f3f3f33
2577 F20101220_AAAFCG majumdar_s_Page_155.txt
b57582abbbd32ce0db6d589c7a806cfd
3a7a59719527c601b655e5ff8930f3a78393ffec
2114 F20101220_AAAFBS majumdar_s_Page_134.txt
5351aed0fa92aa30416165cd0ce6a24e
150c9bdc6b2f9b70a3e15c66465742941ea380cf
34026 F20101220_AAAEXA majumdar_s_Page_036.pro
d4d0afdcba9cbd7d2d4ab2eb56ce965a
cd0ce19186481069fb352a061dc88a16f2be258c
89073 F20101220_AAAEWM majumdar_s_Page_008.pro
9065dab4fbdefb774819806b1dba3d40
3dc810af55597eaa75d25e9065c3f929d572b601
F20101220_AAAEVX majumdar_s_Page_140.tif
dc4724cfc2afe0b358a9cc52d80847b9
257cfa9cc78b57d7d263af9d0535d80f5c131b40
38436 F20101220_AAADSV majumdar_s_Page_140.pro
d1e292211a75d7047fd5b2f20e7f755f
ec801c35331a5839e1ab303a6901ebfef3481b9a
5532 F20101220_AAADTK majumdar_s_Page_009.QC.jpg
923f926286683805c7b9df6d0bacc044
00b10192d4f18604d2ad73a5612c7899db9c6470
813 F20101220_AAAFCH majumdar_s_Page_158.txt
c3e82d808bcec70dcec83f88d84a563e
4d5012f54c357d07c10414ce4e563187ab571c3f
1488 F20101220_AAAFBT majumdar_s_Page_135.txt
997231fadbe2772189cae803a12010ec
33ef890180619e3ac64e49b5eb5317b1b5e4eee7
23091 F20101220_AAAEXB majumdar_s_Page_043.pro
5f7db4fdc3405ff1579e6de0a31fccca
a7558b4026d5c98c78598e1fde95f5ed258638e4
8724 F20101220_AAAEWN majumdar_s_Page_009.pro
c72fd31a624fca1a618b2091b80a52f0
e57b5291aa4e9190be024e657c07667bf743614a
F20101220_AAAEVY majumdar_s_Page_141.tif
9dc18ae497f016b443419ab2e7b2cd2b
614e8edd812c7f6a9771e5fc0bffd4ecd0dbe91b
31360 F20101220_AAADSW majumdar_s_Page_045.QC.jpg
058448d59d9d225b915f182713a0c023
6b006b6dc0a355dcb335f5b3ba86060ed8cb1b3c
2207 F20101220_AAADTL majumdar_s_Page_011.txt
cdceae8aa0c04a9cb9345a91cf5079af
fcc37538c01384a5d217aedc80374b3d5079eaf8
883 F20101220_AAAFCI majumdar_s_Page_159.txt
f1cdde95a61cbf56d362f0fc5a741286
1a615115f1bb8e8c04f7ebcd190087b76f946cfc
1472 F20101220_AAAFBU majumdar_s_Page_137.txt
ca9fde5869b58f8b4ceba8b569a49aae
4efbb8c4bbc87fd95138a1daccd38f68ce38a0e1
45836 F20101220_AAAEXC majumdar_s_Page_045.pro
eaf9328be8a62fc10fbbf397cadb1a43
443f9d3ea24034d8496e622a422dcac25ab00619
53112 F20101220_AAAEWO majumdar_s_Page_010.pro
77c0487c9613d8b8ad7bedd6913cf586
133d44c6d43ea86cde9cf5fa4f65317743d9c48c
F20101220_AAAEVZ majumdar_s_Page_142.tif
61de56bd748d3af9dd4208e4d3bf9c49
eb8405d4e3423276925332c9e35816f1d6200a3a
2516 F20101220_AAADSX majumdar_s_Page_006thm.jpg
077ba88028d68a5af5b5631b2339ed15
342a6da06acf88f505a126ad14215f2ac2f4ee5f
8698 F20101220_AAADUA majumdar_s_Page_053thm.jpg
ff3128fd9ba095df0f8415c0e3b5c56e
1dab515f343d389092a1feb541d960431ad10017
30878 F20101220_AAADTM majumdar_s_Page_040.QC.jpg
b6ecd0e84f2f20c01788c3f26f48290b
e8e33453a2b56f313c6c56c5b3e064d1553d6377
6813 F20101220_AAAFCJ majumdar_s_Page_130thm.jpg
ff9715119b564c241c2d8826f8472dc6
4d1f881bde552991842bb90c8a0d306b33f8010b
1784 F20101220_AAAFBV majumdar_s_Page_138.txt
d581cf00adaf83b12ab3971277681293
33e7cf026404c1e3ace5840653aeb6dcdbce5b82
52796 F20101220_AAAEXD majumdar_s_Page_047.pro
b4f78a6fcef31a0cd6abc2faa02fec9b
f3056dbedf6cca63817d035d3273ff7de77c32c4
54302 F20101220_AAAEWP majumdar_s_Page_011.pro
e7ee85ce19705a73141f7bb1cd5500be
d47239cd02fb17c62d649ef88e552276da8edd42
F20101220_AAADSY majumdar_s_Page_049.tif
1d6539504d184019d5bb68a5a1a094a7
3af5e2c3cdf52501ee4a16fd1083c1bb3b96053e
81312 F20101220_AAADUB majumdar_s_Page_129.jpg
77a7f4f6310172f2ea218fd216fb3bff
26449ff61147ae478673d08119a3ced97fd9c6fa
F20101220_AAADTN majumdar_s_Page_090.tif
27a55a463f760fb97e4301d5e0a1112a
cc94a6cb7da0e0623886819634a7b195cae1c2c3
6557 F20101220_AAAFCK majumdar_s_Page_046thm.jpg
e58512b4857c38e49093b133b715ae4f
439e034c98ebc31e6ed5576e096860106602aa04
1865 F20101220_AAAFBW majumdar_s_Page_139.txt
72cd518ec456046c24e6ed1dbb54fde1
f23e1d6059e694b2eaab7b79b8ea0dc05373c1f4
40556 F20101220_AAAEXE majumdar_s_Page_049.pro
74b3f59fd469de31744b624fa13862ce
18866f277e050025e5fdf258f1182476797b221f
64738 F20101220_AAAEWQ majumdar_s_Page_013.pro
1e9468dc7417d64044620c2265de101e
dd183cf55d6ba5d0a4b3521a825121678252a8c9
7176 F20101220_AAADSZ majumdar_s_Page_120thm.jpg
f97ddadde8587b2d02df1740377f8d0e
42abc91cee1a86cb87371e74e42d24fc16b037ab
34363 F20101220_AAADUC majumdar_s_Page_019.QC.jpg
cf94ba48a8ee2eee0bf89a568dcaf076
0f5f44e3877dc4dad6c397dfb5fe5e8385785810
1809 F20101220_AAADTO majumdar_s_Page_118.txt
7d0feff1af2675f46c042459099280eb
e02674880643c1efe511cb00e8ca991d160159f9
5744 F20101220_AAAFDA majumdar_s_Page_096thm.jpg
be68573bd7349762ce015f1e59c94ac9
a21a0847bda5cebdb050a32e6dfca70183410c0d
29370 F20101220_AAAFCL majumdar_s_Page_145.QC.jpg
3c10f050b00f8a25335463d74ff22875
13460454e145fc75018c027884149a32b9c47b1a
1912 F20101220_AAAFBX majumdar_s_Page_143.txt
02c16875b24846825868caf4136f6985
8720dc333d0116c936b245351d816eb56c96c69c
53360 F20101220_AAAEXF majumdar_s_Page_053.pro
5262d6d130afeeab889b424b27d70baa
75b5f54200bae8d798f9a158ff42acb7f29e6959
8809 F20101220_AAAEWR majumdar_s_Page_014.pro
18f3db885709b4a85a14b6fb09d5a539
8ed41722d4b3da5f70dddb6b837764756fd8d232
127168 F20101220_AAADUD majumdar_s_Page_157.jpg
5e38f59771d7aad850c7d0ab11a1f7ee
ef0c526997d8125ef4bc1d5defe4da32a659d78d
7462 F20101220_AAADTP majumdar_s_Page_131thm.jpg
ac8a9d86e2ee255a8f7bdf58afb53d5e
1f3dac03f0bbcfc1823495630811e7b51a811daa
21914 F20101220_AAAFCM majumdar_s_Page_060.QC.jpg
dcf6c377e4304991ca1186b7c75934e5
6a77092c37ac019fbb5d68f2a9833625e7671dae
378 F20101220_AAAFBY majumdar_s_Page_144.txt
99f03b57cc8bc399efbb273032b61b3f
f6c24696117413940d79b497617a23fe910be28b
40088 F20101220_AAAEXG majumdar_s_Page_055.pro
1d463c336c36b6b5785ac614e35e301f
d9243f1a96aa3cfd582fec1dc827407568fa9c9d
35902 F20101220_AAAEWS majumdar_s_Page_016.pro
d0990d88c4911c374953675aaaa296f6
8bfda82cfffd4c713ed5c8a5d6e9f1cc20ad0d44
105153 F20101220_AAADUE majumdar_s_Page_069.jp2
d72d02dde8aa944d9a2250d6f91bc2b2
7b7d5df8ff4542b8bd0a773c1471d91a8f435b07
45660 F20101220_AAADTQ majumdar_s_Page_026.pro
d69bb62511357c354f7e20217b5afbd2
2ca73368f1101d3463c04f64faebc0733cb5077d
27111 F20101220_AAAFDB majumdar_s_Page_007.QC.jpg
c83526fc367e764c6ec66e3202cd7633
14d4226f10b63dcf8e3b4be7f3f928536ad3fedb
33806 F20101220_AAAFCN majumdar_s_Page_051.QC.jpg
a6c56ca8e942c22c2e47eafad81d4e1a
8c959cd370e6cc428c484b6aef1d3c2b42025c9c
2428 F20101220_AAAFBZ majumdar_s_Page_146.txt
231459d558e76f86abe73036413fbd42
8e4fb4fab6bf50fd65e8f357b02534c6ffd7ba2e
25553 F20101220_AAAEXH majumdar_s_Page_056.pro
1d26afb16fb625a338407b848ab6a461
319b898279406063d2d5670ca7c304917b4c9782
53539 F20101220_AAAEWT majumdar_s_Page_019.pro
30fffa822faf140c63830ee87ecef461
3a50ad37098b399ebbfe969901297fa2b3f33eb9
1595 F20101220_AAADUF majumdar_s_Page_091.txt
68e4049b7b6fe3772337ae95861cabd1
d0f136e061b4207b15a42c5e4683de17f210fc73
30721 F20101220_AAADTR majumdar_s_Page_079.pro
d8ee0a0a1d4209f65244c711516be63c
51a89d13b4e1cb7719eac7750d92cdf0cb8ed034
31885 F20101220_AAAFDC majumdar_s_Page_115.QC.jpg
66c4adc7c546c44740ef118bda45cc15
80aa6afaf300a46d3919717c898e2e5c188df188
8089 F20101220_AAAFCO majumdar_s_Page_048thm.jpg
bc05891069cd1b1269dd9cdb33c36215
1732190f25dc90c916b6883b02690974ebc3f58d
52037 F20101220_AAAEXI majumdar_s_Page_057.pro
e774ce1640eae749e4fc2340301921ca
36dc778b9f6ec76c3d02191a65eb121461a19314
52719 F20101220_AAAEWU majumdar_s_Page_020.pro
615994b43432617af7d96e94a34343f5
1be3b08a321c02626ba59192182e027aa4b7c1c0
61423 F20101220_AAADUG majumdar_s_Page_023.jpg
0ee5a12677a180338505cd7b24f66683
f3930d33fdfa932492085cd55882f25b991af229
35175 F20101220_AAADTS majumdar_s_Page_137.pro
64d54e4102ebdb876dbcabe5917a0466
f09996ea9259b1495285f9a2ec35c428b7e2ed2b
44251 F20101220_AAAEAA majumdar_s_Page_039.pro
a8a6ff12257b66ff411477dc61e1fd03
5c49b1fdd9877348d2232f543b5327d735cc5c85
31611 F20101220_AAAFDD majumdar_s_Page_087.QC.jpg
b9036a741f7e222e02ad359e4c16aa6d
4fac880c178d819b674fdf9f25b269a88163a50a
8336 F20101220_AAAFCP majumdar_s_Page_083thm.jpg
0a9c81ca4f49713f972cf5db3a538e3e
4c6d98632e87855bc4fe498b1d987cbf2f34655e
43473 F20101220_AAAEXJ majumdar_s_Page_059.pro
8064268c6d761e216192d4c7cc2a64aa
c4274b7558211f7c08c6fe33af629667a2e2ec27
117278 F20101220_AAADUH majumdar_s_Page_147.jp2
042268aa7430ce9585b3b46b6aab4c78
0c00ab337160421c7a32b0770a41158918563930
1874 F20101220_AAAEAB majumdar_s_Page_084.txt
39d4eb1afaec40aacec26bb3385c03cc
672ee5e5712cd21e351e75a07ec669f24b46ae50
7102 F20101220_AAAFDE majumdar_s_Page_070thm.jpg
2250df7ab91b00a6166c42a54df5f90c
276492a2c1b9db3b43d962eb02c87f55d4a67faf
22289 F20101220_AAAFCQ majumdar_s_Page_088.QC.jpg
5b0d15c09d8d2d4060ccef422e22f7f0
c40ce723ed33bc392759ab395d1392137a2f4927
34410 F20101220_AAAEXK majumdar_s_Page_061.pro
96ba86d8f5f1dd6b9ab1a3f20d5668f8
bdf259da69e3e974213a044a72fe67188fd9e464
21849 F20101220_AAAEWV majumdar_s_Page_022.pro
3c79ab2bffa2762c98db50aeb07d4ed3
c60aac71ae5fc9be7aeebabb0540d61f241483f1
106518 F20101220_AAADUI majumdar_s_Page_067.jpg
7b9e2c0e10a3bf4f06be0d7c0e34567d
33768625996a2035a10af33caf77711197c2e8be
104752 F20101220_AAADTT majumdar_s_Page_072.jpg
c1f11b92fa3323cfd72b86b965fd77da
0c8bdd479e7d76a56b0a52727682190b59fdcd41
110180 F20101220_AAAEAC majumdar_s_Page_025.jp2
f6969a118f309e70ae59fa986c2c118f
dee2234258c9c6b8fa58e3af4eaae1dce68c9b94
7147 F20101220_AAAFDF majumdar_s_Page_140thm.jpg
35c52e2c3f6d77fa4db2d5a396eede9a
aa22fd716215ec9e725854693d410aa0ea63e1fe
32790 F20101220_AAAFCR majumdar_s_Page_038.QC.jpg
085ce4361af313a142d794ab746ea0af
c003f6499ac9d01c237992b977a4ca98698e1252
12580 F20101220_AAAEXL majumdar_s_Page_063.pro
594ee36191888cc18f916a35d1501daf
3d7be81538e4b0bc90f00850ba9316c77eee619a
51286 F20101220_AAAEWW majumdar_s_Page_025.pro
cfa8bcf47d20b6185de020a787d702e3
6c188bdc358b996bdede68f2bd63bd0cb3a9ccb1
127816 F20101220_AAADUJ majumdar_s_Page_149.jp2
50bd958475f9384258342294a30e64e7
7fbd10dc176d567e13010f4e26175f9f2c1c8a30
6664 F20101220_AAADTU majumdar_s_Page_136thm.jpg
bc2996862a09bacd0b50eeb2474af08f
1b8605cbe9d528dc758600eb2df46b94d927c317
35950 F20101220_AAAEAD majumdar_s_Page_153.QC.jpg
c5b1b2a47a5bc14a8a8dcdc74f37344b
1868f07a6a835d59f38e3482441dd7c0f80de25b
29950 F20101220_AAAFDG majumdar_s_Page_026.QC.jpg
c060b721cab522f51fc26be3af534b49
d54caa437679e5b10cafeae01c3e8ea1b7cd4a79
31478 F20101220_AAAFCS majumdar_s_Page_134.QC.jpg
5a1f35c374008a69717628521c5252b9
f3a24aad779675f8228d20a90d2f4e0731be9629
31636 F20101220_AAAEYA majumdar_s_Page_088.pro
42d1aa7ed9cca9ae742cfb5cf00c349c
555ea447152bc17a6137552492c71ffb0c874361
36138 F20101220_AAAEXM majumdar_s_Page_064.pro
936fa219f7cc4bfb2592db3c00f30ac4
a4d8de997f2b5aa8fbfbd695ecbcf6562e8c3ad3
41467 F20101220_AAAEWX majumdar_s_Page_027.pro
0310945666887c0c00e4d4f1d30b6a2d
24567b8d202740e71d46ec79a80a3deeed5409ce
6912 F20101220_AAADUK majumdar_s_Page_035thm.jpg
f0894d39aaf3c32c1740cb9f70d419df
571d54e807653a18de8bc9bd989daa3912619406
47501 F20101220_AAADTV majumdar_s_Page_104.pro
ff89ddc4e26310ae4d5c95679783d36b
24f2998c0b3f75b1ca2af67e4ad4b624c2cfc410
78766 F20101220_AAAEAE majumdar_s_Page_016.jpg
d376d5e9b01f1444c61cb2be3ea2db58
18d2cc0304333824d1d56b909a0856319a64076a
26234 F20101220_AAAFDH majumdar_s_Page_015.QC.jpg
4bbef6f0300552f6b8de9349aa21a389
846a7f58d034178dcaef88090db621a9acbda213
31607 F20101220_AAAFCT majumdar_s_Page_066.QC.jpg
41634568b582f36f762da8397328bbe4
da49216afe61922690f6d7138d4b47bba2a623de
47923 F20101220_AAAEYB majumdar_s_Page_094.pro
908541d72a204b8ec33eda6c45788cb3
8fd3a56fd30a6b1d886663f12e6ce83e17462d8c
50224 F20101220_AAAEXN majumdar_s_Page_065.pro
3b4f04e3555c8661e72982350430225b
6eeb0232d463cef4efb102f214b945dd8a2e381e
48456 F20101220_AAAEWY majumdar_s_Page_029.pro
4e1e0dea2005a84eb9de3d727201be5c
7144dc89f612bc318b8f52f9ca71520a6dad87a9
5902 F20101220_AAADUL majumdar_s_Page_088thm.jpg
1c571e07159a6b8d2466909620d56895
36deee89473ada997683c900af6225217e6b8518
98477 F20101220_AAADTW majumdar_s_Page_145.jpg
48556c457adcb120925b15be34e3ce90
df3cf0962bcb397b52e5121b7f457112a0754369
1727 F20101220_AAAEAF majumdar_s_Page_142.txt
6efb23f4e725f535514d2ac6f865b508
35f98ab4bfa3209d1b97468d8ef8d24981a1a8ca
6842 F20101220_AAAFDI majumdar_s_Page_093thm.jpg
a0bfad879a7b4714d1b4b69518a56de4
bae9443b7f066b3ee0e20d3702049432a11eeb87
25011 F20101220_AAAFCU majumdar_s_Page_061.QC.jpg
488d3cc7b613151ac39c60797a2e7cc8
b4f6a7fcb243da25fb1d4e22b88c4f039d54c92a
49761 F20101220_AAAEYC majumdar_s_Page_098.pro
86b6f4b9555fd90f0e906d922d519b76
183f92d1511dec66ecc3f2dd3972d6b1fc057679
45140 F20101220_AAAEXO majumdar_s_Page_066.pro
05c6f0b9d08e4308dd9dc741c96ed553
66399bc9de4dee68458ce2212ea1b443ec1b323b
28443 F20101220_AAAEWZ majumdar_s_Page_030.pro
5ba51e9f69e1b4e6d7aa192dcee692bb
286a65de815da90eaa66c721a244ccffa333f8b7
1776 F20101220_AAADUM majumdar_s_Page_033.txt
f1a1ac166c103e4af6d96974b92e763e
3b07c46eeb72f143f2f5e977b0fdb8e7bb84ab5d
1389 F20101220_AAADTX majumdar_s_Page_082.txt
cc75dd546d0c61bfd24d70b2f1f0ce0a
373bb19048fb1747fd0326c91644a0495afcac84
100442 F20101220_AAAEAG majumdar_s_Page_098.jpg
36f1adf927d5e4072a6f17cb4504da34
1c7c91ae62e1c46a5efa74224c1c63387ae3250e
103078 F20101220_AAADVA majumdar_s_Page_029.jp2
f9a337d51a15b261050ce2faaefb79cf
8b9f34e03106a4d890dda0086da17c1edf0968b3
4247 F20101220_AAAFDJ majumdar_s_Page_063thm.jpg
0110f52119ebb820b790b11b28246485
2dcf400d9e5391b68104876eaaa229a48745fdee
35907 F20101220_AAAFCV majumdar_s_Page_157.QC.jpg
15e2a283c95269916f67a48788825bce
d30ff4736922f6b94b6ef0d7be8e6567283f7bff
47271 F20101220_AAAEYD majumdar_s_Page_100.pro
f93af1a4bf88743f2b10d8b9312a0cf4
c1e222498a1a47645aab764a4a4070177f9678fb
49054 F20101220_AAAEXP majumdar_s_Page_067.pro
b68ad7f28b1d356c351639351f953c03
f7d38cd8affad4bc8e47fac41a003af1c6519c2e
751522 F20101220_AAADUN majumdar_s_Page_030.jp2
2945db44a730eb8a20e1c5539ad955e9
d44c6997c246435548a30e612211e7e075d16c3d
1440 F20101220_AAADTY majumdar_s_Page_016.txt
7ac7b668e3e221eac7de6040f303b242
42fa0af263483f6ca59cf8b0ce38da815da83d70
33912 F20101220_AAAEAH majumdar_s_Page_143.QC.jpg
b481e26146198a1e0da28d2ac1fd1d8e
9d2086007a09be190282297e1e5fd4d892e89d0a
6634 F20101220_AAADVB majumdar_s_Page_110thm.jpg
352ccf0b616ca5388a5387f7874fbfb8
caf04c72db750a721a845b89b6b819854ec0e2f7
8129 F20101220_AAAFDK majumdar_s_Page_075thm.jpg
8614ea1141978300bef698910006e56f
fd576307b8a5baceb629b23d35febe0312813433
32132 F20101220_AAAFCW majumdar_s_Page_005.QC.jpg
5407083effd3d8516f0530b78fa8208f
d52206669bc20c31408f1ef1b8f94ebea3c8c5ab
49470 F20101220_AAAEYE majumdar_s_Page_101.pro
92602f457912dab6eda1416ec1b5e49f
955f547af7da3bfeb92c2a77141e56ec97e81414
48558 F20101220_AAAEXQ majumdar_s_Page_068.pro
0204fdb25dd6955f15ead27a89c824cc
2413d4d571d3377f3fd39b2b75e37709193a06f3
F20101220_AAADUO majumdar_s_Page_019.tif
07bf9ff96d541cc25de6a232972ad119
324af3aa662d75079fa8ff9211e4e9ff9f2bc1f5
264019 F20101220_AAADTZ majumdar_s_Page_009.jp2
1b0d1b8dd3dadb6271b3e15abb386058
ab373e288f671af25d3e5f8de8340cffd60f39e9
44042 F20101220_AAAEAI majumdar_s_Page_095.pro
c2dd3a5f6b5cf0ef127640596a339d61
f1de0841f3dea1d5518eb94534af4ad07471a190
93712 F20101220_AAADVC majumdar_s_Page_055.jp2
d863fcf9213f8c2bc24dd1abadf6cc1b
cdffa76c15258f0f750752c08b5eba5c0fc13984
6594 F20101220_AAAFEA majumdar_s_Page_105thm.jpg
2d8435f68a6104873b3500a049fd8f46
7532649beab0a31955216decb386acf62d33f1cc
35432 F20101220_AAAFDL majumdar_s_Page_154.QC.jpg
3e23a2045cee81ae67bbf4e23f42814f
dcdbdf667eb7755d582d1bb3fc891d7b5caed013
34056 F20101220_AAAFCX majumdar_s_Page_097.QC.jpg
7dc44e3d05c1c08de252c706e8206825
c40337c4a916d77e461f13b8aa1c8c3e1fdf2880
40490 F20101220_AAAEYF majumdar_s_Page_103.pro
6246a015fad0771749770b6f5759b5ca
a78bcc021c02f7e22356b7a388bd89545a497a73
46848 F20101220_AAAEXR majumdar_s_Page_069.pro
75e75d5ec57347eed8bbeebd1424bd29
db81f5f69b1dddded54c942b98f02153f0b75ed4
5168 F20101220_AAADUP majumdar_s_Page_043thm.jpg
5412b1c5ad3018152311e62ba8a214ce
2707adfa57d5f4bf188ea92da2153b46ab11d36e
26023 F20101220_AAAEAJ majumdar_s_Page_093.QC.jpg
f92e2b329ac036ef9c6aa932dfca8673
2ab40a69e09650c4730c92928c95f1a5250a63b6
F20101220_AAADVD majumdar_s_Page_032.tif
867c66e7bbb6448d665842798c80c3a6
6a6b99970dbd8e1b19fe54e70386a0a636724cb7
5855 F20101220_AAAFEB majumdar_s_Page_060thm.jpg
5c81213265f047003dede5dec916d2fc
78f44988e1c470685e31272b8b6c634ed33a3b1d
8626 F20101220_AAAFDM majumdar_s_Page_153thm.jpg
2798e30f4ee5cc917399898fffdb99ea
d2078ae06d81c7d8772e2318f9a5d93ba5fffa81
6611 F20101220_AAAFCY majumdar_s_Page_077thm.jpg
ee4e254c3e39b9f18822e64555a03f24
549bce8e2119893534ad9b6d11f05f1da9ac51c0
44817 F20101220_AAAEYG majumdar_s_Page_106.pro
956637d4801b8da0b24a27bde0d8a848
8d58b2f87a48cceabf1454360a97833c83bb45f6
41054 F20101220_AAAEXS majumdar_s_Page_070.pro
fa5ab5c606134a434095da8e50f594ed
b98733483534a2ccbaedfb8010868c509c9d8f06
8418 F20101220_AAADUQ majumdar_s_Page_143thm.jpg
59c75779985ef26d717eec020db76c26
7f73ef1962079befa3ae27a2f208d8ee0ee5d119
31204 F20101220_AAAEAK majumdar_s_Page_111.QC.jpg
43366f22811be9ae5a3211b5a3e76619
a397e276d17577fbcad89a2e4b2f97bebbd0264b
34982 F20101220_AAADVE majumdar_s_Page_047.QC.jpg
f14d996ba2bce097b57a5a19438df8d3
ee0e5373c315fd49f60f0e4863f86b5aa7194455
8072 F20101220_AAAFDN majumdar_s_Page_054thm.jpg
d0771f57bf7125c54657484c4531e88b
339296ccbb65140b05ecfb0d0c6c09c5f43ec636
34367 F20101220_AAAFCZ majumdar_s_Page_024.QC.jpg
fea18f0943101ee76fc1fc573fbfabc4
b67756609b621e5008ff0e5b5b8b6d423a2bf919
41278 F20101220_AAAEYH majumdar_s_Page_108.pro
91592416a4d85c225372f5fbf929c0f8
45e09158fe44fe1cb3047df71f62511f8d07cd7d
50158 F20101220_AAAEXT majumdar_s_Page_073.pro
e9b5675532bf204a3b9a332d16aa8a8c
80d0e1c09b2d219cae9df627563c96523de3e821
F20101220_AAADUR majumdar_s_Page_048.tif
db16760cd2bdbc5f052c20bdd73edcbe
b9ead1fc174314576407d0d63cd745f9e9195ca4
47909 F20101220_AAAEAL majumdar_s_Page_041.pro
f5c02275bc11d639e5d08df407f99262
8e2e5f241cd0f8ebafa36493453e10341c280554
106364 F20101220_AAADVF majumdar_s_Page_068.jp2
9fd9ca4c65d737b6fc48c99ff4771b00
565f3f24cad3309ecc1c354c313f153e1c156fa6
F20101220_AAAFEC majumdar_s_Page_069thm.jpg
ad5a1db00086522c8788a97a1a4f3537
482a0b544c8fb3827c54e45f574b2476ac01cd3f
26833 F20101220_AAAFDO majumdar_s_Page_017.QC.jpg
ab3b6db999f937bf97e4a4ee35488f3b
1f6ec2acc88d0be8063f572c494fc1d3b4d4cd3c
34246 F20101220_AAAEYI majumdar_s_Page_109.pro
145c99b4d1bd1739b94e0effbaef5c4a
67eeb9c3542e5146c90eb46655a55f5a5e355827
50574 F20101220_AAAEXU majumdar_s_Page_074.pro
eba765100fbc0e560d80273be4b866ea
efba65e43cf8eba6cde5ecf76dd77e29cd7cafd9
F20101220_AAADUS majumdar_s_Page_106.tif
a3d2acd136eb52d12a82b9deedd3e3de
56a0f9fc35fa97336e3e5f6212f2cb97135ba587
30603 F20101220_AAAEBA majumdar_s_Page_116.QC.jpg
65e72b3f6ad80d18e274f8f5181ec955
235d153c23f1f9806e5e5c6d62a9c4b4c09a4316
F20101220_AAAEAM majumdar_s_Page_075.txt
1e310b86f92c63d1f0a0ade816626436
f2bdccb518679591c298ba41e8b4a21db710df54
28920 F20101220_AAADVG majumdar_s_Page_070.QC.jpg
4f0da4b4aeb628c8af21402d5f23f3af
28f5b09514d52d14168af839af45c0b03cfc37db
8440 F20101220_AAAFED majumdar_s_Page_073thm.jpg
5c9709baf44302f1dd373a335157091f
2f8f3815a12198799a0029fada3758167a775cb5
19391 F20101220_AAAFDP majumdar_s_Page_043.QC.jpg
1fc6507a0fcf1cb228b33d81e44b379e
4f64af5011068e6491c3eeb00ef86390243fb4ad
38536 F20101220_AAAEYJ majumdar_s_Page_110.pro
13765af8237161cdaf5a3ed47563c566
d7979c60d92a88259a50a71e772d5f10fe2c3444
35237 F20101220_AAAEXV majumdar_s_Page_076.pro
246461617e508c65f63527cbcc7710ca
b0e3238ff654760d1df65c70e5f61472ae60adb8
46054 F20101220_AAADUT majumdar_s_Page_037.pro
f9b5eff29fde895f05f2d07e2e53817c
0a20f044b40734029f4cd24c3d8650f86434cd5c
26042 F20101220_AAAEBB majumdar_s_Page_033.QC.jpg
97254db84b97788012c77ec36e03db42
87d34200ea470fd8037821b82b2cff5c0f67c2a0
39969 F20101220_AAAEAN majumdar_s_Page_102.pro
77b11f62421626285ac7b2025bac84e3
9372c7aa94275a975d578c93c2737b922a3ea7c8
75023 F20101220_AAADVH majumdar_s_Page_076.jpg
be60e3d8069519c7e7dcd1477a5699fc
e21b9355ded0a05c5bb823edd369ebd783fd82b1
7397 F20101220_AAAFEE majumdar_s_Page_138thm.jpg
ee0d73a6c32a3fe47e66453988ca2b18
481cbce004f63c03c544afd1d5c69092baa4fe2e
7265 F20101220_AAAFDQ majumdar_s_Page_103thm.jpg
ebe5072e6f4a3bd7f6a70d80a568b88d
8a450137c6db0ae5d17501c7d55b5e94dce26bda
33396 F20101220_AAAEYK majumdar_s_Page_113.pro
a4f4d19faa4311c79f58bc166a3d2fa1
3559392bcfef51af576907e1bae88f603e064111
63760 F20101220_AAAEBC majumdar_s_Page_153.pro
a7255e1e9a7b91003d735573b3ea8407
ca9cc5aafc4b93c798948cb0baa3cf7140183584
1654 F20101220_AAAEAO majumdar_s_Page_004.txt
fd2cb03a38ac6830481a505611d45478
a181632c8cff6ecae8259e6c205478569e1d61fa
43233 F20101220_AAADVI majumdar_s_Page_090.pro
e76a6306f4596ffcf2c572a39dad346d
68356d7db4e844b530638b20f7e0dc2027a0b235
31554 F20101220_AAAFEF majumdar_s_Page_054.QC.jpg
9b4b7d3f540c23c0665e6ee260d1de68
2d7302a8db23b871bebbad854dbe96c4d6cef586
7284 F20101220_AAAFDR majumdar_s_Page_141thm.jpg
7c79087481fada875f084c4e8fbbf4f7
e313338e32e5c321dadcb6233f90ac4f7e453c9e
19482 F20101220_AAAEYL majumdar_s_Page_114.pro
b1b0ff9843ecc74bf528e481ae644f55
feed433b3e1ae0da4e6c3e5a920ce6a109c1e514
39732 F20101220_AAAEXW majumdar_s_Page_077.pro
b7b9307cda9d609434c4f87faf1dbebd
65acd01d611ca2bdedb339231e6611872aa7998b
47507 F20101220_AAADUU majumdar_s_Page_126.pro
01c813ad2bc25126c60a251d64b07f04
f8524d6e48b8878643d90e65db82fa211d147550
6762 F20101220_AAAEBD majumdar_s_Page_015thm.jpg
fd4b1d886eb73e5b729739306232e5a1
8b8d14b4eae3cdee64cc3006b0f25b5e0a6a580d
1624 F20101220_AAAEAP majumdar_s_Page_070.txt
8a0a51ba233ecdeaf78c7829829ce110
619acca4e6b274dc97fcb387e9a2020275bf5055
44355 F20101220_AAADVJ majumdar_s_Page_058.jpg
0859ba824f0f55defe13fe9f8c56d86d
d4724b96a831915320395a72d02d8df0679b7c0b
7510 F20101220_AAAFEG majumdar_s_Page_057thm.jpg
115caa3888087234790ebb865fb5a61c
4d7672d31d4ae48986d059232a39abe2ba4f3126
6326 F20101220_AAAFDS majumdar_s_Page_016thm.jpg
4b95c8918df4b34953ba61a6f380476f
03148fde3e9d63ec3e8c42d8d0ed0dd657ec9ad0
39952 F20101220_AAAEZA majumdar_s_Page_133.pro
edd250cb6fe4b9b99fdd9f825d577862
63e1f65f1196122549881251cd8d0c4d9730ecea
46611 F20101220_AAAEYM majumdar_s_Page_115.pro
3b8201d0a2391f01ca9ccfef817d83dc
34bbf513258df4cab9447d98668b72bbedef2ab5
9830 F20101220_AAAEXX majumdar_s_Page_078.pro
9ec4b5985c2297c7ba26e90609d0cfe5
a9e680c8279235f5ce9cf1d4b7a57a6d5436ed15
391682 F20101220_AAADUV majumdar_s_Page_014.jp2
cec907e029154460d4218669a0b60b92
fcbdc340c90e450f6ff4bd9e2ca865e20663cc86
F20101220_AAAEBE majumdar_s_Page_067.tif
37818a4012473d8e21059d8fbb6de712
247f7655defbb2d3e002dd470c6efeae5495c500
8620 F20101220_AAAEAQ majumdar_s_Page_146thm.jpg
4e2d76bf5d86cb355e450a681869d39f
6a394c14fb34011059fd69f543900eb01f3e389b
37834 F20101220_AAADVK majumdar_s_Page_105.pro
78d1f4a58b49a356eb59ece4c92e7fa5
b923b156e9da23c1b119c31f64e24b32624be3b4
3818 F20101220_AAAFEH majumdar_s_Page_089thm.jpg
b8e8bc8cc2b441701610dc2054d12ab3
35eca60dfc74f118cfa670c25c3431a0e13014bb
3618 F20101220_AAAFDT majumdar_s_Page_114thm.jpg
e139e6fcec6e8ac69936a2b4b6e93d0a
43efcd9498cd9e96082327319c156c9b73c8d11a
48283 F20101220_AAAEZB majumdar_s_Page_134.pro
87e81c63e3dd66bae64337c24a6bfe0c
3a9f55949d8c6d32231552e87404dbcc2cba4f20
45911 F20101220_AAAEYN majumdar_s_Page_116.pro
9be9073b9b663ba072fa072ddfd4cf94
e99702d2fb9be00e58b0e223bf200be21b5309b1
48245 F20101220_AAAEXY majumdar_s_Page_083.pro
4a254c7b5dea569d633fd9bfd33fc604
1827494abb14e9f6b336c56ac909c83d0e400554
51889 F20101220_AAADUW majumdar_s_Page_012.pro
14c842831464103a753c0ed76256d503
c3c51684ab26ca4b36fa7bfdaa2ccb3a98f7f412
84086 F20101220_AAAEBF majumdar_s_Page_017.jpg
e7614d28902e4db309b86977b4bd6fdd
b71fa23478623714ae41ba50b840c5d8b670727f
60392 F20101220_AAAEAR majumdar_s_Page_112.jpg
cdfe2cbbd8074c74d22720d3311d40ac
c0f13d903e0c1ea68fe3dd78a984e2765e4aa9ed
92741 F20101220_AAADVL majumdar_s_Page_039.jpg
38d25be98b3fe98a9f80638d0a8ce32c
10326d36298579f566bdede11738f28d4488a4ff
12048 F20101220_AAAFEI majumdar_s_Page_158.QC.jpg
252c2311823899669dfea8f7fe2668b2
061a9e4d31f6947340601c4e9419f61382ec3d1f
7422 F20101220_AAAFDU majumdar_s_Page_108thm.jpg
ad191332b228fc25b63791fcf5b0e7e8
a0793d902fd5e574a12d1cbca7447334110c2e53
33675 F20101220_AAAEZC majumdar_s_Page_135.pro
836ea2823555d0c5fc5f5439581b1710
f23a025d4c7ffcff822e8acb1012748cc792a2fd
40706 F20101220_AAAEYO majumdar_s_Page_118.pro
a0e3788419a0d638c6bc7113e3437ed2
e3a14eb3a459cfd11b0fd9fe10ff70afdb49bbfb
45089 F20101220_AAAEXZ majumdar_s_Page_087.pro
193db2bd49eca544063b1fa4a177a41c
2e34ac3b6476e45c6db1d57e2389b952d2859c9b
29109 F20101220_AAADUX majumdar_s_Page_086.QC.jpg
2b60e2a2b0dba46b5f08a8e4addf0720
6a5efddd478a9304d0444c9597d1e0346a4ca7b2
34321 F20101220_AAAEBG majumdar_s_Page_127.QC.jpg
a9f51cf099b90bf4649b2d1627e56f08
b08c300fa13bea75a0e71da4624cfd03154ce18d
F20101220_AAADWA majumdar_s_Page_004.tif
7b54fa1f3762bebf3dbc98414e0a5942
e4acc292b5df151c451179bc406a1345657fa1e1
61750 F20101220_AAAEAS majumdar_s_Page_007.pro
e3a3f48c003e27b08c9cb604b94492d3
045e02e58ec599d76d105925f0157939bc93573d
7303 F20101220_AAADVM majumdar_s_Page_099thm.jpg
840247597e0490253739bc9a44eabe1d
8fb951ad8779c516ee6f63bd1210634185232e9f
37871 F20101220_AAAFEJ majumdar_s_Page_148.QC.jpg
5e162d501cb5b6a65a589abcc3cdc6f1
4f3312f7cbe1beaf2ce0bef1d14167402fe0b6fc
6547 F20101220_AAAFDV majumdar_s_Page_017thm.jpg
f2a7287e8db6d09094936591a4987095
d1361686e1539323f06c7f7c4d08166a68820145
41961 F20101220_AAAEZD majumdar_s_Page_138.pro
9313a63d5831b14637fd2af7ae19950e
87f42bb24fe133ea5a603015758104b711b5056e
39232 F20101220_AAAEYP majumdar_s_Page_120.pro
d293f2851a62862f949c880a13a6ba58
fb29c46552dce69c48aeb2e6afa586d95476bf02
110064 F20101220_AAADUY majumdar_s_Page_028.jp2
3be7c056f2b7cd244de0dbbe324485ba
595eaa8e7c0ab5c895d97b94616c1e5d5e089194
6899 F20101220_AAAEBH majumdar_s_Page_031thm.jpg
0eeabb47f14f38ea63a3d6d3c89b141c
e02c702a1274d57f897244968e61feaa2cfd4931
25820 F20101220_AAADWB majumdar_s_Page_016.QC.jpg
a509b3cc4f0a7b5e706e06209d30c210
a5ba2b9b861b11a296299c8ed5226d23f8a0c9df
22514 F20101220_AAAEAT majumdar_s_Page_096.QC.jpg
35406464c41208516e9afb58ef525963
0f85e1767db75f21a3512d1bd69f0591a4c2b86e
6633 F20101220_AAADVN majumdar_s_Page_144.QC.jpg
860b3712f44a90086988e119a66182bd
b9efd1315c917200fd3236e1517a459f3eed1681
8301 F20101220_AAAFEK majumdar_s_Page_008thm.jpg
c73d371c456895faeb02fef1e3ac3662
a4fa83b5ed3270c4aee806a14d77c719730e752f
7738 F20101220_AAAFDW majumdar_s_Page_050thm.jpg
4f28b79eee7041f0892b928398a9b9c4
4f69a181a490e9a8c0d1f25f30b8089cb40605d7
34915 F20101220_AAAEZE majumdar_s_Page_141.pro
47047829b7a7740cdcd2aca44d0f94d0
0115f05fd78dfe789e7b5e78892e08c28c789b28
49582 F20101220_AAAEYQ majumdar_s_Page_121.pro
841913ec4d3f347c243c414f03cc3e10
1f6858d1125ca8f96c89dd843f27c2aca0f5fbf7
120255 F20101220_AAADUZ majumdar_s_Page_151.jp2
78bd9b9042d24599ac7c72d760ea52ba
74a7a39ac02933887e6f2578a39a49a23bcc6817
82211 F20101220_AAAEBI majumdar_s_Page_120.jp2
fe0a6f1aca24edcd4a20a5164010b1f2
1188a4b941083ea3a39d661833293dc404b3a72d
107618 F20101220_AAADWC majumdar_s_Page_038.jp2
9c6e38161c4ce8bdc8b1bd71e5f1e1d0
ae3172ede5c66175d6e0e827279bbae97921e714
9680 F20101220_AAAEAU majumdar_s_Page_001.pro
259a64c7d079162dbe2d2a56c573003d
f9fb4632cb2d03af63e7063db0c00c485d91d234
27097 F20101220_AAADVO majumdar_s_Page_119.QC.jpg
b305596dba933b7ddd738f931704442a
ca41b4e0d35abc233e081983a9a399335a09e321
8452 F20101220_AAAFFA majumdar_s_Page_024thm.jpg
463dca9c3dc94823fca6d2142a06f776
9b1745da06537b2aa18ae72973b6c75337ee8567
8476 F20101220_AAAFEL majumdar_s_Page_154thm.jpg
b90da09ed8cc33e9fdb306165a65ccc8
ef6053e9ae9dd5aade7003fcb34ad25c60bddf53
35423 F20101220_AAAFDX majumdar_s_Page_152.QC.jpg
73b39f0b99995d1ca77924564590ce09
da890bcd6d9b9438054f4f168dfd0eec6a7c12a5
8451 F20101220_AAAEZF majumdar_s_Page_144.pro
1dfc2053bd1ace0054d78452e299cb78
b6f4c7531549fb21c81607d07a4a4b59ef26b518
33426 F20101220_AAAEYR majumdar_s_Page_123.pro
129e1fd703803501970ce6cea8196f3b
c2a20e8c63c7a8cc4ab14caf7747fe9f434bd032
1955 F20101220_AAAEBJ majumdar_s_Page_038.txt
f2e6a6524be7f11b63696b875c8990ea
078a59b29a2bf039b11f48fd0c97049272aee134
40909 F20101220_AAADWD majumdar_s_Page_085.pro
f77ba48f4791ccc104971959b7c42875
6495224e40bcdcb9f4b6a7909e47b649532dbb1a
38874 F20101220_AAAEAV majumdar_s_Page_015.pro
773c7238f95c1949c0626ad7dfd158ed
66cf7fd365eff6c58650afe93735ba6c7f89ee9d
7764 F20101220_AAADVP majumdar_s_Page_011thm.jpg
07acf606bebb1336c24100eda23a8317
e3a34a2d3f1af53c4d817d9428126e57d6ffb1f1
8375 F20101220_AAAFFB majumdar_s_Page_025thm.jpg
ede3b05f3c82953f079a9ed70053fe4e
0d3bdcab14f09e6d4c3280ce730d4074bfac9f69
34284 F20101220_AAAFEM majumdar_s_Page_124.QC.jpg
dc0844e024d1e4c09f0eac207e879a3c
b348a305e357f75048083f6f41314e9dc99b55f1
13914 F20101220_AAAFDY majumdar_s_Page_063.QC.jpg
b199a42d0d25ba286d8d26e88b0aef13
927c2c67d0c21b417fb229943ce22a19cf98fc58
49664 F20101220_AAAEZG majumdar_s_Page_145.pro
37f8966c071b81499382726911631973
a6e94e6b9376ca23e2a75bbc27839d61e49b978d
48395 F20101220_AAAEYS majumdar_s_Page_124.pro
413dfc75b0ebdff32865d83e6cbe55f9
4cae606654d9f109236f54e5c105dafa467d4156
F20101220_AAAEBK majumdar_s_Page_090.txt
82cd076ab801a0f2002835057aee4856
72d8c9661d6961dd4c51b54136967d33633c61a5
93387 F20101220_AAADWE majumdar_s_Page_116.jpg
bc23afb1bbbe2c25f2da8a5883286154
31e585a3289ec549a844a2b2fdfd6cae556a9a3b
F20101220_AAAEAW majumdar_s_Page_075.tif
df96c09e61f158761c91c9a8286b3b4e
617c7a13d2d8cbe303eaf0cf2750e9a161b46391
34808 F20101220_AAADVQ majumdar_s_Page_146.QC.jpg
79f0949c1e6c6af085c22a17dbc215ca
31c9e5bfce1b05225da5d8dccc275fa0ee178175
28425 F20101220_AAAFFC majumdar_s_Page_027.QC.jpg
cedadb9eac3e37b599bdf2191f381751
3f9d8b4b417fd990c431e553fb10142ce5d2f6b5
239771 F20101220_AAAFEN UFE0015480_00001.xml
23534b811f966c55fe04529bd8c4af8e
e8c4e7bfe3b3422de10cbb97d2ee7339ce65a1c9
7516 F20101220_AAAFDZ majumdar_s_Page_107thm.jpg
bda53479b9be302ca8b4649104501754
db44b7d978f39b932cf770337fa1f3166140587a
59669 F20101220_AAAEZH majumdar_s_Page_146.pro
939b0c6be58edee91a7fba33648167ac
73050d1a71a0710ad543d67e7586674ef68270b8
46892 F20101220_AAAEYT majumdar_s_Page_125.pro
22d59e25b210a345be0e63ffe19b045d
94458d05ce0827e4a32b910a33d4f406881b5bb2
1897 F20101220_AAAEBL majumdar_s_Page_041.txt
d6333b58bcbcde79e04b4e6cabf32dbb
33cbd9645c5a17950b82907f05e22d7bcfa8914e
30614 F20101220_AAADWF majumdar_s_Page_060.pro
1e8f61290eb787a0b6d7bbf59be8fae9
b2ff18228252e8d7fdf9e4c8b140a2df37e1dbc5
F20101220_AAAEAX majumdar_s_Page_017.tif
2e069bb9f3af0adf49a2bcab7a387c69
a5fa8a8b9a39bbf6eb7274c472a4b6e9127f55b5
30254 F20101220_AAADVR majumdar_s_Page_096.pro
e6ac148e8fadd6951ba966057f60cc1a
ca2ec2a78d95e64b8e5a1447ad6e165913adb416
111256 F20101220_AAAECA majumdar_s_Page_020.jp2
078666525a9ece6e230c805cb09d2c67
138c49da1aa4182ca3aa6b7502f531aa288fc033
1590 F20101220_AAAFEO majumdar_s_Page_002.QC.jpg
33a3e3c2c57ab5cb9de8d07f8a908edf
b93b8fa31c20005127269fefcbadfe7a98fcc8a2
67241 F20101220_AAAEZI majumdar_s_Page_148.pro
43b1f535e8bf3f21926155c1ebffdc88
4b4f1005bbc719bc5cacc3463ea5c39c0ccf1f1f
51416 F20101220_AAAEYU majumdar_s_Page_127.pro
f81366120779c792e76aec3fb2141141
d5fdee3c162a6ce1f2e517582b01699f95fb9f1e
28458 F20101220_AAAEBM majumdar_s_Page_049.QC.jpg
c4587ca88fc3e73a9c378050176733ab
14e7389f827fa9c6762e94487217bf3c37a628d7
72144 F20101220_AAADWG majumdar_s_Page_084.jp2
1cd829ac857529304c78a8e2b6181e21
41c2b179653c3c28d0c8999fb964b75631f8ad35
F20101220_AAAEAY majumdar_s_Page_016.tif
6eb16cbce28e7c5d64bd9ac58221b861
3536d4d5fa2f3925383d6272ce4f4e19920925fb
1819 F20101220_AAADVS majumdar_s_Page_059.txt
f0c381153c8d15036761ec74bfdc7e7a
a9d4f3bdd1c89e21979b73594929efb226ae1b8c
7124 F20101220_AAAFFD majumdar_s_Page_027thm.jpg
a9b8031cbf55fff9e1b47df00db3a91b
9fcade11e8c8c443e5cd6925712e457ea21c0ac4
9616 F20101220_AAAFEP majumdar_s_Page_006.QC.jpg
a8c9ca8cfc8fe321e582c79823c98de6
05557c12a32db7363e9ffe69677cb663377993aa
62998 F20101220_AAAEZJ majumdar_s_Page_150.pro
006103198f18c592bd311d1a511aa968
1502a84c9d2aacac2d0cba93b7c928b5f6094378
45847 F20101220_AAAEYV majumdar_s_Page_128.pro
a4374af67ba6ef146510ae1f5f16da53
9750896794d052ce9ad9d524bb86d1e71cd708f6
1685 F20101220_AAAEBN majumdar_s_Page_102.txt
e4976aafdfcf1ee64c681cc956c60f86
202919c315a02932599e9e5a528f15a99310384f
F20101220_AAADWH majumdar_s_Page_102.tif
96308d644dc021f9229a53b064408f5e
001646e085386f2029fd07d11ebecc098bace1f0
7149 F20101220_AAAEAZ majumdar_s_Page_033thm.jpg
fc0db5be97613aefae4c8d3a8c14f6fd
f29486c9d3727b4902e76cc2189f5655271fb7e3
12193 F20101220_AAADVT majumdar_s_Page_006.pro
01f563ec0fc298c5912633cc86dae010
a95521ef719c9d6100f3cc0302eea509ddc23f4b
1051985 F20101220_AAAECB majumdar_s_Page_013.jp2
f1fea064270ae54d3b615b57d02b49fc
d169089e5c2ef94165448c791ab268321333d43e
21194 F20101220_AAAFFE majumdar_s_Page_032.QC.jpg
8f60dff31e463c7172c6eec60fa2a392
2a5682d07dc1f32b02464e10d9cacdcaf82d25f8
37097 F20101220_AAAFEQ majumdar_s_Page_008.QC.jpg
d05bc79135a6a370778389495d39f7b1
52dd3ab565c6ec05f453d887fb9baf29ef189a01
64647 F20101220_AAAEZK majumdar_s_Page_152.pro
3e95547535708fe046b36f0a459afcdd
620f8fa479f7f0eb7ddc334c452a1d8f064a718f
40382 F20101220_AAAEYW majumdar_s_Page_129.pro
32436368c87af8bed74186a8549a7a80
f0ea218599b568a436a82aa319b528fddc43c87c
2021 F20101220_AAAEBO majumdar_s_Page_145.txt
ebc1a9554768bc8ad6b212662e639528
9dfd16fd08f2845f6ffaf2239c5aa07f69470abe
F20101220_AAADWI majumdar_s_Page_136.tif
dc00559ea94c7403a51062df26a08960
db5480bd0451c1c2edea4238235f61b71c4ff624
26572 F20101220_AAADVU majumdar_s_Page_082.pro
3f66e52f8671cdd16568bfc213695366
168362d31b21771065b6da70af246d95b99d1df9
49524 F20101220_AAAECC majumdar_s_Page_038.pro
aefbb49aeec8a7b29754a40c6c1c164c
5fb9b6f152e1dfb22e4fa4fe0a03c518e959f461
6036 F20101220_AAAFFF majumdar_s_Page_032thm.jpg
28dc7a73d7c03e92c70793c0b1c6729e
efacc1fb4866bc392b3809c5bc37ca0882b0c5ac
31898 F20101220_AAAFER majumdar_s_Page_010.QC.jpg
5664648aadf3bc8220dd5a61980f5b39
07211a5d87bff21bfd2c4341694e28710164332d
60327 F20101220_AAAEZL majumdar_s_Page_154.pro
dde6f5e928e3c566cec5e59d62d7bac5
d2a4bc0112f4309bf77fc07442175058d33b041f
80600 F20101220_AAAEBP majumdar_s_Page_061.jp2
443608cee42d005aadae7c8c101f77e7
f5b6868ffd7754d3f65ba297b8a39449d86bd4bf
105517 F20101220_AAADWJ majumdar_s_Page_048.jp2
38fa70d0aa7119bae30926b522851e1e
4b0e5694bc9da1f21809bfe74e366a99d45c05b7
7425 F20101220_AAAECD majumdar_s_Page_145thm.jpg
67591ed0d9506cb62608a8c2917d25a8
ae5fc7da723941a172db05c620cb7b12bb08bf42
27117 F20101220_AAAFFG majumdar_s_Page_034.QC.jpg
93560ea1c8dee64f55743b625f744386
a6e7935250539c63cf3140ae245d93fc57a552fe
7625 F20101220_AAAFES majumdar_s_Page_010thm.jpg
17e247d6a263255ee9bda07a68414b84
b61d62a454b733502e4c5ae451a00ff69c2710e7
63676 F20101220_AAAEZM majumdar_s_Page_155.pro
312a01cf70413fe224b6c4aa0dfb6c1f
b01adb8261e5eaf2115c8a5a12c8eef81acdd174
36620 F20101220_AAAEYX majumdar_s_Page_130.pro
4fafedaaf09fe29b93e25579009c6687
32090b51bca3c6eb3537505576ed75f9402bf24a
F20101220_AAAEBQ majumdar_s_Page_080.tif
6c211faf7404d9bf7869d5c570157dba
401926be8a14dc5ece1f7f5be99db15c48ba348d
105113 F20101220_AAADWK majumdar_s_Page_041.jp2
8d18e18789547eb3ba2b19768de61fee
34001d2e81a948c1f79672f99bfe9077b8f40ce2
F20101220_AAADVV majumdar_s_Page_036.tif
dc42572fe5871c9ec40770b4674c2ddf
2568ed354574278e968b27d2a343ffd9b4e3c938
70271 F20101220_AAAECE majumdar_s_Page_096.jp2
50c9079202c2ea098d5779b296dcf4c0
8d04b4dee41fe7df661a93010f17efee3f11a2eb
7226 F20101220_AAAFFH majumdar_s_Page_034thm.jpg
21aec62567509073d85576945424c101
0bb5c577df6ff4698f44d5783438c06e0fe79302
32057 F20101220_AAAFET majumdar_s_Page_011.QC.jpg
35ce33c4767c654538c275c65247a723
b898c35cced2df5ad698e0bcfcff5b36770c92cc
19020 F20101220_AAAEZN majumdar_s_Page_158.pro
f86d9f88b311726c87013d12443c5368
60693cde33ea52243a86dacbb753c1d7722b1056
39837 F20101220_AAAEYY majumdar_s_Page_131.pro
3d588a8a44ebfc43ae42e7d2864892ee
f03c5ac7ed2dbbae3da893a292d4cbb307809d51
38017 F20101220_AAAEBR majumdar_s_Page_031.pro
91a7a9cb94dd801b7bbfcccb31bd9c39
6e2bb56a11c98555f84cc85ac9e4e21db70e8fd2
98753 F20101220_AAADWL majumdar_s_Page_128.jp2
fa3b8675836e42f6bd504e10f3d57eee
2d1a941b230a09af2839ddb01a62e090c7ad094a
4778 F20101220_AAADVW majumdar_s_Page_002.jpg
9d2da061537f0d9cc8353924b42e916c
37fba43560581856c0c4643fd69e1f8cc88e9d14
7788 F20101220_AAAECF majumdar_s_Page_116thm.jpg
8ebdb35d441460fa7757695c4ea67a0e
046e0fe45adb7f865013a9604865bca566451bff
24822 F20101220_AAAFFI majumdar_s_Page_035.QC.jpg
a8794288e2887c06b82f2f19cf992d79
e0d40a9fb4894f03104ac9f9c220fa6ff6ecb5b0
28241 F20101220_AAAFEU majumdar_s_Page_012.QC.jpg
5807913da65b8ddaa65c0e6aa5447c70
d961eddc813580c6dec851af40b89aa41740285b
514 F20101220_AAAEZO majumdar_s_Page_001.txt
778ab95df0f54527d03bca48cc4a6217
aad0aca143443c6cb0844c259ddbf99dcc9115f0
51429 F20101220_AAAEYZ majumdar_s_Page_132.pro
1573e3de98e14a79ae81fb350b4adb60
a5b244ac7effbbd0b6bd1abf3fcfe617da386916
80481 F20101220_AAADXA majumdar_s_Page_064.jp2
4edbcbc157ca4dd1571e329556c9bbd7
07047354f659e6a6d7fdb0ea8504cfef582e5329
40924 F20101220_AAAEBS majumdar_s_Page_017.pro
e7cb6e7986136cf50a8c3dda3180dd5b
acb126a485c2d77f7aa14125e59c669d0a5d96e7
F20101220_AAADWM majumdar_s_Page_078.tif
6804d3cf91a1961146a0ea1878757505
c17fdba0dd70cae6e2abb09259c0d1656c8daf96
26561 F20101220_AAADVX majumdar_s_Page_105.QC.jpg
d9683d34ff7cfb3838e2d82a914cc0c3
4d690d4f15f9dbf4d78760251d2bc093210965dd
84512 F20101220_AAAECG majumdar_s_Page_105.jp2
920f8f722f7f6400dc7fe0fbdbfd264d
0dc49649ccea6e6e57ecd53499175571dde11fa5
21985 F20101220_AAAFFJ majumdar_s_Page_036.QC.jpg
e09b0d40aaf299dd69f0e372282a23bc
164bbeabb848597c1d6965f040e28169f3566f23
9121 F20101220_AAAFEV majumdar_s_Page_013thm.jpg
b03746d5ec363ccff9857cbb9937059b
31461dafaebaebc7b09f095206c93ef240dd4fe0
112 F20101220_AAAEZP majumdar_s_Page_002.txt
d52a864cea8d269569d60911086c1252
cd14a2d682a3f1dde5f01944d100122cfa310e2b
8101 F20101220_AAADXB majumdar_s_Page_100thm.jpg
3bf200f4ab820a4df9d9c75402d7e072
1a665fa8f2c317e9d27c5b9d0ec789df8d734904
47072 F20101220_AAAEBT majumdar_s_Page_040.pro
087fb0d2fa4dcb732f67d7b26145428c
f52c971ff539beff08d96564f3ff6acf02df6f3b
126564 F20101220_AAADWN majumdar_s_Page_156.jpg
277f3bfcc409abc335b055088316ed2a
7aa8b2af607d8a65a9ec9d2f5cadf6411d395c02
106179 F20101220_AAADVY majumdar_s_Page_065.jpg
7fb45d269523eaeeb1222c0a40290002
e560a5a51d74ffb3d0695393e184a77bd1bb1a69
35783 F20101220_AAAECH majumdar_s_Page_018.pro
91a37431d904a70496225b9455931248
1b25c9e7b3112079a31c9d8a487bcacd728647ca
8145 F20101220_AAAFFK majumdar_s_Page_038thm.jpg
9a598676fe286eece9d9a3779a885928
ec675b32c0cb4ebca5e80f5d27013f74d1f513b5
36176 F20101220_AAAFEW majumdar_s_Page_018.QC.jpg
75d7be4c18a63fb6651a444ff7953021
611bcdfcd3e34ed736b3d7df6bd64f6ced2f12ea
118 F20101220_AAAEZQ majumdar_s_Page_003.txt
572dd4abb55d149550cbd59fa0a970da
104a41dd806de71813b298b9abdadea1a323da2e
92401 F20101220_AAADXC majumdar_s_Page_070.jp2
6aed6fe66fbbe91ae167008a2d08cb9f
9defd5a3669cf6d41d46cec9a198c55b099271d5
35471 F20101220_AAAEBU majumdar_s_Page_093.pro
20604860adfa3e813f63428c49a3becd
dad75c2b18b5d3907c23fed329b4c221f73a8c5b
8973 F20101220_AAADWO majumdar_s_Page_018thm.jpg
bb0dab462b6afd9b4c47bd10e0436cb7
98075477ee866e10abf8b6295d24a7b369130a75
33971 F20101220_AAADVZ majumdar_s_Page_151.QC.jpg
7d6dfe1838c3ea5f5c8bc4fbc5056293
cc723f23eb7b9c6e1ecf0a43f0be78c495942ceb
35131 F20101220_AAAECI majumdar_s_Page_067.QC.jpg
2a729dde8d55ea8bd245fe3e9c4f754c
84877d51c7b97c2483a86132462e5d86689d92d8
33580 F20101220_AAAFGA majumdar_s_Page_071.QC.jpg
81479485cf07a1bcd43bcd5b39cf86a1
d185c06cc11d5a0808e5e0828965f644073b3052
29722 F20101220_AAAFFL majumdar_s_Page_039.QC.jpg
fd93f667ee2b9318f2fb07495c3f8975
19129b31e31e42956a28a929fc5ebc2e91de4739
8655 F20101220_AAAFEX majumdar_s_Page_019thm.jpg
2194c19a91817b431bd9e7299e9e830c
6dffe3fe138d0f2dbbf5beae7fa3172d911f113d
1930 F20101220_AAAEZR majumdar_s_Page_005.txt
3804c80ff6f6cbb9fcd77532f036d0ce
c89c3a62ef014d3af7f5398bbc9ea74cf17d2b41
1788 F20101220_AAADXD majumdar_s_Page_087.txt
5b152c06f76c432672e2caa58d7f2825
dd68c9eac8cbf07d40b2fe08c6333babe9235743
F20101220_AAAEBV majumdar_s_Page_029.tif
6262bfb5f6db6d076607f4910bf75807
399c22dbbf06a6eb291eba26e3d7db5931182451
38206 F20101220_AAADWP majumdar_s_Page_119.pro
8ecceb506b74b53f0a51b0302602d182
554c9cc1513927317190af2f8916eef16e30069a
34765 F20101220_AAAECJ majumdar_s_Page_073.QC.jpg
c2a3a6ed6cb4d9909af1b6e25c7ec305
3a0b5cc7a1adb122a1cf1047e5a4d39a675d8723
34740 F20101220_AAAFGB majumdar_s_Page_072.QC.jpg
6ece67b1ead85b59b862502dad4f296a
7541b920c71a9f94e1785345b9dfb288357f9c2c
7903 F20101220_AAAFFM majumdar_s_Page_041thm.jpg
3f23e956ce9f0bcf225aaf909d4e9acd
5a2199e710ae0512256954a3b67edd71546385d0
8403 F20101220_AAAFEY majumdar_s_Page_020thm.jpg
605189548bfe715d016d552aa5962fe7
f01f847d7ccc07d456262e537655feacff40f78d
2651 F20101220_AAAEZS majumdar_s_Page_007.txt
f3ab7b549ec408b539f3fef7272e2078
8b5fe693cbcbdc8f2e1042e9c67865d7193f2330
8512 F20101220_AAADXE majumdar_s_Page_127thm.jpg
0def4235acedcee6786b420422a72ef9
ece81033ed6adfbb0c5c87bdf9fa413327f10106
92507 F20101220_AAAEBW majumdar_s_Page_085.jp2
defc72dfacf254ba8eba424344cc2652
8c6f2d1051479b3571cea4a9927c44c240c4547b
2028 F20101220_AAADWQ majumdar_s_Page_028.txt
70b66c5169e4a88722e1da3fd14302aa
1f99914f94d4cf0e2f369225671bd3b30e826dbc
79825 F20101220_AAAECK majumdar_s_Page_105.jpg
4c2aac62cf4f74bd826ecb4f38ef6d72
4d12728340428b1bcfd51e33881727e41034bbc4
8395 F20101220_AAAFGC majumdar_s_Page_072thm.jpg
2e801236f942c5837ece18bce595a4d3
6faa373fa0d8e7c065c8f2b797b2c5ea79ca0a45
25522 F20101220_AAAFFN majumdar_s_Page_044.QC.jpg
28d98202101e29ddc9f3aeb3809f465a
20448013111f3fd4f4bddae338ece157fad781cc
18566 F20101220_AAAFEZ majumdar_s_Page_022.QC.jpg
c1deda0e3f716a826e93acca70823908
0ee8bd7505b606105b181f9ac5ead2aed5032caf
348 F20101220_AAAEZT majumdar_s_Page_009.txt
bff11d7ad783c8237684b2b96322079b
a4e046805d91510a8e5b17d45cf6d0798f3fda01
99696 F20101220_AAADXF majumdar_s_Page_100.jp2
ce444f1c18eb7ccc6fd2bb8b844a0cb8
2b21ae0523c0b9d63b0bcda7b707015d95bb0ff6
F20101220_AAAEBX majumdar_s_Page_062.tif
f3f3db8834c0cf86231f6e545d60529c
c0fb3d9d2e4e36cbc4cb7b3bfb3fb085a3fadc36
2015 F20101220_AAADWR majumdar_s_Page_100.txt
94eabd1f353314a7314abedb7d3cb2cf
9ef853737e5a6b95601a8f1fcf45efebb678db2c
5600 F20101220_AAAEDA majumdar_s_Page_122thm.jpg
584d6cc17dab518f21ef5e3c31688b94
0f5bfa2df8b850cd794404be7f64cfb8a32c4b51
1736 F20101220_AAAECL majumdar_s_Page_017.txt
c866f780a130f54d4737c952f94fb707
cf5122b122ea2a0908d3de3658d856dc0474698d
35030 F20101220_AAAFGD majumdar_s_Page_074.QC.jpg
feec273427bac870633c85b005531134
1f6add386baf6dd44cb1f0ea27d89cac14f6090c
7094 F20101220_AAAFFO majumdar_s_Page_044thm.jpg
cb49c8100b6a0e4a11609141418cf7eb
733db4c8ed42cf767b6830c0b029cbf5ca508b18
1895 F20101220_AAAEZU majumdar_s_Page_021.txt
78eb9b8a4cc535009e8759bba96519fa
976f43e3e9c9f5fb898ac5b28c3dbda9ddbbcb5a
570024 F20101220_AAADXG majumdar_s_Page_112.jp2
0864db6fb25cbbe42495d94ad7680431
a5cddb0e8ece425e9f7e8e3ea5171f5ca41c5bb1
104342 F20101220_AAAEBY majumdar_s_Page_024.jpg
d7186611f9037db84fd0ebd8c3102b52
fb7487cc25eaeff4c5ad6ff0025f83395212c069
7703 F20101220_AAADWS majumdar_s_Page_021thm.jpg
b99e0296fe3db854ae24a15363cb1903
672b64ae1a67ecf488a4ed112611b3705ef53296
2234 F20101220_AAAEDB majumdar_s_Page_106.txt
db057ea259636bf0762a29d7ac37b25a
0a057e5a063a61646ee05bb732118617668d2ac5
8542 F20101220_AAAECM majumdar_s_Page_132thm.jpg
156853036cb5b065744d7491070254ae
4fbfff6e3f97087f97484e35f920a82eca4366d8
32154 F20101220_AAAFFP majumdar_s_Page_048.QC.jpg
e27ce1caef1502393f0ce367a65ced91
6b7136bc09dd2b94058ba0d94f0fb38fc6648e28
904 F20101220_AAAEZV majumdar_s_Page_022.txt
a8ce7e6f3e4f41d53212bc01c09798c0
03212c7f4d64e94f8e172882e21167829859fffa
98970 F20101220_AAADXH majumdar_s_Page_050.jp2
2682c3be29ea5be407adbd1927713d65
30a24f1634ef9f18aca9d0b5af8fa9e8d46cd3db
122688 F20101220_AAAEBZ majumdar_s_Page_155.jpg
6e841377522e89def327fe09a4a6e22a
dbb52728fe203690dc967131f876dd2a2208f62c
40773 F20101220_AAADWT majumdar_s_Page_004.pro
513c295f38b6d1e8c3d688716cabde8e
010dd490bba40cfc66715cf4787dd9337b552bb1
1577 F20101220_AAAECN majumdar_s_Page_035.txt
873f34d052202424db7a9b9cde3320eb
63b4d3424089dc287a63dd356df00893083d3d08
25541 F20101220_AAAFGE majumdar_s_Page_076.QC.jpg
2770753a14b14425d512455dc87a282c
f476eb975c0750d611cfa484b260da6a4c6ca5a8
8412 F20101220_AAAFFQ majumdar_s_Page_051thm.jpg
1601cb02f539469f29396973095eeada
52d3d72fa7b6dcd65d9c094e3947903ca88ecae0
2012 F20101220_AAAEZW majumdar_s_Page_025.txt
de91afb7e578fd7bd8eb40ba1b1e228c
adc5040d593736f594e120ba0653dc02c6787611
100088 F20101220_AAADXI majumdar_s_Page_048.jpg
c5d162812c6725b85ac0ad91878183af
6d091dc5f1d75af0358b4198329ae969e58b62c8
F20101220_AAADWU majumdar_s_Page_059.tif
02203df263b734b2edc6e4db375b60e0
cd065360773ebcb350a61b6f3c84a1bff27a537d
F20101220_AAAEDC majumdar_s_Page_086.tif
d71468abbc0d0c98bc83881f2b024187
d12a0997dd1d34989f074452ae869263bd412988
718 F20101220_AAAECO majumdar_s_Page_062.txt
055f337a1e6c6275a325bfe917cd4b17
4f6de15e874813faaa02f6371832c14cc7b64857
4019 F20101220_AAAFGF majumdar_s_Page_078thm.jpg
b3bba8fb900321dde7c0bca6c3844e29
d68c8aae527b5d7bf16c360b811e9f964b0cad32
28428 F20101220_AAAFFR majumdar_s_Page_055.QC.jpg
1108e465af67e5c1265424d894ba48af
90b17e9337b29cb492aec871891bd0e3e2fa8313
1681 F20101220_AAAEZX majumdar_s_Page_027.txt
8b2d993928a10600535a645ba7458337
2cf00b177e3e7c6c44303178a47c2f2766cc8d3d
129719 F20101220_AAADXJ majumdar_s_Page_150.jpg
c36146cdd4bed42ff9118faf4b0ac73f
c331ede1045f2864aa1e123b3f036530a88361d8
131781 F20101220_AAADWV majumdar_s_Page_156.jp2
75602bd86d38604e1ec48bbcd7b395d8
b5f6c8ccfa625c9d61e6a3006acda18a86651e62
103329 F20101220_AAAEDD majumdar_s_Page_121.jpg
828b972be05d032940ff488dbb36f603
86dc95324397595c2a8fc8a09b1c3f8c798b4da5
F20101220_AAAECP majumdar_s_Page_033.tif
5321a8b00a7148e34253b5f25e121097
2d17db70c2749d891c2a2f682c04f7ff767ebceb
19950 F20101220_AAAFGG majumdar_s_Page_082.QC.jpg
3faeb1632040cca25155c0250ca8aa42
c61810b73e2a2b98d71afe9a4e49497b447ebb36
4761 F20101220_AAAFFS majumdar_s_Page_056thm.jpg
666b5eb6a72fca4e0e77ce21c87cb3d2
11021c0fb13bb875003865c448159dba07ff5d9b
F20101220_AAADXK majumdar_s_Page_073.tif
8f7bc06d5d62c4c56da6451bb625c931
b689dc8c4fa6be09b52b8a969fdd73a0ab70bb63
100635 F20101220_AAAEDE majumdar_s_Page_115.jp2
42f42c7ca947f8edfc124759a3cd6874
4b8940182f4abb0a219f35c9d8138920558645d1
703436 F20101220_AAAECQ majumdar_s_Page_079.jp2
5e85bdfb3bd32d36a5fbf8cdbc0d3725
36588355a0eb5483de6a3466dfd6123dd1135a64
5979 F20101220_AAAFGH majumdar_s_Page_084thm.jpg
b00192cb65ac60e820b5a19f81ffd2c8
c8fd0f009282ee2737e7cfa07dbbe6937a42a1ce
7591 F20101220_AAAFFT majumdar_s_Page_059thm.jpg
41115d4495996d4dd58dc7919040b6bd
0ce337142430dce31660f29f010c8be6f5796bcb
1247 F20101220_AAAEZY majumdar_s_Page_030.txt
4baf613d0bb1286cc49d9a4320f1a8f9
649ed8c2607faeb6568feeabcd8056664326994e
8554 F20101220_AAADXL majumdar_s_Page_052thm.jpg
fa62341c68d3408c7ca2b1d8c0aeb915
548bba6e89b3c75287d6d4663bde2a61ee6cf121
1859 F20101220_AAADWW majumdar_s_Page_111.txt
fa482b959af36f903dc87ca45d4cc67f
4d7100f9fd26c12504ec3f2202f0fb843bb27f5e
7447 F20101220_AAAEDF majumdar_s_Page_090thm.jpg
0238e1c155e57d6a51e5e2b6dac79337
7c077209bda0be886ba69ae16c1d1549ae1754b3
24523 F20101220_AAAECR majumdar_s_Page_031.QC.jpg
6229004a13cfebe11e2a9e973181da0f
9c103e3cd25d2448711c480becd4bb3f035a4ffc
7142 F20101220_AAAFGI majumdar_s_Page_086thm.jpg
f3339845dd74783d8c6e0331202454f6
5aaef12ccd79f3173440b541f83896382af17c82
15749 F20101220_AAAFFU majumdar_s_Page_062.QC.jpg
961bc8b5ecdec1ae304802bf3ac29701
883eb0bd5e37f9f66fe97a947d632aedc8046fa1
1682 F20101220_AAAEZZ majumdar_s_Page_031.txt
0631354500109f119449315103f5cf50
8996043dcf1929560dd228dd73d2032e47429dda
31348 F20101220_AAADXM majumdar_s_Page_081.QC.jpg
10255aff95c8be5b803f7d12bbea9ede
d79ce5a331dec9a82f84239e88c271026e2bda47
24610 F20101220_AAADWX majumdar_s_Page_030.QC.jpg
363de6c1440f4016a82286a4c2506d16
31004e4115ba605416f5e1d039c584d0912c64f3
F20101220_AAAEDG majumdar_s_Page_040.txt
8b86279da354fd0c7a316f8efcdbf83b
d0ca04bbdd87211a49094c6a624f4473f7250066
4460 F20101220_AAADYA majumdar_s_Page_080thm.jpg
1d11661c7096cf0f6380626cd43aafbb
5ee60b00c912f401c0de9665234fe457023b86d6
61012 F20101220_AAAECS majumdar_s_Page_157.pro
a90f54c56f695c9da3a588b7a499faa4
82e3fca8a697dccea0a3676ff24a95c0cfa09c65
14932 F20101220_AAAFGJ majumdar_s_Page_089.QC.jpg
d1c9bff0ac9e1fa2ed3fd509c7a5ccb5
1d9dc68bf02da291c2c3e034895da811cfde9ac0
35121 F20101220_AAAFFV majumdar_s_Page_065.QC.jpg
b5ddd4a2c8c4ccd51c093358e86ba96e
ea60a6d15a8d4aa7c3d48dc96c1f7144d4a298ac
92654 F20101220_AAADXN majumdar_s_Page_026.jpg
111390ab7e479dcee0724edd1a0486e6
e7ebddab390c780ca77b9a2d13012da7ee32c8bb
7376 F20101220_AAADWY majumdar_s_Page_055thm.jpg
e3a2720aa8dae1ead984d93534efdc4e
e534cec027278c466d7b227a85bbda63eff0755f
45227 F20101220_AAAEDH majumdar_s_Page_050.pro
b3f6f610d6ecacfceae72121de9468b2
2210fda35d1c0dc9709f0587e3c032f33f240745
F20101220_AAADYB majumdar_s_Page_081.tif
0fcfde180cb067c4ae79f0046a88d7d1
c638d62af902b2754247176babe63e9dfa6da46b
46006 F20101220_AAAECT majumdar_s_Page_139.pro
429afb11e57e7b84b2628fc86a0af707
dc765cb8146536cab9a60b17afe00277378d91af
28272 F20101220_AAAFGK majumdar_s_Page_091.QC.jpg
73f1175341494fc0c365d2dc1685e743
0a482a24a5a53010984603f1258915bfe05c28af
8189 F20101220_AAAFFW majumdar_s_Page_065thm.jpg
6a520f903a20a3be7f4060ecebcdbd12
583e74fcb791a13543facc1757162b0b4f43435c
81926 F20101220_AAADXO majumdar_s_Page_130.jp2
61a125f719fae6451f57659c4078d2e0
6934151f822053fad6eadffcfb9a5ca657e2f46c
6473 F20101220_AAADWZ majumdar_s_Page_079thm.jpg
25996705eaa4e69b056cc83d4b338a43
1b4b5c74a1739b351cabd01674e57084e3c74c1f
31220 F20101220_AAAEDI majumdar_s_Page_029.QC.jpg
3e3b6e588444d3c9198c32c28876ef2e
990ae16c03005fa0dba56d45476c2b51249be98c
99170 F20101220_AAADYC majumdar_s_Page_005.jpg
782e57878e2452ff6fb8c1252259f878
e95a8b6e848ec7c6655871017bc5efe9b126fb88
1628 F20101220_AAAECU majumdar_s_Page_141.txt
fc8351026423e3b8eaa07147ae3e1a19
22891da11614afb6024abf8fb05f80bc01becc97
26575 F20101220_AAAFHA majumdar_s_Page_120.QC.jpg
6593fcf7043c90ac423bdacf8b8abc1a
38bad950da75ac883372426a068cc81de8107434
7241 F20101220_AAAFGL majumdar_s_Page_091thm.jpg
dabf245262673f351a5adc8689f6e5c2
789ad735200b3b5872f032381599dbab2e59cf96
34905 F20101220_AAAFFX majumdar_s_Page_068.QC.jpg
8a6baef6cc264ae5c1811326c8fc2b97
b3dcae1ce6d91b3b97e7001388584079982bcad0
93329 F20101220_AAADXP majumdar_s_Page_128.jpg
2da465747ddabc7bdcc725e4eebb3d1d
3abf437cae3971fa7531a04d20d0fde5a9796481
1546 F20101220_AAAEDJ majumdar_s_Page_113.txt
cf16a4b5d4db70fac81a7bb4527e13c6
715f03794d398ff0203fadc4dc3637144c174d32
33793 F20101220_AAADYD majumdar_s_Page_020.QC.jpg
472651a80dcf34b180f5597f8ebc512a
8709deb82315819467d132daf03a5387a1edea84
131811 F20101220_AAAECV majumdar_s_Page_013.jpg
1c6c383ad3c024e97efdeebc4c60b2ac
153ffe3c21d9c39ceae004aec053f67ee2a084d8
33572 F20101220_AAAFHB majumdar_s_Page_121.QC.jpg
882a5ec903f9da3f4ffdf0715510e81b
d6bf9feab3f27bd86225c4eb1d1c9e0c911fa46b
31095 F20101220_AAAFGM majumdar_s_Page_095.QC.jpg
27c57c4b6752b121975b5b4553434c81
4c3d0a95590a9e604a4ce55e28fb09952d469150
8397 F20101220_AAAFFY majumdar_s_Page_068thm.jpg
83046f56a1d678933e23be0f247a7b44
8740fde49b4fae48d3ae82f007e00319a9855925
F20101220_AAADXQ majumdar_s_Page_018.txt
e1c8eb810124cfa3e12a76f7d6799796
61b2ccd823687f9c1a0706c99203fa809052e88a
6479 F20101220_AAAEDK majumdar_s_Page_007thm.jpg
d613637ce4f433c19807e5d224637372
82ce1b957c8df982e31bf05dffec0bc25b59d380
30295 F20101220_AAADYE majumdar_s_Page_142.QC.jpg
795274005d9a7945b814f2d0c225e0e8
17a5b282342b1feac144e26982dcedbbd33673cb
63710 F20101220_AAAECW majumdar_s_Page_156.pro
99c880253c12023aefa2b6d8dce5ebb0
7f82cc015731d207694d58ff865d616901fe8d3c
8422 F20101220_AAAFHC majumdar_s_Page_121thm.jpg
fc5c548bfcf877152b5a8287383d4ad6
37540d8a6348cbeb5f846046402ce9f5915d757b
32194 F20101220_AAAFGN majumdar_s_Page_098.QC.jpg
c5a4d63e7fc705afb913b8c268e16fd1
64416f7e7f0c4bc34a8685774422d4b80020d1de
34072 F20101220_AAAFFZ majumdar_s_Page_069.QC.jpg
c6b6179e447ee690dee5cf8e416c81a5
6cffa8ae5b3d88bb3fdf6fd91783f38ff35d0881
F20101220_AAADXR majumdar_s_Page_154.tif
144f58cd661c6dc535a082b0359d8b91
2b5d1acc720b1ff89d97c7314c3cb81c83884e1c
F20101220_AAAEEA majumdar_s_Page_101.tif
cc8210413bc2f7de120e6fdee68be0a9
5e10c2b1a40c43fd42830c96c19e79f03e7b4580
6799 F20101220_AAAEDL majumdar_s_Page_064thm.jpg
8fec7d8e5442713dd66855af13839b9f
ebbf24eac2fd8a4ce3f7eb7ec0c5e1731b6f51aa
F20101220_AAADYF majumdar_s_Page_096.tif
9f902c3c1def151d92d4d5200d744d7d
b3d086198882d8338ef41560363107ef5373f6a9
29006 F20101220_AAAECX majumdar_s_Page_102.QC.jpg
56abb98f5d69b59ac945a785ac7f2f45
59a9c7e5d2c083824960bf7b0fb10610ff77e2f8
22742 F20101220_AAAFHD majumdar_s_Page_122.QC.jpg
1b91627e5172eda272814d8fc59e5301
7ba24c6c21b72bb92ceb8ac15d7c367ea0804be8
28308 F20101220_AAAFGO majumdar_s_Page_099.QC.jpg
04e1c367e85b0db54a53393ef6258534
a34fc61db8bda84dc4878ac6827f6cd0537e5ba8
91862 F20101220_AAADXS majumdar_s_Page_118.jp2
576c1e2f639fdb2208d97e9227513b8f
d60aa4b4c7a90ee165cff32b2b499545a295278d
19808 F20101220_AAAEEB majumdar_s_Page_023.QC.jpg
91abbdd8d87fa0889d8cd9483fd5a180
23aeefd6de65028c816e092f2e3d632e809bbf6c
1813 F20101220_AAAEDM majumdar_s_Page_045.txt
820f9c5e941e155de26b8b30c381ef1c
ac1e0e2445f85f6f30350925461a65d69b4cef28
61138 F20101220_AAADYG majumdar_s_Page_149.pro
f918ecfc684d421e82a686d54c3da21f
5e0e47cada5e168f45976b00b0afd7c67d3387c4
45686 F20101220_AAAECY majumdar_s_Page_092.pro
7fc1cf4fe01d55a03a9f2bf1cb41a1db
529de54c627fd36a2507c2ce3d3c1c16a3222105
25148 F20101220_AAAFHE majumdar_s_Page_123.QC.jpg
a8e105adb301dd8e558b27a843520514
9199326acbbc14a345bf279f9936ef8f177342a8
32113 F20101220_AAAFGP majumdar_s_Page_100.QC.jpg
7a07ae5a2dd5a0a572df78d139446355
7328567528d3e5c09733083d8c95dbda6e4e7447
6992 F20101220_AAADXT majumdar_s_Page_004thm.jpg
b7101e61a9f13b8c7ae11c1fc0a5a770
f9f1a2cd120ae648caa0f181d098a3a8628b4bfc
5319 F20101220_AAAEEC majumdar_s_Page_042thm.jpg
4ac4036aab2b5f65c7c660db2062513c
2d37fdb2d1436b870c7cabe05fab7bc60e4a25c1
8139 F20101220_AAAEDN majumdar_s_Page_029thm.jpg
0ab5ab7d4ca3fba28882b46b6d630fef
9e7a7dbc7dbf9f96c63e7c20c5177d5f350fedf2
31306 F20101220_AAADYH majumdar_s_Page_117.QC.jpg
d19eb654eacb7fe5e8778b25acdf57f6
71eb6a6b57ebd124bea86bfca144bf5e4748db0c
F20101220_AAAECZ majumdar_s_Page_124.txt
f144c23ba2df074d9bd06b3527ce3b45
60d989c2d4a55ff63c678036524ff4a365d8df7d
8249 F20101220_AAAFGQ majumdar_s_Page_101thm.jpg
e51965728f8c9968d4c8e8062f559c6c
2a1ef8756f957949fccde3ba7b332109c88b67fd
42333 F20101220_AAADXU majumdar_s_Page_099.pro
61e52139dcbd35ef029f1ef11d56322c
93694299597d869919be3c55c443e11c0a4ec987
55511 F20101220_AAAEDO majumdar_s_Page_147.pro
13c2752c4b0793c33a6378c55a0a9787
c125d16a18c7483fe7a743887c6dbfa87c3ca419
F20101220_AAADYI majumdar_s_Page_055.tif
dcd2396b73d058c88df7defb0d85da99
d116b59ce749e734a8c58ab516ac9227a57f6fd7
31543 F20101220_AAAFHF majumdar_s_Page_125.QC.jpg
de7ca86b234e64b67d535540f8a9721e
2fa1405b9a46f6f7674b9668621265c39d941d0e
7202 F20101220_AAAFGR majumdar_s_Page_102thm.jpg
b8946c8f501a14bf46faefdb8ca8472f
50b150714e831d97fb4977a8af20ca834acfac21
F20101220_AAADXV majumdar_s_Page_060.tif
81fc066dea53107b693c39c64708d3bf
7313da2a173a7d5d9576e7479da5cb5899cc2768
100477 F20101220_AAAEED majumdar_s_Page_066.jp2
5b12f416cdbbe0676ebb2fbb0b52ed28
db0b7679aa6ccb471b8957c08a057d8dfcab7b99
98287 F20101220_AAAEDP majumdar_s_Page_142.jp2
511cd4e40901a4a844c42fffa9c273e5
987c0cb895fb711890f151748d17c22285604fee
96448 F20101220_AAADYJ majumdar_s_Page_116.jp2
32977f914b3076e1bf3d7a1135dfc13a
1235871b63b5ee4cc16b5332d336e3039b0021c6
7992 F20101220_AAAFHG majumdar_s_Page_125thm.jpg
985cbc611d6dcfc36e2043b4bcee55bb
c215f97761b034e395c9b0e13f861c0b5439530e
32995 F20101220_AAAFGS majumdar_s_Page_104.QC.jpg
8e905a7ad1789187ba2243e521b1312c
e83a867f3f9a798773048c7d8b95b5734005765e
27089 F20101220_AAADXW majumdar_s_Page_129.QC.jpg
b51cea132f349651bca33b4d81b45969
58640e3a879abc9c16625d705c16ed0e142bfe42
109822 F20101220_AAAEEE majumdar_s_Page_132.jp2
1bad0e8933ce76e2ec9efe37f5b684f0
626c99109c19a05ef6493df1699a02f9b0ed5c16
360 F20101220_AAAEDQ majumdar_s_Page_014.txt
5b4b6a8ef118834cc94ec58039eb51d9
693c6bd05c2da91bd03a998cd5c483581d93009d
5119 F20101220_AAADYK majumdar_s_Page_082thm.jpg
50f2974152d47cf793f89ac0542c2c06
866d0a89a492b6622d8c3238c6d1770271479184
29446 F20101220_AAAFHH majumdar_s_Page_131.QC.jpg
9549062bfe71706f66ef4c580731f4ae
a231f7428b44ffc7eb3f41ed2428aab02679ce49
26148 F20101220_AAAFGT majumdar_s_Page_106.QC.jpg
f868e21f5a0f505554efafef94dd8df8
a64b7ff08c33d3091aaad2d8b2633b2aa4f0a794
93236 F20101220_AAAEEF majumdar_s_Page_107.jpg
27f30fd19eda2fca01af5df6a307879e
98531edc7ca0ad8fd698cd0e7ce1485f0744287b
103826 F20101220_AAAEDR majumdar_s_Page_143.jpg
e39e977d3cf2d73d1a9f145801ac396d
056b2a01dc3e28f83ed875ef610ee40a626b799a
36967 F20101220_AAADYL majumdar_s_Page_013.QC.jpg
6735335727f5ec7a7b20d4df5ad001f9
a1bb8866c690b2d84f15b02849c8ef2deaf895bd
7251 F20101220_AAAFHI majumdar_s_Page_133thm.jpg
edae3cfd87fb4d055283f1a050deb8b7
b79d6b9d600fd51b75e6e6a06c18abf9e690c8a7
25386 F20101220_AAAFGU majumdar_s_Page_109.QC.jpg
8efeaffaa1577b32509d399ec88e53c8
23f049616c0f8fdc50ab97d94aed3e501ac56e78
42233 F20101220_AAAEEG majumdar_s_Page_142.pro
2fe4630ce854f6b5796ce31d59251808
a3452c2e9f9bbe9c94fa160da52b29ec05e992ed
F20101220_AAADZA majumdar_s_Page_119.tif
a6d545df6ebc807a116bbf22c1f542b6
a616c01fa9e0bb57d2a9b1d9b26afab0b9144ce1
33293 F20101220_AAAEDS majumdar_s_Page_147.QC.jpg
9262ae53a33b1ca7050e672d3eca0bb4
3c1576e9564ecdd445439ebb788b56115d5e1600
7391 F20101220_AAADYM majumdar_s_Page_095thm.jpg
968d9ea5b0944d92b93dd34176cbb6d9
c8d29898a1987c627301d686409b27e30c6c7445
1967 F20101220_AAADXX majumdar_s_Page_073.txt
3f072780c6bb3668632d6d00dffb08ac
0a02123ea2e1613b5cc2a2d8a2c31dac7695f8d7
25096 F20101220_AAAFHJ majumdar_s_Page_135.QC.jpg
98e20e5d9ba021af9473d7e118b0497d
387a1f21fa8f3b86696238cacc458a102c57d28e
8082 F20101220_AAAFGV majumdar_s_Page_111thm.jpg
9a15c8f1fe446a57812a3023b50da6eb
709f212a5fb97a4856828650c0a4a5beffa719e6
F20101220_AAAEEH majumdar_s_Page_005.tif
41b486007033265fed566009eeb68f7e
d908c0c3bf6a8810e61186cea3906e16b287700f
116946 F20101220_AAADZB majumdar_s_Page_011.jpg
e6dfae8aad0b20dbd8237828acae780c
9d5c790cac26e1154a3177ecd0a36ca136c48e34
8486 F20101220_AAAEDT majumdar_s_Page_071thm.jpg
ae40611b38246a415a8fade22e29d503
444817da90125c6eddb68b6454cbd9465bbcc44e
1802 F20101220_AAADYN majumdar_s_Page_131.txt
3be7eb56fe72feda8a902b4518fa1b2e
cfb618da5da74122bce41cb0aed884afb3be673e
F20101220_AAADXY majumdar_s_Page_021.tif
10f26343d8e4c721ee83becde5682473
45d6fab3adb1a317d0c27889b550d4cd40d6848f
6523 F20101220_AAAFHK majumdar_s_Page_135thm.jpg
ee7d0131616d40a7eee089d8b5df634f
4518c2406c973f3f3f847092a73ac4a059508540
19526 F20101220_AAAFGW majumdar_s_Page_112.QC.jpg
d4989ed948165fa1cbb240f8d91595ea
308575aecaf7dd041193a190590cbce4800a4ffb
2163 F20101220_AAAEEI majumdar_s_Page_010.txt
0cbd8d12487b197ed76d71c2258f74ad
6492f99a6b0ee2219ccf450ce5cbc64f088d61d9
18719 F20101220_AAADZC majumdar_s_Page_009.jpg
32abe0d47982334811314a9357d7eebf
e472cc5694c3191778c06a8e34fb0b5e3454bc6a
F20101220_AAAEDU majumdar_s_Page_037.tif
dbc8074d6aa6616566136ffd5301feb4
648218d551e2a715db6dbfad0e999ff3f1f6eae7
77042 F20101220_AAADYO majumdar_s_Page_093.jpg
ac211fc469a49acc36dda85eb031ddc7
30d624099ae74e921dc2a413cd6672439672fe66
23625 F20101220_AAADXZ majumdar_s_Page_046.QC.jpg
d521d24216788a77d75f341e92e8f3a6
9c06a507479676a489dff29c2cfe35f3d6e392c5
24004 F20101220_AAAFHL majumdar_s_Page_136.QC.jpg
3befe422a0208b14d88811465ed36360
a00a45c5afe10e6c943048ed2ae1fd97bb7a241d
26192 F20101220_AAAFGX majumdar_s_Page_113.QC.jpg
a61d62428f310591e2b40f8594d1e5fd
80d07c85bb51bf78e11fcaca8af6e15f071a7fcf
F20101220_AAAEEJ majumdar_s_Page_072.txt
f4fb63cb0b04a0bf6bf69f9a7f477391
79c6a7e482c92062d5aa7428f128ccc206b382a6
23663 F20101220_AAADZD majumdar_s_Page_079.QC.jpg
22b9ef7b137704cfb984515de355e6d2
c24ce6ca5ba4c6dd7f7046ffa73cd871f5201ba3
44088 F20101220_AAAEDV majumdar_s_Page_117.pro
d6a4c334d9202f30e6a82d702130bde7
07c6e61718357ad189fd1a5012c87837b89957ec
F20101220_AAADYP majumdar_s_Page_026.tif
9460a23e5b44928dbf82382b7c4627f5
5944f0d668bf855824095572260f2b0a58d502f6
29148 F20101220_AAAFHM majumdar_s_Page_138.QC.jpg
a77d50c6679cfafab1d639c3aa1404af
b0d97d580e0dbd2ba2910c3c4748712a3bb0e733
29284 F20101220_AAAFGY majumdar_s_Page_118.QC.jpg
06ee4ce056e23c6b239a22d2431b9ae7
1eec7b382af4794ab487eee2f9f922c5029bd83d
F20101220_AAAEEK majumdar_s_Page_130.tif
aaa431d91f328258d82550a41cd74749
f4a94b73cd9856371b9bd15c259ad761af2a92f2
8927 F20101220_AAADZE majumdar_s_Page_155thm.jpg
b5b80de3126aa69423dddd4cf9997be1
62944b84ed314ec2be900cd772eddcbb68bd38bb
94700 F20101220_AAAEDW majumdar_s_Page_037.jp2
2165ffe5cb22ad0e5a09f2d9ef85f7a2
c6057a87e621487e53a37c0c4b39b30ed50eaa4e
3772 F20101220_AAADYQ majumdar_s_Page_008.txt
5778209b348b3cb024e510c985cfd7ed
ed48b17cbe364bb0fcb0a37c88330374f78bb4f5
8156 F20101220_AAAFHN majumdar_s_Page_139thm.jpg
9891caa0499af2fa59e8a7d6fc788391
8617e540f5b5c96d102b972f3fdfcc3fade3c570
7249 F20101220_AAAFGZ majumdar_s_Page_118thm.jpg
919fde1fb4572e38f8ab7ab9c4669e91
2c2bbbb3addb1871635727244764b9165b1c672e
18780 F20101220_AAAEEL majumdar_s_Page_058.pro
c72e8f629baa935c16ae5260245eb17d
55204721770d1831ab48ffdbb6520cfac0e9fc5e
103825 F20101220_AAADZF majumdar_s_Page_134.jpg
471f54cbd3ebb824d6eaa7e39f68e668
63854323cb60be886dde2252deee212823938af9
28863 F20101220_AAAEDX majumdar_s_Page_085.QC.jpg
39aa903184506253451e989c259aff42
5691cfe85df945d43fe8a419f963fa319240dc23
626 F20101220_AAADYR majumdar_s_Page_002thm.jpg
37caea458c7a86c49e9582661fd6bcd3
4c0657e7b2a45de12fbfa6d2481cf43c487e7c7c
F20101220_AAAEFA majumdar_s_Page_087.tif
5d12305c4f3d2c7cc0b320b7160f8e7a
bf0bef2c92cb33d033b73a32d79538f2532bebbd
28347 F20101220_AAAFHO majumdar_s_Page_140.QC.jpg
1dc7f647f12db58a187375acdc5fd50f
cf4ba563c999f3a848bb75f5acf76976f88dea06
F20101220_AAAEEM majumdar_s_Page_023.txt
51b93b17a97ad776123da482f3c6ec1f
a2b8a671ae476af4db28ef224b5d6a410b78a4d5
1228 F20101220_AAADZG majumdar_s_Page_056.txt
d6841708054aa8532069460660b7985a
278b65dc90c0c07b20b905358183361bc596ba7b
103461 F20101220_AAAEDY majumdar_s_Page_097.jpg
3dbe65cab0d1cf8daf4508ac6f8e62d5
ed2683d700687a946a177bf07e7980c7aa79abdc
130605 F20101220_AAADYS majumdar_s_Page_150.jp2
5321b7db56d7b51e87e367a5a1d3c5a9
4fcd5cd7bfcae9c20ace6ea890e691806bddd838
156528 F20101220_AAAEFB majumdar_s_Page_008.jpg
436d8487875e897f83abe35349dededd
d9f8a70750e87e9bed3a306a424d5dc8cb2f6bcd
26776 F20101220_AAAFHP majumdar_s_Page_141.QC.jpg
d9ba81862d2eabad9e0e458e39566c08
8d0b5458d3ed3f380373646ebd5cb11e0e46d9b0
1839 F20101220_AAAEEN majumdar_s_Page_064.txt
ad34f7c488e2342ed20239ae828776e6
68fe24ad4f6a095a1c873c958575b2cb45b13c35
F20101220_AAADZH majumdar_s_Page_044.tif
eeaafe37b03abc7436651dac12180c59
80ca798641cb8dcfddc9c82150c6b620aa133f1a
F20101220_AAAEDZ majumdar_s_Page_083.tif
ab2616b882cf58b6261d03f59f2a4c14
cdf28c742b1b7ad554b848dd844e04af446b7140
84551 F20101220_AAADYT majumdar_s_Page_049.jpg
69743735857560c6fd2c358d7de8b5e8
7ad9cd9cd7f4abae9230b5212cb507e807c49cf0
6619 F20101220_AAAEFC majumdar_s_Page_076thm.jpg
af7000ae3196f79ccf20b714dae766aa
80b3db8ad7631ec45aa11fed41c2e6958fe09adb
1862 F20101220_AAAFHQ majumdar_s_Page_144thm.jpg
e4220c856ab350c180dea12e480354a8
3afd3f803ac1ba96004429f8dcb315a1fc5d1263
53820 F20101220_AAAEEO majumdar_s_Page_051.pro
780acd0e587052edb6c24216aaa31716
fc19e9cdb3aee4480e530171b92571b3709181aa
2039 F20101220_AAADZI majumdar_s_Page_052.txt
665bad3d4d614343bdee65c9c7fe62fb
e510cdfba6d1c08061b43282d122d3fdffa751b0
27146 F20101220_AAADYU majumdar_s_Page_046.pro
8ff4b9f347478194f2de8ae7816c6ed0
15966e30d5addb4fb7815c70f4a20a14f5cb163a
8167 F20101220_AAAEFD majumdar_s_Page_097thm.jpg
57571b66567cad2f1e43e9671df80a35
36e5c274c9a39a911cf96caa499698892d29ea7e
8166 F20101220_AAAFHR majumdar_s_Page_147thm.jpg
73ecdb9b9c3f78d3195066bee9ca6bca
e69f7f13f11be8e9a32e90792b1afa22043ea630
16390 F20101220_AAAEEP majumdar_s_Page_042.pro
0159bddbc695bb4f57235e330ae21e84
820579a48da9c04799195a82b4bb940b04d16521
6966 F20101220_AAADZJ majumdar_s_Page_106thm.jpg
dd494607b5f7e1362e0afeaef735915c
f16dba97c804bd787d06936ff10b72475b207042
2704 F20101220_AAADYV majumdar_s_Page_148.txt
63aefcdb7b9530dd7f402c0cfcacaad2
f0082f1ec7cd6eccd3c1655d098d62a93df9b8c7
8931 F20101220_AAAFHS majumdar_s_Page_148thm.jpg
221b193a19ee06c4cff981108f5ca139
e88c8eda0e92f4ffe0723927c554facd92a656c6
86106 F20101220_AAAEEQ majumdar_s_Page_091.jpg
a0acbabec46042ae49eb3a098d93d219
8ed850281ce79a5262958d12189618b88d20b74a
31262 F20101220_AAADZK majumdar_s_Page_092.QC.jpg
07f824e2ec1486220306c05412ce1482
5eed031df4dc9b3abe3e8838120a2782d0a79d6d
1964 F20101220_AAADYW majumdar_s_Page_065.txt
ccdc2e08edf93c2abd625b6596d4fb1d
60f7aa059dcc803489de895642c9311c2e4c17ea
1937 F20101220_AAAEFE majumdar_s_Page_003.QC.jpg
ac1b27ec5eff9e2b88573c9d5f70a535
fcbd4052626e424de4ca5745b4cc84d04e81f07f
8541 F20101220_AAAFHT majumdar_s_Page_149thm.jpg
93ed293b2b84d43dea7764dad9ead726
75dd9ea2a102923eb745e4f7a7abb2506ff37c8e
106751 F20101220_AAAEER majumdar_s_Page_067.jp2
06da62806b00782cc8ac16eeda63337b
c01ecb9dc471370a1479e9c64a8f9174aaa83577
48746 F20101220_AAADZL majumdar_s_Page_005.pro
86c2c418a8a5b19d1105941bd37ff8d0
ff1e063fc5494b9e8acaa54e9bd891eebda7cbb9
104974 F20101220_AAADYX majumdar_s_Page_145.jp2
ced2f64266ac355285ab51f19edfc40f
a8be428ac96a4ec310c26fe5521fcc44ef07f40b
8012 F20101220_AAAEFF majumdar_s_Page_098thm.jpg
6d33e3e55b6ef783d57d7d78702fd020
68eb904364c7aa048d2b3bed510d642a185d7718
36533 F20101220_AAAFHU majumdar_s_Page_150.QC.jpg
eb6d9db31e4f5f50884c0048898cb9e9
717a578c952a57046ea96dd09bea9f3f41522a19
45583 F20101220_AAAEES majumdar_s_Page_081.pro
fd8c6ca10dab9e2159204387f85455d9
49b98ab53d33bb1f91a2ecd26953f46f4d938e20
80454 F20101220_AAADZM majumdar_s_Page_034.jpg
fc8e7e7de5271e3ee18dd5912eb5dd34
a407cc8c97bcd5804e93e45f2ae6002a6db71160
21350 F20101220_AAAEFG majumdar_s_Page_144.jp2
615c57b53f3f76364929d7380d114571
39da93d3a8dd35adfe34c13e7bf68218b2b770fa
8323 F20101220_AAAFHV majumdar_s_Page_151thm.jpg
3357a4cc80dade644e504bddaa6b4c95
b5016404c600b17a2d033d2865b95a4c3434d012
34080 F20101220_AAAEET majumdar_s_Page_052.QC.jpg
523689602bf2296224b7faab5cfdbf10
454b9f29da88cd32a38c7a5e0e32c43798066afe
78916 F20101220_AAADZN majumdar_s_Page_113.jpg
aa221f388d6aabb86b83591d8c0aefc0
4f70314382c1d8ae93d5018567a50e1616484877
8186 F20101220_AAADYY majumdar_s_Page_067thm.jpg
3f01a91d89df92eab8019e7a3e30a0da
8c9e260eb0c411e1463218ce6cf87cb6dd387faf
2282 F20101220_AAAEFH majumdar_s_Page_051.txt
83072eca96ab976522c2125774897f54
dd2f1d7db89faf3bedca91ca9b7bd6ec75b62eaf
8737 F20101220_AAAFHW majumdar_s_Page_152thm.jpg
098203b4d2896badc433ab198a74fd32
7d76314e07d553450106aad121d09935e870260a
F20101220_AAAEEU majumdar_s_Page_068.tif
68d264f6e920f07ebba70caadd492661
ee30419db048b95af55b965cdc3eb2ea579fcbc8
F20101220_AAADZO majumdar_s_Page_124.tif
5b4b8ba3e2364f59207c5c69550e8b10
1b818703c730eb74ecae427fc96af207a622ec70
1775 F20101220_AAADYZ majumdar_s_Page_117.txt
10ed24d82432dc8b17589a5ead8f1a6f
ee9b00fbd9b22e73bf6a8424a2d73cacc58ee129
8216 F20101220_AAAEFI majumdar_s_Page_126thm.jpg
2b3fd6dcd3fbd10baf61313764e74ce2
53a3801f7ff588e179ca3b49d86ae4493d650ec1
8576 F20101220_AAAFHX majumdar_s_Page_157thm.jpg
af8c8320fb46aad54564ea4548f46008
cbfabbd3da14ac1dcaa31a61cce11466d4a08504
105033 F20101220_AAADZP majumdar_s_Page_104.jp2
94a716d612090b5a4665377e1e6d3ad7
e20d4af58a00329d8ce96a9fbf0ec439e95d042f
F20101220_AAAEFJ majumdar_s_Page_115.txt
f59bed26fe883dd9b1d734b1f0477b75
89dd80676d3394381d1347c574a749e13ab052a0
1661 F20101220_AAAEEV majumdar_s_Page_009thm.jpg
ab78f89fca408372c0cd04ee10be83ea
c92c6013713818136c2ef81e399ed87fc049162a
3013 F20101220_AAAFHY majumdar_s_Page_158thm.jpg
81276ba582bfde95645713731d81eb26
0f07840c438c502b9c7f877f3e89a948d4d91987
72972 F20101220_AAADZQ majumdar_s_Page_030.jpg
fcec93f0e06784acdb2afee3051fe990
e638242fdd663a01a31e5f266f9fc08a14726766
67603 F20101220_AAAEFK majumdar_s_Page_036.jpg
bef3e356ea4ef95962a325deec23fc3c
633f485dbc8642f4f2f7ef0fcbec7ca855be1c7d
951786 F20101220_AAAEEW majumdar_s_Page_102.jp2
733592bd6a390320f829de4beb85fb35
0803fc0ca13ab1d3a9f7de51bd9f9a34294b5569
8877 F20101220_AAADZR majumdar_s_Page_150thm.jpg
8c42da55b70f21d5bbdac2c5e07fa098
e8358912d656860cc98f2fe58d0275bbdf9995bb
F20101220_AAAEGA majumdar_s_Page_084.tif
0bc1f2c5e87443365407f652aae5ade2
251f5feb95f444fc4f336db203c041f8117139b0
18479 F20101220_AAAEFL majumdar_s_Page_089.pro
b08283369f6bed9651016549d3e9372a
e53e6d34a227e3e027c6f1a7c1009494b5cb77c8
88648 F20101220_AAAEEX majumdar_s_Page_108.jp2
22077befb82f9df39f22da03422b17d2
cb8064001d188ed657c5afe49fc41ac1363478d7
F20101220_AAADZS majumdar_s_Page_079.tif
279f4e2be68c4e9c893dca017828438f
9d715bea086c2d8e2e97bcda5c9e0536240ff10a
101550 F20101220_AAAEGB majumdar_s_Page_071.jpg
acf6647b72362c3620a49e44c9e3daba
77002d40540849b5f449b80577d25923bc1cf8b2
F20101220_AAAEFM majumdar_s_Page_088.tif
0cc782a7297cbf3772a21999ef1d7bb1
e63f3c688204f5ec88556402c2f316d7281f11d9
132141 F20101220_AAAEEY majumdar_s_Page_152.jp2
7c90ca090c902f7806d3a675f922a648
b4a0f4aed07f0958180cd7c29f42430ee3fa9335
7642 F20101220_AAADZT majumdar_s_Page_045thm.jpg
826d44c180b6d0f81e9db8467a7ce250
b25ed53c5a54bb0817c96f24d2ff2f18dd4c3bae
114296 F20101220_AAAEGC majumdar_s_Page_047.jp2
a78debf7e56663560d8bbc8826e73dc2
f4121d5c6f5416ca9deca8b5214b461452f8894a
40875 F20101220_AAAEFN majumdar_s_Page_086.pro
f071193a0e1bcbc8979556edc5e4ea10
0d74695e74e3495a2a4942275047bc5d1ffceaa8
1246 F20101220_AAAEEZ majumdar_s_Page_112.txt
6e6c79c3647a97a5027eb77047840ff1
45d8db713d64c7be135563630bc7ac8131da0d28
8585 F20101220_AAADZU majumdar_s_Page_047thm.jpg
ad28ab2c44445fdd5391a128f655d7a0
5c1a0ad28d7227d542cd4b7674944ec251c266c7
6089 F20101220_AAAEGD majumdar_s_Page_137thm.jpg
aa1197c962ec865ebf18bb66709dc3bf
6822bb6702c0f4d93a5c512493a57c8af928816b
F20101220_AAAEFO majumdar_s_Page_113.tif
eb6ca9701b6457f945c2afdf834e39cf
f05ee5fe9c152df723ebd9dc05dbf80342fb3b0d
14123 F20101220_AAADZV majumdar_s_Page_114.QC.jpg
cd477968b94ca50f39eb1e78d9c83deb
bafa8ab4571fc2bc2dfc0a38c507db60202645f0
48550 F20101220_AAAEGE majumdar_s_Page_143.pro
f8d1a7b4dc1f3fd1dcce6e124fdb3247
003503fe43ffbdf185204dc1995ea92d2e6dacb1
29710 F20101220_AAAEFP majumdar_s_Page_108.QC.jpg
9a10b2d03b05e0e66c1440ba850403f5
f8979c789e2ec36cba5782074a1fee873079a9a3
33101 F20101220_AAADZW majumdar_s_Page_028.QC.jpg
afde1e44b7aac128791cfd754dab2f45
3e9faa6ab9ee94265345a2a8f9874aeb66e2b2d8
85938 F20101220_AAAEFQ majumdar_s_Page_133.jpg
736273bfd12b38d8796bfa6df5b41643
4f1587fca70f765c670b910d39695fc9a6b1ed5a
32274 F20101220_AAADZX majumdar_s_Page_094.QC.jpg
206b477f60139268f436cc763fa86b7e
da793d723108d3215b4e25c89738d79c18fa79fe
50970 F20101220_AAAEGF majumdar_s_Page_024.pro
1330ce3badbeccc430f41317cfcfdde8
e3b85c0d5993f28da7ab7a82a43ae87e7184ef55
7331 F20101220_AAAEFR majumdar_s_Page_049thm.jpg
5895d22f4fbf7020a0a72cc4c6c18cc5
5666e5cdcc82e9cb0dd78327b6f73f7cf8274826
810 F20101220_AAADZY majumdar_s_Page_063.txt
c77e0ae71389f4f3ebb4d1043bfa1980
e001050a0c992a94eb6ed53794fd2ac9b5a4a773
33039 F20101220_AAAEGG majumdar_s_Page_025.QC.jpg
e35b1e2f5a820659e5964a4c6f284dea
1753c7d963045f085584b01da28e415d55d68e37
8714 F20101220_AAAEFS majumdar_s_Page_074thm.jpg
9fb96cc143da945b452b0a9107c14efe
73e66cd95597e8ae496a4a193074110aad558c3b
48604 F20101220_AAAEGH majumdar_s_Page_097.pro
01db58146f24eef88ffb09f572ef81dc
ba3fc1162663d708e6e7dd6d86257bca14822981
F20101220_AAAEFT majumdar_s_Page_115.tif
29befd3f76c375867e43314302015762
017af3f9c48223bf1c3a80aaf52d3e660e94b689
F20101220_AAADZZ majumdar_s_Page_043.tif
338fadefed15811d0cf95a50d373bfc6
f5f0ca9884730e5392388b618428bff51be4ecca
760 F20101220_AAAEGI majumdar_s_Page_058.txt
5971c32d1da531085ac883d69804d4c3
12ba02b66d26b5ca3b53e27767525e5a8b981cf6
51356 F20101220_AAAEFU majumdar_s_Page_028.pro
ec5ed2d7a752801a86da70759b4a2a7f
b954217a4a17501f51dc5918d3e301c67959e91e
21066 F20101220_AAAEGJ majumdar_s_Page_159.pro
26fbc2714d55ac2a5714897b13e74ca1
3b1fe53f9545e2f8ff74e403ef53d4d43e880ee7
106744 F20101220_AAAEFV majumdar_s_Page_019.jpg
5da036d3ad380e6f81fd3d5111894227
de1adb6c32c9a1a27e3b0f64fa52ff2c9fb96d70
1771 F20101220_AAAEGK majumdar_s_Page_055.txt
39c4d31d39c3867eef3e78c57f4abac7
b5cb6db79d3b42ace2cbf80c8b0cd058d06e46ef
83657 F20101220_AAAEFW majumdar_s_Page_016.jp2
fe5cd8c9bdbbcbecf6c36a4940b3b5d7
349414ad8b99fff5ba33eb0266b7d2b6392d8f31
6766 F20101220_AAAEGL majumdar_s_Page_014.QC.jpg
a48c0fdd9dd58fa17bf5401e1efbcbc6
2823766641eeacd8b38b8ada2b52ecd399a608c4
30641 F20101220_AAAEFX majumdar_s_Page_059.QC.jpg
6a5386ce9fff8ad608d5427c5166ceab
9b4968c73f4165b517464f3033db211a9c8d827f
62624 F20101220_AAAEHA majumdar_s_Page_082.jp2
bdca19d2588f1748a2abed9989c3c315
f212428e66de96ca99298961a3a383c7f5353537
2068 F20101220_AAAEGM majumdar_s_Page_020.txt
db4f7c26c347c4cbbd9329c11065a3e1
727622bbb1cef98180332a7d0d24fa58beba991e
109362 F20101220_AAAEFY majumdar_s_Page_051.jp2
69a04f2a5441a8899c669494e930db0f
1efc363aa8b4509a285451f91db92e3f33593487
7654 F20101220_AAAEHB majumdar_s_Page_087thm.jpg
689f1748e1b9567aeba2febecaf33577
44dea72308ae439376e208e631541fb614331eed
37191 F20101220_AAAEGN majumdar_s_Page_078.jpg
3f0f0a5e7897d4b039ebc67245badba7
bd976f72dc2730420689fa52e32d19fc5e32b7ef
F20101220_AAAEFZ majumdar_s_Page_014thm.jpg
3133940fd54f148e0cba709dcec67c8d
6e9c018fa16cf141ad5e6338f8ee63a95b112777
30801 F20101220_AAAEHC majumdar_s_Page_139.QC.jpg
267575655d126d2fcbb833e81a9651f4
3b6528a5e0207204b5f8fc6f37bfb6d5a8d5463c
45108 F20101220_AAAEGO majumdar_s_Page_114.jp2
4748c50b68112b5280fe6ba9ce5bcedf
2c913275cb8d8de59c9c030fc82ec2fab70f3f72
8000 F20101220_AAAEHD majumdar_s_Page_040thm.jpg
d9facddc620d3efc4f1c029b145a6c9e
a0794d8694adc4bdbff965bd48e5e1049f1030ac
2135 F20101220_AAAEGP majumdar_s_Page_057.txt
485d6aa315f618c28d7ff43b2f5ad28c
72266c5141afedf0530ae286051c6335a1f7b9b4
6656 F20101220_AAAEHE majumdar_s_Page_123thm.jpg
2520951bbc0adfc9faa5d74b69cda026
3bef3561378c446836697b275822b5627d7b5431
F20101220_AAAEGQ majumdar_s_Page_109.tif
dae97902fdebc187c815928f015e4756
06c26669a301af687a8b42d1a3cbadf0467781b8
50155 F20101220_AAAEHF majumdar_s_Page_054.pro
23f2b2df0079559a9cc99d1da4e516b3
9af7cdc47d89dd2ea7b460c17df79fef41734abd
2439 F20101220_AAAEGR majumdar_s_Page_154.txt
d8111a51cdc6e4b613f98c7dc060ac63
9673a8b2057cf73c9f0da2f79aa4d1a6a7eefcde
2044 F20101220_AAAEGS majumdar_s_Page_048.txt
ed6b05f6dbc7621a80f0232a2661c82c
9cb10bd194d9fdbbb934388cb7a568259446f990
6232 F20101220_AAAEHG majumdar_s_Page_036thm.jpg
f6bf7fe7738328884b4cf6df716f147d
c059666f15fcf0cf0b81b93aee6b24b85b6a57ca
1051959 F20101220_AAAEGT majumdar_s_Page_012.jp2
70cab0ce840a27d232061d8d61dcb0df
2e844db95ee6b28b3b16becfa8b314940de40db3
1843 F20101220_AAAEHH majumdar_s_Page_136.txt
06c784e5d49d34930492100235833609
3a57595e630170fcb62694f6aa00f449c69e6579
25223 F20101220_AAAEGU majumdar_s_Page_137.QC.jpg
f52ba5ec30a5c546912b26c114ff6dda
35d54e23dda6906ad8a6c8f13dfea451e7c59f29
13237 F20101220_AAAEHI majumdar_s_Page_062.pro
535f80be932e0ce0f2264654876808e8
8874c2b668aa1d09d7b3751240588c9f90665a19
2010 F20101220_AAAEGV majumdar_s_Page_037.txt
a0f7a6a82bc77ce5e6aeaf4ca09e0df9
e83b547fbc4fa70c9db0bd9977fa3fdd2008a0b9
F20101220_AAAEHJ majumdar_s_Page_146.tif
44558b109d19907b99dd036fd5f63149
cb6eee36c82e280d61290839980c40d8574cde4d
F20101220_AAAEGW majumdar_s_Page_071.tif
a6fee9e40984a68a28b3f09ac49614ac
ec7bc89466ad59dd2d834ce30ef1b150b2e3875e
35715 F20101220_AAAEHK majumdar_s_Page_149.QC.jpg
0dab06c3e428828019236667fba245cd
dbc69b34b0261172ca762171b8dda7a4f9dec785
F20101220_AAAEGX majumdar_s_Page_015.tif
ec18dd52a0a63fc2ab2ae058cab88b25
752cf7675c664df76752d658e0e6617fefbb8241
35011 F20101220_AAAEIA majumdar_s_Page_053.QC.jpg
09914cd2d67f8c054ab33cd881e8c16d
003fdf5ecd768209d0ed638ab7811587743c0335
F20101220_AAAEHL majumdar_s_Page_156.QC.jpg
31a9232b34b4b320f6c212003a9308ce
f3cc069eb72342372548b8fd1014d7c53b6c4685
100584 F20101220_AAAEGY majumdar_s_Page_104.jpg
e16834051a8b05f07f43f8656287d2e3
05fbafc04496f0405df60633bc8b8569df08d46b
69225 F20101220_AAAEIB majumdar_s_Page_096.jpg
3c7074d502ff9fd7e6a988fad63c5b9c
8dca106d3f922063fdb89fe325e8c0c37cc3ba99
F20101220_AAAEHM majumdar_s_Page_131.tif
721ce8632177a2b82eec379b0dd551e6
d381b9c644f844489e4a0662f03d8663d33d1c73
8795 F20101220_AAAEGZ majumdar_s_Page_156thm.jpg
7dce9dd24f072846a4bd8e1bc4904e7b
9f5002f1261c702d03efa53983dc46a73e2413c7
12822 F20101220_AAAEIC majumdar_s_Page_078.QC.jpg
297726fafeef568a2cf151347c34bc71
dd5dc7746d6c340b15430884dc3237fb4598d4c1
5220 F20101220_AAAEHN majumdar_s_Page_023thm.jpg
78dd0338c46f8d0ae015db6df44f3129
a7990dd3262dcb5010985f71ec59120897d2bd79
F20101220_AAAEID majumdar_s_Page_054.tif
61e4ce5e6fb7d862e6b50685865e4722
55c1766b848e410f181ef53d4a70df179944c009
F20101220_AAAEHO majumdar_s_Page_042.tif
8212528ebf29b4cf4afbbfc988bf8536
61586dba14e1424a38e16068ad2fb3388227b569
39220 F20101220_AAAEIE majumdar_s_Page_091.pro
fc37509b1c4b329f0dba0bdb5185b706
485ead144746632dec42463c8743ac34a1c6212a
8317 F20101220_AAAEHP majumdar_s_Page_104thm.jpg
ea3ca539da6ecabc2d0b16932c9fb597
cddfb80271f8271f8ab175b46db7c4b124b1650a
22383 F20101220_AAAEIF majumdar_s_Page_084.QC.jpg
c8dd6cae67825aabb521a0658aba657b
fe9d52066dba77442787df8d00d3eca3dd0bc85d
125727 F20101220_AAAEHQ majumdar_s_Page_146.jp2
dad9111365d449febb0c2d6c92c70166
11ed2ce694d0238983f801fead25c4bf4ef72014
7913 F20101220_AAAEIG majumdar_s_Page_117thm.jpg
aa35f8f7adf6a60cf3829c2634a5681f
3f407d1f9a0c68f2fad09de70b599d706dac4385
30518 F20101220_AAAEHR majumdar_s_Page_107.QC.jpg
c348f22a30984ac9b000f77e967bcb38
904571c54ddf6c7091e23d0cf24e33573f83b052
F20101220_AAAEHS majumdar_s_Page_045.tif
192f700f028ceee51471c2e331a94c5a
b4d04670d1ff502b4f177409fa6ca9e9db92ac6c
12924 F20101220_AAAEIH majumdar_s_Page_080.QC.jpg
76ace37d96a69dac98925c997892176c
f806e896f1089b31399b3f98aae207bcde2f33fa
109432 F20101220_AAAEHT majumdar_s_Page_024.jp2
de3f5e5aed66d2a720ed0548d18f10ad
45bf64be06f21bad90caaee1106a9f82a9c03472
1051971 F20101220_AAAEII majumdar_s_Page_018.jp2
9a9ada3345b730a006048ca66b112d53
f6423b3992607f0810457ce87fc933168e56b50c
F20101220_AAAEHU majumdar_s_Page_129.tif
caa25139b2a52495564bebd0e7f53654
98f6252a1dd2c2ddf3049e20c0b7e05222ac4160
109148 F20101220_AAAEIJ majumdar_s_Page_143.jp2
6c0691c22bec644ade5c636657d70878
2eeabfad5f027169769d408ba7d04037860840d3
F20101220_AAAEHV majumdar_s_Page_052.tif
e686048a398a8112fec6194d63fc4b43
4e0ef66c44a1ed4d78f11bf6cac59b4497188db3
7150 F20101220_AAAEIK majumdar_s_Page_085thm.jpg
5e00273afefa82ff30ec84051c584d42
0a88c864f69060c9e63cf5b4c97fbaf576827fd3
2041 F20101220_AAAEHW majumdar_s_Page_098.txt
2325e596f1ea0b794926e957d7df007f
f049be7c2631fbb55f299a563a36d60703ab052c
1818 F20101220_AAAEJA majumdar_s_Page_026.txt
89291640a4cf1f394baa2e204f0bb360
a25c134f303e5318c4bc66d834779e108d4bdcfa
128280 F20101220_AAAEIL majumdar_s_Page_157.jp2
b5e7981b40ac3bcc805111a967f31fba
ed65d391089bcabe3c9ff20e3b238980a7bf5783
85853 F20101220_AAAEHX majumdar_s_Page_106.jpg
010f785eb9e6fbb11740d90a22eb1665
0219ec839b2e9910dd812acf8ff18e62170d8db6
1435 F20101220_AAAEJB majumdar_s_Page_043.txt
c8a22088068253e6b808390db55da5f3
872e6fb7fcd72342404a9a493df00aeb854c2a9d
98036 F20101220_AAAEIM majumdar_s_Page_111.jp2
99a4d5d89db0abcc15016f4811e7d548
9bd68048bd706c31d628e60de1fc728a4927a427
1805 F20101220_AAAEHY majumdar_s_Page_049.txt
dc56a09e9f3b97ee2c1d282a7e99d3a4
d8778b9591b77c910e6bdad36f6ebe012ab32a17
113242 F20101220_AAAEJC majumdar_s_Page_053.jp2
53054691eba8d85d9da84561ca7a4325
38310c3b0f2a3231c1e46df60bc58a174639402c
91276 F20101220_AAAEIN majumdar_s_Page_086.jp2
33c8a80baaabb7a8ce6e169ac0128dce
7427b869566a909a67c01fd0d1632836d842489c
100813 F20101220_AAAEHZ majumdar_s_Page_038.jpg
c2afec29f1feb330aa1f22f4bba9c0e9
2b0b9f9b94fef77063ee59c1d89ddce9ca200c14
99969 F20101220_AAAEJD majumdar_s_Page_054.jpg
697b478f84d8ca4795b9996483a65b65
7445b5d2c36e1dade7f8c093bd227087a11da3cc
17739 F20101220_AAAEIO majumdar_s_Page_056.QC.jpg
b1554795b0b7aaf54b975dc27830cf86
4fcd00759fa28f109e2abbfbfc7b61b9cdf6537e
102290 F20101220_AAAEJE majumdar_s_Page_069.jpg
e028a4b4605db89bba7b15cf68968745
95decd2ee0d8b32ca1e6ea766c4a193194f81d94
44028 F20101220_AAAEIP majumdar_s_Page_107.pro
a246da9d650c61839133b44d4bc702ae
1f619ce19453a1d1a48f991251420107cadf892b
8267 F20101220_AAAEJF majumdar_s_Page_005thm.jpg
8d186385d9c34fba5360e84138ef4be1
17c98c66e41c803c07ba6619c4730feb0febeddd
100068 F20101220_AAAEIQ majumdar_s_Page_092.jp2
451f5a49cf80f20c8d423f0b5b1761d3
35d5e8860ef37c16575457c2242c8a98dee07256
94839 F20101220_AAAEJG majumdar_s_Page_050.jpg
a6df640a9f7fbcc62ddea1ab4ec74590
783dba6aba8104aa25541da99682580423117974
1873 F20101220_AAAEIR majumdar_s_Page_077.txt
1b7e9b3e593564c9b0d4ef54fc0818f0
58de5113ff2b12fcd85fa275a933d7249936b4bc
4048 F20101220_AAAEJH majumdar_s_Page_159thm.jpg
b395e3f8d242d3724ee68b8acbdb71d1
ff35451ebd0bacc4b87be67c7e31cbc2e0ffc0ea
76021 F20101220_AAAEIS majumdar_s_Page_035.jp2
6c2aa377f870d186af477d0349deba1c
9c2b8956176267122b794c57ee592dc4a0e13384
94385 F20101220_AAAEIT majumdar_s_Page_111.jpg
573377853edf38b13962f5a90660ba41
dff8fe55de179320b40b4dd0358c3721716c77da
26012 F20101220_AAAEJI majumdar_s_Page_103.QC.jpg
c5338890f50ae5f1e8be1cad496f5b31
fc321875fb192d889f8d66b1d1453982ee6c3af1
97481 F20101220_AAAEIU majumdar_s_Page_029.jpg
cb4d92289cc846db802aa97f44dfc48e
8493d5033d731d4c512a7dc627617c29341f24e4
F20101220_AAAEJJ majumdar_s_Page_110.tif
15d46f22dcd45b597a46ccdfb2cc98fc
861cb8c123389bd06b691857bf7e683963d1118d
F20101220_AAAEIV majumdar_s_Page_064.tif
4ac91d3df1e7312bf8a3dc31d8da694f
ca3e7881760844841b85c4095ec9db30ecc8617c
1051986 F20101220_AAAEJK majumdar_s_Page_007.jp2
d5a3bdd376f0bc81e3463c2c9701a9da
3db38201e25e2736884aac886f2adb9a30cb5da3
8294 F20101220_AAAEIW majumdar_s_Page_028thm.jpg
b09479f0de6cff0c403abcc589728cd2
2586c4be3e505842a97a8b3dfa38335293a73d18
90563 F20101220_AAAEJL majumdar_s_Page_099.jp2
5cee0334395ca19c215573ed299f3ab9
9c80c3102c063b4a9f92ea488c547b9a397bf4b6
1536 F20101220_AAAEIX majumdar_s_Page_036.txt
7ccd4c610ad817835b2148cdbb0dc486
15d03e62290e2d81479276d0c9044f0159ea3252
41048 F20101220_AAAEKA majumdar_s_Page_033.pro
57e7eef0dc45f04c8476c4b8edbc7c9c
0b3357953a26c8deda86cefce0e32c88f31ff99f
98786 F20101220_AAAEJM majumdar_s_Page_094.jpg
0863d5dcabfd241d612691b33d84454e
3a90ba8aeba18fee6cd58bf367dfd01f1008cb57
F20101220_AAAEIY majumdar_s_Page_107.tif
4a568116843fda2496548e1488398d66
ea0fb5d192761290201e3feb0e03ef56ff0846af
132177 F20101220_AAAEKB majumdar_s_Page_153.jp2
4fd0280a630c33bbd64fab54361fd2fe
53c1f088434b76cf6cc289fd595ec6e32cf5170a
1770 F20101220_AAAEJN majumdar_s_Page_066.txt
5f9c28cd437196ed636f270622858a76
964bf47dd43eac6c55d9d1109d8e93ea41e15b4f
139773 F20101220_AAAEIZ majumdar_s_Page_148.jp2
e59de0624d06ec48a3f7f347bf8c31f5
75fa9231ee3b5b0d2a132995b54a10caf76994e4
F20101220_AAAEKC majumdar_s_Page_070.tif
9bd77fb699e0d4b656101e6f0e588c9b
7c004700c61e54c655e9a45112825c4d81159d44



PAGE 1

PRODRUG STRATEGIES AIMED AT IM PROVING TOPICAL DELIVERY OF DRUGS USING THE N-ALKYL-N-ALK YLOXYCARBONYLAMINOMETHYL (NANAOCAM) PROMOIETY By SUSRUTA MAJUMDAR A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLOR IDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2006

PAGE 2

Copyright 2006 by Susruta Majumdar

PAGE 3

This document is dedicated to my wife, PUJA and my father, BABA

PAGE 4

iv ACKNOWLEDGMENTS I would like to thank my advisor, Dr. Ken Sloan, wholeheartedly for allowing me to pursue his and my ideas independently in his lab. His constant support, patience, ability to keep me focused, thorough unders tanding of literature, and stress on basic principles proved vital in my finishing this manuscript. The rigorous training imparted to me in and outside the lab was responsible in my doing well in the lab, for the publications that have or will come out of this diss ertation and talking to people in various conferences and interviews I a ttended during my stay at Flor ida. I greatly appreciate his ability to communicate with me on a daily ba sis the answers to my questions in an articulate manner. I feel confident enough to ta ke myself to the next level in search of something new again. There are two people who inspire me the mo st: one of them is my father whom I call baba and second is my wife, Puja. I would like to dedicate 4 years of my work to my father and my wife. My father and my advisor have two th ings in comman. They both believe in keeping things simple and have great faith in basic principles and honestly I thought I had those under control till I joined the Sloan lab. My father introd uced me to science at an early age. He along with my mother made it possible for me to have the best education. I went to the best private schools back home ju st because they valued education a lot in spite of facing financial hardsh ips sometimes. I did not pick my college major, chemistry;

PAGE 5

v he did. He said, “Just trust me on this on e” and I am so glad I did. My dad being a pharmacist influenced me to do what he did. I got my chance at Flor ida and I loved it. I dated my present wife for 6 years before we got married. She keeps me going everyday day after day with t hose constant words of encouragement. If my father was responsible for me being in science, my wi fe ensured that his dream of my being a scientist gets fulfilled. I admire the strength in her character to stay from me to finish her education. I would like to thank my mother and sister for their love and affection. My mother was responsible for me being independent, tole rant and disciplined. I admire my sister’s ability to fight ‘time’ against all odds. I would like to thank my graduate collea gues Dr. Scott Wasdo, Dr. Joshua Thomas and Maren Muellar Spaeth. Scott actually was my second advisor; sometimes his explanations for a physical chemistry concept were just too easy to follow. I hope he decides to teach one day. I do not have words to describe Josh. He is too nice, too good and focused. I would like to thank him for the critical discussions we had in the lab on science, religion, politics and everything on earth. I admire hi m as a wonderful scientist; I do not know of too many people who will run an experiment for 36 hrs non stop week after week. Such dedication to work amazes me. Maren was an undergraduate exchange student who worked with me. Together we finished couple project s in the limited time she had in her disposal. I appreciate her a dding insight and thoughtfulness into our work. I would like to thank my committee members Dr. M.O.James, Dr. Raymond G. Booth and Dr. William Dolbier. I would like to thank Dr. James for her constant encouragement and her writing good recommen dation letters for me. Dr. Dolbier was

PAGE 6

vi largely responsible for a project I did with Ma ren; I thank him for adding insight into the project and for being a part of my committee. Finally I would like to thank Dr. Gee ti Bansal (MIT), Dr. Sushma Chauhan (Ranbaxy) and Dr. Gagan Kukreja (Ranbaxy) w ho taught me basically how to operate in an organic chemistry lab like running TLC’s, column chromatography and doing crystallizations during my stay as an underg rad student at the Un iversity of Delhi.

PAGE 7

vii TABLE OF CONTENTS page ACKNOWLEDGMENTS.................................................................................................iv LIST OF TABLES...............................................................................................................x LIST OF FIGURES..........................................................................................................xii ABSTRACT....................................................................................................................... xv CHAPTER 1 INTRODUCTION........................................................................................................1 The Skin....................................................................................................................... .1 Topical Delivery...........................................................................................................8 Approaches to Increase Permeation across the Skin..................................................11 Theory of Percutaneous Diffusion..............................................................................13 Mathematical Modeling of Flux through Human Skin. Derivation of RobertsSloan equation from Fick’s law of Diffusion..........................................................17 Prodrugs......................................................................................................................2 1 Prodrugs for Dermal and Transdermal delivery.........................................................33 Research Objectives....................................................................................................41 2 DESIGN, SYNTHESIS, HYD ROLYSIS OF N-ALKYL-NALKYLOXYCARBONYL-AMINOMETHYL DRUG DERIVATIVES AND ITS IMPLICATIONS ON PRODRUG DESIGN.......................................................43 Introduction.................................................................................................................43 Synthesis of N-methyl-N-methylox ycarbonylaminomethyl and N-aryl-Nmethyloxy-carbonylaminomethyl Prodrugs.....................................................45 N-Methyl-N-methyloxycarbonylaminomethyl chloride synthesis...............48 N-Aryl-N-methyloxycarbonylaminomet hyl chloride synthesis...................49 Alkylation of Phenols, 6-Mercaptopu rine, Dimethylaminobenzoic acid and Naproxen with N-methyl-N-methyloxy carbonylaminomethyl chloride or N-aryl-N-methyloxycarbonylaminomethyl chloride.......................................51 Hydrolysis Studies......................................................................................................59 Implications of NANAOCAM-phenol Hydrolysis on Prodrug Design.......67 Implications of NArNAOCAM-carboxy lic acid Hydrolysis on Prodrug Design.......................................................................................................70

PAGE 8

viii 3 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-NALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF A MODEL PHENOLIC DRUG:ACETAMINOPHEN.................................................................74 Experimental Procedure..............................................................................................75 Materials and Methods.................................................................................75 Synthesis of Prodrug Derivatives.................................................................75 Synthesis of NANAOCAM-Cl.....................................................................76 Determination of Solubilities and Partition Coefficients.............................82 Determination of Flux through Hairless Mice Skins...................................84 Determination of Prodrug Hydrolysis by UV Spectroscopy........................87 Calculation of Maximum Flux.....................................................................87 Physicochemical Properties of NANAOCAM Prodrugs of APAP............................88 Solubilities....................................................................................................88 Diffusion Cell Experiments..........................................................................91 Prodrug Bioconversion to Parent Drug........................................................92 Permeability Coefficients and Solubility Parameter Values........................92 Residual Amounts in Skin............................................................................93 Second Application Fluxes...........................................................................94 Modelling the Flux of NANAOCAM prodr ugs of APAP through Hairless Mouse Skin from IPM using the RS equation....................................................................95 Conclusions.................................................................................................................97 4 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-NALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF AN IMIDE CONTAINING DRUG: THEOPHYLLINE...............................................................99 Experimental Procedure............................................................................................101 Materials and Methods...............................................................................101 Synthesis of Prodrug Derivatives...............................................................102 Synthesis of NANAOCAM-Cl...................................................................102 Determination of Solubilities and Partition Coefficients...........................108 Determination of Flux through Hairless Mice Skins.................................110 Determination of Prodrug Hydrolysis by UV Spectroscopy......................113 Calculation of Maximum Flux...................................................................113 Physicochemical Properties of NA NAOCAM Prodrugs of Theophylline...............114 Melting Point Behaviour of NANAOCAM Prodrugs of Theophylline.....114 Solubilities..................................................................................................114 Diffusion Cell Experiments........................................................................116 Prodrug Bioconversion to Parent Drug......................................................118 Permeability Coefficients and Solubility Parameter Values......................120 Residual Amounts in Skin..........................................................................121 Second Application Fluxes.........................................................................121 Modelling the Flux of NANAOCAM Prodrugs of Acetaminophen and Theophylline through Hairless Mouse Skin from IPM using the RS equation....122 Conclusions...............................................................................................................125

PAGE 9

ix 5 SUMMARY OF RESULTS OBTA INED AND FUTURE WORK........................126 LIST OF REFERENCES.................................................................................................129 BIOGRAPHICAL SKETCH...........................................................................................143

PAGE 10

x LIST OF TABLES Table page 1-1 x, y, z, r2 and Average Residual Errors for Various Databases Fit to RS................21 1-2 Physicochemical Characterization of 1-Alkyloxycarbonyl esters of 5-FU..............35 1-3 Physicochemical Characteriza tion of Alkyloxycarbonyl esters of Acetaminophen.........................................................................................................38 1-4 Physicochemical Characterization of PEG esters of Indomethacin.........................40 2-1 N-methyl-N-methyloxycarbonylaminomet hyl-phenol Conjugates Synthesized.....46 2-2 N-methyl-N-methyloxycarbonylaminomet hyl and NArNAOCAM Conjugates of Naproxen..................................................................................................................46 2-3 Correlation of Rates of Hydrolysis of NANAOCAM-Y with pKa and Sigma Values of the Leaving Group (Y-)............................................................................61 2-4 Effect of pH of Buffer on Rates of Hydrolysis of 7 .................................................61 2-5 N-aryl-N-alkyloxycarbonylaminomethyl Derivatives of p-nitrophenol (PNP).......70 2-6 Hydrolysis of N-aryl-N-alkyloxycarbonyl aminomethyl Derivatives of Naproxen.72 2-7 Effect of pH of Buffer on Rates of Hydrolysis of 14. ..............................................72 3-1 NANAOCAM Prodr ugs of APAP...........................................................................80 3-2 Molecular Weights, Melting Points, L og Solubilities in Isopropyl Myristate Log Solubilities in Water and Log Solubilities in pH 4.0 Buffer............................90 3-3 Molar Absortivities in Acetonitrile a nd Buffer, Log Solubility Ratios between IPM and Water, the Differences Between Log SRIPM:AQ, the Log of Partition coefficients Between IPM and pH 4.0 Bu ffer, and the Differences Between Log KIPM:4.0......................................................................................................................90 3-4 Solubilities in IPM, Solub ilities in Water and Flux through in vitro Hairless Mouse Skins from IPM............................................................................................92

PAGE 11

xi 3-5 Log Permeability Values for the APAP from IPM through Hairless Mouse Skins and Solubility Parameter values...............................................................................93 3-6 Residual Skin Concentrations of To tal APAP and Ratios of Dermal versus Transdermal Fluxes..................................................................................................94 3-7 Second Application Theophylline Flux data for Flux of Theophylline from Propylene Glycol......................................................................................................94 3-8 Experimental Flux, Calculated Flux a nd Error in Predicting Flux for Compounds 1, 17-26 through Hairless Mouse Skins from IPM..................................................96 4-1 NANAOCAM Prodrugs of Theophylline..............................................................107 4-2 Melting Point Comparisons of N ANAOCAM-Th with AOC-Th and ACOM-Th.115 4-3 Molecular Weights, Melting Points, Log Solubilities in Isopr opyl Myristate, Log Solubilities in Water and Estimated Log Solubilities in pH 4.0 Buffer.................117 4-4 Molar Absortivities in Acetonitrile a nd Buffer, Log Solubility Ratios between IPM and Water, the Differences Between Log SRIPM:AQ, the Log of Partition Coefficients Between IPM and pH 4.0 Bu ffer, and the Differences Between Log KIPM:4.0....................................................................................................................118 4-5 Solubilities in IPM, Solubilities in Water and Fl ux through in vitro Hairless Mouse Skins from IPM..........................................................................................119 4-6 Log Permeability values for Theophylline Prodrugs from IPM through Hairless Mouse Skins and Solubility Parameter Values......................................................120 4-7 Residual Skin Concentrations of Total Theophylline Species ..............................121 4-8 Second Application Theophylline Flux data for Flux of Theophylline from Propylene Glycol....................................................................................................122 4-9 Experimental Flux, Calculated Flux a nd Error in Predicting Flux for Compounds 1, 17-26 through Hairless Mouse Skins from IPM................................................124

PAGE 12

xii LIST OF FIGURES Figure page 1-1 Cross sectional view of human skin ..........................................................................2 1-2 Brick and mortar model of dr ug absorption through the skin....................................6 1-3 Structures of ceramides seen in th e lipid bilayers of the lamellar bodies..................7 1-4 Illustration of a typical flux profile..........................................................................14 1-5 Two compartment diffusion model..........................................................................15 1-6 Esterase mediated hydrolysis of prodrugs................................................................23 1-7 Soft alkyl prodrug hydrolysis...................................................................................24 1-8 Hydrolysis pathways for Saccharin base d O-imidomethyl derivative of estradiol..26 1-9 Hydrolysis of phosphoryloxymethyl prodrug mediated by phosphatases...............27 1-10 Hydrolysis of PEG conjugated to drug using a hydroxyl-benzylalcohol linker in vivo ...........................................................................................................................30 1-11 PEG-Ala-Campothecan............................................................................................30 1-12 Ionic complexes formed by oligoarginin e of Tat with the pho sphate groups in cell membranes.........................................................................................................32 1-13 Chemical hydrolysis of oligoarginin e conjugates of cyclosporine and taxol...........33 1-14 Structure of testosterone and indomethacin esters with polarisable side chains......39 2-1 Design of NANA OCAM promoiety........................................................................44 2-2 Structures of N-methyl-N-met hyloxycarbonylaminomethyl prodrugs of dimethylaminobenzoic acid and 6MP......................................................................47 2-3 Synthesis of NANAOCAM prodrugs......................................................................47 2-4 Synthesis of NArNAOCAM prodrugs.....................................................................48

PAGE 13

xiii 2-5 Hydrolysis of NANAOCAM-Y in aqueous buffers.................................................60 2-6 Pseudo-first order rate constants (sec-1) versus of parent phenol.......................62 2-7 Pseudo-first order rate constants (s ec-1) versus acidic pKa of parent.....................62 2-8 pH rate profiles of compds 7 and 14 ........................................................................63 2-9 SN2 type of hydrolysis of NANAOCAM-Y with Yor carbamate as the leaving group.......................................................................................................................... .64 2-10 SN1 type of hydrolysis of NANAOCAM-Y.............................................................64 2-11 Hydrolysis of N-alkylamidomethylcarboxyl ic acid esters in aqueous buffers........65 2-12 Hydrolysis of N-imidomethyl deri vatives of phenols in aqueous buffers................66 2-13 Attempts at the synthesis of NA NAOCaminoethylidene chloride and NANAOCaminobenzylidene chloride.....................................................................68 2-14 Hydrolysis of NArNAOCAM-carbo xylicacid conjugates at pH 9.2.......................73 3-1 Synthesis of NANAOCAM-Cl from 1, 3, 5-trialkylhexahydrotriazine...................76 3-2 Preperation of alkyl chloroformate in situ from alcohol and synthesis of NANAOCAM-Cl from alkyl amine.........................................................................77 3-3 A Franz diffusion cell...............................................................................................86 3-4 Plot of solubility parameter versus log PMIPM for 1 17 20 ......................................93 3-5 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 3.15..............................................................96 3-6 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 3.16..............................................................97 4-1 Carbocations formed as intermedia tes by hydrolysis of Mannich bases of theophylline and NANAOCAM-Th.......................................................................100 4-2 Synthesis of NANAOCAM-Cl from 1, 3, 5-trialkylhexahydrotriazine.................102 4-3 Synthesis of NANAOCAM-Cl from al kyl amine and preperation of alkyl chloroformate in situ from alcohol.........................................................................104 4-4 Alkylation of theophylline with NANAOCAM-Cl................................................106 4-5 Plot of solubility parameter versus log PMIPM for 21-26........................................120

PAGE 14

xiv 4-6 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 4.13 for n = 69............................................124 4-7 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 4.14 for n = 74............................................125

PAGE 15

xv Abstract of Dissertation Pres ented to the Graduate School of the University of Florida in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy PRODRUG STRATEGIES AIMED AT IM PROVING TOPICAL DELIVERY OF DRUGS USING THE N-ALKYL-N-ALK YLOXYCARBONYLAMINOMETHYL (NANAOCAM) PROMOIETY By Susruta Majumdar August 2006 Chair: Kenneth. B. Sloan Major Department: Medicinal Chemistry Topical delivery is an attr active route to deliver drugs into systemic circulation; however the poor biphasic solubility of drug molecules limits delivery across the skin. NAlkyl-N-alkyloxycarbonylaminomethyl (NANA OCAM)-drug conjugates were designed as prodrugs with good biphasic so lubilities to increase the topical de livery of phenol and imide containing drugs. Prodrugs are biological inactive deri vatives of a drug which hydrolyse in vivo to the parent drug molecule. These derivatives mask polar functional groups present in a drug molecule which, in this case, leads to incr eased solubility of the drug in the skin. Prodrugs must hydrolyse to exhibit their pha rmacological activity. To elucidate the mechanism of chemical hydrolysis, a seri es of NANAOCAM conjugates of phenols, thiols and carboxylic acids were synthesized and their rates of hydrolysis determined in aqueous buffers. The hydrolysis followed ps eudo-unimolecular firs t order kinetics and was dependent on the nucleofugacity of the leaving group. The hydrolysis was also

PAGE 16

xvi independent of the pH of buffers. To furthe r elucidate the mechanism of hydrolysis, Naryl-N-alkyloxycarbonylaminomethyl (NAr NAOCAM) conjugates of phenols and carboxylic acids were also synthesized and thei r rates of hydrolysis determined. Since the hydrolysis of NArNAOCAM conjugates were slower than NANOCAM conjugates, the NANAOCAM conjugates are proposed to hydrolyse by a SN1 type of pathway with the lone pair on the nitrogen stabilizing the carbocation formed as an intermediate. To investigate if the NANAOCAM promoiet y increases the dermal delivery of phenolic drugs and imide containing dr ugs, a homologous series of NANAOCAMacetaminophen and NANAOCAM-the ophylline were synthesi zed. These derivatives were characterized by determin ation of their solubilities in IPM and water, partition coefficients between IPM and pH 4.0 buffer and flux through hairless mouse skins from IPM. Only two prodrugs of acetaminophen, C1 alkyloxy and C2 alkyloxy, increased flux through the skin. These derivatives were the mo st water soluble prodrug s in the series of more lipophilic prodrugs. In the theophylline series, only one derivative, C2 alkyloxy, increased delivery through the skin. This de rivative was the most lipid and most water soluble member of the series. The fl ux of NANAOCAM prodrugs from IPM was accurately predicted by the Roberts-Sloan equation.

PAGE 17

1 CHAPTER 1 INTRODUCTION The Skin Skin is the largest organ in the human body, accounts for 10% of the total body weight and has a surface area of 2m2 (Schaefer and Redelmeir, 1996). It acts as a physical and chemical barrier, protecting the body from the surrounding environment. Besides this, it enables the body to control fluid lo ss, regulate body temper ature and intercept external stimuli. The skin can be divided in to three distinct laye rs, the hypodermis, the dermis and the epidermis (Block, 2000). A micr oscopic view of skin is shown in Figure 1-1. The hypodermis is made up of a network of connective fibers and adipocytes which play an important role in energy storage a nd metabolism as well as providing insulation and protection against injury. Th e intracellular fat droplets may also act as a reservoir of hydrophobic compounds which may have penetrated the stratum corneum (the outermost layer).The hypodermis is 1-2 mm thick. It houses blood vessels whose prime function is to deliver nutrients to the skin and rem ove waste products, metabolites and xenobiotics from the skin. The dermis is the thickest layer of the skin and is 2 mm thick. It is responsible for maintaining the structural integrity of the skin. The dermis consists of a network of collagen and elastin fibers which provide flex ibility and tensile st rength to the dermis. Proteoglycans fill up most of the intracellu lar space and these macromolecules are responsible for the water-retaining propertie s of the dermis. These are polysaccharides

PAGE 18

2 covalently bound to a polypeptide backbone. The polysaccharide side chains are frequently sulfated. Examples of proteoglycans frequently seen in the dermis are heparin, Figure 1-1 Cross sectional view of human sk in (Reproduced with permission from K.G. Siver, Ph.D. Dissertation, Un iversity of Florida, 1987). chondroitin sulfate and dermatin sulfate. Th e anionic charge associated with these proteoglycans also allows a lot of water to be associated with the carboxylate or the sulfate groups and impedes th e ability of lipophillic compounds to cross the dermis. The dermis has an extensive vascular network wh ich participates in various processes like nutrition, exchange of gases, repair of ti ssues, immune responses and thermoregulation. Nerve endings sensitive to vibration, pressure pain and temperature are seen in dermis along with mast cells, macrophages and t-cell s which are present for protection against foreign antigens. A variety of appendages which permeate the stratum corneum like sweat glands, hair follicles and sebaceous gl ands are derived from this region. The hair

PAGE 19

3 follicles and exocrine sweat glands have pores that extend to the skin surface and provide openings to the epidermis which contains the stratum corneum: the main permeability barrier of the skin. Thus xenobi otics can use this route, also called the shunt route, to penetrate the dermis; this is especially true for highly polar molecules whose permeability is limited by the stratum corneum. However these pores constitute only 0.1 % of the total skin surface area and are responsible for early diffusion processes (Scheuplein and Blank, 1971; Stuttgen, 1982). Sebaceous glands are loca ted within the hair follicles and secrete sebum which makes its way on to the skin surf ace. Sebum is a complex mixture of fatty acids, triglycerides, squalene and waxes. Eccrine sweat glands are also present in the dermis and their primary purpose is thermore gulation. Since the epidermis is devoid of any vasculature, it depends on the dermis fo r supply of nutrients, oxygen and removal of waste metabolites. The presence of papillae fr om each layer interlocked with one another at the border of the dermis a nd epidermis facilitates this pr ocess of exchange between the two layers by increasing the surface area. Th e papillary layer is 50 nm thick and has capillaries which feed the epidermis with the required nutrients (Bisset, 1987). The epidermis, contains the stratum corneu m, provides the main barrier function to the skin and prevents the entry of foreign particles and loss of water. Keratinocytes (keratin producing cells) make up most of the viable epid ermis which is 50-100 m thick. This protein is very polar with every th ird amino acid in the backbone of keratin containing an ionizable side group (-COOH, -NH2 and –SH) (Flynn, 1990). Besides the keratinocytes the viable epidermis also has melanocytes which are responsible for skin pigmentation, langerhans cells for immune response and merkel cells responsible for sensory reception. The epidermis also acts as a store for antioxidants like ascorbic acid,

PAGE 20

4 tocopherols and tocotrienols, glutathi ones, urates, ubiquinone-10 and enzymatic antioxidants like catalases, superoxide dismut ases, glutathione peroxidases. The primary function of these antioxidants is to offer prot ection to the skin against the ultra violet radiation of the sun (Thiele et al., 2002). Division and differe ntiation of the keratinocytes lead to the formation of five distincts layers within the epidermis: stratum basale, stratum spinoum, stratum granulosum, stratum lucidum and finally stratum corneum. The cells migrate from the basal cell layer to the skin surface while gradually changing their structure and function resulting in the formation of physically and chemically resistant cell remnants called corneocytes which ma ke up the stratum corneum. Once on the surface of the skin the cells are shed off as a part of desquamation. This cycle of cell division followed by differentiat ion, proliferation and migrati on from basal to the surface and finally desquamation repeats itself over and over again with the new cells rapidly replacing the old ones. The transition from a terminally differentiated keratinocyte to corneocyte takes 24 h in the epidermis. The process of cornification and desquamation is intimately linked; synthesis of stratum corneum occurs at the same rate as loss. The outermost layer of the epidermis is called the stratum corneum, and it is the main rate limiting barrier to drug delivery (Stuttgen, 1982; Berti and Lipsky, 1995). It is 10-20 m thick consisting of polyhedral flat and nonnucleated cells called the corneocytes (Berti and Lipsky, 1995).The pH of the stratum corneum lipids is 4-6.5. The stratum corneum has 5-20 layers of corneo cytes. These cells are remnants of the terminally differentiated cells called kera tinocytes which are found in the viable epidermis. Their cell organelles and cytopl asm have disappeared during the process of cornification. Corneocytes are composed of insoluble kera tins surrounded by a cell

PAGE 21

5 envelope stabilized by cross linked protei ns and covalently bound lipids. These corneocytes are further interconnected by lipids. The presence of these intracellular lipids is required for a competent skin barrier and follows a tortuous path. These lipids are synthesized and assembled into lamellar st ructures which surround the corneocytes. These lamellar bodies which envelope the st ratum corneum store a complex mixture of lipids and lipid-like materials like free fa tty acids, choleste rol and hydroxyamide derivatives called ceramides. Interconnecti ng corneocytes of the stratum corneum are polar structures such as corneodesmosom es which contribute to stratum corneum adhesion. The stratum corneum is not uniform ly homogeneous and the layers represent various stages of corneocyte and lipid maturation. In short, the stratum corneum can be visualized as a brick and a mortar model with the flattened cornified cells being the offset layers of bricks lying one over another and the lipid rich intracellular matrix as the mortar separating the bricks or corneocytes (Figur e 1-2). By physically stripping the outermost layer of the skin an increase in permeability of various ch emicals and water can be seen proving stratum corneum to be the main rate li miting barrier. Thus t opical approaches at increasing flux through the skin have relied on increasing the solubi lity of compounds in the stratum corneum (Sloan et al.1989, 1992 and 2003). It is primarily believed that drugs cannot penetrate the protein rich corneocytes cells but need to ta ke a tortuous path alongside the corneocyte s through the interconnecting lipid s (Michaels et al., 1975). Thus the drug enters systemic circulation through th is narrow channel of lip ids and need to be hydrophobic so that they can permeate thes e semi-fluid matrix lipid barriers.

PAGE 22

6 Figure 1-2 Brick and mortar model of drug absorption through the skin. Unlike cell membranes in most parts of the body which are composed of phospholipids, the skin is devoid of any phospholipids. However, the presence of functional groups which are capable of hydr ogen bonding in ceramides (Figure 1-3), free fatty acids, and cholesterol su lfate in the lamellar bodies which surround the corneocytes makes the stratum corneum hydrophilic as well as lipophilic. The stratum corneum is about 30% water by weight and most of it is due to the association of water with these polar groups seen in the lamellar lipids. Thus, drugs with good biphasi c solubility can permeate the stratum corneum better than drugs which are merely hydrophobic. Lipid matrix Epidermis Corneocyte Dermis

PAGE 23

7 O O O N H OH OH O N H OH OH O N H OH OH OH O O O N H OH OH OH O N H OH OH OH O N H OH OH OH OH O N H OH OH OH OH O N H OH OH OH Ceramide 1 Ceramide 2 Ceramide 3 Ceramide 4 Ceramide 5 Ceramide 6 Ceramide 7 Ceramide 8 Figure 1-3 Structures of ceramides seen in the lipid bilayers of the lamellar bodies. The heterogenous composition of the lipids and disorder in packaging of these lipids leadS to the formation of lipid micr odomains. Ruthenium te troxide staining of normal skin shows the presence of altern ate hydrophilic region s connecting lipophilic bands in the bilayer structur e (Hou et al., 1991). The struct ure and arrangement of the barrier is such that drugs need to pa ss through alternate layers of hydrophobic and

PAGE 24

8 hydrophilic regions, formed as a result of the pa cking disorder of the lipids present, to reach the systemic circulation and thereby must possess adequate lipid as well as water solubilities (van Hal et al., 1996). The experimental evidence for this concept of biphasic solubility being important in terms of perm eability through the skin was first provided by Scheuplein and Blank (1973) for the diffusion of a homologous series of alcohols from water through human skin in vitro.The al cohol which gave maximum flux was not the most lipid soluble but was the most water so luble. Sloan et al. (1997) confirmed these results in in vitro hairless mice skin. Topical Delivery Most drugs developed today ar e delivered through the oral route. This is primarily because it is economical for the company de veloping the drug. The delivery of the drug does not require a visit to a physician or a trai ned medical representati ve as would be the case for an intravenous or parental formulati on. Drugs given orally also have the ability to be given in large doses because of the high permeability of the enterocyte cells present in the GI tract. However, the pH of the stomach is acidic, so the stability of molecules is compromised. Oral bioavailability of drugs is sometimes limited by efflux of active drugs by Mrp or P-gp transporters which prevent drugs from reaching intestinal vasculature (Wacher et al., 1996; Watkins, 1997; Schinkel, 1997 and De Mario et al., 1998) and CYP 450 catalysed metabolism of drugs (Watkins, 19 92). The portal vein carries the drug from the intestine to the liver by a process known as “enterohepatic cycling” before the drug finally enters systemic circulation. The liver is the largest drug me tabolizing organ in the body and has enzymes like CYP 450, GSH/GST and UDP/UGT which do not have strict substrate structure specificity. These enzymes transform the drug molecule to an inactive

PAGE 25

9 metabolite or lead to the formation of toxi c by-products and hence limit the therapeutic effectiveness of the drug. To circumvent these problems associated with oral drug deliver y, an alternate and useful site of delivery can be the skin. De rmal delivery evades first pass metabolism of drugs because once the drug permeates the skin it reaches the systemic circulation and hence the bioavailability is not limited by me tabolism, and side effects arising out of toxic metabolites are minimized. Dermal drugs are more likely to reach systemic circulation intact because of the absence of high concentrations of drug-metabolizing enzymes like CYP 450 enzymes, GSH/GST (con centration in nmol amounts, Shindo et al., 1994) or P-gp efflux transporters. CYP isoz ymes have been shown to be induced in skin (Ahmad et al., 1996, 2004 and Swanson, 2004) and P-gp transporters are seen in epidermal cells but their primary function seem s to be limited to clearing out endogenous compounds (Laupeze et al., 2001). The concentra tion of the enzymes is low and there is no systematic arrangement of the enzymes and transporters on the surface of the skin so they cannot clear the drugs efficiently or aff ect the therapeutic efficacy and availability of drugs. Topical delivery can be used for delivery of potent molecules whose dose requirements are low or require slow and sustained serum concen tration levels of drug for a prolonged period of time. It is po ssible to deliver about 30 mg/4.9 cm2 of an appropriately soluble drug through the skin over a period of 24 h (Beall et al., 1996). Dermal delivery means delivery into the skin, i.e., the epidermal and dermal skin cells. Such delivery is particularly useful for skin cancers. Transdermal de livery means delivery through the skin into systemic circula tion. Drugs with high transdermal delivery invariably show high dermal delivery too, t hough it may be possible to increase dermal

PAGE 26

10 absorption by making a hydrolytically labile prodrug which hydr olyses to give a lipophilic promoiety whose permeation th rough the dermis is limited and hence selectively accumulates in the dermis. Skin is a useful target organ for skin disorders and local action. Attempts are currently being made to deliver soft estroge ns locally because estrogen receptors are expressed in the skin (Labaree et al., 2001 and 2003). The idea is to increase uptake locally and prevent systemic circ ulation and hence the side effects that may result from it. These locally active estrogens can be used to treat vaginal dyspare unia without the risk involved with systemic administration. These so ft drugs are inactivated by esterases so that their action is geographically limited to the site of action. Delivery of 5-FU through the skin enables treatment of actinic keratosis (Dillaha et al., 1965) and may be useful for psoriarsis (T suji and Sugai, 1972) and yet spare the body from most of its systemic effects. Nicotine, fentanyl, estradiol and nitroglycerine are used in some transdermal patches available in the market today. Some attractive targets for transdermal delivery include alcohol cessation agents like naltrexone, testosterone, and antioxidants like vitamin C and vitamin E. Currently, the annual US market for transdermal patches is greater than $3 billion dollars; many companies are thus recognizing the value of transdermal delivery (Prausnitz et al., 2004). The problems associated with topical delive ry include local irritation or allergic reactions on the skin because of formulati on contents and poor penetration of drugs through the stratum corneal ba rrier due to poor physicochemical properties of the molecule.

PAGE 27

11 Approaches to Increase Permeation across the Skin The three approaches commonly used in incr easing transdermal delivery of drugs are. 1. Mechanical or electromechanical me thods like ultrasound, iontophoresis and microneedles. 2. Penetration enhancers and hydration. 3. Prodrugs. Ultrasound can be used to increase the tr ansport of both low molecular weight compounds and macromolecules like insulin a nd interferon. It reli es on usage of low frequency waves which causes disorganiza tion of lipid bilayers and increased permeability (Mitragotri and Kost, 2004). Iontophoresis is the use of an electric curre nt applied across the skin to drive drugs through the epithelium. The flow of electric current increas es the permeability of the skin. The current does not pass through the skin uniform ly but transappendageally through pores or sometimes through lipid channe ls. The electrical potential provides an electromotive force that is capable of dr iving charged molecules through the stratum corneum (Riviere and Heit, 1997). The formati on of HCl and NaOH by th e electrolysis of NaCl leads to a lowering of skin pH and are responsible for the irritation associated with iontophoresis (Mitragotri et al., 1996). Microneedles have also been used for tr ansdermal delivery of macromolecules. Micron sized needles in the pa tch pierce the skin into 10-15 m of the upper stratum corneal layer so that they do not stimulate th e nerves found in the lower layers and hence cause no pain while increasing the permeability of the drug used (Henry et al., 1998).

PAGE 28

12 The second approach to increase permeati on is by using penetration enhancers and hydration. The two distinct mechanisms by wh ich penetration enhan cers work are, the ‘push’ and the ‘pull’ mechanisms. The ‘pus h’ mechanism relies on the use of volatile components in a formulation to drive a drug into the skin. Evaporation of the volatile components leads to a supersaturated soluti on of the drug with thermodyanamic activity greater than one and results in increased flux through the membrane (Kadir, 1987). The ‘pull’mechanism on the other hand increases topical absorption by th e use of vehicles which interact with the skin and decreas e the diffusional resistance by disrupting the barrier, i.e., increase the de gree of hydration, leach the li pid components in the stratum corneal barrier or increases the solubilizing cap acity of the skin, so that flux of drug can increase (Barry, 1987). It is possible to incr ease the flux of a compound by about 10 fold by merely altering the vehicle properties before damage to the skin occurs (Sloan, 1992). Commonly used penetration enhancers in clude azone, DMSO, propylene glycol and decylmethyl sulphoxide. Keratolytic agents like salicyclic acid also increase penetration through the skin but cause damage. Hydration of skin leads to an increase in elasticity and permeability of the stratum corneal barrier. Occlusion is the most comma n way to increase the hydration of the skin as it prevents loss of moisture from the surface of skin by evaporation. It also leads to an increase in temperature and humidity on the surface and thereby to increased permeability of the drug. Topical formulations with fats and oils like glycols, glycerols, paraffins, waxes, silicones and clay also increase hydration (Block, 2000). Prodrugs represent yet another way in increasing topical ab sorption. They are biologically inactive and labile derivatives of a drug which revert to the active drug

PAGE 29

13 molecule by chemical or enzymatic hydrolysis. In this the case the dr ug in the form of a prodrug has better solubility in the skin and he nce gets pulled into the skin. An advantage of prodrugs over penetration enhancers is that prodrugs are a 1:1 molecular combination of drug and the promoiety compared to pe netration enhancers wh ere excess amounts are used which may cause allergic reactions or local irritation. Prodr ugs thus increase solubility of the drug in the skin while pene tration enhancers increa se the solubalization capacity of the skin for a drug molecule. Co mbination of prodrug with a penetration enhancer in the same formulation may prove to be more useful (Waranis and Sloan, 1987) but hasn’t been fully utilized yet. Theory of Percutaneous Diffusion The mechanism of permeation across human skin relies on passive diffusion which is driven by a difference in the concentrati on gradient across the membrane. Any solute diffusing through the skin shows an initial, nonlinear increase in drug concentration which represents a build up of the drug in ba rrier region. The emergence of drug from the barrier region is different from drug to drug because of the time required to saturate the membranes. This is also true for most controlled release systems like transdermal patches. This is called a lag-time effect. Once steady state is reached a linear increase of drug concentration is seen which represents a condition where the exodus of solute from the dermal side is equal to the mass of ma terial entering the epidermal side (Poulsen, 1971). By simply extrapolating the steady stat e line to the absci ssa it is possible to determine the time to reach steady state. It also gives an estimate of how much drug permeates through the transfollicular shunt rout e. This is very well illustrated by Figure 1-4.

PAGE 30

14 Figure 1-4 Illustration of a typical flux profile. The rate of mass transfer across a membra ne or flux (J) is proportional to the concentration gradient expressed across the membrane. Imagine two solution filled compartments containing different concentrations of some compound (CD and CR) and separated by a permeable membrane of thic kness h (Figure 1-5).The rate at which the drug diffuses across the membrane from one co mpartment to the other is described by Fick’s first law. Equation 1-1 shows the rela tionship in a mathematical form and forms the basis of Fick’s first law (Fick, 1855). J = (dM/dt) unit area = -D (dC/dx) (1-1) where dM is the amount in mass or moles of solute passing through the membrane in time dt, dC/dx is the concentr ation gradient within the membrane over infinitely small distances and D is called the diffusion coefficient (diffusivity): its units are area per unit time (cm2/s). The negative sign indicates that th e concentration decreases with distance.

PAGE 31

15 CD Donor compartment (CD>>C1) CR Receptor compartment (C2>>CR) h C1 C2 Figure 1-5 Two compartment diffusion model. To utilize Fick’s law experimentally, th e concentration in both compartments (CD and CR) are maintained constant so as to ha ve a constant concentration gradient (C1-C2) across the membrane once equilibrium is esta blished and sink conditions are maintained i.e., CR 0. The partial differential can be replaced by C1, C2 and h. The concentration gradient can further be simplified as dC/dt = (C1-C2)/h (1-2) where C1 is concentration of the solute in the donor side of the membrane, C2 is the concentration of the solute on th e receptor side of the membra ne and h is the thickness of the membrane as shown in Figure1-5. Co mbining (1-1) and (1-2) we get J = (dM/dt) = -D (C1 – C2)/h (1-3) Both C1 and C2 are difficult to measure be ing inside the membrane. However under sink conditions, C1-C2 C1, C1 = SSkin (solubility in the skin), J = JMV (maximum flux from a saturated solution of drug in a vehicle). To maintain sink conditions it is necessary that the concentra tion of drug in the donor compartment doesn’t change with time and hence a suspension in equilibrium with a saturated solution is generally used for in vitro diffusion experiments and excess drug is used in a transdermal patch formulation. This type of trans port process follows zero order kinetics.

PAGE 32

16 JMV = D SSkin (1-4) h SSkin = SV. K Skin: V (1-5) Inserting (1-5) in (1-4) JMV = (D K Skin: V SV) (1-6) h where SV is the solubility of solute in the vehicle, JMV/ (SV) = P: P = (K Skin: V D) (1.7) h P is known as the permeability coefficient and can be determ ined experimentally. Since DA/h is constant, permeability coefficient is proportional to vehicl e/membrane partition coefficient of the drug. The more soluble th e drug is in the vehicle, the lower the permeability coefficient for the delivery of the drug from that vehicle (Sloan, 1992). The partition coefficient between drug in vehicle and in the membrane can be calculated from theory using equation (1-8). ln K = [( i – v) 2 v 2– ( i – s) 2 s 2]Vi (1-8) RT where i is the solubility parameter of the drug, v of the vehicle (8.5 (cal/cm3)1/2) for IPM (isopropyl myristate) and s is the solubility parameter of skin (10 (cal/cm3)1/2), Vi is the molar volume of the drug (cm3/mol), R is the gas constant (1.98 cal/K) and T is the temperature (305 K) (Sloan et al., 1986; Sh erertz et al., 1987; Sl oan et al.,1986a). The solubility parameter of the drug can be dete rmined experimentally or from individual

PAGE 33

17 group contribution methods (Sloan et al., 1986; Sherertz et al., 1987; Sloan et al., 1986a; Fedors et al., 1974; Martin et al., 1985; Martin et al., 1985a). Mathematical Modeling of Flux through Human Skin. Derivation of Roberts-Sloan equation from Fick’s law of Di ffusion (Roberts and Sloan, 1999). When the vehicle is water, equation (1-7) which relates permeability P with partition coefficient between skin and the vehicle can replaced by equation (1-9). P = (K Skin: AQ D)/h (1-9) The diffusivity or diffusion coefficient can be estimated from molecular volume through the following relationship (Cohen and Turnbull, 1959). D = D0e-z MV (1-10) The partition coefficient between skin and the vehicle is difficult to measure and thus can be estimated from the partition coefficien t between OCT (octanol ) or IPM (isopropyl myristate) and water (AQ) where a lipid like vehicle (OCT or IPM) replaces skin, which is considered to be lipid-like. K Skin: AQ = (KOCT: AQ) y (1-11) Here y represents the difference between the pa rtitioning domain of th e skin with respect to the solvent that replaces it, in this case OC T. The closer y is to 1, the closer the solvent is to being is a good surrogate of stratum co rneum lipids, e.g., ether has a y value of 0.53 while OCT has a y value of 0.7. Thus, OCT mi mics the skin more closely than ether does. By substituting equations (1-10) and (1-11) in equation (1-9) we get equation (1-12) P = [(KOCT: AQ) y D0 e-z MV]/h (1-12)

PAGE 34

18 By collecting the constants, taking the log of both sides and repl acing MV (molecular volume) by MW (molecular weight), the Po tts-Guy equation (Potts and Guy, 1992) can be obtained. log P = y log KOCT: AQ – z MW + x (1-13) where x = Do/h The Roberts-Sloan equation previously known as the transformed Potts-Guy model can be derived from the Potts-Guy model. The Potts-Guy is useful in predicting permeability through the skin but its prime lim itation is that it correlates permeability with partition coefficient between a lipid vehi cle and polar vehicle a nd hence is inversely proportional to solubility of the drug in a polar vehicle like water. This has serious implications in drug design and misleads medi cinal chemists to synthesize more lipid soluble derivatives in order to optimize topi cal delivery of a drug. We will talk about the importance of biphasic solubility on topical deli very in the chapters that follow. A model for flux (J) instead of permeability (P) is more clinically relevant because it actually tells us how much solute in moles (amount) is go ing into the skin compared to permeability. Since: JMAQ = (P) (SAQ) (1-14) Inserting equation (1-14) in equation (1-13) we get log (J/SAQ) = y log KOCT: AQ – z MW + x (1-15) log JMAQ – log SAQ = y log KOCT: AQ – z MW + x log JMAQ – log SAQ = y log SOCT – y log S AQ – z MW + x log JMAQ = y log SOCT – y log SAQ –z MW + log SAQ + x log JMAQ = x + y log SOCT + (1-y) log SAQ – z MW (1-16)

PAGE 35

19 Equation (1-16) is commonly referred as the Roberts-Sloan equation ( RS ) and in it flux is proportional to both the lipi d and the water solubilitie s of a drug and inversely proportional to molecular weight. If IPM instead of water was used as th e vehicle in diffusion cell studies, because some prodrugs were unstable, a diffe rent derivation is required. Starting at equation (1-6), wh ich was previously derived, bu t using IPM as the vehicle and D = Do exp (-z MW) as in equation (1-10) we get JMIPM = Do exp (-z MW) K Skin: IPM.SIPM h Taking the log of both sides and combining constants (x = Do/h) we get log JMIPM = x + log K Skin: IPM + log SIPM – z MW (1-17) Since, K Skin: IPM = K Skin: AQ/ K IPM: AQ (1-18) And since equation 1-11 relate s the partition coefficient betw een skin and the vehicle to the partition coefficient between OCT and AQ; where the vehicle is IPM, we can replace OCT with IPM to give equation (1-19). K Skin: AQ = (K IPM: AQ) y (1-19) Taking the log of both sides of equation (1-18) and substituting (1-19) for KSkin:AQ we get equation (1-20) log KSkin: IPM = y log K IPM: AQ – log K IPM:AQ log KSkin:IPM = y log SIPM – y log SAQ – log SIPM + log SAQ (1-20) Substituting equation (1-20) into equation (1-17) log JMIPM = x + y log SIPM – y log SAQ – log SIPM + log SAQ + log SIPM – z MW

PAGE 36

20 Collecting the terms we arrive at the RS equation. log JMIPM = x + y log SIPM + (1-y) log SAQ – z MW (1-21) or log JMV = x + y log SLIPID + (1-y) log SPOLAR – z MW (1-22) Equation 1-22 is the general form of the RS equation. From equation 1-4 JMV = D SSkin (1-4) h Inserting equation 1-10 (D = D0 exp (MV)) into equation 1-6 we arrive at: JMV = D0 exp (MV) SSkin (1-23) h Taking the log of both sides and collecting the constants we get: log JMV = x + log SSkin – z MV (1-24) where x = D/h and z = Correlating equation 1-24 with equation 1-22 ( RS ) we get log SSkin = y log SLIPID + (1-y) log SPOLAR (1-25) Equation 1-25 illustrates that solubility in skin can be modeled by solubility in two phases: solubility in a lipid phase and solubility in a polar phase. Biphasic solubility thus becomes an important determinant in optimizing flux through the skin. The RS equation has been used to predict th e topical delivery of homologous series of prodrugs across hairless mouse skin from their suspensions in isopropyl myristate (Wasdo and Sloan, 2004) and water in vitro (Sloan et al., 2003) and permeation of nonsteroidal anti-inflammatory drugs through human skin from mineral oil in vivo

PAGE 37

21 (Wenkers and Lippold, 1999 and Roberts and Sloan, 2001), permeation of solutes, chemicals and drugs from water in vitro (Flynn, 1990 and Majumdar et al., 2004) and penetration of sunscreens and antimicrobials in in vivo human skin from PG/water (Leweke and Lippold, 1995 and Majumdar and Sloan, 2005). In all cas es a significant dependence of flux on water solubility was obs erved regardless of the vehicle used. Table 1-1 shows the coefficients of x, y, z and r2 of these databases. Th e RS equation can used to predict flux of any drug molecule acr oss skin from any vehicle if three physicochemical parameters SLIPID (solubility in a lipid lik e vehicle like OCT or IPM), SPOLAR (solubility in a polar vehicle like wa ter or propylene glycol) and MW are known. Table 1-1 x, y, z, r2 and Average Residual Errors fo r Various Databases Fit to RS. Fit to RS (see text) Model Database Vehicle n x y z r2 logJM in vivo Human Skin Wenkers and Lippold (1999) Mineral oil 10 -1.459 0.722 0.00013 0.93 0.133 in vitro Hairless Mouse Skin Sloan and coworkers (2003) Water 18 -1.497 0.66 0.00469 0.77 0.193 in vitro Hairless Mouse Skin Wasdo and Sloan (2004) Isopropyl Myristate 61 -0.491 0.52 0.00271 0.91 0.15 in vivo Human Skin Flynn (1990) Water 103 -2.571 0.56 0.00444 0.9 0.44 in vivo Human Skin Leweke and Lippold (1995) 30% PG/ water 10 -2.116 0.45 0.00048 0.97 0.11 Prodrugs The word prodrug was coined by Adrien Albert to descri be compounds that undergo biotransformation prior to eliciting th eir pharmacological effects (Albert, 1958). It is impossible to review prodrugs of all cl asses; we will therefore cover only the basic

PAGE 38

22 principles involved in prodrug de sign and their applications in clinical practice (Ettmayer et al., 2004). Prodrugs have been primarily designed to increase oral bioava ilability, solubility, enhance chemical stability, prevent prematur e metabolism, decrease toxicity and improve taste (Stella, 1985). The primary function of a prodrug is to mask a polar functional group (-XH) where X can be –OH (phenolic or alc oholic), -COOH, -SH, -NH (amide, imide or amine) in a transient manner so that once the pr odrug is in the target site (which may be a tissue, cell or membrane) it hydrolyses to release the active drug molecule (Bundgaard, 1991). Since the polar functional group is mask ed, the tendency of the drug molecule to form intramolecular hydrogen bonding is also blocked. This leads to improved solubility properties of the prodrug in both lipid a nd aqueous phases with respect to the drug (Bundgaard, 1991). By merely increasing biphasic solubility of drugs it is possible to improve absorption and permeability across biological membrane barriers like the enterocyte cells of the GI tract or stratu m corneum of skin (Sloan and Wasdo, 2003). An increase in absorption and permeability resu lts in increased bioa vailability. Prodrugs containing charged promoieties like phosphate s, amino acids, hemisuccinates and amines have often been used in the promoiety to in crease the aqueous solubility of drugs which leads to increased dissolution rates and e nhanced oral (Fleisher et al., 1996) and transdermal absorption of the drug (Sloan and Wasdo, 2003). Masking of a functional group transiently also may allow drugs to evad e P-gp mediated efflux across the GI tract. (Jain et al., 2004). To make a hydrolytically la bile prodrug it is necessary to atta ch the drug to a promoiety which is stable enough to reach the ta rget site but labile enough to release the

PAGE 39

23 drug efficiently. Most prodrugs utilize an es ter promoiety because of the presence of esterases which are largely nonspecific and found in most tissues, biological fluids, organs and blood etc, and which hydrolyse the prodrug to give the corresponding drug (Beamount et al., 2003). A sc hematic representation is shown below (Figure 1-6). X O R' XH R'COOH O OR COOH ROH DRUG ESTERASES DRUG + DRUG DRUG + ESTERASES X = N, O, S; R = ALKYL; R' = OALKYL, N-ALKYL Figure 1-6 Esterase mediated hydrolysis of prodrugs. Carbonates of drugs have been made where the esters were too labile. Insertion of an oxygen atom in the promoiety led to grea ter stability of the corresponding prodrug in vivo because of the +I effect imparted by the oxygen atom which decreases the electrophilicity of the carbonyl group towards esterases. Si milarly a nitrogen atom can be inserted in the promoiety if a more stable derivative is desired. Since a prodrug needs to hydrolyse to be e ffective, the inability of esterases to efficiently transform penicillin esters to peni cillin led to the design of soft alkylated derivatives which are alkyl carbonyloxymethyl (ACOM) pr odrugs. The ACOM promoiety relies on a ‘OCH2’ spacer between the drug functi onal group and the labile ester functionality. Penicillin esters are steri cally hindered towards enzymatic hydrolyses however insertion of a ‘OCH2’ spacer made it easier for the esterases to freely access the ester functionality and hydr olyze it efficiently (Jansen and Russell, 1965).These soft alkylated derivatives rely on esterase hydrolysis to yield a hydroxymethyl derivative of

PAGE 40

24 the parent drug which is chemically lab ile and yields the parent molecule and formaldehyde (Figure 1-7). These types of promoieties rely on both enzymatic and chemical hydrolyses to release the drug molecu le at the target site In cases where the ACOM moiety was not sufficiently stab le, the alkyloxycarbonyloxymethyl (AOCOM) promoiety have been used where the ester is replaced by a carbonate functional group. The use of soft alkylation has been extended to other drugs containi ng various functional groups like imides (Bodor and Sloan, 1977; Buur and Bundgaard, 1985 and Taylor and Sloan, 1998), amines, phenols (Sloan et al., 1983a and 1983b; Bundgaard, et al., 1986 and Seki et al., 1988); alcohols (Beamount et al.), thiols (Sloan, 1983) etc. O O O O R O O OH COOH O O R X X OH XH DRUG ESTERASES DRUG DRUG -HCHO DRUG ESTERASES DRUG DRUG -HCHO X = N, O, S; R = ALKYL or OALKYL Figure 1-7 Soft alkyl prodrug hydrolysis. One of the critical issues involving prodrugs is that they should be labile but if they are too labile they won’t reach the target s ite and their purpose will be lost. Thus it is important to design derivatives accordingly and use esters or carbonates (ACOMs or AOCOMs) depending on the problem in hand a nd fine tune stabil ity to meet design directives. Sometimes it is necessary to rel ease drugs slowly and in such cases prodrug derivatives need to be more st able so that the residence time in the body is enhanced. We will look at some examples of such prodrugs later on. One of the prime reasons for esters being so widely used as prodrug promoieties is that they are easy to make and are economi cal. They release non-toxic side products on

PAGE 41

25 hydrolysis which is an importa nt factor in drug developmen t. Soft alkylated prodrugs release formaldehyde which is relatively innocuous and biocom patible since it is released as a byproduct during O or N-dealkylation of drugs by CYP 450 catalyzed oxidative reactions in liver and intes tines (Beamount et al., 2003). Another type of soft alkylating promoiety which has been useful in increasing oral bioavailability of phenolic dr ugs like estradiol is O-imidomethyl saccharin. The oral bioavailability of estradiol is drastically re duced by sulfation and glucuronidation of the phenolic functional group which leads to ra pid elimination of the drug from the body before or after it is absorbed. Such premat ure metabolism can be prevented by transiently masking the phenolic group with an imidom ethyl group such as O-imidomethyl-saccharin (Figure 1-8). The potency of the drug deliver ed as a prodrug was increased by about 8 times compared to an equimolar dose of estr adiol alone (Patel et al., 1991). The prodrug has a half life of 100 min under physiological conditions and the mechanism of hydrolysis is believed to be SN2 (Getz and Sloan, 1993), al though others suggest an addition to the carbonyl group followed by a vi nylogous elimination (Iley et al., 1998). Both mechanisms may be operating. This t ype of prodrug approach is independent of enzymatic hydrolysis and can be useful in cas es where enzymatic va riability becomes an issue; the ester promoiety is enzymatically too labile or efficient hydr olysis to the active principle is limited by strict structure specificity of the enzymes as in case of blood (Beamount et al., 2003). Although pharmaceutical scientists have often utilized esterases to biotransform a prodrug to its active parent drug, human alkaline phosphatases are another class of

PAGE 42

26 O N S O O O OH O O H NH S O O O O H -HCHO + SN2 S N O O O O OH O OH S O O N OH O H -OH + Figure 1-8 Hydrolysis pathways for Sacch arin based O-imidomethyl derivative of estradiol. enzymes which are found throughout various ti ssues (Strigbrand a nd Fishman, 1984) and which have been used by chemists to dephosphorylate phosphor yloxymethyl prodrugs. Fosphenytoin (Stella, 1996) is one such dr ug which is activated by phosphatases to give hydroxymethyl phenytoin which spontaneously loses formaldehyde to generate phenytoin (Figure 1-9). Delivery of phenytoin was a probl em because of its poor aqueous solubility

PAGE 43

27 (20-25 g/mL) and was formulated at pH 12 when given parentally; crystallization of drug at the injection site was seen. The a queous solubility was enhanced by using the phosphoryloxymethyl promoiety by about 4410 ti mes. The water solubility of the prodrug increased to 142 mg/mL (88. 2 mg/mL equivalent of phenytoin). O O N N H O P O H O O H O O N N H O H O O N H N H FOSPHENYTOIN PHOSPHATASES -HCHO PHENYTOIN Figure 1-9 Hydrolysis of phosphoryloxymet hyl prodrug mediated by phosphatases. This promoiety has also been used to incr ease the solubility of amines and alcohols (Safadi et al., 1993 and Krise et al., 1999). Thus phosphoryloxymethyl is another example of soft alkylating promoiety. The ge neric chemical structure of soft alkylating promoities is shown below. Phosphoryloxymethyl has two X’’’R’s, i.e., X’-P=X”(X”’R’)2.

PAGE 44

28 X R X' Y X'' X''' R' DRUG X = N, O, S; R = H or ALKYL; X' = N or O; Y= C or P; X" = O; X"' = ALKYL, N or O; R' =ALKYL and H The following discussion about the use of pr odrugs to increase delivery covers some miscellanenious examples which include the use of a novel enzyme system (amidoreductases), use of a water solubl e polymer (polyethylene glycol) and a polypeptide (Tat protein). Amidoximes are bioconverted to amidines by reductases expressed in the kidneys, liver, brain, lungs and GI tract (Clement, 2002). The double prodrug Ximelagatran relies on amidoreductases and esterases to yield the active drug melagatran. N H N O N H N N H2 OH O O N N O N H N N H2 H O O H H H MELAGATRAN + + XIMELAGATRAN Melagatran is a charged mo lecule at physiological pH with the carboxylate anion (acidic pKa ~ 2), amidine (basic pKa ~ 11. 5) and secondary amine (basic pKa ~ 7) functional groups making it very hydrophilic. As a result absorption acr oss the GI tract is decreased and its oral availability compromi sed. In the prodrug, the carboxylate ion is blocked as an ester. Since the ester is electr on withdrawing the pKa of the secondary amine is reduced to 4.5 and it is no longer charged at physiological pH. The amidine is protected as an amidoxime whose basic pKa wa s reduced to 5.2 so it is no longer charged

PAGE 45

29 either. Thus, the resultant molecule is ne utral at physiological pH, 170 times more lipophilic based on K values and about 3-6 fold more bioavailable as a result of increased absorption (Gustafsson et al., 2001 and Clement and Lopian, 2003). In the prodrugs we have talked about till now, the drug was attached to the labile promoiety directly or through a linker. In th e following example, a drug is conjugated to the linker (which should be a labile and bifunctional group), through a bridging functional groups, the linker in tu rn is attached to a promoi ety (which may be something that increases the solubility of the drug or increases its uptake). This type conjugate is a new class of prodrugs called tripartate prodrugs. Amino acids, aminoethoxyalcohols, hydroxybenzylalcohols, aminobenzylalcohols and o-hydroxyphenylprop ionic acids have all been used as bifunctional linkers through which PEGs can be transiently attached to drugs (Greenwald et al., 1999 and 2000). Th e active drug molecule is released by hydrolysis in two steps. An example utiliz ing hydroxyl-benzylalcohol as the linker and CO2 as the bridging functional group is shown below for an amine drug like Daunorubicin (Figure 1-10).These polyethylenegl ycol ether (PEGs) prodrugs have been used to increase the systemic circulati on time. Greenwald and coworkers (1996, 2001, 2003) have evaluated a series of PEGyla ted conjugates of anti cancer drugs like Campothecan and Taxol with PEGs of various molecular weights. PEG40000-AlaCampothecan (Prothecan) is presently in phase II clinical trials for treatment of lung, pancreatic and gastric cancers. Here the mo lecule has the aminoacid alanine acting as a linker between the Campothecan and PEG (Figure 1-11).

PAGE 46

30 O O PEG O O NHDRUG O N H DRUG O O O CO2DRUG-NH2 OH2 OH O H ESTERASES + + Figure 1-10 Hydrolysis of PE G conjugated to drug using a hydroxyl-benzylalcohol linker in vivo. O N O N O O O N H O O PEG OH N O N O O Figure 1-11 PEG-Ala-Campothecan These conjugates have higher water sol ubility than Campothecan which allows increased dissolution of the drug. Also, since the molecular weight of the conjugates is close to 45KDa (which is the renal threshol d limit), these drugs are retained in the body longer because of a phenomenon known as ‘e nhanced permeation retention’ (EPR) (Maeda et al., 1992). These prodrugs need to circulate in the body fo r longer periods and release the drug slowly in a c ontrolled manner; they have ha lf lives >10 h compared to other traditional prodrugs with half-lives of 20 min. These molecules evade glomerular filteration of kidneys which excretes molecu les whose size is 30KDa (Yamaoka et al., 1994). Thus the drug selectively accumulates in the cancer cells taking advantage of the

PAGE 47

31 leaky tissues and reduced drainage seen in cancerous tissues. This selectively towards cancerous cells leads to reduced toxicity a nd better targeting of anti cancer agents. Drugs have also been conjugated to oligoa rginine residues to increase their uptake across cell membranes and skin. Certai n proteins contain subunits like Tat 49-57 (RKKRRQRRR) of HIV-1, that en able the translocation of proteins across the plasma membrane into the cells (Green and Lo evenstein, 1988; Ande rson et al., 1993 and Lindgren et al., 2000). The intact Tat protein has been conjugat ed to proteins to enhance their delivery (Kim, 1997 and Nagahara, 1998). The chirality of the arginine residue (D or L) didn’t affect cellular uptake. The Tat pr otein efficiently crosses membranes of cells in an energy dependent fashion after endocyt osis (Mann and Franke l, 1991; Vives, 2003 and Fuchs and Raines, 2004). There is some evidence for guanidium rich molecules undergoing receptor mediated endocytosis due their big size i.e. MW >3000. An alternative mechanism of uptak e is believed to be electrostatic interaction between the positively charged guanidine (pKa ~ 12-13) and the carboxylate ion of the lipid bilayer or phosphate group of the phospholipids bilayer to fo rm a transient ion pair complex (Figure 1-12) which is less polar than the drug-Arg conjugate (Luedt ke et al., 2003 and Rothbarg et al., 2002). The driving force for the passage through the membrane is voltage potential across most cell membranes. The positively charged complex formed due to incomplete ion pairing with anionic cell components moves along the direction of transmembrane potential (intracellular K+levels >>>extracellular K+ levels). Uptake is decreased when membrane potential decreases (e xtracellular and intracellular K+ levels equal) while it increases when a peptide antibiotic like valinomycin which selectively shuttles K+ across the membrane is used in the assay. The co mplexes dissociate on th e inner leaf of the

PAGE 48

32 membrane. Truncation studies and synthe sis of a series of analogues of Tat 49-57 revealed that short chain oligomers (7-9 residues) of arginines are more efficient in translocation than the entire protein (We nder et al., 2000). Wender and coworkers analyzed a series of Cyclosporin-Arg7 and Paclitaxel-Arg8 conjugates for uptake across human, mice skins and various in vitro cell line surrogates of plasma membrane. They found that it is necessary to have the guanidin e moiety; oligolysine, oligohis tidine or citru line residues were not as successful as oligomers of arginine (Mitchell et al., 2000). When the guanidine residues were al kylated the complex formation was hindered and uptake diminished. A bidentate ligand like guanidine is able to form stronger ionic complexes with a phosphate than the regular amine of lysine : as a result uptake is higher for arginine rich residues than other charged ami no acid residues (Rothbard et al., 2005). N H O N H NH2 N H P O O O O Figure 1-12 Ionic complexes formed by oligoargin ine of Tat with the phosphate groups in cell membranes. Too few arginine residues di minishes cell surface adhere nce while too many positively charged guanidines lead to reduced escape fr om the inner leaf of the membrane. The active drug is released from the conjugate hydrol ytically with half lives depending on the pH sensitive linker being used (Figure 1-13). CyclosporineArg7 conjugates release the active drug at pH 7.4 and 37C with a half lif e of 90 min. The mechanism of hydrolysis is intramolecular nucleophilic a ttack by the secondary am ine on the ester carbonyl functional group (Rothbard et al., 2000) Similarly in case of TaxolArg8 conjugates, the hydrolysis rates vary depending on the R group a ttached to the amine from 1 min for R =

PAGE 49

33 H to 107 min for R = Boc. Thus it is possible to control the rates of hydrolysis just by varying the R group from an electron dona ting to an electron withdrawing group (Kirschberg et al., 2003). N H O N O O CSA O Ph NHArg7-COOH N N O O O NHArg7-COOH Ph O O S RHN NH-Arg8-CONH2 O TAXOL RNS O O H2NCO-8grA-HN + CSA pH 7.4 pH 7.4 TAXOL + R = H, Ac, Piv, Boc; CSA Cyclosporin. Figure 1-13 Chemical hydrolysis of oligoarginine conjugates of cyclosporine and taxol. Prodrugs for Dermal and Transdermal delivery Although the previous paradigm (Guy and Hadgraft, 1988; Flynn, 1990) for increasing dermal delivery focused on increasing KOCT:AQ, most effective prodrug approaches aimed at improvi ng the delivery of drugs acro ss the skin have relied on increasing the solubility in a lipid vehicle (SLIPID) like octanol or IPM and the solubility in a polar vehicle like water (SAQ) of the prodrug over the parent drug. It is believed that an increase in biphasic solubility of the drug le ads to an increase in permeability of drugs across the stratum corneum (Sloan et al., 1984; Sloan, 1989 and 1992; Sloan and Wasdo, 2003). In a homologous series of lipophilic pr odrugs, the more water soluble of the more lipid soluble member of the series gave the highest flux (Sloan et al., 1984, 1984, 1992, 2003 and 2004). Thus the balance between so lubility in lipid and aqueous phases

PAGE 50

34 becomes paramount and flux is better modele d by a combination of these two parameters rather than K (partition coefficient). Previ ously it was shown that by merely masking polar functional groups transien tly it is possible to increa se biphasic solubility and thereby flux. While it is easy to see ho w addition of carbon atoms to the promoiety conjugated to the drug increases SLIPID, it is difficult to visualize why a simulataneous increase in SAQ occurs. For example, one may compare caffeine, theophylline and theobromine to illustrate this increase in SAQ (Windholz et al., 1983). Theobromine has two intramolecular hydrogen bonding sites; theophylline has one hydrogen bonding site while caffeine has none. A look at the melting points and SAQ of these three compounds reiterates the fundamental idea behind prodrug synthesis. Th e masking of polar functional groups leads to decreased intramolecular hydrogen bonding and in turn leads to a decrease in lattice energy, melting points and increase in biphasic solubilities. N N N N H O O N N N N O O N H N H N N O O CAFFEINE THEOPHYLLINE THEOBROMINE mp: 357 270-274 238 Saq: 3 mmol/l 46.55 mmol/l 112.64 mmol/l Codeine, the ether derivative of morphine is 40 times more water soluble than morphine and 2400 times more lipid soluble. Thus masking of a phenolic functional group increases solubility in both phases. There are two types of prodrug promoieties th at have been used in dermal delivery; the acyl based approach (N-acyl, O-acyl a nd S-acyl) and soft alkyl based approach (ACOM or AOCOM). In the discussion that follows we will look at the importance of

PAGE 51

35 solubilities in optimizing flux across the skin with examples. Consider the table below for series of 1-alkyloxycarbonyl -5-FU prodrugs and 5-FU with their physicochemical properties (Table 1-2). Melting points (mp), molecular weight (MW), log solubility in isopropyl myristate (log SIPM), log solubility in water (log SAQ), log partition coefficients between IPM and pH 4 buffer (log KIPM: AQ) and log maximum flux of total species delivered by the prodrug (and 5-FU) through hairless mice skins in vitro from an IPM donor phase (log JMIPM) (Beall et al., 1993) are given. Table 1-2 Physicochemical Characterization of 1-Alkyloxycarbonyl esters of 5-FU. Compound mp MW log SIPM log SAQ log KIPM:AQ log J MIPM C1 160 188 0.328 2.05 -1.72 0.42 C2 128 202 1.117 2.24 -1.12 0.77 C3 126 216 1.182 1.63 -0.45 0.36 C4 98 230 1.529 1.37 0.16 0.35 C6 67 258 2.186 0.7 1.48 0.19 C8 98 286 1.561 -0.89 2.46 -0.53 5-FU 284 130 -1.308 1.93 -3.24 -0.62 The melting points of the prodrugs decr ease with the addition of each CH2 unit from C1 to C6 while the melting point of C8 prodrug is higher than the C6 probably because of van der Waals interaction between the alkyl side chains (Yalkowsky, 1977). This increase in melting point al so leads to a decrease in SIPM. All members of the series are more lipid soluble than 5-FU. The C6 pr odrug derivative is the mo st lipid soluble of the series, has the highest K and SIPM. So, if SIPM were the most important determinant, then its log JMIPM should be the highest instead it is the ne xt to lowest in the series. On the other hand, the C2 prodrug has a higher lipid so lubility than 5-FU (not the highest) and highest SAQ in the series (1.8 times more water so luble than 5-FU) and gives the highest JMIPM (25 fold higher than 5-FU) across the sk in. Sloan and coworkers (1983, 1984 and 2003) have reported such dependence on bi phasic solubility fo r a series of 6-

PAGE 52

36 mercaptopurine (6MP), ThH and 5-FU prodr ugs. It was first observed for 7-ACOM prodrugs of ThH (Sloan et al., 1982) but not recognized as a new paradigm until later (Sloan et al., 1984). There are two schools of thought for optimizi ng flux across the sk in. The first relies on increasing the lipid solubility without incr easing aqueous solubility of the prodrug and uses increased KOCT: AQ as an indicator of increased li pophicity. Since skin is primarily a lipophilic barrier it relies on ma king a prodrug with higher K than the parent drug so that penetration across the barrier can be enhanced. In this school of thought, any dependence of flux on aqueous solubility is attributed to the use of a polar ve hicle, the nature of mouse skins (which are more hydrophilic than human skin), in vitro experimental conditions and metabolic ra tes of conversion. In in vitro cell experiments, the skin is abnormally hydrated particularly when water is used as a vehicle. Thus some argue that the dependence of flux on SAQ could be due to the necessity fo r increased solubility in the vehicle. This school of thought also argues th at lipid soluble prodru gs undergoing fast rates of hydrolysis to the more water solubl e parent drug bypasses the hydrophilic region of the skin dermis easily and permeates the skin better. However in case of lipid soluble prodrugs undergoing slower hydrolysis, the dermis becomes a rate limiting barrier and the prodrug gets trapped in the dermis, co mpromising delivery across the skin. Thus water solubility becomes important only if the designed prodrugs are stable to hydrolysis during their passage through the skin (Stin chcomb and coworkers, 2002 and 2005). The second school of thought relies on the importance of biphasic solubility in order to increase flux. It reli es on increasing both lipid and water solubility at the same time to optimize delivery. It is important to note that flux is inde pendent of metabolic

PAGE 53

37 conversion rates of prodrug to the drug because flux is dependent only on the solubility in the membrane (Equation 1.4). The observations that flux depends on SAQ and SLIPID holds true for prodrugs with a half -life of 1-5 min (7-AC-Th, Sloan et al., 2000) to prodrugs which permeate intact in diffusion cells experiments (1-ACOM-FU, >50% intact prodrug obtained, Taylor and Sloan, 1998) run on hair less mice skins. The argument against the dependence of water solubility due to the pres ence of stagnant water layers in presence of a polar vehicle or in in vitro conditions when the skin is heavily hydrated comes from experiments carried out with isopropyl myrist ate as a vehicle (a non polar vehicle in which the longer chain prodrugs were more soluble). The same dependence on SAQ was again observed where IPM was the vehicle, reemphasizing the fact that this dependence is a result of the inhere nt properties of the skin. In Vivo human skin (human skin is less hydrophilic than mouse) experiments using mi neral oil also show dependence on water solubility. Irrespective of the ve hicle used, the best performing prodrug of a series from a vehicle like IPM is also the be st performing prodrug from a di fferent vehicle like water. The best prodrug was the one with the best biphasic solubility. The increase in flux though varies from vehicle to vehicle dependi ng on the interaction of the skin with the vehicle. IPM causes more damage than water does; it leaches out the lipids from the stratum corneum hence compromises the barrier and leads to increased permeability of prodrugs compared to water (Sloan et al., 2003a). Water so lubility is important in improving flux across the skin whether it is hum an skin or mouse skin, polar or non polar vehicle, in vitro or in vivo, and prodrugs which are labile or stable to hydrolysis. In the 5-FU prodrug series we considered above, the prodrug exhibiting the best flux had a higher SAQ and SLIPID than 5-FU. It is not alwa ys possible to increase SAQ of the

PAGE 54

38 prodrug compared to the parent drug. In such cases, the best perfor ming prodrug is the one which shows minimum decrease in SAQ with respect to the parent drug, e.g. methyloxycarbonyl-APAP prodrug shows the highest flux through skin in the homologous series of alkyloxycarbonyl-APA P prodrugs investigated by Wasdo and Sloan (Table 1-3). This particular derivativ e was 6.3 times more lipid soluble and about 3.5 times less water soluble than APAP, yet was the most water soluble prodrug of the series being investigated. Table 1-3 Physicochemical Characteri zation of Alkyloxycarbonyl esters of Acetaminophen. Compound mp MW log SIPM log SAQ log KIPM:AQ log J MIPM C1 112 209 1.08 1.31 -0.16 0.0 C2 120 223 0.97 0.58 0.32 -0.76 C3 104 237 1.37 0.43 0.9 -0.45 C4 118 251 1.14 -0.43 1.5 -1.01 C6 108 279 1.22 -0.37 2.71 -1.49 APAP 171 151 0.28 2.0 -1.72 -0.29 Similarly in the 7-alkyloxycar bonyl-Th series (Sloan, 2000), C3-Th was most water soluble prodrug member of the lipid soluble series. This prodrug derivative was 1.3 times less water soluble than ThH and s till gave higher flux than ThH. Ever since SAQ of a drug was recognized as being important to optimize dermal delivery, attempts have been made by Sloan and coworkers (Sloan et al., 1984; Sloan et al., 1988; Saab et al., 1989 and 1990) to in corporate basic amino groups into the promoiety. The rationale behind introducing a polar functional group like amine into a promoiety is to increase the wa ter solubility of poorly solubl e drugs. Insertion of simple alkyl groups into the promoiet y does increase lipid solubil ity but increases in water solubility are modest and are restricted to the shorter alkyl chain members. Mannich bases (DrugX-CH2-NR2, X = S, N, O; R = alkyl) of 6MP, 5-FU and ThH were thus

PAGE 55

39 designed to improve SAQ of the prodrugs without decreasing SLIPID compared to the parent drug and hence to increase flux. Hussain and coworkers (Milosovich et al., 1993 and Jona et al., 1995) added polarisable amino groups to the alcohol portion of testosterone and indomethacin ester prodrugs. When the 4-dime thylaminobutyrate hydrochloride ester of testosterone was examined in vitro using human skin, a 35 fold flux enhancement was observed (Figure 1-14). Similarly when 2-di ethylaminoethyl group was built into the ester promoiety of indomethacin the SAQ was enhanced compared to the parent drug and flux through skin increased by a bout six fold (Figure 1-14). N O Cl O MeO O N(CH2CH3)2 O O N(CH3)2.HCl O Figure 1-14 Structure of testos terone and indomethacin este rs with polarisable side chains. Also, attempts have been made by Bonina and coworkers (1995) to increase SAQ and SLIPID by incorporating short ch ain polyethylene glycolic et hers into the promoiety. Thus NSAIDS esters with small PEGs have been evaluated for their flux across human skin. These polyethers did increase both SAQ and SLIPID, e.g. for the indomethacin esters addition of a -OCH2CH2 unit increased SAQ by 1.3 fold and SLIPID by 1.02 times and as a result flux also increased. Although all the derivatives were more lipid soluble than indomethacin, the prodrug containing n = 5 -OCH2CH2 units, which was 1.77 times more water soluble and 9 fold more lipid soluble than indomethacin, gave the highest flux, (Table 1-4).

PAGE 56

40 N O Cl O O(CH2CH2O)nCH2CH2OH MeO PEG-esters of Indomethacin Prodrug promoieties containing s hort PEGs can thus increase the biphasic solubility of lipid soluble drugs with very poor aqueous solubi lity. It is interesting to note even in this series of ‘ethylene oxy’ homol ogous series it is the more water soluble derivative that gave the highest flux just as in case of simple alkyl derivatives where a ‘CH2’unit is inserted for ‘O’along the series. Thus, the importance of the balance between SLIPID and SAQ of the prodrugs is important in optimizing delivery of drug molecules topically. Table 1-4 Physicochemical Characteriza tion of PEG esters of Indomethacin. COMPOUNDSSOCT (mmol mL-1102) SAQ (mol mL-1 102) JM (mol cm-2 102) Indomethacin 27.7 22 0.84 n = 1 221.9 6.7 0.4 n = 2 225.8 9.2 0.65 n = 3 240.1 17 0.73 n = 4 244.3 25 2.83 n = 5 251.8 39 3.12

PAGE 57

41 Research Objectives N-alkyl-N-alkyloxycarbonylamin omethyl (NANAOCAM) promoi ety has been used to make prodrugs of 6-mercaptopurine for topical delivery (Siver, 1990). The mechanism of hydrolysis however wasn’t clearly established. The purpose of this research project was to explore the use of NANAOCA M promoiety as prodrugs of ot her functional groups like phenols, carboxylic acids, imides and evaluate its potential use for enhancing the skin penetration of model phenolic and imide containing drugs. 1. Design, synthesize, and investigate ra tes of hydrolysis and mechanism of hydrolysis of N-alkyl-N-alkyloxycar bonylaminomethyl (NANAOCAM) and Naryl-N-alkyloxycarbonylaminomethyl (NAr NAOCAM) prodrug derivatives of phenols and carboxylic acid. 2. Synthesis of homologous series of NANAOCAM prodrugs of acetaminophen (APAP, model phenolic drug) and their physicochemical characterization which includes: measuring solubilities in isopropyl myristate (IPM) and water, partition coefficients of prodrugs between IPM and pH 4.0 buffer, investigation of flux of compounds through hairless mice skins from IPM. 3. Synthesis of homologous series of NANAOC AM prodrugs of theophylline (ThH, imide containing drug) and their physicoch emical characterization which includes: measuring solubilities in isopropyl myristat e (IPM) and water, partition coefficients of prodrugs between IPM and pH 4.0 buffer, investigation of flux of compounds through hairless mice skins from IPM. 4. Mathematical modeling of flux These goals are discussed in three separa te chapters. Chapter 2, talks about the design of NANAOCAM promoiety, synthesi s of NANAOCAM-drug derivatives by alkylation of drug with N-alkyl-N-al kyloxycarbonylaminomethyl chlorides, determination of rates of hydrolysis in aqueous buffers, its implication on prodrug design leading to the synthesis and hydrolysis of N-aryl-N-alkyloxycarbonyl-aminomethyl (NArNAOCAM) prodrugs of phe nols and carboxylic acids.

PAGE 58

42 Chapter3 deals with alkylation of acetaminophen with N-alkyl-Nalkyloxycarbonylaminomethyl chlorides to synthesize a homologous series of NANAOCAM prodrugs, evaluation of physicochemical properties and transdermal and dermal penetration of these prodrugs and pred iction of flux of APAP prodrugs using the RS equation. Chapter4 deals with alkylation of the ophylline with N-alkyl-N-alkyloxycarbonylaminomethyl chlorides to synthesize a homologous series of NANAOCAM prodrugs, evaluation of physicochemical properties and tr ansdermal and dermal penetration of these prodrugs and prediction of fl ux of ThH prodrugs using the RS equation, and all NANAOCAM prodrugs when fitted to the existing n = 63 database.

PAGE 59

43 CHAPTER 2 DESIGN, SYNTHESIS, HYDROLYSIS OF N-ALKYL-N-ALKYLOXYCARBONYLAMINOMETHYL DRUG DERIVATIVES AN D ITS IMPLICATIONS ON PRODRUG DESIGN. Introduction Drugs containing polar functional gr oups pose problems of membrane permeability, solubility and premature metabolism which limit their oral and dermal delivery. The prodrug approach, which involves masking these polar functional groups as labile derivatives which then hydrolyze to the native drug either enzymatically or chemically, has proved useful in numerous cases (Bundgard, 1991 and Sloan and Wasdo, 2003). In most cases drug functional groups ar e masked as simple esters. Acyloxymethyl (ACOM, R’COOCH2-) and alkyloxycarbonyloxymethyl (AOCOM, R’OCOOCH2-) promoieties have been used to derivatize car boxylic acids in cases where the simple ester approach wasn’t useful because, although si mple esters were reasonably stable chemically so that they could be convenie ntly formulated, they were not sufficiently labile enzymatically (Jansen and Russell, 1965 ; Bundgard et al., 1986; Seki et al., 1988 and Beaumont et al., 2003). Similarly, simple alkylation of phenolic groups with alkyl halides gives derivatives that are not efficiently reversible in vivo, while ACOM or AOCOM gives derivatives that are too unstable during the or al absorption process to protect the phenolic drug from premature metabolism. Replacing the oxygen atom in OCH2 with nitrogen (N-R, R = alkyl) in R’OCOOCH2to give a N-alkyl-Nalkyloxycarbonylaminomethyl (NANAOCAM, R’OCONRCH2-) promoiety could give medicinal chemists an additional handle and flexibility to improve solubility (better

PAGE 60

44 balance between solubilities in lipid and wate r) and stability (enzymatic versus chemical) of prodrugs. The evolution of NANAOCAM promoiety from simple esters to ACOM/AOCOM to NANAOCAM is shown in Figure 2-1. O O O R N H O O R N O O R R' R O O O R O R O ESTER OR CARBONATE-DRUG CONJUGATE Insert 'CH2O' Spacer Insert 'O' 'CH2O' Spacer DRUG-X AOCOM DRUG CONJUGATE X = O, S, N DRUG-X alkylate N DRUG-X R= ALKYL N-ALKYL-N-ALKOXYCARBONYLAMINOMETHYL DRUG CONJUGATE (NANAOCAM) X = O, S, N DRUG-X DRUG-X DRUG-X ACOM DRUG CONJUGATE X = O, S, N R= ALKYL R, R' = ALKYL Replace 'O' with 'N' Figure 2-1 Design of N ANAOCAM promoiety. Only one example of the use of a NA NAOCAM promoiety has been reported: 6mercaptopurine (Siver and Sloan, 1989). Th e use of a close analogue of NANAOCAM (R’CONRCH2-) in which the promoiety is an amid e instead of a carbamate has been reported for carboxylic acids (Bundg ard et al., 1991; Moreira et al., 1996 and Iley et al., 1997). Here we extend the use of the NANAOCA M promoiety to other drug functional groups and investigate the mech anism of chemical hydrolysis and its implications in

PAGE 61

45 prodrug design of these soft alkylat ed derivatives with the goal of being able to tailor the promoiety to give the appropri ate rates of conversion to th e parent drug based on the route of administration. In the discussion that follows we will talk about the synthesis of N-methyl-Nmethyloxycarbonylaminomethyl derivatives of phenols, carboxylic acids and 6mercaptopurine (6MP) and N-aryl-N-a lkyloxycarbonylaminomethyl (NArNAOCAM) derivatives of phenols and carboxylic acids. We will then investigat e the mechanism of hydrolysis of N-methyl-N-methylox ycarbonylaminomethyl and NArNAOCAM derivatives of phenols, carboxylic acids and 6MP. Synthesis of N-methyl-N-methyloxycarbo nylaminomethyl and N-aryl-N-methyloxycarbonylaminomethyl Prodrugs. Ten N-methyl-N-methyloxycarbonylaminomethyl and six N-aryl-Nmethyloxycarbonyl aminomethyl derivatives we re synthesized (Tables 2-1 and 2-2). Alkylation of the parent compound with N-methyl-N-methyloxycarbonylaminomethyl chloride or N-aryl-N-methyloxycarbonylaminom ethyl chloride was accomplished in the presence of a base like triethylamine with CH2Cl2 or DMSO as the solvent. In every case it was necessary to synthesize the co rresponding alkylating agent: N-methyl-Nalkoxycarbonylaminomethyl chloride or Naryl-N-methyloxycarbonylaminomethyl chloride.

PAGE 62

46 Table 2-1 N-methyl-N-methyloxycarbonylaminom ethyl-phenol Conjugates Synthesized. O X N R O O CH3 Z Compd X Z R 1 NHCOMe H Me 2 CN H Me 3 CHO H Me 4 H CHO Me 5 COMe H Me 6 COOMe H Me 7 NO2 H Me 8 NO2 H 4’-C6H4-OMe 9 NO2 H 4’-C6H4-COOEt 10 NO2 H C6H5 Table 2-2 N-methyl-N-methyloxycarbonylam inomethyl and NArNAOCAM Conjugates of Naproxen. CH3O O O N R O O CH3 Compd R 11 Me 12 C6H5 13 4’-C6H4-OMe 14 4’-C6H4-COOEt

PAGE 63

47 N O O N R O O R' N N N H N S N R O O R' R = R' = CH3R = R' = CH3 15 16 Figure 2-2 Structures of N-methyl-N-m ethyloxycarbonylaminomethyl prodrugs of dimethylaminobenzoic acid and 6MP. CH2=O RNH2 NN N R R R NN N R R R O O Cl R' O O N R Cl R' NaOH O O N R Cl R' Y-H TEA O O N R Y R' CH2Cl2CH2Cl2R, R' = CH3 + + + Y = 6MP,phenol or carboxylic acid Compounds 1-7, 11, 15, 16 Figure 2-3 Synthesis of NANAOCAM prodrugs

PAGE 64

48 NH2 X N H X O O CH3 X N Cl O O CH3 X N Cl O O CH3 (CH2O)n X N Y O O CH3 Naproxen p-nitrophenol CH3OCOCl X = OCH3, COOC2H5, H. YH = Naproxen, p-nitrophenol. Py TMSCl TEA or Compounds 8-10, 12-14 Figure 2-4 Synthesis of NArNAOCAM prodrugs N-Methyl-N-methyloxycarbonylaminomethyl chloride synthesis (Figure 2-3): The N-methyl-N-methyloxycarbonylaminomet hyl chloride was synthesized as reported by Siver et al., ( 1990) from 1, 3, 5-trimethylhexahydrotriazine. (a) 1, 3, 5-Trimethylhexahydrotriazine was s ynthesized from equimolar equivalents of aqueous formaldehyde, methyl amine and NaOH according to the protocol originally developed by Graymore et al., (1932) and modi fied by Siver et al., (1990). Methyl amine (0.4 mol, 40% aqueous) was placed in an i ce bath and an equivalent of 37% aqueous formaldehyde was added dropwise over a period of 10 min. The solution was allowed to equilibrate to room temperature and stirred for one hour, then an equivalent of NaOH was added and the contents were stirred for 1.5 h more. The solution was extracted with 4 50 mL CH2Cl2, dried over Na2SO4, filtered and concentrated to a clear colorless CH2Cl2 solution containing the hexahydrotriazine de rivative. Complete concentration of CH2Cl2

PAGE 65

49 wasn’t carried out as it resulted in some lo ss of the desired product. For quantification purposes the CH2Cl2 ‘methylene peak’at 5.3 and N-CH2-N peak of hexahydrotriazine derivative at 3.2 were used: yield = 82% in CH2Cl2, 1H NMR (400 MHz; CDCl3; Me4Si): 3.2(s, 6H), 2.3(s, 9H). (b) N-Methyl-N-methyloxycarbonylaminomethyl ch lorides were synthesized from 1, 3, 5-trimethylhexahydrotriazine by reacting it with three equivalents of methyl chloroformate in CH2Cl2 .To well stirred solution of methylchloroformate in CH2Cl2 cooled with an icebath was added an equivale nt of 1, 3, 5-trimethylhexahydro-triazine (freshly prepared) in CH2Cl2 over a period of 10 minutes. The white suspension that was observed was allowed to equlilibrate to r oom temperature and stirred overnight. The suspension was filtered and the filtrate concentr ated to oil. The oil contained the desired product and some of the correspondi ng bis (N-methyl-N-m ethyloxycarbonylamino)methane byproduct. The oils were purif ied by trituration with hexane overnight followed by ether overnight. The clear soluti on was decanted leaving the white residue (bis derivative) behind. Th e clear solution was then concentrated. The peak at 4.8 due to the ‘CH2 ’ of the bis derivative and peak at 5.3 due to the ‘CH2’ of N-methyl-N-methyloxycarbonylaminomethyl chloride were used to quantitate the amount of product formed: yield = 90%, 1H NMR (400 MHz; CDCl3; Me4Si): 5.31-5.33 (2s, 2H), 3.73-3.79 (2s, 3H), 2.9-3.0 (2s, 3H). N-Aryl-N-methyloxycarbonylaminomethyl chloride synthesis (Figure 2-4): N-Aryl-N-methoxycarbonylaminomet hyl chlorides were made from aromatic amines in two steps. Methylchloroformate was reacted wi th aromatic amines in the presence of pyridine and dichloromethane to give N-aryl carbamic acid methyl esters. The chloromethyl derivative of the carbamic acid derivative was then made by a synthetic

PAGE 66

50 procedure reported by Moreira et al., (1994) for N-methylamides. The N-Methyl carbamic acid alkyl ester was refluxed with thirteen equivalents of trimethylsilyl chloride and 1.7 equivants of paraformaldehyde to gi ve the appropriate Naryl-N-alkoxycarbonylaminomethyl chloride. (a) N-Aryl carbamic acid methyl ester: To a solution of methylchlo roformate (3.5 mmol) in 15 mL CH2Cl2 was added dropwise an equivalent of pyridine and aromatic amine. The reaction mixture was allowed to warm to r oom temperature and subsequently stirred overnight. The clear solution was washed with 10 mL brine 3 times, and the organic layer was dried over Na2SO4 and concentrated to a solid. The solids obtained were recrystallized from CH2Cl2: hexane. N(Phenyl)carbamic acid methyl este r: yield = 98 %, mp = 44-45C, 1H-NMR (400 MHz; CDCl3; Me4Si): 7.2-7.37(m, 4H), 7.06 (m, 1H), 6.63(s, 1H), 3.76 (s, 3H). N-(4’-Ethoxycarbonylphenyl )carbamic acid methyl ester: yield = 97 %, mp = 152-154C, 1H-NMR (400 MHz; CDCl3; Me4Si): 8.0 (d, 2H), 7.45 (d, 2H), 6.9(s, 1H), 4.37 (q, 2H), 3.8 (s, 3H), 1.39 (t, 3H). N-(4’-Methoxyphenyl)carbamic aci d methyl ester: yield = 94 %, mp = 85-86C, 1HNMR (400 MHz; CDCl3; Me4Si): 7.27 (d, 2H), 6.85 (d, 2H), 3.78(s, 3H), 3.75(s, 3H). (b) N-Aryl-N-methyloxycarbonylaminomethyl chloride: A suspension of N-aryl carbamic acid alkyl ester (2.5 mmol), 1.7 e quivalents of paraformaldehyde and 13 equivalent of trimethylsilyl ch loride was refluxed using a CaCl2 drying tube and a water condenser for 18 h over an oil bath. The suspension was diluted with ~10 mL CH2Cl2 and filtered to get rid of the unreacted paraformaldehyde. The clear filterate was concentrated

PAGE 67

51 using a rotavapor at 40C under reduced pressu re. The yellow oil obtained was triturated with hexane overnight. The white suspension obtained was filtered and the filtrate was concentrated to give the desired alkylating agent. N(Phenyl)-N-methyloxycarbonylaminom ethyl chloride: yield = 75%, 1H NMR (400 MHz; CDCl3; Me4Si): 7.32-7.44 (m, 5H), 5.56(s, 1H), 3.78 (s, 3H). N(4’Ethyloxycarbonylphenyl)-N-methyloxy carbonylaminomethyl chloride: Complete conversion to product wasn’t seen in this ca se, the crude mixture was thus used in the next step. The peak at 6.9 due to the ‘NH’ of the N-(4’-ethy loxycarbonylphenyl) carbamic acid methyl ester and the peak at 5.56 due to the ‘CH2’ of N-(4’ethyloxycarbonylphenyl)-N-methyloxycarbonylaminom ethyl chloride were used to quantify the amount of product formed: yield = 27%, 1H NMR (400 MHz; CDCl3; Me4Si): 8.1 (d, 2H), 7.5 (d, 2H), 5.56(s, 1H), 4.38 (q, 2H), 3.81 (s, 3H), 1.39 (t, 3H). N-(4’-methoxyphenyl)-N-methyloxycarbonylaminomethyl chloride: yield = 82%, 1H NMR (400 MHz; CDCl3; Me4Si): 7.23 (d, 2H), 6.93 (d, 2H), 5.52(s, 1H), 3.82 (s, 3H), 3.76 (s, 3H). Alkylation of Phenols, 6-Mercaptopurin e, Dimethylaminobenzoic acid and Naproxen with N-methyl-N-methyloxycarbony laminomethyl chloride or N-arylN-methyloxycarbonylaminomethyl ch loride (Figures 2-3 and 2-4). Typical procedure for phenols: In a round bo ttom flask was dissolved 1 equivalent of phenol (~0.01 mol) and 1.1 equiva lents triethylamine in 20 mL CH2Cl2. The contents were stirred for an hour under reflux conditi ons with a water condenser and oil bath. NMethyl-N-alkoxycarbonyl aminomethyl chlo ride or N-aryl-N-methyloxycarbonylaminomethyl chloride (1.1 equivalents) in 5 mL CH2Cl2 was then added dropwise. An exothermic reaction occurred and white fumes could be seen. The clear solution or

PAGE 68

52 suspension (depending on the phenol used) was stirred overnight. The reaction was worked up by filtering the suspension [NEt3 +Cl-:, 1HNMR(CDCl3): 3.1 (q,2H), 1.5 (t,3H)], diluting the filtrate to 40 mL with CH2Cl2 and washing it with 3 30 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and filtered. The solution was concentrated using a rotavapor under vacuum at 40C until solvent free. The resulting material was purified by recrys tallization and, if necessary, column chromatography until a sharp melting point was obtained, a si ngle spot was seen on TLC and a clean 1HNMR was obtained. The particular results for each synthesis are listed below. 1 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride, triethylamine and acetaminophen in CH2Cl2. Recrystallization from CH2Cl2: hexane (1:3) twice gave white crystals: yi eld = 70%, mp = 86-88C, Rf (0.36, ether). Elemental analysis (Found: C, 56.81; H, 6.34; N, 11.1. Calc. for C12H16N2O4 : C, 57.13; H, 6.39; N, 11.1%). UV: max (pH 8.8 buffer)/nm 243.4 ( /Lmol-1cm-10.95 10 4). UV: max (pH 7.1 buffer)/nm 240 ( /Lmol-1cm-1 1.01 10 4 0.09 10 4).1H NMR(400 MHz; CDCl3; Me4Si): 7.6(s,1H), 7.39(d,2H), 6.96-6.87(2d,2H), 5.28-5.21(2s,2H), 3.723.7(2s,3H), 3.0-2.97(2s,3H), 2.0(s,3H). 2 was prepared from N-methyl-N-m ethyloxycarbonylaminomethyl chloride, triethylamineand p-cyanophenol in CH2Cl2 Recrystallization from ethyl acetate:hexane (1:2) twice gave white crystals : yield = 55%, mp = 56-58C, Rf (0.17, ethyl acetate:hexane, 1:4). Elemental analysis (Found: C, 59.54; H, 7.27; N, 9.94. Calc. for C11H12N2O3 : C, 60.02; H, 7.14; N, 10%). UV: max (pH 8.8 buffer)/nm 245 ( /Lmol1cm-1 1.26 10 4).1H NMR (400 MHz; CDCl3; Me4Si): 7.6(d, 2H), 7.1-6.96(2d, 2H), 5.38-5.31(2s, 2H), 3.8(s, 3H), 3.06-3.0(2s, 3H).

PAGE 69

53 3 was prepared from N-methyl-N-m ethyloxycarbonylaminomethyl chloride, triethylamine and p-hydroxybenzaldehyde in CH2Cl2. Purification on a silica gel column with hexane: acetone (4:1) as the eluent gave a colorless oil: yield = 67%, Rf (0.37, ethyl acetate:hexane, 1:2). Elemental analysis (Found: C, 59.08; H, 5.86; N, 6.3 Calc. for C11H13NO4 : C, 59.19; H, 5.87; N, 6.27%).UV: max (pH 8.8 buffer)/nm 276.6 ( /L mol-1cm-1 1.37 10 4).1H NMR(400 MHz; CDCl3; Me4Si): 9.9(s,1H), 7.83(d,2H), 7.1-7.03(2d,2H),5.42-5.35(2s,2H), 3.8(s,3H), 3.07-3.01(2s,3H). 4 was prepared from N-methyl-N-m ethyloxycarbonylaminomethyl chloride, triethylamine and salicyldehyde in CH2Cl2. Recrystallization fr om acetone gave white crystals: yield = 87%, mp = 65-67C, Rf (0.76, ether).Elemental analysis (Found: C, 59.06; H, 6.01; N, 6.24 Calc. for C11H13NO4 : C, 59.19; H, 5.87; N, 6.27%). UV: max (pH 8.8 buffer)/nm 315 ( /Lmol-1cm-11.27 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 10.49(s,1H), 7.85(d,1H), 7.55(t,1H) 7.2(m,2H), 5.47-5.38(2s,2H), 3.76(s,3H), 3.08-3.03(2s,3H). 5 was prepared from N-methyl-N-m ethyloxycarbonylaminomethyl chloride, triethylamine and p-hydroxyacetophenone in CH2Cl2. Purification on a silica gel column with hexane: acetone (4:1) as the eluent gave a colorless oil: yield = 82%, Rf (0.75, ether). Elemental analysis (Found: C, 60.45; H, 5.91; N, 6.22 Calc. for C11H13NO4 : C, 60.75; H, 6.37; N, 5.9%). UV: (pH 8.8 buffer)/nm 269.7( /Lmol-1cm-1 1.12 10 4).1H NMR(400 MHz; CDCl3; Me4Si): 7.93(d,2H), 7.05-6.94(2d,2H), 5.39-5.32(2s,2H), 3.8(s,3H), 3.05-3.0(2s,3H), 2.6(s,3H). 6 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride, triethylamine and methyl p-hydroxybenzoate in CH2Cl2. Purification on a silica gel

PAGE 70

54 column with ethyl acetate: hexane as elue nt gave a colorless oil. This oil, after recrystalization from CH2Cl2 :hexane (1:2), gave white crystals: yield = 21%, mp = 5254C, Rf (0.49, ethyl acetate:hexane,1:4).Elementa l analysis (Found: C, 56.98; H, 5.93; N, 5.49.Calc. for C12H15NO5 : C, 56.91; H, 5.97; N, 5.53%). UV: max (pH 8.8 buffer)/nm 253 ( /Lmol-1 cm-1 1.49 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 8.0(d,2H), 7.02-6.92(2d,2H), 5.37-5.3(2s,2H), 3.9(s,3H), 3.8(s,3H), 3.052.99(2s,3H). 7 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride, triethylamine and p-nitrophenol in CH2Cl2. Recrystallization from CH2Cl2 :hexane (1:4) gave pale yellow crystals: yield = 76%, mp = 77-79C, Rf (0.37,ether: hexane, 1:1).Elemental analysis(Found: C, 49. 99; H, 4.94; N, 11.57.Calc. for C10H12N2O5 : C, 50.0; H, 5.04; N, 11.66%). UV: max (pH 8.8 buffer)/nm 310.6 ( /Lmol-1cm-10.76 104). UV: max (pH 7.1 buffer)/nm 310 ( /Lmol-1cm-1 0.75 10 4). 1H NMR (400 MHz; CDCl3; Me4Si): 8.21(d, 2H), 7.1-6.99(2d, 2H), 5.42-5.35(2s, 2H), 3.77(s, 3H), 3.07-3.01(2s, 3H). 8 was prepared from N-(4’-methoxyphenyl )-N-methyloxycarbonylaminomethyl chloride, triethylamine and p-nitrophenol in CH2Cl2. Purification on a silica gel column with ethyl acetate: hexane as eluent gave a colorless oil: yield = 64%, Rf (0.17, ethyl acetate:hexane, 1:5), UV: max (pH 8.8 buffer)/nm 310 nm ( /Lmol-1cm-1 1.06 10 4 ). 1H NMR(400 MHz; CDCl3; Me4Si): 8.2(d,2H), 7.16(d,2H), 7.05(d,2H), 6.89(d,2H), 5.64(s,2H), 3.81(s,3H), 3.73(s,3H).

PAGE 71

55 9 was prepared from N-(4’-ethyloxycarbonylphe nyl)-N-methyloxycarbonylaminomethyl chloride, triethylamine and p-nitrophenol in CH2Cl2. A white solid residue was seen. This residue was dissolved in CH2Cl2 and hexane was added till th e solution became turbid and white crystals were seen. The white crystals were filtered and discarded while the filterate was reconcentrated to give more white crystals which were filtered. The filterate was purified on a silica gel column with ethyl acet ate: hexane as eluent to give a colorless oil: yield = 17%, Rf (0.29, ethyl acetat e:hexane, 1:3). UV: max (pH 8.8 buffer)/nm 309 ( /Lmol-1cm-1 1.03 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 8.21(d,2H), 8.07(d,2H), 7.37(d,2H), 7.05(d,2H), 5.69(s,2H), 4.38(q,2H), 3.77(s,3H), 1.39(t,3H). 10 was prepared from N-(phenyl)-N-methyloxycarbonylaminomethyl chloride, triethylamine and p-nitrophenol in CH2Cl2 Purification on a silica gel column with ethyl acetate: hexane as eluent gave a colorless oil which, on recrystallization from ether: petroleum ether (1:2), gave white crys tals: yield = 69%, mp = 105-106C, Rf (0.26, ethyl acetate: hexane, 1:9). Elemental analysis (Found: C, 59.49; H, 4.63; N, 9.21. Calc. for C15H14N2O5 : C, 59.6; H, 4.67; N, 9.27%). UV: max (pH 8.8 buffer)/nm 305 nm ( /Lmol-1cm-1 1.19 10 4).1H NMR (400 MHz; CDCl3; Me4Si): 8.2(d, 2H), 7.277.42(m, 5H), 7.05(d, 2H), 5.67(s, 2H), 3.75(s, 3H). 11 was prepared from naproxen (0.01 mol) stirre d with triethylamine (0.01mol) in 50 mL CH2Cl2 for an hour. A clear colorless solu tion was seen. N-Methyl-N-methyloxycarbonylaminomethyl chloride (0.01mol) was added to the reaction mixture and the contents were stirred over night. The clear solution was washed 3-times with 10 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and then evaporated

PAGE 72

56 under reduced pressure to give white cr ystals: yield = 97%, mp = 100-101C, Rf (0.49, ethyl acetate:hexane,1:4). Elemental analysis (Found: C, 65.05; H, 6.45; N, 4.2 Calc. for C18H21NO5 : C, 65.24; H, 6.39; N, 4.23%). UV: max (pH 7.1 buffer)/nm 271.5 and 245 ( /Lmol-1cm-1 0.52 10 4, 0.77 10 4 L/mole.1H NMR(400 MHz;CDCl3;Me4Si): 7.69(t,3H), 7.4(d,1H), 7.11-7.15(m,2H), 5.41-5.29(dd,2H), 3.91(s,3H), 3.85(q,1H), 3.7-3.65(2s,3H), 2.89-2.85(2s,3H), 1.57(d,3H). 12 was prepared from naproxen (0.001 mol) st irred with triethylamine (0.001mol) in 50 mL CH2Cl2 for an hour. A clear colorless soluti on was seen. N-(Phenyl)-N-methyloxycarbonylaminomethyl chloride (0.001mol) wa s added to the reaction mixture and the contents were stirred over night. The clear solution was washed 3-times with 10 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and then evaporated under reduced pressure to give a yellow oil. Purification of the oil on a si lica gel column with ethyl acetate: hexane as eluent gave a colorless oil: yield = 60%, Rf (0.17, ethyl acetate:hexane, 1:5), UV: max (pH 7.1 buffer)/nm 272.8 and 245, ( /Lmol-1cm-10.35 10 4, 0.83 10 4). 1H NMR(400 MHz;CDCl3;Me4Si): 7.69(t,3H), 7.36-7.39(dd,1H), 7.13-7.17(m,5H), 6.9(d,2H), 5.5-5.68(dd,2H), 3.93(s,3H), 3.88(q,1H), 3.65(s,3H), 1.57(d,3H). 13 was prepared from naproxen (0.001 mol) st irred with triethylamine (0.001mol) in 50 mL CH2Cl2 for an hour. A clear colorless soluti on was seen. N-(4’-Methoxyphenyl)-Nmethyloxycarbonylaminomethyl chloride (0.001 mol) was added to the reaction mixture and the contents stirred overnight. The clea r solution was washed 3-times with 10 ml water. The CH2Cl2 solution was dried over Na2SO4 for an hour and then evaporated under reduced pressure to give to give a yell ow oil. Purification of the oil on a silica gel

PAGE 73

57 column with ethyl acetate: hexane as el uent gave a colorless oil: yield = 70%, Rf (0.1, ethyl acetate:hexane,1:5), UV: max (pH 7.1 buffer)/nm 271.5 and 245, ( /Lmol-1cm10.26 10 4, 0.91 10 4 ). 1H NMR(400 MHz;CDCl3;Me4Si):7.69(t,3H), 7.367.39(dd,1H), 7.13-7.17(m,2H), 7.69(t,3H), 7.37(dd,1H), 6.8(d,2H), 6.5(d,2H), 5.5-5.64(dd,2H), 3.92(s,3H), 3.88(q,1H), 3.68(s,3H), 3.65(s,3H), 1.57(d,3H). 14 was prepared from naproxen (0.001 mol) st irred with triethylamine (0.001mol) in 50 mL CH2Cl2 for an hour. A clear colorless soluti on was seen. N-(4’-Ethyloxycarbonylphenyl)-N-methyloxycarbonylaminomethyl chloride (0.001mol) was added to the reaction mixture and the conten ts were stirred overnight. Th e clear solution was washed 3-times with 10 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and then evaporated under reduced pressure to give white crystals. This residue was dissolved in CH2Cl2 and hexane was added till the solution became turbid and white crystals were seen. The white crystals were filtered and discarded while the filterate was reconcentrated to give more white crystals. After purification on a silica gel column with ethyl acetate: hexane as eluent the filtrate gave a colorless oil: yield = 13%, Rf (0.25, ethyl acetate: hexane, 1:5), UV: max (pH 7.1 buffer)/nm 270 and 245 ( /Lmol-1cm-10.25 10 4, 0.95 10 4. UV: max (pH 4 buffer)/nm 245( /Lmol-1cm-10.88 10 4). UV: max (pH 6 buffer)/nm 245 ( /Lmol-1cm-1 0.9 10 4). UV: max (pH 8.25 buffer)/nm 245 ( /L mol-1cm-1 0.92 10 4). UV: max (pH 9.2 buffer)/nm 245 ( /Lmol-1cm-10.94 10 4). 1H NMR(400 MHz;CDCl3;Me4Si): 7.76(d,2H), 7.63-7.71(m,3H),7.34-7.37(dd,1H), 7.13-7.17(m,2H), 6.98(d,2H), 5.5-5.7(dd,2H), 4.3(q,2H), 3.94(s,3H), 3.88(q,1H), 3.66(s,3H), 1.57(d,3H), 1.38(t,3H). 15 was prepared from dimethyl aminobenzoic acid (0.01 mol) stirred with triethylamine

PAGE 74

58 (0.01mol) in 50 mL CH2Cl2 for an hour. To the white suspension that formed was added N-methyl-N-methyloxycarbonylaminomethyl chlo ride (0.01 mol) and the contents were stirred overnight. The clear solution was washed 3-times with 10 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and then evaporated under reduced pressure to give white crystals: yield = 97%, mp = 100-101C, Rf (0.49, ethyl acetate: hexane, 1:4), Elemental analysis: (Found: C, 57.73; H, 7.02; N, 10.6. Calc. for C13H18N2O4 : C, 57.64; H, 6.81; N, 10.52 %). UV: max (pH 8.8 buffer)/nm 315 and 287 ( /Lmol-1 cm-11.41 10 4, 1.15 10 4). 1H NMR(400 MHz;CDCl3;Me4Si): 7.9(d,2H), 6.6(d,2H), 5.58-5.54(2s,2H), 3.76-3.72(2s,3H), 3.05(s,9H). 16 was synthesized using the protoc ol developed by Siver et al.7 To 0.01 mol 6MP in 15 mL DMSO was added 1.1 equivalents of N-methyl-N-methyloxycarbonylaminomethyl chloride. The yellow solution was stirred at r oom temperature for 1.5 h. Triethyl amine, 2.5 equivalents and 45 mL CHCl3 was added and stirring continued for one more hour. The reaction mixture was th en diluted with 100 mL CH2Cl2 and washed with 10 ml 1N HCl, 20 ml saturated NaHCO3 solution and 350 mL brine solution. The organic layer was dried over Na2SO4 and concentrated to give a yellow oil. The oil was triturated with hexane to give yellow solids which we re further recrystallised with CH2Cl2: hexane (1:5) to give yellow crystals: yield = 62%, mp = 162-164C (lit mp = 163C), Rf = 0.46(10:3, ether: methanol), Elemental analysis (Found: C, 42.9; H, 4.08; N, 27.78. Calc. for C9H11N5O2S : C, 42.68; H, 4.38; N, 27.65 %). UV: max (pH 7.1 buffer)/nm 288.4 ( /Lmol-1cm-1 0.71 10 4). UV: max (pH 8.8 buffer)/nm 310.2 ( /Lmol-1cm-10.55 10 4) .UV: (MeOH)/nm 286 ( / Lmol-1cm-10.41 10 4). 1H NMR (400 MHz;CDCl3;Me4Si): 8.71(s,1H), 8.1-8.37(2s,1H), 5.68(s,2H), 3.75-3.85 (2s, 3H), 3.13-3.09(2s,3H).

PAGE 75

59 Hydrolysis Studies. S6-(N-Methyl-N-methyloxycarbonyl) aminomet hyl6MP was synthesized by Siver et al. This derivative reverted to 6MP with a half life of 91 minutes in pH 7.1 buffer at 32 C. An SN1 mechanism of hydrolysis was propos ed but not firmly established. We decided to probe the reactivity of NANAOCAM -phenol conjugates with acetaminophen (APAP) acting as our model phenolic drug. Since NANAOCAM-APAP type derivatives we re designed as a hydrolytically labile prodrugs, their rates of hydrolysis in aqueous buffers were investigated. Hydrolysis of NANAOCAM derivatives of APAP at 32 pH and 7.1 buffer were much slower than those of 6MP. The rate of hydrolysis of N-Methyl-N-methoxycarbonylaminomethylAPAP (1) at pH 8.8 and 46 C was found to be 60 h. so all rates of hydrolysis were determined at 46 C and pH 8.8 buffer S6-(N-Methyl-N-methyloxycarbonyl) aminomethyl6MP (16), resynthesized according to Siver et al. (1990), had a half life of 19 minutes under the same conditions. The anion of APAP (pKa~9.5) is not a good leaving group and as a result the hydrolysis of its prodrug is slow compared to 6MP (pKa~7.5). On the other hand, the NANAOCAM derivative of p-nitrophenol (7, Tables 21 and 2-3) had a half life of 22 min at 46C and pH 8.8 buffer. The hydrolysis rate was higher and t 1/2 lower since the pKa of the leaving group was much lower:7.4. Thus NMethyl-N-alkyloxycarbonylamin omethyl derivatives of phenols with an electron withdrawing group like –NO2 on the ring hydrolyzed faster than those with an electron releasing group on the ring like –NHCOCH3. In order to establish the mechanism of hydrolysis and probe the effect of electron withdrawing groups on hydrolysis rates of NANAOCAM-phenol conjugates, five more phenols (2-6, Table 2-1) with an electron withdraw ing group on the aromatic ring were

PAGE 76

60 synthesized using the syntheti c protocol developed for APAP and rates of hydrolysis were determined at pH 8.8 and 46 C (Table 2-3). To further establ ish the effect of pKa on rates of hydrolysis, the N-Methyl-N -methyloxycarbonylaminomethyl ester of dimethylaminobenzoic acid (15, Figures 2-1 and 2-3) was also synthesized and its rate of hydrolysis determined.Thus, rates of hydrol ysis were determined where YH = 6MP, phenol or carboxylic acid and the correspondi ng anions acted as the leaving group (Figure 2-5). N R Y O OR' N R O H O OR' N R H O OR' N R CH2 O OR' Y OH2 -CH2=O + YH + Figure 2-5 Hydrolysis of NANAOCAM-Y in aqueous buffers. Rates of hydrolysis of NANAOCAM-Y we re dependent on the acidity (leaving group ability) of the parent compound. The mo re acidic YH was, the faster the rate was. When YH was cyanophenol with a pKa of 7.95, the half life was 149 minutes. Increasing the pKa by 0.1 unit as in the case of the methyl paraben derivative, 5 raised the half life to 189 minutes. This sensitivity to small changes in pKa of YH derivative suggests that Ywas acting as the nucleofuge by either a SN2 or SN1 mechanism. The effect of electon withdrawing groups in the para position of the phenol on rates hydrolysis was also

PAGE 77

61 quantified using the Ha mmett plots between substituents versus log K. (Table 2-3). Plot of log K and sigma ( -) were linear and indicated th at rates of hydrolysis were dependent on the electron wit hdrawing effect imparted by th e substituent at the para position (Figure 2-6). Table 2-3 Correlation of Rates of Hydrol ysis of NANAOCAM-Y with pKa and Sigma Values of the Leaving Group (Y-). Compd Y log k (sec-1) t 1/2(min.) pKa 15 p-Me2N-C6H4COO-1.30 0.22 5.03 4 o-OHC-C6H4O-3.03 12 6.79 16 6MP -3.22 19 7.5 7 p-O2N-C6H4O-3.28 22 7.14 1.25 3 p-OHC-C6H4O-3.81 75 7.66 0.94 2 p-NC-C6H4O-4.11 149 7.95 0.99 5 p-MeOC-C6H4O-4.21 189 8.05 0.82 6 p-MeOOC-C6H4O-4.39 290 8.47 0.74 1 p-MeOCHN-C6H4O-5.49 3600 9.5 0.19 When log k (rate constant) was plotted against the pKa of the leaving group (Y-), a negative correlation was found with a r2 of 0.98 (Figure 2-7). Ra te of hydrolysis were also independent of the pH of the buffer. Wh en rates were studied in various buffers (pH 4.6, 7.1, 8.8) at 46 C for 7 and log K was plotted against buffer pH a stra ight line with zero slope was obtained (Table 2-4, Fi gure 2-8). The pH rate profile of 14 will be discussed later. Table 2-4 Effect of pH of Bu ffer on Rates of Hydrolysis of 7 pHt1/2 (min) log k 4.622.83 -3.29588 7.121.83 -3.27655 8.822.83 -3.29596

PAGE 78

62 y = 2.0288x 5.889 R2 = 0.968 -6 -5 -4 -3 -2 -1 0 00.511.5 SigmaLog k -NO2 -CHO -CN -COCH3 -COOMe -NHCOCH3 Figure 2-6 Pseudo-first order ra te constants (sec-1) versus of parent phenol. y = -0.9325x + 3.4017 R2 = 0.9828-6 -5 -4 -3 -2 -1 0 46810pKaLog k 15 4 16 7 3 5 2 6 1 Figure 2-7 Pseudo-first order rate constants (sec-1) vers us acidic pKa of parent.

PAGE 79

63 -5 -4.8 -4.6 -4.4 -4.2 -4 -3.8 -3.6 -3.4 -3.2 -3 3.55.57.59.5pHLog k 7 14 Figure 2-8 pH rate profiles of compds 7 and 14 Several mechanisms for base catalyse d hydrolysis of NANAOCAM-Y can be proposed (see above).Figure 2-9A shows an SN2 type of pathway where hydroxide ion acts as a nucleophile and displaces Yto give a hydroxymethyl-N-alkylcarbamic acid alkyl ester. This hemiaminal derivative s pontaneously hydrolyzes in water to give formaldehyde and N-alkylcarba mic acid alkyl ester in the same way that hydroxymethyl amides do (Johansen et al., 1979 and Bundga rd et al., 1980). Similarly the hydroxide anion can act as a nucleophile and displaces the N-alkylcarbamic acid alkyl ester anion as in Figure 2-9B. The hydroxymethyl conjugate of the drug, YH, formed as an intermediate reverts to the parent drug by loss of form aldehyde. This particular mechanism however can be ruled out because of the lower pKa of YH (~5.2-9.5) compared to the Nalkylcarbamic acid alkyl ester (~14) making Ya better leaving group than the Nalkylcarbamic acid alkyl ester anion.

PAGE 80

64 O N O R Y O N O R OH O N O R H O N O R Y O N O R Y OH CH2=O YH Y -CH2=O OH2 OH2O N O R H + OH OH YH + OH + OH + Figure 2-9 SN2 type of hydrolysis of NANAOCAM-Y with Yor carbamate as the leaving group. O N O R Y O N O R O N O R OH2 O N O R H OH2 -CH2=O Y OH2 + YH + OH+ + Figure 2-10 SN1 type of hydrolysis of NANAOCAM-Y.

PAGE 81

65 A SN1 type of pathway is another possibili ty (Figure 2-10). The lone pair of electrons on nitrogen can donate its electrons to stabilize an incipient carb ocation with Yleaving. This carbocation can subsequently react with water to give hydroxymethyl-Nalkylcarbamic acid alkyl ester which then fa lls apart to give N-alkylcarbamic acid alkyl ester. However none of the data plotted in Figures 2-6 and 2-7 provi des an insight into the mechanism of hydrolysis since both SN1 and SN2 mediated hydrolys is are dependent on the leaving group ability of th e ionized parent molecule, Y-. However the fact that the hydrolyses were pH indepe ndent strongly favors a SN1 mechanism. There is also some precedent in literature suggesting the mechanism of hydrolysis to be SN1. NAlkylamidomethyl esters of carboxylic acid hydrolyze by a SN1 mechanism (Moreira et al., 1994) (Figure 2-11). O N O R O R' O N R R'COO O N OH R Ph Ph + + Ph H O 2 Figure 2-11 Hydrolysis of Nalkylamidomethylcarboxylic acid esters in aqueous buffers. Hydrolysis proceeds by donation of electrons from the amide nitrogen resulting in a carbocation intermediate with the carboxylate group leavi ng. In the subsequent step, the carbocation reacts with wate r to give the hydroxymethylamide. When R’ was naproxen and R was methyl the t 1/2 for hydrolysis of the prodrug wa s 14 min at pH 7.4 and 32 C, while when R was –CH2COOEt t 1/2 for hydrolysis was 2520 min. Thus, introducing an electron withdrawing group on the amide nitr ogen diminishes its ability to donate electrons and slows down reac tion rate, thereby suggesting the mechanism of hydrolysis to be SN1.

PAGE 82

66 The hydrolysis of O-Imidomethyl derivatives of phenols has been reported by Getz et al., (1992). Figure 2-12 above compares the halflives of imidomethyl derivatives of pnitrophenol (PNP) with (N-Methyl-N-methoxycarbonyl) aminomethyl-PNP. The proposed hydrolytic mechanism for the im idomethyl derivatives where saccharin, phthalimide and succinimide served as the imide, was SN2. Thus, presence of two electron withdrawing groups on th e nitrogen disfavors SN1, (as observed in case of N-alkylamido methyl esters of carboxylic ac ids) to the extent that SN2 becomes the major pathway. t 1/2(min) 0.75(25C) 4.9(25C) 7.43(25C) 22(46C) NO2O N S O O O NO2O N O O NO2O N O NO2O OH NO2 NO2O N O O Figure 2-12 Hydrolysis of Nimidomethyl derivatives of phenols in aqueous buffers. Values are shown for t1/2 at th e temperature (in parenthesis).

PAGE 83

67 Implications of NANAOCAM-phenol Hydrolysis on Prodrug Design. NANAOCAM-phenol conjugates are chemica lly stable and the suggestion that their mechanism of hydrolysis is SN1 is based on past literature We were interested in designing derivatives which would be labile under physiological conditions and which would illustrate that the mechanism of hydrolysis was SN1. Hence the syntheses of NANAOCaminoethylidene (ROCO-NR’CH(CH3)), NANAOCaminobenzylidene (ROCO-NR’CH(Ph)) and NArNAOCAM (ROCO-N(Ph)CH2) promoieties were examined. NANAOCaminoethylidene and NANAOCaminobenzylidene derivatives of phenols will stabilize positive charge on the methine carbon leading to a more labile derivative if hydrolysis follows a SN1 type of pathway and will hinder an SN2 type path by creating more steric hinderance. Also if the mechanism is SN2, the rate of hydrolysis should be accelerated by an electron withdrawing group on an N-aryl group where a positive charge on CH2 in N-CH2-O is increased making the CH2 a better target for nucleophilic attack. On the other hand, if the mechanism is SN1, the rate of hydrolysis should be decelerated by an electron withdrawing group on an N-aryl group where a positive charge on CH2 in N-CH2-O is destabilized. Unfortunately our attempts to synthesize NANAOCaminoethylidene and NANAO C-aminobenzylidene derivatives of phenols were unsuccessful. The synthetic prot ocol used is shown in Figure 2-13. An aldehyde was reacted with aqueous methyl amine at room temperature to give Nmethylimines which were reacted with methyl chloroformate under nitrogen at -78C to 0C. The major product obtained was the pa rent aldehyde, N-methyl carbamic acid methyl ester and 2-3% of the desired alkylating agent (NANAOCaminoethylidene chloride or NANAOCaminobenz ylidene chloride) based on 1H-NMR.

PAGE 84

68 Y O N O Y O N X O O O X = H, OCH3, COOEt Y O N O X O X = H, OCH3, COOEt NANAOaminoethylidene-Phenol NANAOaminobenzylidene-Phenol NArNAOCAM-Phenol Attempts to isolate the alkylating agent by column chromatography led to complete decomposition of the alkylating agent. Re action of phenols with the crude reaction mixture containing the alkylating agent also lead to hydrolysis of the alkylating agent to the parent aldehyde and N-methyl carbam ic acid methyl ester quantitatively. RCHO + CH3NH2 RCH=NHCH3 Cl N COOCH3 CH3OCOCl RCHO CH3NHCOOCH3 RCH + + major minor R = Methyl or Aryl NANAOC amino ethylidene chloride or NANAOC amino benzylidene chloride Figure 2-13 Attempts at the synthesis of NANAOCaminoethylidene chloride and NANAOCaminobenzylidene chloride. However our attempts to make NAr NAOCAM conjugates of phenols were successful. NArNAOCAM chlorides (R’OCONRCH2-, R = aryl, R’= CH3) were synthesized and used to alkylate pnitrophenol (Figure 2-3, Table 2-1, 8-10). The halflives of hydrolyses clearly illustrate that when an N-alkyl group (Table 2-3, t 1/2 for 7 = 22 min) was replaced by N-aryl (Table 2-5, t 1/2 for 8 and 10 = 400-520 min while t 1/2 for

PAGE 85

69 9 > 24 h) the rates of hydrolyses were slow er. An electron donati ng substituent on the Naryl ring like –OCH3 stabilizes the SN1 transition state more than an electron withdrawing group like –COOC2H5 or -H and the half lives are in the order of 9 >10 >8. Thus, hydrolysis of NArNAOCAM and N-aryl-N-alk yloxycarbonylaminomethyl derivative of phenols follow a SN1 type of mechanism. Howe ver, although NANAOCAM-phenols hydrolyse by a SN1 type of pathway, they are chemically too stable to revert to the parent drug at a sufficient rate to be effec tive prodrugs based on chemical hydrolysis. Hydrolyses of NANAOCAM-phenols does occur enzymatically. When 1 was used in diffusion cell experiments where hairless m ouse skin was the membrane, about 23% of acetaminophen was regenerated from the prodr ug during its passage through the skin. We will talk more about diffusion cell experiments in Chapter 3. Thus NANAOCAM-phenols represent a novel class of prodrugs which are sufficiently chemically stable to allow form ulation but may be sufficiently enzymatically labile to revert to the pa rent drug at a useful rate. Shorter chain NANAOCAM prodrugs of phenols have both higher lipid and water solubilities compared to ACOM and AOCOM phenolic conjugates (solubililities sh own in Chapter 3). Thus, replacing the oxygen atom in O-CH2 of ROCOOCH2 with a substituted nitrogen (N-R, R = alkyl) makes it possible to increase solubility in a membrane which should increase permeability across a biological barrier such as skin and oral absorption across the GI tract.

PAGE 86

70 O O2N N O O X Table 2-5 N-aryl-N-alkyloxycarbonylaminomet hyl Derivatives of p-nitrophenol (PNP) a. Compd X log kobsv(sec-1) t (min.) 8 OMe -4.54 400 9 COOEt >24 h 10 H -4.65 519 a Hydrolysis experiments in pH 8.8 and 46C Implications of NArNAOCAM-carboxylic acid Hydrolysis on Prodrug Design Besides NANAOCAM derivatives of phe nols, NANAOCAM derivatives of carboxylic acids have also been examined. Ca rboxylic acids, like phenols, are polar and being ionized at physiological pH penetrate membranes with difficulty. By transiently masking the negative charge it has been s hown that it is possible to increase the permeation of carboxylic acids across biological barriers (Boni na et al., 1995 and Rautio et al., 1999). N-Alkyl-N-al kyloxycarbonylaminomethyl derivatives of carboxylic acids are chemically too unstable to serve as usef ul derivatives (compared to phenols which were chemically stable) because the leaving group has a pKa of ~3-5 (compared to 6.89.5), e.g. 15, t 1/2 ~ 6 min at pH 7.1 and 39C. Th us, the goal here was to design derivatives which were chemically more stable so that they could be easily formulated but would hydrolyze independent of enzymes. It has been previously shown that Oimidomethyl derivatives of phenol s like estradiol were enzymatically stable but had a half life of 100 min in pH 7.4 buffe r (Patel et al., 1994 and 1995). This derivative was about 8 times more potent than estradiol alone when given orally. Thus prodrugs whose

PAGE 87

71 hydrolysis is not dependent on enzymes are us eful because their hydrolysis isn’t limited by enzymatic variability and st rict substrate specificity of some esterases in the blood which could lead to incomplete hydrolysis to the parent drug (B eamount et al., 2003). Here, naproxen was chosen as a model ca rboxylic acid drug for which to prepare NANAOCAM prodrugs (Table 2-2). The NANAOCAM deriva tives of naproxen were made by alkylating naproxen with NANAOCAM-Cl in presence of triethyl amine in dichloromethane (Figure 2-3). 11, Table 2-2 had a half life of 2 min at pH 7.1 and 39 C which would make pharmaceutical formulation difficult. Si nce the mechanism of hydrolysis of NANAOCAM esters of carboxylic acids should also be SN1, the NArNAOCAM promoiety should lead to a chemically more stable and useful prodrug of a carboxylic acid since the phenol NArNAOCAM derivatives were much more stable. NArNAOCAM ester derivatives of naproxen (12-14, Table 2-2) were synthesi zed by alkylating naproxen with NArNAOCAM-Cl (Figure 2-4) and their rate s of hydrolysis determined (Table 2-6). As expected the substituted Naryl derivatives increased the half-lives of the hydrolyses from 2 min to over 150 min. As in the case of phenols the order of rates of hydrolyses was, -COOEt < -H < -OMe which is consistent with a SN1 type of hydrolysis. All three NArNAOCAM naproxen derivatives represent potentially useful prodrugs which are reasonably stable but should be sufficientl y labile enough to rel ease the drug at an appropriate rate to express its pharmacological activity. Moreover, since 14 would eventually release p-aminobenzoic acid, a co mponent of sunscreens, it may be the most attractive candidate.

PAGE 88

72 CH3O O O N O O X Table 2-6 Hydrolysis of N-aryl-N-al kyloxycarbonylaminomethyl Derivatives of Naproxen.b Compd X log kobsv.(sec-1). t (min.) 12 H -4.015 119.62 13 OMe -3.63 49.83 14 COOEt -4.13 156.46 b Hydrolysis experiments in pH 7.1 and 39C The kinetics of decomposition of N-(4’-ethyloxycarbonylphenyl)-N-methyloxycarbonylaminomethyl ester of naproxen, 14, was also studied in aqueous buffers at 39 C over a wide pH range (Figure 2-3). Table 2-7 Effect of pH of Bu ffer on Rates of Hydrolysis of 14. pH t1/2 (min) log k 4 166.76 -4.16 6 156.29 -4.13 7 156.46 -4.13 8.25 152.72 -4.12 9.2 35.45 -3.49 The rates of hydrolysis were independent of the pH of bu ffers from pH 4.0-8.25 so the mechanism of hydrolyses along this pH range is believed to be SN1 (Moreira et al., 1996 and Iley et al., 1997). At pH 9.2, a sharp increase in rates of hydrolysis was observed. This is probably due to a change in the mechanism of hydrolysis from SN1 to addition-elimination where nucleophilic addi tion occurs on the ca rbonyl functional group of the ester followed by elim ination of carboxylate ion to form hydroxymethyl-N-methyl

PAGE 89

73 carbamic acid methyl ester (Bundgard et al., 1991). N-Methyl carbamic acid methyl ester is formed in the subsequent step by the loss of formaldehyde (Figure 2-14). Attempts to make NArNAOCAM-naproxen derivatives with enhanced water solubility are currently under investigation. NArNAOCAM-naproxen co njugates are thus prodrugs of carboxylic acids which unlike ACOM or AOCOM esters are not dependent on enzymatic hydrolysis and have sufficient chemical stability to be formulated. O H N O COOEt O H N O COOEt O N O COOEt O O O R -CH2=O RCOOH OH + Figure 2-14 Hydrolysis of NArNAOCAM-carboxylicacid conjugates at pH 9.2.

PAGE 90

74 CHAPTER 3 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-NALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF A MODEL PHENOLIC DRUG:ACETAMINOPHEN Topical approaches to masking a phenolic functional group have been limited to morphine (Drustrup et al., 1991) naltrexone (Stinchcomb et al ., 2002; Pillai et al., 2004; Valiveti et al., 2005; Hammell et al., 2005; Vaddi et al., 2005, Valivetti et al., 2005a), buprenorphine (Stinchcomb et al., 19 96), nalbuphine (Sung et al., 1998) and acetaminophen (Wasdo and Sloan, 2004). Only three promoieties, alkylcarbonyl (AC), alkyloxycarbonyl (AOC) and alkylaminocarbonyl ( AAC), have been utilized but no soft alkylated derivatives of phenol have been used for topica l delivery. Both AC and AOC derivatives of phenols rely on esterase catalysed hydrolysis or addition-elimination type mechanism to revert to the parent drug.Th e ACOM and AOCOM soft alkyl approach is presently being investigated in our lab to improve topical deli very of phenols. Insertion of ‘N(R’)CH2’ into the AOC (ROCO-) promoiety gives the NANAOCAM (ROCONR’CH2-) promoiety which should act as a so ft alkyl promoiety of phenols since it did for 6MP (Siver and Sloan, 1990). It is of interest to see if this insertion improves the biphasic properties and fl ux through skin of phenols sinc e addition of heteroatoms into the promoiety improves aque ous solubility of drugs. In order to test this hypothesis acetaminophen (APAP) was chosen as the model phenolic drug. The performance of the prodrug series in diffusion cell experiments will be compared with that predic ted by the Roberts-Sloan (RS) equation. The results will be

PAGE 91

75 added to the Sloan and coworkers database to generate new coefficients for the parameters in the equation and give a more robust RS equation. Experimental Procedure Materials and Methods Isopropyl myristate (IPM) was obtained from Givaudan Corp (Clifton, NJ). Theophylline (ThH) was purchased from Sigma Chemical Co. (St. Louis, MO, USA); all other reagent chemicals were from Aldric h Chemical Co. (Milwaukee, WI, USA). The water was obtained from a Millipore Milli-Q water ultra filteration system. Ultraviolet spectra were recorded on a Shimadzu UV2501 PC spectrophotometer. A radiometer pH meter 26 was used to determine pH of soluti ons.The vertical, Fran z type diffusion cells were from Crown Glass (Somerville, NJ, USA) (surface area 4.9cm2, 20 mL receptor phase volume, 15 mL donor phase volume). Th e diffusion cells were maintained at 32C with a Fischer (Pittsburgh, PA, USA) circ ulating water bath model 25. The female hairless mice (SKH-hr-1) were from Charle s River (Boston, MA, USA). Statistical analyses were carried out by using SAS 9.0. All animal sacrifices and preparation of membranes were carried out by Professor Ke n Sloan using IACAC approved protocols. Synthesis of Prodrug Derivatives Synthesis begins by the al kylation of APAP with N-alkyl-N-alkyloxycarbonyl aminomethyl chloride (NANAOCAM-Cl) in presence of a base like triethylamine and CH2Cl2 as the solvent. In every case it was necessary to synthesize the corresponding alkylating agent, NANAOCAM-Cl.

PAGE 92

76 N O O Cl R CH2O CH3NH2 NN N Cl O OR R= CH3 and C2H5 DCM + NaOH Figure 3-1 Synthesis of NAN AOCAM-Cl from 1, 3, 5trialkylhexahydrotriazine. Synthesis of NANAOCAM-Cl (Figure 3-1) a) 1, 3, 5-Trimethylhexahydrotriazine was s ynthesized from equimolar equivalents of aqueous formaldehyde, methyl amine and NaOH according to the protocol originally developed by Graymore et al., (1932) and m odified by Siver et al ., (1990). Methyl amine (0.4 mol of 40% aqueous) was placed in an ice bath and an equivalent of 37% aqueous formaldehyde was added dropwise over a peri od of 10 min. The solution was allowed to equilibrate to room temperature and stirred for one hour, then an equivalent of NaOH was added and the contents were stirred for 1.5 h more. The solution was extracted with 4 50 mL CH2Cl2 and the collected CH2Cl2 were dried over Na2SO4, filtered and concentrated to a clear colorless CH2Cl2 solution containing the the hexahydrotriazine derivative. Complete evaporation of CH2Cl2 wasn’t carried out as it resulted in loss of the desired product. For quantif ication purposes the ‘CH2’ of CH2Cl2 at 5.3 and N-CH2-N peak of hexahydrotri azine derivative at 3.2 were used, yield = 82% in CH2Cl2, 1H NMR (CDCl3): 2.3 (s, 9H), 3.2 (s, 6H). Next the 1, 3, 5-trimethylhexahydrot riazine (freshly prepared) in CH2Cl2 was added to an ice cold solution of 3 equivalent of alkyl chloroformate in CH2Cl2 over a period of 10 minutes. The white suspension that was obser ved was allowed to equlilibrate to room temperature and stirred overnight. The suspension was filtered and the filtrate concentrated to an oil. The oil containe d the desired product and corresponding bis(N-

PAGE 93

77 Alkyl-N-alkyloxycarbonyl)ami nomethanes with a ‘CH2’ peak at 4.8.The oil was purified by trituration with hexane overni ght followed by ether overnight. The clear solution was decanted leaving the white resi due (bis derivative ) behind. The clear solution was then concentrated. The peak at 4.8 due to the ‘CH2 ’ of the bis derivative and peak at 5.3 due to the ‘CH2’ of N-alkyl-N-alkyloxycarb onylaminomethyl chloride were used to quantitate the amount of product formed. N-Methyl-N-methyloxycarbonylaminom ethyl chloride: yield = 90%, 1H NMR (CDCl3): 2.9 (s, 3H), 3.75 (s, 3H), 5.3 (s, 2H). N-Methyl-N-ethyloxyoxycarbonylaminom ethyl chloride: yield = 89%, 1H NMR (CDCl3): 1.3 (t, 3H), 2.9 (s, 3H), 4.22 (q, 2H), 5.33 (s, 2H). N-Methyl-N-propyloxycarbonylaminomethyl chloride, N-methyl-N-butyloxycarbonylaminomethyl chloride, N-ethyl-N-methyl oxycarbonylaminomethyl chloride and Nmethyl-N-hexyloxycarbonylaminomethyl chloride were synthesized in an alternate way via a N-alkyl carbamic acid alkyl ester (Figure 3-2). R'NH2 RO O N H R' TMSCl THF (CH2O)n RO O N R' Cl Cl3CO OCCl3 O O Cl RO O Cl RO R' = CH3, C2H5R = C3H7, C4H9, C6H13 + TEA 3 ROH + TEA Figure 3-2 Preperation of alkyl chloroformat e in situ from alcohol and synthesis of NANAOCAM-Cl from alkyl amine.

PAGE 94

78 b) N-Alkyl carbamic acid alkyl ester. To a solution of chloroformate (33 mmol) in 75 mL CH2Cl2 mounted in an ice bath, was added an equivalent of triethylamine and a queous alkyl amine. Th e reaction mixture was allowed to warm to room temperature a nd stirred overnight. Th e clear solution was washed with 3 10 mL brine and the organic layer was dried over Na2SO4 and concentrated to an oil. This oil was purifi ed by trituration with hexane overnight. The suspension that resulted was filtered and th e filtrate evaporated to a yellow oil. N-Methyl carbamic acid pr opyl ester: yield = 60 %, 1H-NMR (CDCl3 ): 0.97 (t, 3H), 1.7 (m, 2H), 2.9 (d, 3H), 4.06 (t, 2H) 4.58 (s, 1H). N-Methyl carbamic acid but yl ester: yield = 49 %, 1H-NMR (CDCl3 ): 0.92 (t, 3H), 1.38 (m, 2H), 1.6 (t, 2H), 2.8 (d, 3H), 4.06 (t, 2H) 4.58 (s, 1H). In the case of N-methyl carbamic acid hexyl ester it was necessary to synthesize the chloroformate by reacting three molar equiva lents of hexanol with an equivalent of triphosgene and three equivale nts of a poorly nucleophilic ba se, triethylamine (Figure 32). A solution of triphosgene (11 mmol) in 100 mL CH2Cl2 was first prepared and placed in an ice bath. To this solution was added a mixture of triethylamine (33 mmol) and the alcohol (33 mmol) in 25 mL CH2Cl2 dropwise over 20 min. The exothermic reaction was allowed to proceed, the contents were allowe d to warm to room temperature and stirred overnight. To this preformed chloroformate wa s added methyl amine and triethylamine as stated above in the synthesis of N-alkyl carbamic acid alkyl esters. N-Methyl carbamic acid he xyl ester: yield = 59%, 1H NMR (CDCl3): 0.89 (t, 3h), 1.31 (m, 6H), 1.58 (m, 2H), 2.79 (d, 3H), 4.04 (t, 2H) 4.69(s, 1H). (c) N-Alkyl-N-alkyloxycarbonylaminomethyl chloride:

PAGE 95

79 A suspension of N-alkyl carbamic acid alkyl ester, 1.7 equivalents of paraformaldehyde and 13 equivalents of trimethylsilyl chloride were refluxed using a CaCl2 drying tube and water condenser for 2.5 h over an oil ba th. The suspension was diluted with CH2Cl2 and filtered to get rid of the unreacted paraformaldehyde. The clear filterate was concentrated with a rotavapor at 40C under reduced pressu re. The yellow oil obtai ned was triturated with hexane overnight, the white suspension obtained was filtered, and the filtrate was concentrated to give the desired alkylating agent. N-Methyl-N-propyloxycarbonylaminom ethyl chloride: yield = 85%, 1H NMR (CDCl3): 0.97 (t, 3H), 1.7 (m, 2H), 3.0 (s, 3H), 4.12 (t, 2H), 5.35 (s, 2H). N-Methyl-N-butyloxycarbonylaminomet hyl chloride yield = 82%, 1H NMR (CDCl3): 0.95 (t, 3H), 1.41 (m, 2H), 1.65 (m, 2H), 3.0 (s, 3H), 4.17 (t, 2H), 5.33 (s, 2H). N-Methyl-N-hexyloxycarbonylaminom ethyl chloride: yield = 83%, 1H NMR (CDCl3): 0.97 (t, 3H), 1.3 (m, 6H), 1.6 (m, 2H), 3.02 (s, 3H), 4.15 (t, 2H), 5.33 (s, 2H). Synthesis of NANAOCAM-APAP prodrugs (Table 3-1): Briefly a suspension of APAP (0.01mol) and triethylamine (0.011mo l) in 25 mL dichloromethane was stirred under reflux conditions for an hour followed by the addition of the alkylating agent, NANAOCAM-Cl (0.011mol). The contents we re stirred overnight and subsequently diluted with 50 mL dichloromethane and washed with water (3 10 mL). The dichloromethane layer was, dried over Na2SO4 and concentrated at 40C over a rotary evaporator. The yellow oil obtained was then purified by column chromatography using ethyl acetate: he xane as eluent.

PAGE 96

80 Table 3-1. NANAOCAM Prodrugs of APAP. O NHCOCH3 N R' O O R Compound N-R’O-R 1 17 18 19 20 CH3 CH3 CH3 CH3 CH3 CH3 C2H5 C3H7 C4H9 C6H13 1 was prepared in 70 % yield from N-methyl-N-methyloxycarbonylaminomethyl chloride, triethylaminie and acetaminophen in CH2Cl2 after recrystallization of the oil obtained using CH2Cl2: hexane 1:3: mp = 86-88C, Rf (0.36,ether), 1H NMR(CDCl3): 7.6(s,1H), 7.39(d,2H), 6.96-6.87(2d,2H), 5.28-5.21(2s,2H), 3.72-3.7(2s,3H), 3.02.97(2s,3H), 2.0(s,3H). Anal calcd for C12H16N2O4 : C, 57.13; H, 6.39; N, 11.1. Found: C, 56.81; H, 6.34; N, 11. 17 was prepared in 65% yield from N-Met hyl-N-ethyloxycarbonyl aminomethyl chloride, triethylamine and acetaminophen in CH2Cl2 after trituration with hexane overnight to give yellow crystals which were recrystalliz ed from ethyl acetate:h exane (1:3) to give white crystals: mp = 75-77C, Rf (0.6, Et2O), 1H NMR(CDCl3): 7.38(d,2H), 7.12(s,1H), 6.96(dd,2H), 5.3(s,2H), 4.15(q,2H), 3.0(s,3H), 2.15(s,3H), 1.25(3H,t). Anal calcd for C13H18N2O4 : C, 58.64; H, 6.81; N, 10.52. Found: C, 58.53; H, 6.93; N, 10.47.

PAGE 97

81 18 was prepared in 76% yield from N-Methyl-N-propyloxycarbonyl aminomethyl chloride, triethylamine and acetaminophen in CH2Cl2 after silica gel column chromatography in ethyl acetate:hexane (3:2) followed by trituration in hexane overnight to give pale white crystals. These crystals were further recrystallized from ethyl acetate:hexane (3:2) to give white crystals: mp = 58-59C, Rf (0.2, ethyl acetate:hexane 3:2), 1H NMR(CDCl3): 7.38(d,2H), 7.14(s,1H), 6.96(dd,2H), 5.3(s,2H), 4.05(t,2H), 3.0(s,3H), 2.15(s,3H), 1.65(2H,m) 0.91(3H,t). Anal calcd for C14H20N2O4 : C, 60.01; H, 5.45; N, 12.73. Found: C, 60.1; H, 5.35; N, 12.58. 19 was prepared in 66 % yield from N-Methyl-N-butyloxy carbonyl aminomethyl chloride, triethylamine and acetaminophen in CH2Cl2 to give a colorless oil which was purified after silica gel column chromatogra phy in ethylacetate:hex ane (3:2) followed by trituration in hexane overnight to give a colorless oil: Rf = 0.13(3:7, Ethyl acetate: hexane), 1H NMR(CDCl3): 7.38(d,2H), 7.14(s,1H), 6.96(dd,2H), 5.3(s,2H), 4.05(t,2H), 3.0(s,3H), 2.15(s,3H), 1.65(2H,m), 1.4(2H,m), 0.91(3H,t). Anal calcd for C15H23N2O4 : C, 61.21; H, 7.53; N, 9.52. Fou nd: C, 61.16; H, 7.65; N, 9.24. 20 was prepared in 63 % yield from N-methyl-N-hexyloxy carbonylaminomethyl chloride, triethylamine and acetaminophen in CH2Cl2 to give a colorless oil which was purified after silica gel column chromatogra phy in ethyl acetate:hex ane (4:1) followed by trituration in hexane overnight to give a colorless oil: Rf (0.36, 7:3, ethyl acetate : hexane), 1H NMR(CDCl3): 7.38(d,2H), 7.29(s,1H), 6.95-6.89(2d,2H), 5.295.23(2s,2H), 4.11-4.07(m,2H), 3.02-2.98(2s,3H), 2.15(s,3H), 1.63(2H,m), 1.3(6H,m), 0.89(3H,m). Anal calcd for C17H27N2O4 : C, 62.33; H, 8.13; N, 8.69. Found: C, 61.96; H, 8.14; N, 8.36.

PAGE 98

82 Determination of Solubilities and Partition Coefficients Molar absorbtivities were determined in tr iplicate for each member of the series in acetonitrile (ACN) and pH 7.1 phosphate buffe r at the maximum absorption wavelength. The molar absorbtivities were calculated using Beer’s law ( = A/c). The so lubilities of the prodrugs in isopropyl myristate (IPM) were determined in triplicate by stirring suspensions of the compound in 3 mL IPM w ith a magnetic stirrer for 24 h at room temperature (23 1C) (Marti n and coworkers, 1985 and Beall et al., 1994). The test tubes containing the suspensions were sealed and thermally insulated from the stirrer. After stirring, the suspensions were filtere d through a 0.45 m nylon membrane filter. An aliquot (~0.1-0.3 mL) was withdrawn from th e clear filtrate of saturated solutions and diluted to 10 mL in a volumet ric flask with ACN. The samples were then analyzed by UV spectroscopy using absorbances determ ined at 240 nm for APAP prodrugs. The solubility in IPM was calculated from the following relationship (equation 3-1): SIPM = (A/ ) (Dilution factor) (3-1) Dilution factor = (Vfinal/Valiquot) (3-2) where A is the absorbance of the sample at 240 nm, is the molar absortivity of the sample at 240 nm in ACN and Valiquot is the volume of the satu rated filterat e aliquot and Vfinal is the final diluted sample volume. In the case of prodrug derivatives which were oils, direct solubility measurements were not possible. Thus partition coefficients between IPM and pH 4.0 buffers were used to estimate SIPM. Solubilities in water (SAQ) were determined by stirri ng suspensions in deionized water for 1 h to limit the extent of hydrolysis of the prodrugs. The samples were filtered through nylon filters diluted with ACN and analyzed by UV spectroscopy. SAQ was determined using the following equation:

PAGE 99

83 SAQ = (A/ ) (Dilution factor) (3-3) Determination of SAQ of compounds which were oils was carried out by stirring the compound in deionized water for 1 h and ensuring that a biphasic solution was present at all times. The test tubes cont aining the biphasic solution we re centrifuged for 2 minutes; an aliquot (~0.1-0.3 mL) was withdrawn from the water layer and diluted to 10 mL with ACN in a volumetric flask. The samples were then analyzed by UV spectroscopy as above. For determination of partition coeffici ents between IPM and pH 4.0 buffer (KIPM: 4.0) for compounds which were solids at room temperature, a measured volume (~0.5 mL1 mL) of the filtered saturated IPM solutions from the lipid solubility experiments were mixed with a measured volume of pH 4.0 acet ate buffer (~1-5 mL) in a 10 mL test tube (Beall et al., 1993). The test tube was capped and vigorously shaken for 10 seconds and subsequently centrifuged for 2 min to allo w the clear separation of two phases. An aliquot (~0.3 mL) was withdraw n from the IPM layer and dilu ted to 10 mL with ACN in a volumetric flask and analyzed by UV spectroscopy. The KIPM: 4.0 was calculated using the following relationship: KIPM: 4.0 = (V4.0/VIPM) AF/ (AI-AF) (3-4) where V4.0 is the volume of pH 4.0 buffer used, VIPM is the volume of IPM used, AI is the initial absorbance of the saturated IP M solution before partitioning and AF is the absorbance of the compound remaining after partitioning. The pH 4.0 buffer solubility was estimated from KIPM: 4.0 using the following equation: S4.0 = SIPM / KIPM: 4.0 (3-5)

PAGE 100

84 Determination of partition coeffi cients between IPM and water (KIPM: AQ) for compounds which were oils at room temper ature was carried out by using a measured volume (~0.5 mL – 1.0 mL) of saturated solution used for determination of SAQ placed in a 10 mL test tube and a measured volume (~1-10 mL) of IPM. The test tubes were centrifuged; an aliquot was ta ken from the water layer and di luted with ACN to 10 mL in a volumetric flask. Samples were subse quently analyzed by UV spectroscopy. KIPM: AQ and SIPM were calculated usi ng the following equations: KIPM: AQ = (V4.0/VIPM) (AI-AF)/AF (3-6) SIPM = KIPM: AQ SAQ (3-7) Solubility ratios (SR) were calculated from the ratio of SIPM / SAQ. The methylene values were calculated using equation 3-8: = (log SR n+m – log SR n)/m (3-8) where n is the number of methylene units in the promoiety of one prodrug (the lowest member of the homologous series) and m is the number of additional units in the promoiety in the higher member of the hom ologous series. Similarly the methylene values (Leo et al., 1971 and Hansch and Leo, 1979) using K values are also reported. = (log K n+m – log K n)/m (3-9) Determination of Flux through Hairless Mice Skins (Beall et al., 1994) The mice were rendered unconscious using CO2 and sacrificed by cervical dislocation. Full thickness skins were removed by dissection; the pieces were scraped to remove excess fat, cut into proper sizes a nd placed dermal side down on the diffusion cells. A Franz diffusion cell consists of two compartments; donor compartment and a receptor compartment. The receptor compartment has a side arm which can be used to sample the compartment. The skins were he ld in place using rubber rings, and the two

PAGE 101

85 halves of the cells were clamped together. The receptor phase wa s maintained at 32C with a circulating water bath. A fully assemb led Franz diffusion is shown in Figure 3-3. The receptor side was filled with 20 mL pH 7.1 buffer containing 0.1% v/v formaldehyde (2.7 mL/37% aqueous formaldehyde) to preven t microbial growth (S loan et al., 1991). No air bubbles were present in the receptor side. A magnetic stir bar was added through the side arm of the receptor compartment a nd suspended over a stir plate to stir the contents throughout the experiment. The mouse sk ins were kept in contact with buffer for 48 h prior to application of the donor phase to condition the membranes; the receptor phase was replaced with fresh buffer at leas t twice to leach out any water soluble UV absorbing material present in the skin which would interfere with the UV quantification of acetaminophen. Pre-applica tion leach periods from 2-120 h were found to have no effect on the subsequent flux of theophy lline from a theophylline/propylene glycol suspension (33 mg/0.5 mL) (Sloan et al., 1986). The vehicle used to deliver the prodrugs was IPM; IPM is widely used in dermatological formulations. It is colorless, odorless and non-irritating to the skin (S tenback and Shubik, 1974 and Fr osch and Kligman, 1977) and has been used extensively in th is lab to create the database. In all cases, the prodrug was applied as a suspension in IPM. These suspensions were prepared by stirring the test compound fo r 24 h in 2 mL IPM at room temperature; the final suspension concentra tion exceeded the compounds solubi lity by at least ten fold. Application of suspensions of test co mpound in the donor phas e ensured that all compounds tested were at the same th ermodyanamic activity (Higuchi, 1960 and Woodford and Barry, 1982) and allowed ca lculation of the maximum flux for a compound.

PAGE 102

86 A 0.5 mL aliquot of a well stirred IPM suspension was evenly applied to the conditioned membrane surface. To obtain a sa mple from the receptor compartment, 5-6 mL of buffer Figure 3-3 A Franz diffusion cell (Reproduced with permission from S.C. Wasdo, Ph.D dissertation, University of Florida, 2005) was removed using a Pasteur pipette from the si de arm of the receptor and placed in a test tube for quantification using UV spectroscopy. In order to maintain sink conditions, the entire receptor contents we re changed each time a sample was removed. Samples were collected after 8 h, 19 h, 22 h, 25 h, 28 h, 31 h and 48 h of the initial application of the donor phase. Receptor phases were analyzed by UV within 24 h of sample collection. After the 48 h diffusion period, the rema ining donor suspension was removed by thoroughly washing the skin with methanol. Methanol wash was found to have minimal effect on the barrier properties of the skin in control studies (Koch et al., 1986). In order to quantify the amount of dermal penetrati on of the prodrug, the skins were kept in contact with buffer for an additional period of 24 h. The length of the post-application leach period was sufficient to remove 8590% of the residual compound in the skin (Siver, 1987). To evaluate the integrity of membra ne, a suspension of 33 mg/0.5 mL of ThH/propylene glcol was applied uniformly to the membrane surface. Samples were

PAGE 103

87 taken after 1 h, 2 h, 3 h, and 4 h and placed in test tubes for analysis. The entire receptor phase was changed with fresh buffer every ti me a sample from the receptor phase was removed. An increase in the flux of ThH comp ared to controls was an indication that the barrier function of the skin had been i rreversibly affected by the drug/vehicle combination (Sloan et al., 1986). Determination of Prodrug Hydrolysis by UV Spectroscopy Absorbance at any wavelength was assumed to be a combination of the absorbances drug and any intact prodrug. Usi ng Beer’s law, the mathematical expression will be A = CPP + CDD (3-10) where A was the absorbance at a particular wavelength, CP concentration of prodrug, CD concentration of drug, P, molar absortivity of prodrug and D molar absortivity of drug at wavelength By measuring absorbances at two wa velengths it was possible to calculate CD and CP. A 1 = CPP 1 + CDD 1 (3-11) A 2 = CPP 2 + CDD 2 (3-12) Simulataneously solving these equations we arrive at CD and CP. CP = (A 1D 2 A 2D 1) / ( P 1D 2 P 2D 1) (3-13) CD = (A 1 CPP 1) / D 1 (3-14) CP and CD were then added to arrive at the to tal species of acetaminophen present. For APAP prodrugs, 1 was 240 nm and 2 was 280 nm. Calculation of Maximum Flux Maximum flux was calculated from the plot of the cumulative amounts of drug species delivered through the skin versus time. The cumulative amount permeated can be

PAGE 104

88 calculated by adding amount permeating thr ough the skin at each time interval or sampling time. The slope of the best fit li ne passing through the steady-state portion divided by the cross sectional ar ea of the diffusion cell (4.9 cm2) gives us the maximum flux, JM.in molecm-2h-1 A typical plot between cumula tive amount of drug species and time is shown in Figure 1-4 of Chapter 1. Physicochemical Properties of NANAOCAM Prodrugs of APAP All prodrugs of APAP had lower melting poi nts than the parent drug (Table 3-2). Only three of the five prodrugs were solids; 1, 17 and 18 while 19 and 20 were oils compared to the AOC-APAP series where al l prodrugs were solids. The melting points decreased as carbon chain lengths increased. Thus insertion of ‘CH2N(R’)’ into the AOC (ROCO-) promoiety to give the NANAOCAM promoiety leads to a greater decrease in crystalline lattice energy and hence melting points compared to AOC-APAP derivatives. Solubilities The SD of the solubilities in isopropyl my ristate and water were all less than 5%. The solubilities of prodrugs in IPM, water a nd solubility in pH 4.0 buffer are shown in Table 3-2 while molar absortivit ies, partition coefficients and values are shown in Table 3-3. Lipid solubilities measur ed in IPM increased as car bon chain lengths increased for the APAP series. The most lipid soluble member of the series 20 was 69 fold more soluble than APAP while the first member of the series 1 was 7.4 fold more soluble than APAP. The IPM solubilities of NANAOCAM-APAP were higher than AOC-APAP prodrugs (Wasdo and Sloan, 2004) probably because th e melting points of these prodrugs were considerably lower. Unlike the AOC-APAP series a regular increase in solubilities in IPM was seen along the series using the NANAOCAM promoiety.

PAGE 105

89 The direct water solubilities or pH 4. 0 of all APAP prodrugs were lower than APAP. The most water soluble member of the series 1 was 2 fold less water soluble than APAP. This is consistent with AOC-APAP pr odrugs where the most soluble member of the series, C1–AOC-APAP, was about 4 fold less so luble than APAP. Thus, the decrease in melting points is not enough to increase the solubility in water, because masking the hydrogen bonding phenolic group with NANAO CAM leads to an increase in the molecular weight to an extent that the decrea se in lattice energy isn’t able to compensate. Regardless of the irregular be havior of the absolute solubilities, the ratios of the solubilities in IPM and AQ (SRIPM: AQ) were reasonably well behaved. The average methylene SR was 0.53 0.05. The values obtained for NANAOCAM-APAP prodrugs closely relate to AOC-APAP se ries which had a value of 0.57. The SD for partition coefficients determined between IPM and pH 4.0 buffer (KIPM: 4.0) were all less than 10%. The average methylene K was 0.56 0.05 for the series. The value obtained is in close agreement w ith with other series of prod rugs (Beall, 2001; Sloan, 2003 and Wasdo, 2004). Thus values obtained using solubility ratios are in close agreement with values obtained using part ition coefficients between IP M and pH 4.0 buffer. This consistency makes values a robust indicator of cons istent homologous series behaviour.

PAGE 106

90 Table 3-2 Molecular Weights (MW), Melting Po ints (mp), Log Solubilities in Isopropyl Myristate (Log SIPM), Log Solubilities in Water (Log SAQ) and Log Solubilities in pH 4.0 Buffer (Log S4.0). Compound MW mp (C) Log SIPM (mM) Log SAQ (mM) Log S4.0 (mM) APAP 151 167-170 0.28 2 1.84 1, R = CH3, R’ = CH3 252 86-88 1.15 1.66 1.61 17, R = C2H5, R’ = CH3 266 75-77 1.3 1.2 1.22 18, R = C3H7, R’ = CH3 280 59-60 1.61 0.95 0.91 19, R = C4H9, R’ = CH3 294 1.83 0.56 nd 20, R = C6H13, R’ = CH3 322 2.12 -0.16 nd Table 3-3 Molar Absortivities in Acetonitrile and Buffer ( ), Log Solubility Ratios between IPM and Water (log SRIPM:AQ ), the Differences Between Log SRIPM:AQ ( SR), the Log of Partition coeffi cients Between IPM and pH 4.0 Buffer (Log KIPM:4.0), and the Differences Between Log KIPM:4.0( K). a Units of 1 104 L/mole. b Molar absortivities measured at 240 nm for compounds APAP, 1, 17-20. c Buffer: pH 7.1 phosphate buffer with 0.11 % formaldehyde. d Molar absortivities measured at 240nm for compounds APAP, 1, 17-20. e Molar absortivities measured at 280nm for compounds APAP, 1, 17-20. Buffer a, c Compound CH3CNa b d e Log SRIPM:AQ SR Log KIPM:4.0 K APAP 1.36 0.8 0.12 -1.72 1 1.43 1.11 0.1 -0.51 -0.45 17 1.42 1.16 0.13 0.1 0.61 0.08 0.53 18 1.45 1.26 0.15 0.66 0.56 0.69 0.61 19 1.44 1.23 0.13 1.27 0.58 20 1.47 1.14 0.14 2.28 0.51

PAGE 107

91 Diffusion Cell Experiments The maximum flux obtained for NANAOCAM prodrugs of APAP are presented in Table 3-4. All JMIPM values were within the 30% variation in J values seen for in vitro hairless mouse skin diffusion cell experiments. Only two derivatives 1 (2.18 ) and 17 (1.22 ) gave higher delivery of tota l species from IPM than APAP itself. 18 in the APAP series gave a flux comparable to APAP alone. All other prodrugs delivered less parent drug + prodrug species thro ugh the skin than APAP. The C6 derivative, 20, performed worse in the series yet it was the mo st soluble in IPM. All prodrugs derivatives had higher lipid solubility than the parent drug however it was the most water soluble derivative that gave highest flux through the skin for each series. 1 was 7.4 times more lipid soluble, 0.46 times as water soluble AP AP but 3 that of other members of the series and gave the greatest flux through sk in. The most lipid soluble member of the series 20 (69 ) higher than APAP had the lowest flux (0.43 ) of APAP. 1 showed the least decrease in water solubility compared to APAP at the same time while exhibiting higher lipid solubility compared to the parent drug and hence performed better than other more lipid soluble members of the series whose water solubility was compromised. NANAOCAM prodrugs of AP AP perform marginally better than AOC-APAP derivatives. The best performing prodrug C1-AOC-APAP was 6.3 fold more lipid soluble, 0.29 fold water soluble and exhibited 1.7 fo ld higher flux than APAP through skin. The marginal increase in flux from C1-NANAOCAM-APAP could be accounted for by the higher aqueous solubility of the prodrug.

PAGE 108

92 Table 3-4 Solubilities in IPM (SIPM), Solubilities in Water (SAQ) and Flux (JMIPM) through in vitro Hairless Mouse Skins from IPM. Compound SIPM (mM) SAQ (mM) JMIPM ( molcm2h-) APAP 1.91 100 0.51 1, R = CH3, R’ = CH3 14.13 45.71 1.11 17, R = C2H5, R’ = CH3 19.95 15.85 0.62 18, R = C3H7, R’ = CH3 40.74 8.91 0.51 19, R = C4H9, R’ = CH3 67.61 3.63 0.43 20, R = C6H13, R’ = CH3 131.83 0.69 0.22 Prodrug Bioconversion to Parent Drug. NANAOCAM prodrugs of APAP are stable to chemical hydrolysis as seen before in Chapter 2. In comparison to chemical hydrolysis, NANAOCAM derivatives of APAP are far more susceptible to enzymatic hydrol ysis. The percentage of intact prodrug found in the receptor phase was indicative of enzyma tic conversion to the parent drug. For the APAP series, the percentages of intact prodrug C1 to C6 (1, 17-20) in the receptor phase were 78, 77, 78, 76 and 80% respectively. Th e percentages of intact prodrug seen in receptor phases for the APAP series are not consistent with AOC-APAP series where the bioconversion of prodrug to APAP increases with increase in carbon chain length while in this case percentage of intact prodrug rema ins constant irrespecti ve of the alkyl side chain. Permeability Coefficients and Solubility Parameter Values When fluxes from IPM (JIPM) were divided by their corresponding solubility in IPM (SIPM) permeability coefficients (PMIPM) were obtained. The log PMIPM values of the prodrugs synthesized are given in Table 3-5.

PAGE 109

93 Table 3-5 Log Permeability Values for the APAP from IPM through Hairless Mouse Skins (log PMIPM) and Solubility Parameter values. Compound Log PMIPM i (cal cm-3)1/2 1 -1.10 12.71 17 -1.51 12.42 18 -1.90 12.17 19 -2.19 11.95 20 -2.78 11.58 PMIPM values decreased along with their resp ective calculated so lubility parameter for the both series. A plot of of log PMIPM vs i values for APAP prodrugs (1, 17-20) gave a positive slope (Figure 3-4). Such dependen ce has been seen before for lipophilic drugs of polar heterocyclic drugs like 5-FU and phe nolic drugs like APAP (Roberts and Sloan, 1999; Wasdo and Sloan, 2004). y = 1.4798x 19.901 R2 = 0.9994 -3 -2.5 -2 -1.5 -1 -0.5 0 11.51212.513 Solubility ParameterLog PMIPM 1 17 18 19 20 Figure 3-4 Plot of solubil ity parameter versus log PMIPM for 1, 17-20. For NANAOCAM-APAP prodrugs, log PMIPM decreases linearly with increasing size of the promoiety. This decrease in PMIP M can be explained by the increase in SIPM and decrease of JMIPM with increasing alkyl chain length. Residual Amounts in Skin The residual skin concentrations (Crs) for NANAOCAM prodrugs of APAP are presented in Table 3-6.

PAGE 110

94 Table 3-6. Residual Skin Concentrations of Total APAP (Crs) and Ratios of Dermal versus Transdermal Fluxes (D/T). Compound Crs SD ( mol) D/T 1 4.793 1.8 4.32 17 1.574 0.14 2.53 18 5.442 0.66 10.67 19 5.79 0.94 13.47 20 6.215 0.92 28.27 The most lipid soluble member of the series, 20, gave highest dermal delivery into the skin and also had the hi ghest D/T ratio. D/T ratios increase with increase in lipophilicity of the prodrugs except for 17. Compounds exhibiting higher JMIPM (trandermal flux) were not as effective in delivering total APAP species into the skin (dermal flux, Crs) and had lower D/T ratios. Thus if delivered appropriately these prodrugs can act as a reser voir of phenolic drugs. Second Application Fluxes. The second applicati on theophylline flux (JJIPM) values are presented in Table 3-7. Table 3-7 Second Application Theophylline Flux (JJIPM) data for Flux of Theophylline from Propylene Glycol. Compound JJIPM SD ( molcm2h-1) APAP 0.74 1 0.49 0.09 17 0.87 0.16 18 0.52 0.24 19 1.23 0.1 20 0.49 0.09 Skin penetration by theophylline from pr opylene glycol, was approximately the same or lower than control for skins treated with NANAOCA M prodrugs of APAP. Normalization of the JMIPM values by the respective JJIPM values did not change the rank order of the performances of APAP, 1, 17-20. Thus, the differences in JJIPM must be due

PAGE 111

95 to differences in the abilities of prodrugs to deliver APAP and not damage to the skin barrier. Modelling the Flux of NANAOCAM prodrugs of APAP through Hairless Mouse Skin from IPM using the RS equation. Application of the Roberts-Sloan (RS) equation to analysis of flux obtained from NANAOCAM prodrugs data allows quantification of the effect of IPM solubility, water solubility and molecular wei ght on flux through hairless mice skin.The first attempt to predict flux of the APAP prodr ugs was carried out using the RS equation derived from n = 63 compound database (e quation 3-15; Wasdo, 2005). Log JMIPM = -0.502 + 0.517 log SIPM + (1 0.517) log SAQ – 0.00266 MW (3-15) The inclusion of five APAP prodrugs (1, 17-20) revised the coefficients of the RS model as shown in equation 3-16. Log JMIPM = -0.356 + 0.53 log SIPM + (1 0.53) log SAQ – 0.00336 MW (r2 = 0.91, n = 68) (3-16) NANAOCAM prodrugs of APAP underperformed regardless of the model used. The residual values (exp log JMIPM – predicted log JMIPM = log JMIPM) for compounds 1, 1720 was 0.27 log units according to equation 3.15 and 0.23 log units using equation 3.16. A plot experimental vs calculated log JMIPM through hairless mouse skins is shown using equation 3.15 and 3.16 in Figures 3-6 and 3-7, respectively. The residual values for the entire database of n = 68 was ~0.16 using e quations 3.15 and 3.16 respectively. Both the models correctly identified the best perf orming members of the APAP series and rank order of the performance of prodrugs was also correctly identified.The experimental flux, calculated flux and error in predicting flux ( log JMIPM) using each model is given in Table 3-8.

PAGE 112

96 Table 3-8 Experimental Flux (log JMIPM), Calculated Flux (Calc. log JMIPM) and Error in Predicting Flux ( log JMIPM) for Compounds 1, 17-26 through Hairless Mouse Skins from IPM. -2.5 -1.5 -0.5 0.5 1.5 2.5 3.5 -2.5-0.51.53.5 Calculated log JMIPMlog JMIPM = 0.502+0.517 log SIPM + (1-0.517) log SAQ0.00266 MWExperimental log JMIPM n = 63 database NANAOCAM prodrugs of APAP Figure 3-5 Experimental vers us calculated log maximum flux values through hairless mouse skin from IPM using equation 3.15. Compound log JMIPM Calc.log JMIPM Eq 3.15 log JMIPM Eq 3.15 Calc. Log JMIPM Eq 3.16 log JMIPM Eq 3.16 1 0.05 0.22 0.18 0.18 0.14 17 -0.21 0.04 0.25 0.0009 0.21 18 -0.29 0.04 0.34 0.002 0.29 19 -0.37 -0.07 0.29 -0.11 0.26 20 -0.66 -0.34 0.32 -0.39 0.27

PAGE 113

97 -2.5 -1.5 -0.5 0.5 1.5 2.5 3.5 -2.5-0.51.53.5 Calculated log JMIPMlog JMIPM = 0.356+0.53 log SIPM + (1-0.53) log SAQ 0.00336 MWExperimental log JMIPM n = 63 database NANAOCAM prodrugs of APAP Figure 3-6 Experimental vers us calculated log maximum flux values through hairless mouse skin from IPM using equation 3.16. Conclusions NANAOCAM derivatives of acetaminophen were found to be enzymatically labile. The slow hydrolysis rates of NANAOCAM de rivatives of phenol containing drugs makes them potentially useful candidates to prev ent their premature metabolism during oral drug delivery in addition to increasing their topical delivery. The delivery of the total acetaminophen (A PAP) containing speci es by its N-alkylN-alkyloxycarbonylaminomethyl (NANAOCAM) de rivatives from IPM is enhanced compared to the parent drug molecule. The more water soluble member of the more lipid soluble series was the most effective at e nhancing the delivery of total APAP species through mouse skin from IPM. Insertion of ‘CH2(NR’)’ into the AOC promoiety increases biphasic solubility and flux of phenolic drugs and the NANAOCAM-APAP derivatives perform better than AOC-APAP

PAGE 114

98 The amount of drug species delivered could be reasonably predicted by the RS equation. The addition of 5 new compounds to the database of exis ting 63 compounds for the RS equation gave new coefficients which we re not significantly different from the previous coefficients. The result reinforces the importance of biphasi c solubility to flux. The y coefficient in the RS equation (3.16) suggests the c ontribution of solubility in a lipid phase (SLIPID) to be 0.53 and solubility in a water phase (SPOLAR) to be 0.47 on a scale of 1. The dependence of flux on water so lubility holds regardle ss of the degree of hydration in vitro or in vivo, human skin or mouse skin, mineral oil, propylene glycol, water or IPM (Sloan and Wasdo, 2004).

PAGE 115

99 CHAPTER 4 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-NALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF AN IMIDE CONTAINING DRUG: THEOPHYLLINE Just like the phenolic func tional group, an imide (aci dic –NH group) is commonly found in drug molecules; examples include 6MP, 5-FU, 5-Iodo-2-deoxycytosine and 5fluorocytosine. We chose theophylline (ThH ) as our model imide containing drug. Theophylline is commonly used to treat as thma and is partially effective when given orally or topically to treat psoriasis (Iancu et al., 1979 and Berenbein et al., 1979). It inhibits phosphodiesterases and leads to an increase in cAMP leve ls whose levels in psoriatic skin are severely compromised (Bour ne et al., 1974; Voorh ees and Duell, 1971). Since theophylline exhibits a narrow therapeu tic range increasing the oral dose to treat psoriasis is not a viable op tion. Topical delivery of the ophylline is limited by its poor solubility in the skin. Prod rugs of theophylline could potentially solve this problem enabling this old drug to be topically effectiv e in treating psoriasis. Sloan and coworkers have reported ACOM-Th, AOC-Th, AC-Th and mannich bases of ThH as useful prodrugs of ThH (Sloan and Bodor, 1982; Sloa n et al., 1984; Kerr et al., 1998 and Sloan et al., 2000). AOC, AC and Mannich bases (-CH2NRR’) of ThH rely on chemical hydrolysis to give ThH. While AOC and AC hydrolyse by addition elimination type of mechanism, Mannich bases hydrolyse by a SN1 type of mechanism. Since the leaving group in both cases is Thwhere ThH has a pKa of 8.6, the rates of hydrolysis are very fast, e.g. 7-AOC-Th has a t 1/2 = 1-3 min, 7-AC-Th has a t 1/2 <1 min and Mannich bases of ThH have t 1/2 <1 min. Prodrugs with such short half lives make pharmaceutical

PAGE 116

100 formulation very difficult. The sh elf life of compounds with su ch short half-lives in water means they require anhydrous st orage conditions. This makes it difficult to keep costs of marketing the compound down. The NANAOCA M promoiety, where nitrogen is built into the promoiety that is conjugated to ThH, should have improved stability because it doesn’t rely on an addition elimin ation type of pathway but on a SN1 type of mechanism that is more stable than Mannich bases. The ability of the nitrogen to donate electrons and stabilize the carbocation formed in the transition state is diminished in NANAOCAM derivatives (ROCONRCH2-, R = alkyl) compared to Mannich bases (RR’N-CH2-, R = R’ = alkyl). This is because of presence of an electron withdrawing alkyloxycarbonyl (ROCO) attached dir ectly to the NR’-CH2 nitrogen in NANAOCAM compared to Mannich bases where the nitroge n is attached to electron don ating alkyl groups which aid in stabilizing the ca rbocation and increase its rate of hydrolysis over the NANAOCAM promoiety (Figure 4-1). Introduc tion of a nitrogen hetero atom in the promoiety should also give better biphasic so lubility because nitrogen is basic and can act as hydrogen bond acceptor and, hence improve flux through the skin. Th N R R' Th N COOR R' N R R' N COOR R' + + Th Th + + more stable less stable Figure 4-1 Carbocations formed as interm ediates by hydrolysis of Mannich bases of theophylline and NANAOCAM-Th. In Chapter 2, we looked at the chemi cal hydrolysis of NANAOCAM-X conjugates in aqueous buffers, where X was phenol, carboxylic acid or 6MP. In the preceding

PAGE 117

101 chapter we looked at the topical deliver y of NANAOCAM prodrugs of acetaminophen, here we extend the use of the NANAOCAM promoiety to imide containing drugs like theophylline. In this chapter we will i nvestigate the synthesis, physicochemical characterization and diffusi on of NANAOCAM derivatives of theophylline through in vitro hairless mouse skins from IPM. The performance of the NANAOCAM prodr ugs of theophylline in diffusion cell experiments were compared with that predicted by the Roberts Sloan (RS) equation. The results were added to the Sloan database to generate new coefficients for the parameters in the equation and give a more robust RS equation. Experimental Procedure Materials and Methods Isopropyl myristate (IPM) was obtained from Givaudan Corp (Clifton, NJ). Theophylline (ThH) was purchased from Sigma Chemical Co. (St. Louis, MO, USA); all other reagent chemicals were from Aldric h Chemical Co. (Milwaukee, WI, USA). The water was obtained from a Millipore Milli-Q water ultra filteration system. Ultraviolet spectra were recorded on a Shimadzu UV2501 PC spectrophotometer. A radiometer pH meter 26 was used to determine pH of soluti ons. The vertical, Franz type diffusion cells were from Crown Glass (Somerville NJ, USA) (surface area 4.9cm2, 20 mL receptor phase volume, 15 mL donor phase volume). Th e diffusion cells were maintained at 32C with a Fischer (Pittsburgh, PA, USA) circ ulating water bath model 25. The female hairless mice (SKH-hr-1) were from Charle s River (Boston, MA, USA). Statistical analyses were carried out by using SAS 9.0. The animal research adhered to the NIH “Principles of Laboratory Animal Care.”

PAGE 118

102 Synthesis of Prodrug Derivatives Synthesis begins by the alkylation of ThH with N-alkyl-N-alkyloxycarbonylaminomethyl chloride (NANAOCAM-Cl) in pr esence of a base like triethylamine and CH2Cl2 as the solvent. In every case it was necessary to synthesize the corresponding alkylating agent, NANAOCAM-Cl. N O O Cl R CH2O CH3NH2 NN N Cl O OR R= CH3 and C2H5 DCM + NaOH Figure 4-2 Synthesis of NAN AOCAM-Cl from 1, 3, 5trialkylhexahydrotriazine. Synthesis of NANAOCAM-Cl a) 1, 3, 5-Trimethylhexahydrotriazine was s ynthesized from equimolar equivalents of aqueous formaldehyde, methyl amine and NaOH according to the protocol originally developed by Graymore et al., (1932) and m odified by Siver et al ., (1990). Methyl amine (0.4 mol of 40% aqueous) was placed in an ice bath and an equivalent of 37% aqueous formaldehyde was added dropwise over a peri od of 10 min. The solution was allowed to equilibrate to room temperature and stirred for one hour, then an equivalent of NaOH was added and the contents were stirred for 1.5 h more. The solution was extracted with 4 50 mL CH2Cl2, dried over Na2SO4, filtered and concentrated to a clear colorless CH2Cl2 solution containing the the hexahydrotriazine derivative. Complete evaporation of CH2Cl2 wasn’t carried out as it resulted in lo ss of the desired product. For quantification purposes the ‘CH2’ of CH2Cl2 at 5.3 and N-CH2-N peak of hexahydr otriazine derivative at 3.2 were used, yield = 82% in CH2Cl2, 1H NMR (CDCl3): 2.3 (s, 9H), 3.2 (s, 6H).

PAGE 119

103 Next the 1, 3, 5-trimethylhexahydrot riazine (freshly prepared) in CH2Cl2 was added to an ice cold solution of 3 equivalent of alkyl chloroformate in CH2Cl2 over a period of 10 minutes. The white suspension that was observe d was allowed to equlilibrate to room temperature and stirred overnight. The suspension was filtered and the filtrate concentrated to oil. The oil contained th e desired product and co rresponding bis(N-AlkylN-alkyloxycarbonyl)aminomethanes with a ‘CH2’ peak at 4.8.The oil was purified by trituration with hexane overnight followed by ether overnight. The clear solution was decanted leaving the white residue (bis deri vative) behind. The clear solution was then concentrated. The peak at 4.8 due to the ‘CH2 ’ of the bis derivative and the peak at 5.3 due to the ‘CH2’ of N-alkyl-N-alkyloxycarbonylaminom ethyl chloride were used to quantitate the amount of product formed. N-Methyl-N-methyloxycarbonylaminom ethyl chloride: yield = 90%, 1H NMR (CDCl3): 2.9 (s, 3H), 3.75 (s, 3H), 5.3 (s, 2H). N-Methyl-N-ethyloxyoxycarbonylaminom ethyl chloride: yield = 89%, 1H NMR (CDCl3): 1.3 (t, 3H), 2.9 (s, 3H), 4.22 (q, 2H), 5.33 (s, 2H). N-Methyl-N-propyloxycarbonylaminom ethyl chloride, N-methyl-Nbutyloxycarbonyl aminomethyl chloride, Nethyl-N-methyloxycarbonylaminomethyl chloride and N-methyl-N-hexyloxycarbonylaminom ethyl chloride were synthesized in an alternate way via a N-alkyl carbamic acid alkyl ester (Figure 4-3A).

PAGE 120

104 R'NH2 RO O N H R' TMSCl THF (CH2O)n RO O N R' Cl Cl3CO OCCl3 O O Cl RO O Cl RO R' = CH3, C2H5R = C3H7, C4H9, C6H13 + TEA 3 ROH + TEA Figure 4-3 Synthesis of NANAO CAM-Cl from alkyl amine and preperation of alkyl chloroformate in situ from alcohol b) N-Alkyl carbamic acid alkyl ester. To a solution of chloroformate (33 mmol) in 75 mL CH2Cl2 mounted in an ice bath, was added an equivalent of triethylamine and a queous alkyl amine. Th e reaction mixture was allowed to warm to room temperature and stirred overnight. The clear solution was washed with 3 10 mL brine and the organic layer was dried over Na2SO4 and concentrated to an oil. This oil was purifi ed by trituration with hexane overnight. The suspension that resulted was filtered and th e filtrate evaporated to a yellow oil. N-Methyl carbamic acid propyl ester: yield = 60 %, 1H-NMR (CDCl3 ): 0.97 (t, 3H), 1.7 (m, 2H), 2.9 (d, 3H), 4.06 (t, 2H) 4.58 (s, 1H). N-Methyl carbamic acid but yl ester: yield = 49 %, 1H-NMR (CDCl3 ): 0.92 (t, 3H), 1.38 (m, 2H), 1.6 (t, 2H), 2.8 (d, 3H), 4.06 (t, 2H) 4.58 (s, 1H). N-Ethyl carbamic acid met hyl ester: yield = 69 %, 1H-NMR (CDCl3): 1.05 (t, 3H), 3.1 (q, 2H), 3.7 (s, 2H), 4.58 (s, 1H). In the case of N-methyl carbamic acid hexyl ester it was necessary to synthesize the chloroformate by reacting three molar equiva lents of hexanol with an equivalent of

PAGE 121

105 triphosgene and three equivalents of a poorly nucleophilic base, trie thylamine (Figure 43B). A solution of triphosgene (11 mmol) in 100 mL CH2Cl2 was first prepared and placed in an ice bath. To this solution wa s added a mixture of triethylamine (33 mmol) and the alcohol (33 mmol) in 25 mL CH2Cl2 dropwise over 20 min. The exothermic reaction was allowed to proceed, the contents were allowed to warm to room temperature and stirred overnight. To this preformed chloroformate was added methyl amine and triethylamine as stated above in the synthe sis of N-alkyl carbamic acid alkyl ester. N-Methyl carbamic acid hexyl ester: yield = 59%, 1H NMR (CDCl3): 0.89 (t, 3h), 1.31 (m, 6H), 1.58 (m, 2H), 2.79 (d, 3H), 4.04 (t, 2H) 4.69(s, 1H). (c) N-Alkyl-N-alkyloxycarbonylaminomethyl chloride: A suspension of N-alkyl carbamic acid alkyl ester, 1.7 equivalents of paraformaldehyde and 13 equivalents of trimethylsilyl chlo ride was refluxed fo r 2.5 h using a CaCl2 drying tube, water condenser and an oil bath The suspension was diluted with CH2Cl2 and filtered to get rid of the unr eacted paraformaldehyde. The clear filterate was concentrated with rotavapor at 40C under reduced pressu re. The yellow oil obtai ned was triturated with hexane overnight. The white suspension obtained was filtered, and the filtrate was concentrated to give the desired alkylating agent. N-Methyl-N-propyloxycarbonylaminom ethyl chloride: yield = 85%, 1H NMR (CDCl3): 0.97 (t, 3H), 1.7 (m, 2H), 3.0 (s, 3H), 4.12 (t, 2H), 5.35 (s, 2H). N-Methyl-N-butyloxycarbonylaminomet hyl chloride yield = 82%, 1H NMR (CDCl3): 0.95 (t, 3H), 1.41 (m, 2H), 1.65 (m, 2H), 3.0 (s, 3H), 4.17 (t, 2H), 5.33 (s, 2H). N-Methyl-N-hexyloxycarbonylaminom ethyl chloride: yield = 83%, 1H NMR (CDCl3): 0.97 (t, 3H), 1.3 (m, 6H), 1.6 (m, 2H), 3.02 (s, 3H), 4.15 (t, 2H), 5.33 (s, 2H).

PAGE 122

106 N-Ethyl-N-methyloxyoxycarbonylaminomet hyl chloride: yield = 85%, 1H NMR (CDCl3): 1.25 (t, 3H), 3.45 (s, 2H), 3.8 (s, 3H), 5.33 (s, 2H). (d) Synthesis of NANAOCAM-Th (Figure 4-4). Theophylline (5.5 mol, 1 equivalent), triethylamine (1.1 equivalents) and 20 mL CH2Cl2 were stirred for 20 min. A white suspensi on formed. The alkylating agent (N-alkyl-Nalkyloxycarbonylaminomethyl chloride) was then added to the suspension. An exothermic reaction occured and the suspen sion cleared to give a solution which was stirred overnight at room temperature. Th e reaction mixture was diluted with 50 mL CH2Cl2 and extracted with 10 mL 1N HCl, 20 mL NaHCO3 solution and 3 50 mL water. The CH2Cl2 layer was then dried over Na2SO4 and concentrated to give a white solid which was crystallized from CH2Cl2: ether (1:4) to give pur e white crystals of N7(Nalkyl-N-alkyloxycarbonyl)amin omethyl theophyllines. N N N N O O N O OR R' N N N N H O O N R' Cl O OR TEA, DCM,Rt. Overnight Figure 4-4 Alkylation of th eophylline with NANAOCAM-Cl.

PAGE 123

107 Table 4-1 NANAOCAM Prodrugs of Theophylline. N N N N O O N R' O O R Compound N-R’ O-R 21 22 23 24 25 26 CH3 CH3 CH3 CH3 CH3 C2H5 CH3 C2H5 C3H7 C4H9 C6H13 CH3 21: N7-(N-Methyl-N-methyloxycarbonyl)aminomethyl theophylline. Purified using CH2Cl2: hexane (1:4) to give white crys tals, yield = 73%, mp = 165-166C, Rf (0.49, EtOAc), 1H NMR(CDCl3): 7.98-7.75 (2s,1H), 5.8 (s,2H), 3.8-3.75 (2s,3H), 3.61 (s,3H), 3.43 (s, 3H). Anal calcd for C11H15N5O4 : C, 46.97, H, 5.38; N, 24.9. Found: C, 46.88; H, 5.22; N, 24.77. 22: N7-(N-Methyl-N-ethyloxycarbonyl)aminomet hyl theophylline. Purified using CH2Cl2: ether (1:4) followed by CH2Cl2: hexane (1:4) to give pur e white crystals, yield = 84%, Rf (0.21, ether), mp = 115-117 C, 1H NMR (CDCl3): 7.98-7.78 (2s,1H), 5.8 (s,2H), 4.2-4.11 (2q,3H), 3.61 (s,3H), 3.43 (s,3H), 3.1 (s,3H), 1.36-1.28 (2t,3H). Anal calcd for C12H17N5O4 : C, 48.81, H, 5.8; N, 23.72. Found: C, 48.8; H, 5.84; N, 23.67. 23: N7-(N-Methyl-N-propyloxycarbonyl)aminomethyl theophylline. Purified using CH2Cl2: hexane (1:4) followed by hot EtOH to gi ve pure white crystals, yield = 80%, mp = 128-129C, Rf (0.24, ether), 1H NMR (CDCl3): 7.98-7.75 (2s, 1H), 5.8 (s, 2H),

PAGE 124

108 4.17-4.08 (2t, 2H), 3.6 (s, 3H), 3.43 (s, 3H), 3.1 (s, 3H), 1.74-1.61 (m, 2H), 1-0.92 (2t, 3H). Anal calcd for C13H19N5O4 : C, 50.48; H, 6.19; N, 22.64. Found: C, 50.60; H, 6.29; N, 22.62. 24: N7-(N-Methyl-N-butyloxycarbonyl)aminomethyl theophylline. Purified using CH2Cl2:hexane (1:3) to give white crys tals, yield = 71%, mp = 103C, Rf (0.29, ether); 1H NMR (CDCl3): 7.98-7.78 (2s, 1H), 5.8 (s, 2H), 4.2-4.12 (2t, 2H), 3.61 (s, 3H), 3.42 (s, 3H), 3.01 (s, 3H), 1.7-1.63 (m, 2H), 1.4-1.35 (m, 2H), 0.94 (2t, 3H). Anal calcd for C14H21N5O4 : C, 52.0; H, 6.55; N, 21.66. Found: C, 52.17; H, 6.73; N, 21.68. 25: N7-(N-Methyl-N-hexyloxycarbonyl)aminomethyl theophylline. Purified using CH2Cl2:petroleum ether (1:3) to give white cr ystals, yield = 59%, mp = 74-75C, Rf (0.22, ether); 1H NMR (CDCl3): 7.99-7.74 (2s, 1H), 5.8 (s, 2H), 4.2-4.12 (2t, 2H), 3.61 (s, 3H), 3.42 (s, 3H), 3.01 (s, 3H), 1.63 (m, 2H), 1.31 (m, 6H), 0.89 (m, 3H). Anal calcd for C16H25N5O4 : C, 54.69,H, 7.17; N, 19.93. Found: C, 54.18; H, 7.13; N, 19.53. 26: N7-(N-Ethyl-N-methyloxycarbonyl)aminomet hyl theophylline. Purified using CH2Cl2: hexane (1:4) followed by CH2Cl2: hexane (1:4) to give pure white crystals, yield = 80%, Rf (0.14, ether), mp = 145-147C, 1H NMR(CDCl3): 8.03-7.78 (2s,1H), 5.81 (s,2H), 3.84-3.77 (2s,2H), 3.61 (s,3H), 3.53 (q, 2H), 3.43 (s,3H), 1.13 (2t,3H). Anal calcd for C12H17N5O4 : C, 48.81, H, 5.8; N, 23.72. Found: C, 48.78; H, 5.74; N, 23.77. Determination of Solubilities and Partition Coefficients Molar absorbtivities were determined in tr iplicate for each member of the series in acetonitrile (ACN) and pH 7.1 phosphate buffer at the absorption wavelength. The molar absorbtivities were calculated using Beer’s law ( = A/c). The solubilities of the prodrugs

PAGE 125

109 in isopropyl myristate (IPM) were determined in triplicate by stirring suspensions of the compound in 3 mL IPM with a magnetic stirre r for 24 h at room temperature (23 1C) (Beall et al., 1994). The test tubes containing the suspensions were sealed and thermally insulated from the stirrer. After stirring, the suspensions were filtered through a 0.45 m nylon membrane filter. An aliquot (~0.1-0.3 mL) was withdrawn from the clear filtrate of saturated solutions and dilute d to 10 mL in a volumetric flask with ACN. The samples were then analyzed by UV spectroscopy and absorbances determined at 273 nm. The solubility in IPM was calculated from the following relationship (equation 4-1): SIPM = (A/ ) (Dilution factor) (4-1) Dilution factor = (Vfinal/Valiquot) (4-2) where A is the absorbance of the sample at 273 nm, is the molar absortivity of the sample at 273 nm in ACN and Valiquot is the volume of the satu rated filterat e aliquot and Vfinal is the final diluted sample volume. Solubilities in water (SAQ) were determined by stirri ng suspensions in deionized water for 1 h to limit the extent of hydrolysis of the prodrugs. The samples were filtered through nylon filters and analyzed by UV spectroscopy. SAQ values were determined using the following equation: SAQ = (A/ ) (Dilution factor) (4-3) For determination of partition coeffici ents between IPM and pH 4.0 buffer (KIPM: 4.0) a measured volume (~0.5 mL-1 mL) of the filtered saturated IPM solutions from the lipid solubility experiments were mixed w ith measured volume of pH 4.0 acetate buffer (~1-5 mL) in a 10 mL test tube (Beall et al., 1993). The test tube was capped and vigorously shaken for 10 seconds and subsequently centrifuged for 2 min to allow the

PAGE 126

110 clear separation of two phases. An aliquot (~0.3 mL) was withdrawn from the IPM layer and diluted to 10 mL with ACN in a volum etric flask and analyzed by UV spectroscopy as above. The KIPM: 4.0 was calculated using the following relationship: KIPM: 4.0 = (V4.0/VIPM) AF/ (AI-AF) (4-4) where V4.0 is the volume of pH 4.0 buffer used, VIPM is the volume of IPM used, AI is the initial absorbance of the saturated IP M solution before partitioning and AF is the absorbance of the compound remaining after partitioning. The pH 4.0 buffer solubility can be estimated from KIPM: 4.0 using the following equation: S4.0 = SIPM / KIPM: 4.0 (4-5) Solubility ratios (SR) were calculated from the ratio of SIPM / SAQ. The methylene values were calculated using equation: = (log SR n+m –log SR n)/m (4-6) where n is the number of methylene units in the promoiety of one prodrug (the lowest member of the homologous series) and m is the number of additional units in the promoiety in the higher member of the hom ologous series. Similarly the methylene values (Leo et al., 1971 and Hansch and Leo, 1979) using K values are also reported. = (log K n+m –log K n)/m (4-7) Determination of Flux through Hairless Mice Skins (Beall et al., 1994) The mice were rendered unconscious using CO2 and sacrificed by cervical dislocation. Full thickness skins were removed by dissection; the pieces were scraped to remove excess fat, cut into proper sizes a nd placed dermal side down on the diffusion cells. A Franz diffusion cell consists of two compartments; donor compartment and a receptor compartment. The receptor compartment has a side arm which can be used to inject and eject sample into or out of the compartment. The skins were held in place using

PAGE 127

111 round rubber rings and the two halves of the cells were clamped together. The receptor phase was maintained at 32C with a circul ating water bath. A fully assembled Franz diffusion is shown in Figure 3-3 in the previous chapter. The receptor side was filled with 20 mL pH 7.1 buffer containing 0.1% v/v formaldehyde (2.7 mL/ L of 37% aqueous formaldehyde) to prevent microbial growth (Sloan et al., 1991) ensuring that no air bubbles were present in the re ceptor side. A magnetic stir bar was added through the side arm of the receptor compartment and suspende d over a stir plate to stir the contents throughout the experiment. The mouse skins were kept in contact with buffer for 48 h prior to application of the donor phase to condition the memb ranes; the receptor phase was replaced with fresh buffer at least twic e to leach out any water soluble UV absorbing material present in the skin which would inte rfere with the quantification of theophylline. Pre-application leach periods from 2-120 h were found to have no effect on the subsequent flux of theophylline from a th eophylline/propylene glycol suspension (33 mg/0.5 mL) (Sloan et al., 1986). The vehicle used to deliver the prodrugs was IPM; IPM is widely used in dermatological formulati ons. It is colo rless, odorless an d non-irritating to the skin (Stenback and Shubik, 1974 and Frosch and Kligman, 1977) and has been used extensively in this lab to create the database. In all cases, the prodrug was applied as a suspension in IPM. These suspensions were prepared by stirring the test compound fo r 24 h in 2 mL IPM at room temperature; the final suspension concentration exceeded the compounds solubility by at least ten fold. Application of suspensions of test co mpound in the donor phase ensures that all compounds tested are at the same thermodya namic activity (Higuchi, 1960 and Woodford and Barry, 1982) and allows calculation of the maximum flux for a compound.

PAGE 128

112 A 0.5 mL aliquot of a well stirred IPM suspension was evenly applied to the conditioned membrane surface. To obtain a sa mple from the receptor compartment, 5-6 mL of buffer was removed using a Pasteur pi pette from the side ar m of the receptor and placed in a test tube for quantification usi ng UV spectroscopy. In order to maintain sink conditions, the entire receptor contents we re emptied and filled with fresh buffer. Samples were collected after 8 h, 19 h, 22 h, 25 h, 28 h, 31 h and 48 h of the initial application of the donor phase. Receptor pha ses were analyzed by UV within 24 h of sample collection using the molar absortivities as in Table 4-4. After the 48 h diffusion period, the rema ining donor suspension was removed by thoroughly washing the skin with methanol. Methanol wash was found to have minimal effect on the barrier properties of the skin in control studies (Koch et al., 1986). In order to quantify the amount of dermal penetrati on of the prodrug, the skins were kept in contact with buffer for an additional period of 24 h. The length of the post-application leach period was sufficient to remove 8590% of the residual compound in the skin (Siver, 1987). To evaluate the integrity of membra ne, a suspension of 33 mg/0.5 mL of ThH/propylene glycol was applied uniformly to the membrane surface. Samples were taken after 1 h, 2 h, 3 h, 4 h and placed in test tubes for further analysis. The entire receptor phase was changed with fresh buffer every time a sample from the receptor phase was taken. An increase in the flux of theophylline compared to controls was an indication that the barrier function of the skin had been irreversibly affected by the drug/vehicle combination (Sloan et al., 1986).

PAGE 129

113 Determination of Prodrug Hydrolysis by UV Spectroscopy Absorbance at any wavelength was assumed to be a combination of the absorbances drug and any intact prodrug. Usi ng Beer’s law, the mathematical expression will be: A = CPP + CDD (4-8) where A was the absorbance at a particular wavelength, CP concentration of prodrug, CD concentration of drug, P, molar absortivity of prodrug and D molar absortivity of drug at wavelength By measuring absorbances at two wa velengths it was possible to calculate CD and CP. A 1 = CPP 1 + CDD 1 (4-9) A 2 = CPP 2 + CDD 2 (4-10) Simultaneously solving these equations we arrive at CD and CP. CP = (A 1D 2 A 2D 1) / ( P 1D 2 P 2D 1) (4-11) CD = (A 1 CPP 1) / D 1 (4-12) CP and CD were then added to arrive at the tota l species of theophylline present. For ThH prodrugs, 1 was 260 nm and 2 was 284 nm. Calculation of Maximum Flux Maximum flux was calculated from the pl ot of the cumulative amounts of drug species permeated through the skin versus time. The cumulative amount permeated can be calculated by adding amount permeating th rough the skin at each time interval or sampling time. The slope of the best fit li ne passing through the steady-state portion divided by the cross sectional ar ea of the diffusion cell (4.9 cm2) gave us the maximum flux, JM.in mole cm-2 h-1 A typical plot between cumula tive amount of drug species and time is shown in Figure 1-4 of Chapter 1.

PAGE 130

114 Physicochemical Properties of NANAO CAM Prodrugs of Theophylline Melting Point Behaviour of NANAOCAM Prodrugs of Theophylline All prodrugs of ThH had lower melting point s than the parent drug (Table 4-2 and 4-3). All prodrugs of the ho mologous series were solids at room temperature. All prodrugs had lower melting points than ThH itself. The decrease in melting points with increasing carbon chain lengths along the series were co mparable to the AOC-Th and ACOM-Th prodrug derivatives (Table 4-2). Th e even carbon chain member of the series had higher melting points than the odd carbon ch ain length member. Th is alternate rise and fall of melting points on addition of a methylene unit to the alkyl chain of a promoiety along a series has previously been observed for several series of homologous series (Chikos, 2001 and Wasdo and Sloan, 2004). Solubilities The SD of the solubilities in isopropyl my ristate and water were all less than 5%. The solubilities of prodrugs in IPM, water a nd solubility in pH 4.0 buffer are shown in Table 4-3 while molar absortivities, partition coefficients and values are shown in Table 4-4. NANAOCAM prodrugs in the theophylline series showed an irregular increase and decrease in IPM solubility was seen. All prodr ugs were more lipid soluble than ThH. IPM solubility generally increases as melting point decreases along the se ries. IPM solubility

PAGE 131

115 Table 4-2 Melting Point Comparisons of NANAOCAM-Th with AOC-Th and ACOMTh. N N N N O O O O R N N N N O O O O R N N N N O O N R' O O R NANAOCAM-Th AOC-Th ACOM-Th NANAOCAM-Th AOC-Th ACOM-Th R R’ mp (C) R mp (C) R mp (C) CH3 C2H5 C3H7 C4H9 C6H13 CH3 CH3 CH3 CH3 CH3 CH3 C2H5 165-166 115-117 128-129 103 75-77 145-147 CH3 C2H5 C3H7 C4H9 C6H13 174-175 139-141 85.5-87.5 80.5-82 77-78.5 CH3 C2H5 C3H7 C4H9 C5H11 163.5-165 146-147 104-105 86-87 58-60 decreases after C2 member of the series. The initial in crease in solubility occurs because the promoiety masks a polar N-H group and th e short alkyl chains decrease crystal packing efficiency. As the alkyl chain grow s longer van der Waal s interaction between chains become stronger, leading to a decrea se in crystal lattice energy and decrease solubility (Yalkowsky, 1977). ACOM-6MP a nd 1-alkylcarbonyl 5FU prodrugs show similar behaviour (Waranis and Sloan, 1988; Beall et al., 1996 and Patrick et al., 1997). All NANAOCAM prodrugs of ThH were less water soluble than the parent drug. Water solubility increased on going from 21 to 22 and decreased thereafter from 23 to 25. The most lipid member of the series,22, was 2.5 fold less soluble than ThH. In comparison to AOC-Th or ACOM-Th, the solubilities in both IPM and water of NANAOCAM derivatives were lower.

PAGE 132

116 Regardless of the irregular behavior of the absolute solubilities, the ratios of the solubilities in IPM and AQ (SRIPM: AQ) (Table 4-3) were reas onably well behaved. The average methylene SR was 0.55 0.09. The SD for part ition coefficients determined between IPM and pH 4.0 buffer (KIPM: 4.0) were all less than 10%. The average methylene K was 0.5 0.08. The value obtained is in close agreement with with other series of prodrugs (Beall, 2001; Sloan, 2003 and Wasdo, 2004). Thus values obtained using solubility ratios are in close agreement with values obtained using partition coefficients between IPM and pH 4.0 buffer. This consistency makes values a robust indicator of homologous series behaviour. Diffusion Cell Experiments The maximum flux obtained for NANAO CAM prodrugs of theophylline are presented in Table 4-5. All JMIPM values were within the 30% variation in J values seen for in in vitro hairless mouse skin diffusion cell experiments. Only 22 (1.58) performed better than ThH at delivering total species from IPM. All other prodrugs delivered less parent drug + prodrug species through the skin than by ThH itself. All prodrugs derivatives had higher lipid solubility than the parent drug however it was the most water soluble derivative that gave highest flux through the skin. 22 was 0.4 fold as water soluble as ThH while being 64 times more lipid soluble than ThH and gave the highest deliver y of total species through the skin. 22 was the most lipid soluble and water soluble member of the series and hence gave the highest delivery through skin. 25 was the second most lipid sol uble member of the series (58) but its water solubility was lowest in the series (0.003) of ThH and it ended up giving the lowest delivery through skin (0.06) of ThH. In the 7-AOC-Th series (Sloan et al., 2000), the best performing prodrug was 133 fold fold more lipid soluble and 0.77 as water

PAGE 133

117 Table 4-3 Molecular Weights (MW), Melting Po ints (mp), Log Solubilities in Isopropyl Myristate (Log SIPM) Log Solubilities in Water (Log SAQ) and Estimated Log Solubilities in pH 4.0 Buffer (Log S4.0). Compound MW mp (C) log SIPM (mM) log SAQ (mM) log S4.0 (mM) ThH 179 270-274 -0.47 1.66 1.66 21, R = CH3, R’ = CH3 280 165-166 0.43 0.97 0.93 22, R = C2H5, R’ = CH3 294 115-117 1.34 1.25 1.38 23, R = C3H7, R’ = CH3 308 128-129 0.88 0.44 0.47 24, R = C4H9, R’ = CH3 322 103 1.04 -0.08 -0.02 25, R = C6H13, R’ = CH3 350 75-77 1.27 -0.88 -0.7 26, R = CH3, R’ = C2H5 294 145-147 0.95 0.99 1.17 soluble as ThH and gave 3 fold increase of flux across the skin. Unfortunately insertion of ‘N(R’)CH2’ moiety into the AOC moiety doesn’t increase lipid solubility by much and leads to a drastic reduc tion of water solubility in compar ison to ThH. As a result, increase in delivery of total ThH containing species due to the AOC moiety was twice compared to the NANAOCAM moiety. Similarly in the 7-ACOM-Th series, the best performing prodrug C3 was about 0.65 times as water soluble as ThH and 41 times more lipid soluble than ThH and improved flux by about 4 fold. The decreased biphasic solubility of the NANAOCAM-Th prodrugs leads to decr eased flux across hairless mouse skins compared to the 7-ACOM-Th prodrugs..

PAGE 134

118 Table 4-4 Molar Absortivities in Acetonitrile and Buffer ( ), Log Solubility Ratios between IPM and Water (log SRIPM:AQ ), the Differences Between Log SRIPM:AQ ( SR), the Log of Partition Coefficients Between IPM and pH 4.0 Buffer (Log KIPM:4.0), and the Differences Between Log KIPM:4.0( K). a Units of 1 104 L/mole. b Molar absortivities measured at 273 nm. c Buffer: pH 7.1 phosphate buffer with 0.11 % formaldehyde. d Molar absortivities measured at 260 nm.. e Molar absortivities measured at 284 nm. Prodrug Bioconversion to Parent Drug. NANAOCAM prodrugs of ThH are stable to chemical hydrolys is as seen before in Chapter 2. In comparison to chemical hydr olysis, NANAOCAM deri vatives of ThH are far more susceptible to enzymatic hydrolys is based on the amount of intact prodrug obtained after their passage through hairless mouse skins. The percentage of intact prodrug found in the receptor pha se was indicative of enzyma tic conversion to the parent drug. The percentages of intact prodrug C1 to C6 (21-26) in the receptor phase were 37, 26, 34, 28, 29 and 32% respectively. Irrespec tive of chain length the prodrug conversion for the members of the series remains constant. This particular trend was also seen in the NANAOCAM-APAP series, the am ount of intact prodrug seen for the ThH series were lower than for the APAP series which could be accounted by the lower pKa of ThH (8.6) Buffer a, c Compound CH3CNa b d e Log SRIPM:AQ SR Log KIPM:4.0 K ThH 0.8 0.62 0.51 -2.12 -2.14 21 0.79 0.45 0.63 -0.55 0.4-0.51 22 0.78 0.47 0.63 -0.11 0.5-0.04 0.47 23 0.83 0.49 0.65 0.44 0.60.41 0.45 24 0.82 0.44 0.6 1.12 0.51.07 0.61 25 0.79 0.47 0.55 2.16 1.97 0.45 26 0.84 0.53 0.64 -0.04 -0.13 0.38

PAGE 135

119 Table 4-5 Solubilities in IPM (SIPM), Solubilities in Water (SAQ) and Flux (JMIPM) through in vitro Hairless Mouse Skins from IPM. Compound SIPM (mM) SAQ (mM) JMIPM ( molcm2h-1) ThH 0.34 45.71 0.48 21, R = CH3, R’ = CH3 2.69 9.33 0.16 22, R = C2H5, R’ = CH3 21.88 17.78 0.76 23, R = C3H7, R’ = CH3 7.59 2.75 0.09 24, R = C4H9, R’ = CH3 10.96 0.83 0.07 25, R = C6H13, R’ = CH3 18.62 0.13 0.03 26, R = CH3, R’ = C2H5 8.91 9.77 0.34 versus APAP (9.5).The more acidic leaving gr oup is more sensitive to esterase catalysed hydrolysis (Barton et al., 1994) Conversion of prodrug to drug rarely has a substantial influence on the transdermal delivery through skin of total species from a prodrug because flux depends on the solubility of the drug in the skin (Bando et al., 1997 and Sloan, unpublished results). Carbamates are generally considered to be stable to enzymatic hydrolysis compared to simple esters or carbonates but there is precedence in literature that hydrolysis does occur. The marketed drug bambuterol is a carbamate derivative of phenol which undergoes enzymatic hydrolysis by non specific c holinesterases to yield the parent drug (Tunek et al., 1988). O O OH N H O N O N Bambuterol

PAGE 136

120 Permeability Coefficients and Solubility Parameter Values When flux from IPM (JIPM) was divided by their corres ponding solubility in IPM (SIPM) permeability coefficient (PMIPM) was obtained. The log PMIPM values of the prodrugs synthesized here are given in Table 4-6. Table 4-6 Log Permeability values for Theophylline Prodrugs from IPM through Hairless Mouse Skins (log PMIPM) and Solubility Parameter Values. Compound Log PMIPM i (cal cm-3)1/2 21 -1.23 13.49 22 -1.46 13.15 23 -1.93 12.85 24 -2.19 12.59 25 -2.79 12.36 26 -1.42 13.15 PMIPM values decreased along with their respec tive calculated sol ubility parameter A plot of of log PMIPM versus i values for compounds 21-26 gave a positive slope (Figure 4-5). Such dependence has been seen before for lipophilic drugs of polar heterocyclic drugs like 5-FU and phenolic drugs like APAP (Roberts and Sloan, 1999; Wasdo and Sloan, 2004). y = 1.3893x 19.802 R2 = 0.9504 -3 -2.5 -2 -1.5 -1 -0.5 0 1212.51313.514 Solubility ParameterLog PMIPM 21 22 26 23 24 25 Figure 4-5 Plot of solubil ity parameter versus log PMIPM for 21-26.

PAGE 137

121 For NANAOCAM-Th prodrugs, log PMIPM decreases linearly with increasing size of the promoiety. This decrease in PMIPM can be explained by the increase in SIPM and decrease of JMIPM with increasing al kyl chain length. 22 however had a higher JMIPM and SIPM than 21 but a lower PMIPM because the increase in JMIPM on going from 21 to 22 is lower than the increase in SIPM from 21 to 22 and hence the ratio JMIPM/SIPM is lower. Residual Amounts in Skin The residual skin concentrations (Crs) for NANAOCAM prodrugs of theophylline are presented in Table 4-7. 22 gave the highest Crs values. This deriva tive also gave the highest flux through the skin. 22 thus had the most solubility in the skin and gave higher transdermal and dermal flux. The best perf orming prodrug giving both higher transdermal and dermal delivery has been observed be fore in the AOC-APAP series (Wasdo and Sloan, 2004). The other prodrugs in the seri es deliver similar amounts of theophylline into the skin and no regular trend was seen. Table 4-7. Residual Skin Concentrat ions of Total Theophylline Species (Crs). Compound Crs SD ( mol) 21 1.358 0.42 22 2.064 0.41 23 1.19 0.26 24 1.204 0.14 25 1.3 0.15 26 2.31 0.23 Second Application Fluxes The second application theophylline flux (JJIPM) values are presented in Table 4-7.

PAGE 138

122 Table 4-8: Second Application Theophylline Flux (JJIPM) data for Flux of Theophylline from Propylene Glycol. Compound JJIPM SD ( molc m 2h-1 ) ThH 0.810.08 21 0.71 0.13 22 0.59 0.16 23 0.82 0.27 24 0.6 0.19 25 0.52 0.11 26 0.69 0.003 Skin penetration by theophylline from pr opylene glycol, was approximately the same or lower for skins treated w ith NANAOCAM prodrugs of theophylline. Normalization of the JMIPM values by the respective JJIPM values did not change the rank order of the performances of theophylline and its prodrugs 21-26. Thus, the differences in JJIPM must be due to differences in the abilities of prodrugs to deliver theophylline and not damage to the skin barrier. Modelling the Flux of NANAOCAM Prodru gs of Acetaminophen and Theophylline through Hairless Mouse Skin from IPM using the RS equation. Application of the Roberts-Sloan (RS) equation to analysis of flux obtained from NANAOCAM prodrugs data allows quantification of the effect of IPM solubility, water solubility and molecular weight on flux through hairless mice skin. First, the flux of the theophyllin e prodrugs was predicted using the RS equation derived from n = 63 compound database (equa tion 3-15; Wasdo and Sloan, 2005). Log JMIPM = -0.502 + 0.517 log SIPM + (1 0.517) log SAQ – 0.00266 MW (3-15) Inclusion of NANAOCAM-Th prodrugs (21-26) revised the coefficients of the RS model as shown in equation 4-13. Log JMIPM = -0.232 + 0.549 log SIPM + (1 0.549) log SAQ – 0.00389 MW (r2 = 0.91, n = 69) (4-13)

PAGE 139

123 Finally, all NANAOCAM prodrugs of acetaminophen and theophyl line were added to the n = 63 database from IPM to give the final form of the RS equation as shown by equation 4-14. Log JMIPM = -0.166 + 0.555 log SIPM + (1 0.555) log SAQ – 0.00422 MW (r2 = 0.90, n = 74) (4-14) NANAOCAM prodrugs of theophylline underperformed regardless of RS equation used in each case. The residual values (experimental log JMIPM – predicted log JMIPM = log JMIPM) for compounds 21-26 was 0.28 log units according to equation 3-15 and 0.16 log units using equation 4-13.The av erage error in calculating log JMIPM was 0.17 log units for the entire n = 69 database which is comparable to the log JMIPM of 0.16 log units obtained for the n = 63 database. A plot experimental vs calculated log JMIPM through hairless mouse skins is shown usi ng equation 4-13 in Figure 4-6. The residual values when all new prodrugs of APAP and ThH (NANAOCAM database) were fit to equation 4-14 for n = 74 database was found to be 0.2 log units and 0.13 log units respectively. The av erage error of predicting log JMIPM values for entire database (n = 74) is ~ 0. 16 log units using equation 414 A plot experimental vs calculated log JMIPM through hairless mouse skins for th e n = 74 database using equation 4-14 is shown in Figure 4-7 The behaviour of these prodrugs is similar to AOC-APAP prodrugs which also underperfor med based on their predicted log JMIPM of 0.27 log units. Both the models correctly identified the best performing members of the ThH series and rank order of the performance of prodrugs is also correctly identified.All the models correctly identified the best perf orming members of the APAP and ThH series

PAGE 140

124 and rank order of the performance of prodr ugs was also correctly identified.The experimental flux, calculated flux and error in predicting flux ( log JMIPM) using each model is given in Table 4-9. Table 4-9 Experimental Flux (log JMIPM), Calculated Flux (Calc. log JMIPM) and Error in Predicting Flux ( log JMIPM) for Compounds 1, 17-26 through Hairless Mouse Skins from IPM. Compound Log JMIPM Calc. log JMIPM Eq 3.15 log JMIPM Eq 3.15 Calc. log JMIPM Eq 4.13 log JMIPM Eq 4.13 Calc. log JMIPM Eq 4.14 log JMIPM Eq 4.14 1 0.05 0.15 0.10 17 -0.21 -0.033 0.17 18 -0.29 -0.031 0.26 19 -0.37 -0.14 0.22 20 -0.66 -0.42 0.24 21 -0.79 -0.56 0.24 -0.65 0.15 -0.68 0.119 22 -0.12 0.012 0.13 -0.076 0.0042 -0.11 0.0124 23 -1.05 -0.66 0.39 -0.75 0.297 -0.78 0.26 24 -1.15 -0.86 0.29 -0.95 0.205 -0.98 0.17 25 -1.52 -1.20 0.32 -1.29 0.23 -1.33 0.19 26 -0.46 -0.31 0.15 -0.41 0.061 -0.44 0.00297 -2.5 -1.5 -0.5 0.5 1.5 2.5 3.5 -2.5-0.51.53.5 Calculated log JMIPMlog JMIPM = 0.232+0.549 log SIPM+ (1-0.549) log SAQ 0.00389 MWExperimental log JMIPM n = 63 database NANAOCAM prodrugs of ThH Figure 4-6 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 4.13 for n = 69.

PAGE 141

125 -2.5 -1.5 -0.5 0.5 1.5 2.5 3.5 -2.5-0.51.53.5Calculated log JMIPMlog JMIPM = -0.502 +0.517 log SIPM + (1-0.517) log SAQ 0.00266 MWExperimental log JMIPM n = 63 database NANAOCAM prodrugs of APAP and ThH Figure 4-7 Experimental versus calculated log maximum flux values through hairless mouse skin from IPM using equation 4.14 for n = 74. Conclusions For the 7-NANAOCAM-Th series of prodrugs the most lipid soluble and the most water soluble member of the series was the most effective in delivering total ThH species from IPM through hairless mouse skins. The 7-NANAOCAM-Th prodrugs were generally less effective than both 7-AOC a nd 7-ACOM prodrugs of ThH because they were generally less soluble in lipid (IPM) and water. However, they were more stable than their AOC counterparts which should make formulation more feasible. The addition of the 7-NANAOCAM-Th series to the RS database and subsequent fitting of n = 69 to the RS equation gave new coefficients that were not different from the previous parameter estimates. The flux of NANAOCAM prodrugs is accurately predicted by the RS equation which reflects the fact that solubility in lipid and water are important criteria for optimizing flux through the skin.

PAGE 142

126 CHAPTER 5 SUMMARY OF RESULTS OBTAIN ED AND FUTURE WORK There were four major objectives to this work. The first objective was the synthesis and characterization of N-alkyl-N-al kyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenols, carboxylic acids, th eophylline, 6-mercaptopurine. The second was; synthesis and charac terization of N-aryl-N-a lkyloxycarbonylaminomethyl (NArNAOCAM) derivatives of phenols and carb oxylic acids followed by investigation of the mechanism of chemical hydrolysis of their NANAOCAM and NArNAOCAM derivatives in aqueous buffers.The third object ive was to evaluate the delivery of total APAP and ThH by their NANAOCAM derivativ es across hairless mouse skins from IPM. The fourth objective was to combine this new data with previously synthesized prodrugs series of 5-FU and 6MP and fit th e combined database to the Roberts Sloan equation (RS) to predict flux. All the objectiv es of the study were completed. An optimized synthesis of NANAOCAM de rivatives of phenols, carboxylic acids, theophylline and 6-mercaptopurine has been deve loped. The method gave better yields of the desired product and isolation of pure product was less cumbersome than reported before (Siver and Sloan, 1990). A new synt hetic route was deve loped to synthesize NArNAOCAM derivatives of phenols and carbo xylic acids in moderate yields. The new compounds synthesized were completely ch aracterized by TLC, UV, NMR and elemental analysis. The mechanism of hydrolysis of NANAOCAM and NArNAOCAM drug derivatives was found to be SN1 type. The hydrolysis was dependent on pKa of the

PAGE 143

127 leaving group and independent of pH of buffe r. Carboxylic acid prodrugs had higher rates of hydrolysis than phenols. NANAOCAM-carboxy lic acids were too uns table to serve as useful prodrugs and were stabalised by making their analogous NArNAOCAM promoiety. Both NANAOCAM and NArNAOCAM derivatives served as chemically labile derivatives of carboxylic acids so they do not rely on enzymatic processes to release the active drug molecule. A mo re water soluble NArNAOCAM prodrug of carboxylic acid would be predicted to increa se membrane permeability if given orally. NANAOCAM-phenol derivatives are chemica lly stable but enzymatically labile derivatives. The ThH prodrugs were more la bile enzymatically than APAP prodrugs. Both NANAOCAM and NArNAOCAM promoieties if conjugated to phenolic drugs like morphine and estradiol shoul d limit their first pass metabolism and increase oral bioavailability. The physicochemical properties of NANAO CAM prodrugs of AP AP and ThH such as melting points, solubilities in IPM and wa ter, partition coeffici ents between IPM and pH 4.0 acetate buffers were determined. NANAOCAM derivatives of both acetaminophen and theophylline increased flux across the skin by 2.1 and 1.6 fold respectively. The derivative gi ving the highest flux was more lip id soluble than the parent drug and exhibited the highest water solubility in the series. The addition of APAP and ThH prodrugs to the IPM database reinforced the conclusion reached previously. The relative importance of biphasic solubility on fl ux is exemplified by the coefficients of y in RS equation. The flux of both APAP and ThH prodrugs was accurately predicted by the RS equation. A slightly increased dependence on lipid solubility and less dependence on water solubility was seen compared to older RS parameter estimates. The error in

PAGE 144

128 predicting log J values and st andard deviations were low. All parameter estimates were statistically significant and had p-values less than 0.05. As the sample size increases, the precision of parameter estimates will increase and the estimations will get closer to the true parameter valu e of the population.

PAGE 145

129 LIST OF REFERENCES Ahmad, N.; Agarwal, R.; and Mukhtar, H. Cytochrome P-450 and Drug Development for Skin Diseases. Skin. Pharmacol. 1996, 9(4), 231-241. Ahmad, N.; and Mukhtar, H. Cytochro me P-450 and Drug Development for Skin Diseases. J. Invest. Dermatol. 2004, 123(3), 417-25. Albert, A. Chemical Aspects of Selective Toxicity. Nature 1958, 182, 421-422. Anderson, D.C.; Nichols, E.; Manger, R.; W oodle, D.; Barry, M.; and Fretzberg, A.R. Tumor Cell Retention of Antibody Fab Fragments Is Enhanced by an Attached HIV TAT Protein-Derived Peptide. Biochem. Biophys. Res. Commun. 1993, 194, 876-884. Bando, H.; Mohri, S.; Yamashita, F.; Takakura, Y.; and Hashida, M. Effects of Skin Metabolism on Percutaneous Pene tration of Lipophilic Drugs. J. Pharm. Sci. 1997, 86(6), 759-761. Barry, B. W. Penetration Enhancer s: Mode of action in Human Skin. Pharmacology and the Skin, Vol 1 (B Shroot, H Schaefer, eds.). Karger, Basel (1987) pp. 121-137. Barton, P.; Laws, A.P.; and Page, M.I. Struct ure-Activity Relationships in the Esterase Catalysed Hydrolysis and Transester ification of Esters and Lactones. J. Chem. Soc. Perkin. Trans.2 1994, 2021-2029. Beall, H.; Getz, J.J.; and Sloan, K.B. The Estimation of Water Solubility for Prodrugs unstable in Water. Int. J. Pharm 1993, 93, 37-47. Beall, H.; Prankerd, R.; and Sloan, K.B. Transdermal delivery of 5-Fluorouracil (5-FU) through Hairless Mice Skin by 1-al kyloxycarbonyl-5-FU Prodrugs: Physicochemical Characterization of Prodr ugs and Correlations with Transdermal Delivery. Int. J. Pharm. 1994, 111, 223-233. Beall, H.D.; Prankerd, R.; and Sloan, K.B. Transdermal delivery of 5-Fluorouracil (5-FU) by 1-Alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 1996, 129, 203-210. Beall, H.D.; and Sloan, K.B. Topical Delivery of 5-Fluorouracil (5-FU) by 3Alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 2001, 217, 127-137.

PAGE 146

130 Beamount, K.; Webster, R.; Gardner, I.; a nd Dack, K. Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist. Current Drug Metabolism, 2003, 4, 461-485. Berenbein, B.A.; Mikhailov, G.S.; and Shumay N.T. Immediate results of Psoriasis treatment with Phosphodiesterase Inhibitors. Vestn. Dermatol. Venerol. 1979, 5, 21-25. Berti, J. J.; and Lipsky, J. L. Transcut aneous Drug Delivery: A practical Review. Mayo Clin. Proc. 1995, 70, 581-586. Bisset, D. L. Anatomy and Biochemistry of the skin. Transdermal Delivery of Drugs, Vol. I (A. F. Kydonieus and B. Berner eds.). Marcel Dekker, New York (1992) pp. 179-204. Block, L.H. Medicated Topicals. Remington, The Science and Practice of Pharmacy, 20th edition. (Gennaro, A.R. ed.). Lippincott Williams & Wilkins, Philadelphia (2000) pp 836-857. Bonina, F.P.; Montenegro, L.; De Caprariis, P. ; Palagiano, F.; Trapani, G.; and Liso, G. In vitro and in vivo evaluation of Pol yoxyethyleneIndomethacin Esters as Dermal Prodrugs. J. Controlled. Release. 1995, 34, 223-232. Bonina, F.P.; Puglia, C.; Barbuzzi, T.; De Capr ariis, P.; Palagiano, F.; Rimoli, M.G.; and Saija, A. In vitro and in vivo evaluati on of Polyoxyethylene Esters as Dermal Prodrugs of Ketoprofen, Naproxen and Diclofenac. Eur. J. Pharm. Sci. 2001, 14, 123-134. Bourne. H.R.; Lichtenstein, L.M.; Melmon, K.L.; Henney, C.S.; Weinstein, Y.; and Shearer, G.M. Modulation of Inflammation and Immunity by cyclic AMP. Science 1974, 184, 19-28. Bundgaard, H.; and Johansen, M. Prodrugs as Drug Delivery systems VIII. Bioreversible Derivatization of Hydant oins by N-hydroxylation. Int. J. Pharm. 1980, 5, 67-77. Bundgaard, H.; Klixbull, U.; and Falch, E. Prodrugs as Drug Delivery Systems. 43. OAcyloxymethyl salicylamide N-Mannich bases as double prodrug forms for Amines. Int. J. Pharm. 1986, 29, 19-28. Bundgaard, H. Design and Application of Prodrugs. In A Textbook of Drug Design and Development; Krogsgaard-Larsen, P., Bundgaard, H., Eds.; Harwood: Reading, U.K., 1991; pp113-91. Bundgaard, H.; and Rasmussen, G.J. Prodrugs of Peptides 11. Chemical and Enzymatic Hydrolysis Kinetics of N-Acyloxymethyl Derivatives of Peptide-like bond Pharm. Res. 1991, 8, 1238-1242.

PAGE 147

131 Buur, A.; Bundgaard, H.; and Falch, E. Pr odrugs of 5-fluorouracil. IV. Hydrolysis Kinetics, Bioactivation and Physic ochemical Properties of various NAcyloxymethyl derivatives of 5-Fluorouracil. Int. J. Pharm. 1985, 24, 43-60. Buur, A.; and Bundgaard, H. Prodrugs of 5-Fluorouracil: V. 1-Alkyloxycarbonyl Derivatives as potential Prodrug forms for improved Rectal or Oral delivery of 5Fluorouracil. J. Pharm. Sci. 1986, 75, 522-527. Chikos, J.S.; and Nichols, G. Simple Re lationships for the Estimation of Melting Temperatures of Homologous Series. J. Chem. Eng. Data. 2001, 46, 562-573. Clement, B. Reduction of N-Hydr oxylated compounds: Amidoximes (NHydroxyamidines) as Prodrugs of Amidines. Drug Metab. Rev. 2002, 34, 565-579. Clement, B.; and Lopian, K. Ximelagatr an, an Amidoximean Ester-Prodrug. Drug. Metab. Disp. 2003, 31, 645-651. Cohen, H.; and Turnbull, D. Molecular transport in Liquids and Gases, J. Chem. Phys. 1959, 31, 1164-1169. Conover, C.D. Campothecan Delivery Systems: The utility of Aminoacids Spacers for the Conjugation of Campothecan with Poly ethylene Glycol to create Prodrugs. Anti-Cancer Drug Design 1999, 14, 459-506. De Mario, M.D.; and Ratain, M.J. Oral Chem otherapy: Rationale and Future Directions. J. Clin. Oncol. 1998, 16, 2557–2567. Dillaha, C. J.; Jansen, G.T.; Honeycutt, W.M.; and Holt, C.A. Further Studies with Topical 5-Fluorouracil. Arch. Dermatol. 1965, 92, 410-417. Drustrup, J.; Fullerton, L.; Christrup, L.; and Bundgaard, H. Utilization of Prodrugs to Enhance the Transdermal Absorption of Morphine. Int. J. Pharm. 1991, 71, 105116. Ettmayer, P.; Amidon, G.; Clement, B.; and Testa, B. Lessons Learned from Marketed and Investigational Prodrugs. J. Med. Chem. 2004, 47, 2393-2404. Fedors, R. F.A Method of Estimating both the Solubility Parameters and Molar Volumes of Liquids. Polym. Eng. Sci. 1974, 14, 147-154. Fick, A. Ann. Physik. Chem 1855, 94, 59. Fleisher, D.; Bong, R.; and Stewart, B. H. Improved Oral Drug Delivery: Solubility Limitations overcome by the use of Prod rugs. Advanced Drug Delivery Reviews, 1996, 19, 115-130.

PAGE 148

132 Flynn, G. L. Physicochemical Determinates of Skin Absorption. In J.R.Gerrity and C. J. Henry (eds.), Principles of Route-to Route Ex trapolation for Risk assessment. Elsevier, Amsterdam, 1990, pp 93-127. Frosch, P.J.; and Kligman, A.M. “The Cham ber-Scarification test for assessing and the Irritancy of Topically Applied Substances in Cutaneous Toxicity, eds., V.A. Drill and R. Lazer, Academic Press, New York, pp. 127-154 (1977). Fuchs, S.M.; and Raines, R.T. Pathway for Polyarginine entry into Mammalian Cell. Biochemistry 2004, 43, 2438-2444. Getz, J.J.; Prankerd, R.; and Sloan, K.B. Mechanism of Hydrolysis of O-Imidomethyl Derivatives of Phenols. J.Org.Chem. 1993, 58, 4913-4918 Graymore, J. Reduction products of cer tain Cyclic Methyleneamines II J. Chem. Soc., 1932, 1353-1357. Green, M.; and Loevenstein, P.M. Autonom ous functional domain s of Chemically Synthesized Human Imm unodeficiency Virus Tat Trans-Activator Protein. Cell. 1988, 55, 1179-1188. Greenwald, R.B.; Gilbert, C.; Pendri, A.; C onover, C.; Yang, R.; Xia, J.; and Martinez, A. Drug Delivery Systems: Water Soluble Taxol 2’-Poly (ethylene glycol) Ester Prodrugs-Design and in Vivo Effectiveness. J. Med. Chem. 1996, 39, 424-431. Greenwald, R.B.; Pendri, A.; Conover, C.; G ilbert, C.; Yang, R.; and Xia, J. Drug Delivery Systems. 2. Campothecan 20-O-Po ly (ethylene glycol) Ester Transport Forms. J. Med. Chem. 1996, 39, 1938-1940. Greenwald, R.B.; Pendri, A.; Conover, C.; Zh ao, H.; Choe, Y.H.; Martinez, A.; Shum, K.; and Guan, S. Drug Delivery Systems Employing 1,4or 1,6-Elimination: Poly (ethylene glycol) Prodrugs of Amine-Containing Compounds. J. Med. Chem. 1999, 42, 3657-3667. Greenwald, R.B.; Choe, Y.H.; Conover, C.; Shum, K.; Wu, D.; and Royzen, M. Drug Delivery Systems Based on Trimethyl Lock Lactonization: Poly (ethylene glycol) Prodrugs of Amine-Containing Compounds. J. Med. Chem. 2000, 43, 475-487. Greenwald, R.B.; PEG drugs: An Overview. J. Controlled. Release. 2001, 159-171. Greenwald, R.B.; Choe, Y. H.; McGuire, J.; and Conover, C. D. Effective Drug Delivery by PEGylated Drug Conjugates. Adv. Drug. Del. Rev. 2003, 55, 217-250. Gustafsson, D.; Nystrom, J.E.; Carlsson, S.; Bredberg, U.; Eriksson, U.; Gyzander, E.; Elg, M.; Antonsson, T.; Hoffmann, K.J.; Ungell, A.L.; Sorenson, H.; Nagard, S.; Abrahamsson, A.; and Bylund, R. The Dire ct Thrombin Inhibitor Melagatran and its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodyanamic Effects. Thrombosis Research. 2001, 101, 171-181.

PAGE 149

133 Guy, R.H.; and Hadgraft, J. Physicochemical Aspects of Percutaneous Penetration and its Enhancement. Pharm Res. 1988, 5, 753-758. Hammell, D.C.; Stolarczyk, E.I.; Klausner, M.; Valiveti, S.; Hamad, M.O.; Crooks, P.A.; and Stinchcomb, A.L. Bioconversion of Naltrexone and its 3-O-Alkyl-Ester Prodrugs in a Human Skin Equivalent. J.Pharm. Sci. 2005, 94(4), 828-836. Hansch, C.; and Leo, A. Substituent Constants for Correlation analysis in Chemistry and Biology. Wiley & sons, 1979. Henry, S.; McAllistair, D.V.; Allen, M.G. ; and Prausnitz, M.R. Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery. J.Pharm.Sci. 1998, 87, 922-926. Higuchi, T. Physical Chemical Analysis of Percutaneous Absorption Process from Creams and Ointments. J. Soc. Cosmet. Chem. 1960, 11, 85-97. Higuchi, T. Design of Chemical Stru cture for Optimal Dermal Delivery. Curr. Probl. Dermatol, vol 7 (G. A. Simon et al .’ ed.). Karger, Basel (1978) pp. 121-131. Hou, S.Y.E., Mitra, A.K., White, S.H., Menon, G.K., Ghadially, R.; and Elias, P.M. Membrane Structures in Normal and Essential Fatty Acid-Deficient Stratum Corneum: Characterization by Ruthen ium Tetroxide Staining and X-Ray Diffraction J. Invest. Dermatol. 1991, 96, 215-223. Iancu, L.; Shneur, A.; and Cohen, H. Trials with Xanthine derivatives in Systemic treatment of Psoriasis. Dermatologica 1979, 159, 55-61. Iley, J.; Moreira, R.; Calheiros, T.; and Mendes, E.Acyloxymethyl as a Drug Protecting Group: Part 4. The Hydrolysis of Te rtiary Amidomethyl Ester Prodrugs of Carboxylic acid agents. Pharm. Res. 1997, 14, 1634-1639. Iley, J.; Calheiros, T; and Moreira, R. Phthalimidomethyl as a Drug Pro-moiety. Probing its Reactivity. Bioorg. Med. Chem. Lett. 1998, 8, 955-958. Jain, R.; Majumdar, S.; Nashed, Y.; Pal, D.; and Mitra, A. Circumventing PGlycoprotein-Mediated Cellu lar Efflux of Quinidine by Prodrug Derivatization. Mol.Pharm. 2004, 1(4), 290-299. Jansen, A.B.A.; and Russell, T.J. Some Novel Penicillin Derivatives. J. Chem. Soc. 1965, 2127-2132. Johansen, M.; and Bundgard, H. Prodrugs as drug delivery systems.VI. Kinetics and Mechanism of the Decomposition of N-Hydr oxy methylated Amides and Imides in Aqueous Solution and Assessment of thei r Suitability as Possible Prodrugs. Arch. Pharm. Chem., Sci. Ed. 1979, 7, 175-192.

PAGE 150

134 Jona, J.A.; Dittert, L.W.; Crooks, P.A.; Milo sovich, S.M.; and Hussain, A.A. Design of Novel Prodrugs for the Enhancement of the Transdermal Penetration of Indomethacin. Int. J. Pharm. 1995, 123, 127-136. Kadir, R. Delivery of Theophylline into Excised Human Skin from Alkanoic acid Solutions: a Push-Pull mechanism. J. Pharm. Sci., 1987, 76, 774. Kerr, D.; Roberts, W.J.; Tebbett, I.; and Sl oan, K.B. 7-Alkylcar bonyloxymethyl Prodrugs of Theophylline: Topical Delivery of Theophylline Int. J. Pharm. 1998, 167, 37-48. Kim, D.T.; Introduction of Soluble Proteins into MHC class I pathway by Conjugation to an HIV-Tat Peptide. J. Immunol. 1997,159, 1666-1668. Kirschberg, T. A.; VanDeusen, C. L.; Rothbard, J. B.; Yang, M.; and Wender, P. A. Arginine-Based Molecular Transporters: The Synthesis and Chemical Evaluation of Releasable Taxol-Transporter Conjugates Org. Lett. 2003, 5, 3459-3462. Koch, S.A.M. Prodrug Approaches to Increas e the Topical Delivery of 5-Fluorocytosine and 5-Iodo-2’Deoxycytidine. PhD dissertation, University of Florida, Gainesville, FL (1986). Krise, J.P.; Zygmunt, J.; Georg, G.I.; a nd Stella, V.J. Novel Prodrug Approach for Tertiary Amines: Synthesis and Prelim inary Evaluation of N-Phosphonooxymethyl Prodrugs. J.Med.Chem. 1999, 42, 3094-3100. Labaree, D. C.; Reynolds, T. Y.; and Hochbe rg, R. B. Estradiol-16-Carboxylic Acid Esters As Locally Active Estrogens. J. Med. Chem. 2001, 44, 1802-1814. Labaree, D. C.; Zhang, J.; Harris, H.; O’ Connor, C.; Reynolds, T. Y.; and Hochberg, R. B. Synthesis and Evaluation of B-, C-, and D-Ring-Substituted Estradiol Carboxylic Acid Esters As Locally Active Estrogens. J. Med. Chem. 2003, 46, 1886-1904. Laupeze, B.; Amiot, L.; Bertho, N.; Grosset, J.M.; Lehne, G.; Fauchet, R.; and Fardel, O. Differential Expression of the Efflux Pumps P-glycoprotein and Multidrug Resistance-Associated Protein in Hu man Monocyte-Derived Dendritic Cells.Hum. Immunol. 2001, 62(10), 1073-80. Leo, A.; Hansch, C.; and Elkins, D. Pa rtition Coefficients and Their Uses. Chem. Rev. 1971, 71, 525-616. Leweke, U.H.; and Lippold, B.C. Abso rption of Sunscreens and Other Compounds Through Human Skin in Vivo: Derivation of a method to Predict Maximum Fluxes. Pharm. Res. 1995, 12, 1354-1360. Lindgren, M.; Hallbrink, M.; Prochiantz, A. and Langel, U.; Cell-Penetrating Peptides. Trends Pharmacol. Sci. 2000, 21, 99-103.

PAGE 151

135 Luedtke, N.W.; Carmichael, P.; and Tor, Y. Cellular Uptake of Aminoglycosides, Guanidinoglycosides and Polyarginine. J. Am. Chem. Soc. 2003, 125, 1237412375. Maeda, H.; Seymour, L.; and Miyamoto, Y. Conjugates of Anti-cancer Agents and Polymers: Advantages of Macromolecular Therapeutics in Vivo. Bioconjugate Chem. 1992, 3, 351-362. Majumdar, S.; Thomas, J.D.; Wasdo, S.C.; and Sloan, K.B. The Effect of Water Solubility of Solutes on Their Flux th rough Human Skin: The Extended and Edited Flynn Database. The AAPS Journal 2004, 6(4), Abstract W4250. Majumdar, S.; and Sloan, K.B. Predicti on of the Flux of Sunscreens and Other Compounds from PG/water through Human s Skin in vivo using the Roberts Sloan equation. The AAPS Journal 2005, 7(S2), Abstract R6075. Mann, D.A.; and Frankel, A.D. Endocyto sis and Targeting of exogenous HIV-1 Tat protein. EMBO J. 1991, 10, 1733-1739. Martin, A.; Wu, P. L.; and Valesquez, T. Extended Hildebrand Solubility Approach: Sulfonamides in Binary and Ternary Solvents. J. Pharm. Sci. 1985, 74, 277-282. Martin, A.; Wu, P. L.; Liron, Z.; and Cohen, S. Dependence of Solute Solubility Parameters on Solvent Polarity. J. Pharm. Sci. 1985a, 74, 638-642. McKenzie, A.W.; and Atkinson, R.M. Topical Activities of Betamethasone Esters in Man. Arch. Dermatol. 1964, 89, 741-746. Michaels, A.S.; Chandrasekaran, S.K.; and Shaw, J.E. Drug Permeation through Human Skin: Theory and in vitro Experimental Measurement. Am. Inst. Chem. Eng. 1975, 21, 985-996. Milosovich, S.; Hussain, A.; Dittert, L.; A ungst, B.; and Hussain, M. Testosteronyl-4dimethylaminobutyrate HCl: A Prodrug w ith improved Skin Permeation Rate. J. Pharm. Sci. 1993, 82, 227-228. Mitchell, D.J.; Kim, D.T.; Steinman, L.; Fathman, C.G.; and Rothbarg, J.B. Polyarginine enters cell more efficiently than other Polycationic Homopolymers. J. Pep. Res. 2000, 56, 318-325. Mitragotri, S.; Blankschtein, D.; and Lange r, R. Transdermal Drug Delivery using Low Frequency Sonophoresis. Pharm. Res. 1996, 13, 411-420. Mitragotri, S.; and Kost, J. Low Frequency Sonophoresis. A review Adv.Drug.Deliv .Rev. 2004, 56(5), 589-601.

PAGE 152

136 Moreira, R.; Mendes, E.; Calheiros, T.; Bacelo, M.J.; and Iley, J. A New Direct Synthesis of Tertiary N-Acyloxymethylamide Pr odrugs of Carboxylic Acid Drugs. Tetrahedron Lett. 1994, 35, 7107 Moreira, R.; Calheiros, T.; Cabrita, J. ; Mendes, E.; Pimentel, M.; and Iley, J. Acyloxymethyl as Drug Protecting Group. Part 3. Tertiary O-Amidomethyl Esters of Penicillin G: Chemical hydrol ysis and Antibacterial Activity. Pharm. Res. 1996, 13, 70-75. Nagahara, H. Transduction of full-length Ta t Fusion proteins into Mammalian cells: Tatp27kip/ induces cell migration. Nature Med 1998, 4, 1449-1452. Pannatier, A.; Testa, B.; and Etter, J. Enzymatic Hydrolysis by Mouse Skin Homogenates: Structure-Metabolism Relatio nships of Para-Nitrobenzoate Esters. Int. J. Pharm. 1981, 8, 167-171. Patel, J.; Prankerd, R.; and Sloan, K.B. A Prodrug Approach to Increasing the Oral Potency of a Phenolic Drug. Part 1. Synthe sis, Characterization and Stability of an O-Imidomethyl Derivati ve of 17-Estradiol. J. Pharm. Sci. 1994, 83,1477-1481. Patel, J.; Katovich, M.J.; Sloan, K.B.; Curr y, S.H.; and Prankerd, R. A Prodrug Approach to Increasing the Oral Potenc y of a Phenolic Drug. Part 2. Pharmacodyanamics and Preliminary Bioavailability of an Orally Administered O-Imidomethyl Derivative of 17-Estradiol. J. Pharm. Sci. 1995, 84,174-178. Patrick, A.I.; Beall, H.D.; Gilroy, P.; and Sloan, K.B. Effect of Vehicles on Topical Delivery of 5-Fluorouracil (5-F U) by 1-Acyl-5-FU prodrugs. Int. J. Pharm. 1997, 154, 39-48. Paudel, K.S.; Nalluri, B.N.; Hammell, D.C. ; Valiveti, S.; Kiptoo, P.; Hamad, M.O.; Crooks, P.A.; and Stinchcomb, A.L. Tran sdermal delivery of Naltrexone and its Active Metabolite 6-b-Naltrexol in Human Sk in in vitro and Guinea Pigs in vivo. J.Pharm. Sci. 2005, In press. Perrin, D.; and Dempsey, B. Buffers for pH and Metal ion control; J. Wiley and Sons, New York, 1974. Pillai, O.; Hamad, M.O.; Crooks, P.A.; and Stinchcomb, A.L. Physicochemical Evaluation, In Vitro Human Skin Diffusion and Concurrent Biot ransformation of 3O-Alkyl Carbonate Prodrugs of Naltrexone. Pharm. Res. 2004, 21(7), 1146-1152. Ponec, M.; Kempencar, J.; Shroot, B.; and Caro n, J. C. Glucocortico ids: Binding Affinity and Lipophilicity. J. Pharm. Sci. 1986, 75, 973-975. Poulsen, B. J., Design of topica l drug products: Biopharmaceutics, in Drug Design : Medicinal Chemistry, ed., E. J. Ariens, Academic Press, New York, Vol. 4, pp. 149-192 (1971).

PAGE 153

137 Potts, R.O.; and Guy, R.H. Predicting Skin Permeability Pharm Res. 1992, 9, 663-669. Prausnitz, M.; Mitragotri, S.; and Langer, R. Current Status and Future Potential of Transdermal Drug Delivery. Nat. Rev. Drug Discovery 2004, 3, 115-124. Riviere, J.E.; and Heit, M.C. Electrica lly Assited Transdermal Drug Delivery. Pharm. Res. 1997, 14(6), 687-697. Rautio, J.; Nevalainen, T.; Taipale, N.; Vepsalainen, J.; Gynther, J.; Pederson.; and Jarvinen, J. Synthesis and in vitro evaluation of aminoacy loxyalkyl esters of 2-(6methoxy-2-naphthyl)propionic acid as nove l naproxen prodrugs for dermal drug delivery. Pharm. Res. 1999, 16, 1172-1178. Roberts, W.J.; and Sloan, K.B. Correlation of Aqueous and Lipid Solubilities with Flux for Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine: a Potts-Guy approach. J. Pharm. Sci. 1999, 88, 515-532. Roberts, W.J.; and Sloan, K.B. Application of the Transformed Potts-Guy Equation to In Vivo Human Skin Data J. Pharm. Sci. 2001, 90, 1318-1323. Rothbard J. B.; Garlington, S.; Lin, Q.; Ki rschberg, T.; Kreider, E.; McGrane, P. L.; Wender, P. A.; and Khavari. P. A. Conjugation of Arginine Oligomers to Cyclosporin A Facilitates Topical De livery and inhibition of inflammation Nature Medicine 2000, 6, 1253-1257. Rothbard, J.B.; Kreider, E.; VanDeusen, C. L.; Wright, L.; Wylie, B.L.; and Wender, P. A. Arginine-Rich Molecular Transporters for Drug Delivery: Role of Backbone Spacing in Cellular Uptake J. Med. Chem. 2002, 3612-3618 Rothbard, J. B.; Jessop, T. C.; and Wender, P. A. Adaptive Translocation: The Role of Hydrogen Bonding and Membrane Potential in the Uptake of Guanidinium-rich Transporters into Cells Adv. Drug Delivery Rev. 2005, 57, 495-504. Saab, A.N.; and Sloan, K.B. The Eff ect of Aminomethyl (N-Mannich base) Derivatization on the Ability of S6-Pivaloyloxymethyl-6-M ercaptopurine Prodrug to deliver 6-Mercaptopurine through Hairless Mouse Skin. Int. J. Pharm. 1989, 57, 253-261. Saab, A.N.; Sloan, K.B.; Beall, H.; and Villanueva, R. Effect of Aminomethyl (NMannich base) Derivatiza tion on the Ability of S6-Acetyloxymethyl-6Mercaptopurine prodrug to deliver 6-Merc aptopurine through Hairless Mouse Skin. J. Pharm. Sci. 1990, 79, 1099-1104. Safadi, M.; Oliyai, R.; and Stella, V. J. Phosphoryloxymethyl Carbamates and Carbonates-Novel Water-Soluble Prodrugs for Amines and Hindered Alcohols. Pharm.Res. 1993, 10, 1350-1355.

PAGE 154

138 Schaefer, H.; and Redelmeier, T. E. Skin Barrier : Principles of percutaneous absorption. New York: S. Karger AG Publishers; 1996 Scheuplein, R. J.; and Blank, I. H. Permeability of the Skin. Physiological Rev. 1971, 51, 702-747. Schinkel, A.H. The Physiological functi on of Drug-transporting P-glycoproteins. Sem. Cancer Biol. 1997, 8, 161–170. Seki, H.; Kawaguchi, T.; and Higuchi, T. Sp ecificity of Esterases and Structure of Prodrug Esters: Reactivity of various Acylated Acetaminophen compounds and Acetylaminobenzoated compounds. J. Pharm. Sci. 1988, 77,855. Sherertz, E. F.; Sloan, K. B.; and McTier nan, R.G. Use of Theoritical Partition Coefficients determined from Solubility Parameters to predict Permeability Coefficients for 5-Fluorouracil. J. Invest. Dermatol. 1987, 89, 147-151. Shoemaker, D.P.; Garland, C.W.; and Stinfeld, J.I. In Experiments in Physical Chemistry: R.H.Summersgill, J.Stern, M. Eichberg, Eds., Mcgraw-Hill, New York, 1974, pg 283-286. Shindo, Y.; Witt, E.; Han, D.; Epstein, W.; and Packer, L. Enzymatic and Non-Enzymatic Antioxidants in Epidermis and Dermis of Human Skin. J. Invest. Dermatol. 1994, 102, 122-124. Siver, K.G. Prodrug Approaches to Increase the Topical Delivery of 6-Mercaptopurine PhD dissertation, University of Florida, Gainesville, FL (1987). Siver, K.G.; and Sloan, K.B. The Effect of Structure of Mannich base Prodrugs of 6Mercaptopurine on their Ability to De liver 6-Mercaptopurine through Hairless Mice Skin. Int. J. Pharm. 1988, 48, 195-206. Siver, K.; and Sloan, K.B. Alkylation of 6-Mercaptopurine (6MP) with N-Alkyl-NAlkyloxycarbonylaminomethyl Chlorides: S6-(N-Alkyl-N-Alkyloxycarbonylaminomethyl-6MP Prodrug Structure Eff ect on the Dermal Delivery of 6MP. J. Pharm. Sci. 1990, 79, 66-73. Sloan, K.B. Prodrugs for Dermal Delivery. Adv. Drug. Del. Rev. 1989, 3, 67-101. Sloan, K. B. Functional Group Consider ations in the Development of Prodrug Approaches to Solving Topical Delivery Problems. Topical and Ocular Drug Delivery (K. B. Sloan, ed.). Me rkel Dekker, New York (1992) pp. 17-116. Sloan, K. B. Use of Solubility Parameters from Regular Theory to Describe PartitioningDriven Processes. Topical and Ocular Drug Delivery (K. B. Sloan, ed.). Merkel Dekker, New York (1992) pp. 179-204.

PAGE 155

139 Sloan, K.B.; and Bodor, N. Hydroxym ethyl and Acyloxymethyl Prodrugs of Theophylline: Enhanced Delivery of Polar Drugs through Skin. Int. J. Pharm. 1982, 12, 299-313. Sloan, K.B.; Hashida, M.; Alexander, J.; Bodor, N.; Higuchi, T. Prodrugs of 6Thiopurines : Enhanced Delivery through the Skin. J. Pharm. Sci. 1983, 72, 372377. Sloan, K.B.; and Koch, S.A.M. Effect of Nucleophilicity and Leaving Group Ability on the SN2 Reactions of Amines with (Acyloxy) alkyl -Halides: A Product Distribution Study J. Org. Chem. 1983a, 48, 635-640. Sloan, K.B.; and Koch, S.A.M. Reactions of (Acyloxy) alkyl -Halides with Phenols : Effect of Nucleofugacity and Nu cleophilicity on Product Distribution J. Org. Chem. 1983b, 48, 3777-3783. Sloan, K.B.; Koch, S.A.M.; and Siver, K.G. Mannich base derivatives of Theophylline and 5-Fluorouracil: Synthesis, Properties and Topical Delivery Characterstics. Int. J. Pharm. 1984, 21, 251-264. Sloan, K. B.; Siver, K. G. S.; and Koch, S. A. M. The Effect of Vehicle on the Diffusion of Salicyclic Acid through Hairless Mouse Skin. J. Pharm. Sci. 1986, 75, 744-749. Sloan, K. B.; Koch, S. A. M.; Siver, K. G. S.; and Flowers, F. B. Use of Solubility Parameters to Predict Flux through Skin. J. Invest. Dermatol. 1986a, 87, 244-252. Sloan, K.B.; Beall, H.D.; Weimer, W.R.; a nd Villaneuva, R. The Effect of Receptor Phase Composition on the Permeability of Hairless Mouse Skin in Diffusion Cell Experiments. Int. J. Pharm. 1991, 73(2), 97-104. Sloan, K.B.; Della Vecchia, S.A.; Estes, J.V.; and Roberts, W. J. 7-Alkylcarbonyl and 7Alkyloxycarbonyl Prodrugs of Theophylline Int. J. Pharm. 2000, 205, 53-63. Sloan, K.B.; and Wasdo, S. Designing for Topical Delivery: Prodrugs can make a the Difference.Medicinal Research Reviews. 2003, 23, 763-793. Sloan, K.B.; Wasdo, S.C.; Ezike, U.M.; Murray, T.; Nickels, D.; Singh, S.; Shanks, T.; Tovar, J.; Ulmer, K.; and Waranis, R. Topical Delivery of 5-Fluorouracil and 6Mercaptopurine by their Alkyloxycar bonyloxymethyl prodrugs from Water: Vehicle Effects on Design of Prodrugs. Pharm. Res. 2003a, 20(4), 639-645. Sloan, K.B.; and Wasdo, S.C. “Chapter 4: The Role of Prodrugs in Penetration Enhancement.” Percutaneous Penetration Enhancers(Smith and Maibach, ed.) 2nd edn(2004), pp.51-64. Stella, V.J.; Charman, W.N.A.and Naringr ekar, V.H.; Prodrugs. Do they have Advantages in Clinical Practice? Drugs 1985, 29, 455-473.

PAGE 156

140 Stella, V.J. A Case for Prodrugs. Fosphenyltoin. Adv. Drug.Deliv.Rev 1996, 19(2), 331330. Stenback, F.; and Shubik, P. Lack of Toxi city and Carcinogenicity of some commonly used Cutaneous Agents. Toxicol. Appl. Pharmacol. 1974, 30, 7-13. Stigbrand, T.; and Fishman, W.H. Human Alkaline Phosphatases; Alan R.Liss: New York, 1984, Chapter 1. Stinchcomb, A.L.; Paliwal, R.; Dua, R.; Imoto, H.; Woodard, R.W.; and Flynn, G.L. Permeation of Buprenorphine and its 3Alkyl-Ester Prodrugs through Human Skin. Pharm. Res. 1996, 13, 1519-1523. Stinchcomb, A.L.; Swaan, P.; Ekabo, O.; Harris, K.K.; Browe, J.; Hammell, P.D.; Cooperman, T.A.; and Pearsall, M. Strai ght –chain Naltrexone Ester Prodrugs: Diffusion and Concurrent Esterase Biotransformation in Human Skin. J. Pharm. Sci. 2002, 91, 2571-2578. Stuttgen, G. Drug absorption by intact a nd damaged skin.Dermal and Transdermal absorption (R. Brandau and B. H. Lipphold, eds.). Wissenschalftliche Verlagsgesellschaft mbH, Stuttgart (1982) pp. 27-40. Swanson, H. I. Cytochrome P450 expre ssion in Human Kerati nocytes: An Aryl Hydrocarbon Receptor Perspective.Chem Biol Interact. 2004,149 (2-3):69-79. Sung, K.C.; Han, R.Y.; Hu, O.Y.P.; and Hs u, L.R. Controlled Release of Nalbuphine Prodrugs from Biodegradable Polymeri c Matrices: Influences of Prodrug Hydrophilicity and Polymer Composition. Int. J. Pharm. 1998, 172, 17-25. Vaddi, H.K.; Hamad, M.O.; Chen, J.; Banks, S.L.; Crooks, P.A.; and Stinchcomb, A.L. Human Skin Permeation for Branched Chain 3-O-Alkyl Ester and Carbonate Prodrugs of Naltrexone. Pharm. Res. 2005, 22(5), 758-765. Valiveti, S.; Hammell, D.C.; Paudel, K.S.; Hamad, M.O.; Crooks, P.A.; and Stinchcomb, A.L. In Vivo Evaluation of 3-O-Alkyl Es ter Transdermal Prodrugs of Naltrexone in Hairless Guinea Pigs. J. Controlled. Release. 2005, 102(2), 509-520. Valiveti, S.; Paudel, K.S.; Hammell, D.C.; Hamad, M.O.; Chen, J.; Crooks, P.A.; and Stinchcomb, A.L. In Vitro/In Vivo Co rrelation of Transdermal Naltrexone Prodrugs in Hairless Guinea Pigs. Pharm.Res. 2005a, 22(6), 981-989. van Hal D.A., Jeremiasse, E., Junginger, H.E., Spies, F.; and Bouwstra, J.A. Structure of Fully Hydrated Human Stratum Corneu m: A Freeze-Fracture Electron Microscopy Study. J. Invest. Dermatol. 1996, 106, 89-95. Vives, E. Cellular Uptake of the Tat Peptid e: an Endocytosis Mechanism following Ionic Interactions. J. Mol. Recog. 2003, 16, 265-271.

PAGE 157

141 Voorhees, J.J.; and Duell, E.A. Psoriasis as a Possible Defect of the Adenyl CyclaseCyclic AMP Cascade. Arch. Dermatol. 1971,104, 352-358. Taylor, H.E.; and Sloan, K.B. 1-Alkylcarbonyloxymet hyl Prodrugs of 5-Fluorouracil (5FU): Synthesis, Physicochemical Prope rties and Topical Delivery of 5-FU. J. Pharm. Sci. 1998, 87, 15-20. Thiele, J.J.; Dreher, F.; and Packer, L. Antioxidant Defense systems in skin. J. Toxicol. Cut& ocular Toxicol. 2002, 21, 1960. Tsuji, T.; and Sugai, T. Topically Ad ministered 5-Fluorour acil in Psoriarsis. Arch. Dermatol. 1972,105, 208-212. Tunek, A.; Levin, E.; and Svensson, L.A. Hydrolysis of 3H-Bambuterol, a Carbamate Prodrug of Terbutaline, in Blood from Hu mans and Laboratory Animals in vitro. Biochem. Pharmacol. 1988, 37, 3867-3876. Wacher,V.J.; Salphati, L.; and Benet, L.Z., Active Secretion and Enterocytic Drug Metabolism Barriers to Drug Absorption. Adv. Drug Deliv. Rev. 1996, 20, 99–112. Waranis, R.P.; and Sloan, K.B. The Effects of Vehicles and Prodrug Properties and their Interactions on the Delivery of 6-Mercaptopurine, thr ough Skin: Bisacyloxymethyl6Mercaptopurine prodrugs. J. Pharm. Sci. 1987, 76, 587. Waranis, R.P.; and Sloan, K.B. The Effects of Vehicles and Prodrug Properties and their interactions on the Delivery of 6-Mercaptopurine, through Skin: S6Acyloxymethyl-6Mercaptopurine prodrugs. J. Pharm. Sci. 1988, 77, 210-215. Wasdo, S.C.; and Sloan, K.B. Topical delivery of a Model Phenolic Drug: Alkyloxycarbonyl Prodrugs of Acetaminophen. Pharm. Res. 2004, 21, 940-946. Wasdo, S.C. Topical delivery of a Model Phenolic Com pound: Alkyloxycarbonyl Prodrugs of Acetaminophen Ph.D. Disseratati on University of Florida, Gainesville (2005). Watkins, P.B. Drug Metabolism by Cytochromes P450 in the Liver and Small Bowel. Gastrointest. Pharmacol. 1992, 21, 511–526. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; and Rothbard, J. B. The Design, Synthesis, a nd Evaluation of Molecules That Enable or Enhance Cellular Uptake: Pept oid Molecular Transporters Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 13003-13008 Wenkers, B.P.; and Lippold, B.C. Skin Pene tration of Nonsteroidal Anti-Inflammatory Drugs out of a Lipophilic Vehicle: In fluence of the Viable Epidermis. J. Pharm. Sci. 1999, 88, 1326-1331.

PAGE 158

142 Windholz, M.; Budavari, S.; Blumetti, R. F.; and Otterbein, E. S. In The Merck Index, Merck & Co., INC. Rahway, N.J., USA, 1983, Tenth Edition. Woodford, R.; and Barry, B.W. Optimization of Bioavailability of Topical Steroids: Thermodyanamic Control. J. Invest. Dermatol. 1982, 79, 388-391. Yalkowsky, S.H. In Design of Biopharmaceutical Pr operties through Prodrugs and Analogues; Roche, E.B., Ed.; American Phar maceutical Association Academy of Pharmaceutical Sciences: Washington, D.C., 1977; pp 392-408. Yamaoka, T.; Tabata, Y.; and Ikeda, Y. Distri bution and Tissue Uptake of Poly (ethylene glycol) with Different Molecular Weight s after Intraveneous Administration to Mice. J. Pharm. Sci. 1994, 83, 601-606.

PAGE 159

143 BIOGRAPHICAL SKETCH Susruta Majumdar was born in Calcutta, India, on 21st October 1977 to Dipak and Subhra Majumdar. He and his family lived all over Northern India from Rishikesh (in the foothills of the Himalayas), to desert like Gurgaon and finally the nation’s capital, New Delhi. Susruta went to the University of Delhi and got a bachelor’s and master’s in chemistry in 2000. After a brief research stin t with Professor J.M.K hurana at Delhi where he worked on reduction of chalcones, he arri ved at Brigham Young University in Provo, UT, in 2001. He transferred to the University of Florida to pursue a Ph.D. in medicinal chemistry in 2002 under the superv ision of Professor Ken Sloa n. He married Antara, who is a graduate student in bi ostatistics at the University at Buffalo, NY, in 2004.


Permanent Link: http://ufdc.ufl.edu/UFE0015480/00001

Material Information

Title: Prodrug Strategies Aimed at Improving Topical Delivery of Drugs Using the N-Alkyl-N-Alkyloxycarbonylaminomethyl (NANAOCAM) Promoiety
Physical Description: Mixed Material
Copyright Date: 2008

Record Information

Source Institution: University of Florida
Holding Location: University of Florida
Rights Management: All rights reserved by the source institution and holding location.
System ID: UFE0015480:00001

Permanent Link: http://ufdc.ufl.edu/UFE0015480/00001

Material Information

Title: Prodrug Strategies Aimed at Improving Topical Delivery of Drugs Using the N-Alkyl-N-Alkyloxycarbonylaminomethyl (NANAOCAM) Promoiety
Physical Description: Mixed Material
Copyright Date: 2008

Record Information

Source Institution: University of Florida
Holding Location: University of Florida
Rights Management: All rights reserved by the source institution and holding location.
System ID: UFE0015480:00001


This item has the following downloads:


Full Text












PRODRUG STRATEGIES AIMED AT IMPROVING TOPICAL DELIVERY OF
DRUGS USING THE N-ALKYL-N-ALKYLOXYCARBONYLAMINOMETHYL
(NANAOCAM) PROMOIETY















By

SUSRUTA MAJUMDAR


A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL
OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT
OF THE REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

UNIVERSITY OF FLORIDA


2006

































Copyright 2006

by

Susruta Majumdar




























This document is dedicated to my wife, PUJA and my father, BABA















ACKNOWLEDGMENTS

I would like to thank my advisor, Dr. Ken Sloan, wholeheartedly for allowing me

to pursue his and my ideas independently in his lab. His constant support, patience,

ability to keep me focused, thorough understanding of literature, and stress on basic

principles proved vital in my finishing this manuscript. The rigorous training imparted to

me in and outside the lab was responsible in my doing well in the lab, for the publications

that have or will come out of this dissertation and talking to people in various

conferences and interviews I attended during my stay at Florida. I greatly appreciate his

ability to communicate with me on a daily basis the answers to my questions in an

articulate manner. I feel confident enough to take myself to the next level in search of

something new again.

There are two people who inspire me the most: one of them is my father whom I

call baba and second is my wife, Puja. I would like to dedicate 4 years of my work to my

father and my wife.

My father and my advisor have two things in command. They both believe in

keeping things simple and have great faith in basic principles and honestly I thought I had

those under control till I joined the Sloan lab. My father introduced me to science at an

early age. He along with my mother made it possible for me to have the best education. I

went to the best private schools back home just because they valued education a lot in

spite of facing financial hardships sometimes. I did not pick my college major, chemistry;









he did. He said, "Just trust me on this one" and I am so glad I did. My dad being a

pharmacist influenced me to do what he did. I got my chance at Florida and I loved it.

I dated my present wife for 6 years before we got married. She keeps me going

everyday day after day with those constant words of encouragement. If my father was

responsible for me being in science, my wife ensured that his dream of my being a

scientist gets fulfilled. I admire the strength in her character to stay from me to finish her

education.

I would like to thank my mother and sister for their love and affection. My mother

was responsible for me being independent, tolerant and disciplined. I admire my sister's

ability to fight 'time' against all odds.

I would like to thank my graduate colleagues Dr. Scott Wasdo, Dr. Joshua Thomas

and Maren Muellar Spaeth. Scott actually was my second advisor; sometimes his

explanations for a physical chemistry concept were just too easy to follow. I hope he

decides to teach one day. I do not have words to describe Josh. He is too nice, too good

and focused. I would like to thank him for the critical discussions we had in the lab on

science, religion, politics and everything on earth. I admire him as a wonderful scientist; I

do not know of too many people who will run an experiment for 36 hrs non stop week

after week. Such dedication to work amazes me. Maren was an undergraduate exchange

student who worked with me. Together we finished couple projects in the limited time

she had in her disposal. I appreciate her adding insight and thoughtfulness into our work.

I would like to thank my committee members Dr. M.O.James, Dr. Raymond G.

Booth and Dr. William Dolbier. I would like to thank Dr. James for her constant

encouragement and her writing good recommendation letters for me. Dr. Dolbier was









largely responsible for a project I did with Maren; I thank him for adding insight into the

project and for being a part of my committee.

Finally I would like to thank Dr. Geeti Bansal (MIT), Dr. Sushma Chauhan

(Ranbaxy) and Dr. Gagan Kukreja (Ranbaxy) who taught me basically how to operate in

an organic chemistry lab like running TLC's, column chromatography and doing

crystallizations during my stay as an undergrad student at the University of Delhi.
















TABLE OF CONTENTS

page

ACKNOW LEDGM ENTS ........................................ iv

LIST OF TABLES ................. ........ ..... ......................x

LIST OF FIGURES ........... ........... .............. .......... xii

ABSTRAC T ............. ............ ................. ........ ........ xv

CHAPTER

1 INTRODUCTION ................... ................ ... ............. ...... ....... .........

The Skin........................................................ 1
Topical Delivery .............. .... ...... ..... ......... ...... ... ......... 8
Approaches to Increase Permeation across the Skin ..................................................11
Theory of Percutaneous Diffusion................... ...................... 13
Mathematical Modeling of Flux through Human Skin. Derivation of Roberts-
Sloan equation from Fick's law of Diffusion................. ...............17
Prodrugs ................... ............. .. ....... ......... ......... 21
Prodrugs for Dermal and Transdermal delivery ................................. ...........33
Research Objectives................ .......... ................. 41

2 DESIGN, SYNTHESIS, HYDROLYSIS OF N-ALKYL-N-
ALKYLOXYCARBONYL-AMINOMETHYL DRUG DERIVATIVES AND
ITS IMPLICATIONS ON PRODRUG DESIGN .................................................43

Introduction ................... ................. ............ .. ...................... 43
Synthesis of N-methyl-N-methyloxycarbonylaminomethyl and N-aryl-N-
methyloxy-carbonylaminomethyl Prodrugs........................45
N-Methyl-N-methyloxycarbonylaminomethyl chloride synthesis............48
N-Aryl-N-methyloxycarbonylaminomethyl chloride synthesis ...................49
Alkylation of Phenols, 6-Mercaptopurine, Dimethylaminobenzoic acid and
Naproxen with N-methyl-N-methyloxycarbonylaminomethyl chloride or
N-aryl-N-methyloxycarbonylaminomethyl chloride ....................................51
H ydrolysis Studies. ..................................... .. ... ..... ..............59
Implications of NANAOCAM-phenol Hydrolysis on Prodrug Design.......67
Implications of NArNAOCAM-carboxylic acid Hydrolysis on Prodrug
D e sig n .................. .......... ........................................... 7 0









3 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-N-
ALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF A MODEL
PHENOLIC DRUG:ACETAMINOPHEN................................74

Experim ental Procedure.................................................. 75
M materials and M ethods ......................................................75
Synthesis of Prodrug Derivatives................................................................75
Synthesis of NANAOCAM-Cl..........................................76
Determination of Solubilities and Partition Coefficients ..........................82
Determination of Flux through Hairless Mice Skins ...................................84
Determination of Prodrug Hydrolysis by UV Spectroscopy ........................87
Calculation of Maximum Flux .......... .................. ................ 87
Physicochemical Properties of NANAOCAM Prodrugs of APAP ............................88
Solubilities............................ ................88
D iffusion C ell Experim ents................................................................... 91
Prodrug Bioconversion to Parent Drug .............................. .................92
Permeability Coefficients and Solubility Parameter Values........................92
Residual Amounts in Skin.....................................93
Second A application Fluxes............................... .. ........................... 94
Modelling the Flux of NANAOCAM prodrugs of APAP through Hairless Mouse
Skin from IPM using the R S equation. ........................................ ............... 95
Conclusions............................. .......... ......... 97

4 SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-N-
ALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF AN IMIDE
CONTAINING DRUG: THEOPHYLLINE........................................... 99

Experim ental Procedure.................................................. 101
M materials and M ethods ..................................... ........ ............ 101
Synthesis of Prodrug D erivatives................ ......................... .................102
Synthesis of NANAOCAM-Cl..............................102
Determination of Solubilities and Partition Coefficients ......................... 108
Determination of Flux through Hairless Mice Skins ............................110
Determination of Prodrug Hydrolysis by UV Spectroscopy .................113
Calculation of Maximum Flux ........... .......... ........................13
Physicochemical Properties of NANAOCAM Prodrugs of Theophylline............1...14
Melting Point Behaviour of NANAOCAM Prodrugs of Theophylline .....114
S olu b ilities ........................................... 1 14
Diffusion Cell Experiments......... ....................................116
Prodrug Bioconversion to Parent Drug. .................. .. .....................118
Permeability Coefficients and Solubility Parameter Values......................120
R esidual A m ounts in Skin .................................................................... 121
Second Application Fluxes..................................................... ................121
Modelling the Flux of NANAOCAM Prodrugs of Acetaminophen and
Theophylline through Hairless Mouse Skin from IPM using the RS equation. ...122
Conclusions........................................ ........ 125









5 SUMMARY OF RESULTS OBTAINED AND FUTURE WORK ......................126

L IST O F R E F E R E N C E S .............. ..... ............ ......................................................... 129

B IO G R A PH IC A L SK E T C H .............. .... ............. ................................................... 143
















LIST OF TABLES


Table page

1-1 x, y, z, r2 and Average Residual Errors for Various Databases Fit to RS. ...............21

1-2 Physicochemical Characterization of 1-Alkyloxycarbonyl esters of 5-FU..............35

1-3 Physicochemical Characterization of Alkyloxycarbonyl esters of
Acetaminophen. .................. ........ ...................38

1-4 Physicochemical Characterization of PEG esters of Indomethacin....................40

2-1 N-methyl-N-methyloxycarbonylaminomethyl-phenol Conjugates Synthesized .....46

2-2 N-methyl-N-methyloxycarbonylaminomethyl and NArNAOCAM Conjugates of
Naproxen. ........................................................46

2-3 Correlation of Rates of Hydrolysis of NANAOCAM-Y with pKa and Sigma
Values of the Leaving Group (Y). ........................................................... 61

2-4 Effect of pH of Buffer on Rates of Hydrolysis of 7.......... ......................61

2-5 N-aryl-N-alkyloxycarbonylaminomethyl Derivatives of p-nitrophenol (PNP). ......70

2-6 Hydrolysis of N-aryl-N-alkyloxycarbonylaminomethyl Derivatives of Naproxen. 72

2-7 Effect of pH of Buffer on Rates of Hydrolysis of 14............. ..... ...........72

3-1 NANAOCAM Prodrugs of APAP. ...................................... ....................80

3-2 Molecular Weights, Melting Points, Log Solubilities in Isopropyl Myristate ,
Log Solubilities in Water and Log Solubilities in pH 4.0 Buffer. ........................90

3-3 Molar Absortivities in Acetonitrile and Buffer, Log Solubility Ratios between
IPM and Water, the Differences Between Log SRIPM:AQ, the Log of Partition
coefficients Between IPM and pH 4.0 Buffer, and the Differences Between Log
KIPM:4.0. ......................................... ............................. 90

3-4 Solubilities in IPM, Solubilities in Water and Flux through in vitro Hairless
M house Skins from IPM ............................................... ............... 92









3-5 Log Permeability Values for the APAP from IPM through Hairless Mouse Skins
and Solubility Parameter values. ............................... .... .......................... 93

3-6 Residual Skin Concentrations of Total APAP and Ratios of Dermal versus
Transdermal Fluxes ........ ........ ......... ..................94

3-7 Second Application Theophylline Flux data for Flux of Theophylline from
Propylene Glycol ................ ............ .... ...... .. ...................... 94

3-8 Experimental Flux, Calculated Flux and Error in Predicting Flux for Compounds
1, 17-26 through Hairless Mouse Skins from IPM. .....................................96

4-1 NANAOCAM Prodrugs of Theophylline. ....................... ............... 107

4-2 Melting Point Comparisons of NANAOCAM-Th with AOC-Th and ACOM-Th. 115

4-3 Molecular Weights, Melting Points, Log Solubilities in Isopropyl Myristate, Log
Solubilities in Water and Estimated Log Solubilities in pH 4.0 Buffer...............117

4-4 Molar Absortivities in Acetonitrile and Buffer, Log Solubility Ratios between
IPM and Water, the Differences Between Log SRIPM:AQ, the Log of Partition
Coefficients Between IPM and pH 4.0 Buffer, and the Differences Between Log
KIPM:4.0. ........................................ ............. ................ 118

4-5 Solubilities in IPM, Solubilities in Water and Flux through in vitro Hairless
Mouse Skins from IPM. ................ ....... ......... ..... .........119

4-6 Log Permeability values for Theophylline Prodrugs from IPM through Hairless
Mouse Skins and Solubility Parameter Values. ..................................... 120

4-7 Residual Skin Concentrations of Total Theophylline Species ...............................121

4-8 Second Application Theophylline Flux data for Flux of Theophylline from
Propylene Glycol ............... ............ ............ .................. 22

4-9 Experimental Flux, Calculated Flux and Error in Predicting Flux for Compounds
1, 17-26 through Hairless Mouse Skins from IPM ......................... ...............124
















LIST OF FIGURES


Figure page

1-1 Cross sectional view of hum an skin ........................................................ 2

1-2 Brick and mortar model of drug absorption through the skin..............................6

1-3 Structures of ceramides seen in the lipid bilayers of the lamellar bodies. ..............7

1-4 Illustration of a typical flux profile. .......................... ............14

1-5 Two compartment diffusion model. ............................... ............... 15

1-6 Esterase m ediated hydrolysis of prodrugs.............................................................23

1-7 Soft alkyl prodrug hydrolysis. ........................................ ................. 24

1-8 Hydrolysis pathways for Saccharin based O-imidomethyl derivative of estradiol..26

1-9 Hydrolysis of phosphoryloxymethyl prodrug mediated by phosphatases. ............27

1-10 Hydrolysis of PEG conjugated to drug using a hydroxyl-benzylalcohol linker in
vivo. .................................................... ......... 3 0

1-11 P E G -A la-C am pothecan ...................................................................................... 30

1-12 Ionic complexes formed by oligoarginine of Tat with the phosphate groups in
cell membranes....................................... ........ 32

1-13 Chemical hydrolysis of oligoarginine conjugates of cyclosporine and taxol...........33

1-14 Structure of testosterone and indomethacin esters with polarisable side chains......39

2-1 Design of NANAOCAM promoiety ...........................................44

2-2 Structures of N-methyl-N-methyloxycarbonylaminomethyl prodrugs of
dimethylaminobenzoic acid and 6MP. .................................. .........47

2-3 Synthesis of NANAOCAM prodrugs ........................................ ............... 47

2-4 Synthesis of NArNAOCAM prodrugs.......................................48









2-5 Hydrolysis of NANAOCAM-Y in aqueous buffers..............................................60

2-6 Pseudo-first order rate constants (sec-1) versus a- of parent phenol ..................62

2-7 Pseudo-first order rate constants (sec-1) versus acidic pKa of parent. ....... .........62

2-8 pH rate profiles of compds 7 and 14 ........................................... 63

2-9 SN2 type of hydrolysis of NANAOCAM-Y with YV or carbamate as the leaving
group. ................................................64

2-10 SNI type of hydrolysis of NANAOCAM-Y.................. ................. ............64

2-11 Hydrolysis of N-alkylamidomethylcarboxylic acid esters in aqueous buffers. .......65

2-12 Hydrolysis of N-imidomethyl derivatives of phenols in aqueous buffers.............66

2-13 Attempts at the synthesis of NANAOCaminoethylidene chloride and
NANAOCaminobenzylidene chloride. .............................................. .....68

2-14 Hydrolysis of NArNAOCAM-carboxylicacid conjugates at pH 9.2. ........ .........73

3-1 Synthesis of NANAOCAM-Cl from 1, 3, 5-trialkylhexahydrotriazine.................76

3-2 Preperation of alkyl chloroformate in situ from alcohol and synthesis of
NANAOCAM -Cl from alkyl amine........................ ..................................... 77

3-3 A Franz diffusion cell ................... ............................ ....... .. ...... ...... 86

3-4 Plot of solubility parameter versus log PMIPM for 1, 17-20. ..................................93

3-5 Experimental versus calculated log maximum flux values through hairless
mouse skin from IPM using equation 3.15. ........................................96

3-6 Experimental versus calculated log maximum flux values through hairless
mouse skin from IPM using equation 3.16. .......................................97

4-1 Carbocations formed as intermediates by hydrolysis of Mannich bases of
theophylline and NANAOCAM-Th.............. ............. ...... .......... 100

4-2 Synthesis of NANAOCAM-Cl from 1, 3, 5-trialkylhexahydrotriazine.................102

4-3 Synthesis of NANAOCAM-Cl from alkyl amine and preparation of alkyl
chloroform ate in situ from alcohol........................ ...................................... 104

4-4 Alkylation of theophylline with NANAOCAM-Cl................................................106

4-5 Plot of solubility parameter versus log PMIPM for 21-26. ........... ...............120









4-6 Experimental versus calculated log maximum flux values through hairless
mouse skin from IPM using equation 4.13 for n = 69............... .. ............ 124

4-7 Experimental versus calculated log maximum flux values through hairless
mouse skin from IPM using equation 4.14 for n = 74.................................. 125
















Abstract of Dissertation Presented to the Graduate School
of the University of Florida in Partial Fulfillment of the
Requirements for the Degree of Doctor of Philosophy

PRODRUG STRATEGIES AIMED AT IMPROVING TOPICAL DELIVERY OF
DRUGS USING THE N-ALKYL-N-ALKYLOXYCARBONYLAMINOMETHYL
(NANAOCAM) PROMOIETY

By

Susruta Majumdar

August 2006

Chair: Kenneth. B. Sloan
Major Department: Medicinal Chemistry

Topical delivery is an attractive route to deliver drugs into systemic circulation;

however the poor biphasic solubility of drug molecules limits delivery across the skin. N-

Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM)-drug conjugates were designed

as prodrugs with good biphasic solubilities to increase the topical delivery of phenol and

imide containing drugs.

Prodrugs are biological inactive derivatives of a drug which hydrolyse in vivo to the

parent drug molecule. These derivatives mask polar functional groups present in a drug

molecule which, in this case, leads to increased solubility of the drug in the skin.

Prodrugs must hydrolyse to exhibit their pharmacological activity. To elucidate the

mechanism of chemical hydrolysis, a series of NANAOCAM conjugates of phenols,

thiols and carboxylic acids were synthesized and their rates of hydrolysis determined in

aqueous buffers. The hydrolysis followed pseudo-unimolecular first order kinetics and

was dependent on the nucleofugacity of the leaving group. The hydrolysis was also









independent of the pH of buffers. To further elucidate the mechanism of hydrolysis, N-

aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM) conjugates of phenols and

carboxylic acids were also synthesized and their rates of hydrolysis determined. Since the

hydrolysis of NArNAOCAM conjugates were slower than NANOCAM conjugates, the

NANAOCAM conjugates are proposed to hydrolyse by a SNI type of pathway with the

lone pair on the nitrogen stabilizing the carbocation formed as an intermediate.

To investigate if the NANAOCAM promoiety increases the dermal delivery of

phenolic drugs and imide containing drugs, a homologous series of NANAOCAM-

acetaminophen and NANAOCAM-theophylline were synthesized. These derivatives

were characterized by determination of their solubilities in IPM and water, partition

coefficients between IPM and pH 4.0 buffer and flux through hairless mouse skins from

IPM.

Only two prodrugs of acetaminophen, Cl alkyloxy and C2 alkyloxy, increased flux

through the skin. These derivatives were the most water soluble prodrugs in the series of

more lipophilic prodrugs. In the theophylline series, only one derivative, C2 alkyloxy,

increased delivery through the skin. This derivative was the most lipid and most water

soluble member of the series. The flux of NANAOCAM prodrugs from IPM was

accurately predicted by the Roberts-Sloan equation.














CHAPTER 1
INTRODUCTION

The Skin

Skin is the largest organ in the human body, accounts for 10% of the total body

weight and has a surface area of 2m2 (Schaefer and Redelmeir, 1996). It acts as a physical

and chemical barrier, protecting the body from the surrounding environment. Besides

this, it enables the body to control fluid loss, regulate body temperature and intercept

external stimuli. The skin can be divided into three distinct layers, the hypodermis, the

dermis and the epidermis (Block, 2000). A microscopic view of skin is shown in Figure

1-1.

The hypodermis is made up of a network of connective fibers and adipocytes which

play an important role in energy storage and metabolism as well as providing insulation

and protection against injury. The intracellular fat droplets may also act as a reservoir of

hydrophobic compounds which may have penetrated the stratum corneum (the outermost

layer).The hypodermis is 1-2 mm thick. It houses blood vessels whose prime function is

to deliver nutrients to the skin and remove waste products, metabolites and xenobiotics

from the skin.

The dermis is the thickest layer of the skin and is 2 mm thick. It is responsible for

maintaining the structural integrity of the skin. The dermis consists of a network of

collagen and elastin fibers which provide flexibility and tensile strength to the dermis.

Proteoglycans fill up most of the intracellular space and these macromolecules are

responsible for the water-retaining properties of the dermis. These are polysaccharides









covalently bound to a polypeptide backbone. The polysaccharide side chains are

frequently sulfated. Examples of proteoglycans frequently seen in the dermis are heparin,


Hair
Shaft



Corneum
Epidermis Sebaccous
Gland


Apcrine
Sweat Gland
Demiis





Subcutaneous -W-030 11ily
pat


Hair Smooth Eccrine Lymphalic
Folliole Muscle Swea Gland Vessel
Figure 1-1 Cross sectional view of human skin (Reproduced with permission from K.G.
Siver, Ph.D. Dissertation, University of Florida, 1987).

chondroitin sulfate and dermatin sulfate. The anionic charge associated with these

proteoglycans also allows a lot of water to be associated with the carboxylate or the

sulfate groups and impedes the ability of lipophillic compounds to cross the dermis. The

dermis has an extensive vascular network which participates in various processes like

nutrition, exchange of gases, repair of tissues, immune responses and thermoregulation.

Nerve endings sensitive to vibration, pressure, pain and temperature are seen in dermis

along with mast cells, macrophages and t-cells which are present for protection against

foreign antigens. A variety of appendages which permeate the stratum corneum like

sweat glands, hair follicles and sebaceous glands are derived from this region. The hair









follicles and exocrine sweat glands have pores that extend to the skin surface and provide

openings to the epidermis which contains the stratum corneum: the main permeability

barrier of the skin. Thus xenobiotics can use this route, also called the shunt route, to

penetrate the dermis; this is especially true for highly polar molecules whose permeability

is limited by the stratum corneum. However these pores constitute only 0.1 % of the total

skin surface area and are responsible for early diffusion processes (Scheuplein and Blank,

1971; Stuttgen, 1982). Sebaceous glands are located within the hair follicles and secrete

sebum which makes its way on to the skin surface. Sebum is a complex mixture of fatty

acids, triglycerides, squalene and waxes. Eccrine sweat glands are also present in the

dermis and their primary purpose is thermoregulation. Since the epidermis is devoid of

any vasculature, it depends on the dermis for supply of nutrients, oxygen and removal of

waste metabolites. The presence of papillae from each layer interlocked with one another

at the border of the dermis and epidermis facilitates this process of exchange between the

two layers by increasing the surface area. The papillary layer is 50 nm thick and has

capillaries which feed the epidermis with the required nutrients (Bisset, 1987).

The epidermis, contains the stratum corneum, provides the main barrier function to

the skin and prevents the entry of foreign particles and loss of water. Keratinocytes

(keratin producing cells) make up most of the viable epidermis which is 50-100 [tm thick.

This protein is very polar with every third amino acid in the backbone of keratin

containing an ionizable side group (-COOH, -NH2 and -SH) (Flynn, 1990). Besides the

keratinocytes the viable epidermis also has melanocytes which are responsible for skin

pigmentation, langerhans cells for immune response and merkel cells responsible for

sensory reception. The epidermis also acts as a store for antioxidants like ascorbic acid,









tocopherols and tocotrienols, glutathiones, rates, ubiquinone-10 and enzymatic

antioxidants like catalases, superoxide dismutases, glutathione peroxidases. The primary

function of these antioxidants is to offer protection to the skin against the ultra violet

radiation of the sun (Thiele et al., 2002). Division and differentiation of the keratinocytes

lead to the formation of five distincts layers within the epidermis: stratum basale, stratum

spinoum, stratum granulosum, stratum lucidum and finally stratum comeum. The cells

migrate from the basal cell layer to the skin surface while gradually changing their

structure and function resulting in the formation of physically and chemically resistant

cell remnants called comeocytes which make up the stratum corneum. Once on the

surface of the skin the cells are shed off as a part of desquamation. This cycle of cell

division followed by differentiation, proliferation and migration from basal to the surface

and finally desquamation repeats itself over and over again with the new cells rapidly

replacing the old ones. The transition from a terminally differentiated keratinocyte to

corneocyte takes 24 h in the epidermis. The process of cornification and desquamation is

intimately linked; synthesis of stratum corneum occurs at the same rate as loss.

The outermost layer of the epidermis is called the stratum comeum, and it is the

main rate limiting barrier to drug delivery (Stuttgen, 1982; Berti and Lipsky, 1995). It is

10-20 [tm thick consisting of polyhedral, flat and nonnucleated cells called the

corneocytes (Berti and Lipsky, 1995).The pH of the stratum corneum lipids is 4-6.5. The

stratum comeum has 5-20 layers of comeocytes. These cells are remnants of the

terminally differentiated cells called keratinocytes which are found in the viable

epidermis. Their cell organelles and cytoplasm have disappeared during the process of

cornification. Corneocytes are composed of insoluble keratins surrounded by a cell









envelope stabilized by cross linked proteins and covalently bound lipids. These

corneocytes are further interconnected by lipids. The presence of these intracellular lipids

is required for a competent skin barrier and follows a tortuous path. These lipids are

synthesized and assembled into lamellar structures which surround the comeocytes.

These lamellar bodies which envelope the stratum corneum store a complex mixture of

lipids and lipid-like materials like free fatty acids, cholesterol and hydroxyamide

derivatives called ceramides. Interconnecting corneocytes of the stratum comeum are

polar structures such as corneodesmosomes which contribute to stratum comeum

adhesion. The stratum comeum is not uniformly homogeneous and the layers represent

various stages of comeocyte and lipid maturation. In short, the stratum corneum can be

visualized as a brick and a mortar model with the flattened cornified cells being the offset

layers of bricks lying one over another and the lipid rich intracellular matrix as the mortar

separating the bricks or corneocytes (Figure 1-2). By physically stripping the outermost

layer of the skin an increase in permeability of various chemicals and water can be seen

proving stratum comeum to be the main rate limiting barrier. Thus topical approaches at

increasing flux through the skin have relied on increasing the solubility of compounds in

the stratum corneum (Sloan et al.1989, 1992 and 2003). It is primarily believed that drugs

cannot penetrate the protein rich corneocytes cells but need to take a tortuous path

alongside the corneocytes through the interconnecting lipids (Michaels et al., 1975). Thus

the drug enters systemic circulation through this narrow channel of lipids and need to be

hydrophobic so that they can permeate these semi-fluid matrix lipid barriers.













Corneocyte


S_ kI


Lipid
matrix -


9
I-


Epidermis



Dermis


Figure 1-2 Brick and mortar model of drug absorption through the skin.
Unlike cell membranes in most parts of the body which are composed of

phospholipids, the skin is devoid of any phospholipids. However, the presence of

functional groups which are capable of hydrogen bonding in ceramides (Figure 1-3), free

fatty acids, and cholesterol sulfate in the lamellar bodies which surround the corneocytes

makes the stratum corneum hydrophilic as well as lipophilic. The stratum corneum is

about 30% water by weight and most of it is due to the association of water with these

polar groups seen in the lamellar lipids.

Thus, drugs with good biphasic solubility can permeate the stratum corneum better

than drugs which are merely hydrophobic.














0 0

HN
'HNOH
OH

Ceramide 1




HN


Ceramrde2 O


OH


Ceramide 2
HN

























CeramCde 6
/\_ tOH
OH









OH










Ceramde eramide 3
HN
OH

























CeramdeCeramide 4
OH

-'O




Ceramide 5C
























Figure 1-3 Structures of ceramides seen in the lipid bilayers of the lamellar bodies.


The heterogenous composition of the lipids and disorder in packaging of these



lipids leadS to the formation of lipid microdomains. Ruthenium tetroxide staining of


normal skin shows the presence of alternate hydrophilic regions connecting lipophilic


bands in the bilayer structure (Hou et al., 1991). The structure and arrangement of the


barrier is such that drugs need to pass through alternate layers of hydrophobic and
barrier is such that drugs need to pass through alternate layers of hydrophobic and









hydrophilic regions, formed as a result of the packing disorder of the lipids present, to

reach the systemic circulation and thereby must possess adequate lipid as well as water

solubilities (van Hal et al., 1996). The experimental evidence for this concept of biphasic

solubility being important in terms of permeability through the skin was first provided by

Scheuplein and Blank (1973) for the diffusion of a homologous series of alcohols from

water through human skin in vitro.The alcohol which gave maximum flux was not the

most lipid soluble but was the most water soluble. Sloan et al. (1997) confirmed these

results in in vitro hairless mice skin.

Topical Delivery

Most drugs developed today are delivered through the oral route. This is primarily

because it is economical for the company developing the drug. The delivery of the drug

does not require a visit to a physician or a trained medical representative as would be the

case for an intravenous or parental formulation. Drugs given orally also have the ability

to be given in large doses because of the high permeability of the enterocyte cells present

in the GI tract. However, the pH of the stomach is acidic, so the stability of molecules is

compromised. Oral bioavailability of drugs is sometimes limited by efflux of active drugs

by Mrp or P-gp transporters which prevent drugs from reaching intestinal vasculature

(Wacher et al., 1996; Watkins, 1997; Schinkel, 1997 and De Mario et al., 1998) and CYP

450 catalysed metabolism of drugs (Watkins, 1992). The portal vein carries the drug from

the intestine to the liver by a process known as "enterohepatic cycling" before the drug

finally enters systemic circulation. The liver is the largest drug metabolizing organ in the

body and has enzymes like CYP 450, GSH/GST and UDP/UGT which do not have strict

substrate structure specificity. These enzymes transform the drug molecule to an inactive









metabolite or lead to the formation of toxic by-products and hence limit the therapeutic

effectiveness of the drug.

To circumvent these problems associated with oral drug delivery, an alternate and

useful site of delivery can be the skin. Dermal delivery evades first pass metabolism of

drugs because once the drug permeates the skin it reaches the systemic circulation and

hence the bioavailability is not limited by metabolism, and side effects arising out of

toxic metabolites are minimized. Dermal drugs are more likely to reach systemic

circulation intact because of the absence of high concentrations of drug-metabolizing

enzymes like CYP 450 enzymes, GSH/GST (concentration in nmol amounts, Shindo et

al., 1994) or P-gp efflux transporters. CYP isozymes have been shown to be induced in

skin (Ahmad et al., 1996, 2004 and Swanson, 2004) and P-gp transporters are seen in

epidermal cells but their primary function seems to be limited to clearing out endogenous

compounds (Laupeze et al., 2001). The concentration of the enzymes is low and there is

no systematic arrangement of the enzymes and transporters on the surface of the skin so

they cannot clear the drugs efficiently or affect the therapeutic efficacy and availability of

drugs. Topical delivery can be used for delivery of potent molecules whose dose

requirements are low or require slow and sustained serum concentration levels of drug for

a prolonged period of time. It is possible to deliver about 30 mg/4.9 cm2 of an

appropriately soluble drug through the skin over a period of 24 h (Beall et al., 1996).

Dermal delivery means delivery into the skin, i.e., the epidermal and dermal skin cells.

Such delivery is particularly useful for skin cancers. Transdermal delivery means delivery

through the skin into systemic circulation. Drugs with high transdermal delivery

invariably show high dermal delivery too, though it may be possible to increase dermal









absorption by making a hydrolytically labile prodrug which hydrolyses to give a

lipophilic promoiety whose permeation through the dermis is limited and hence

selectively accumulates in the dermis.

Skin is a useful target organ for skin disorders and local action. Attempts are

currently being made to deliver soft estrogens locally because estrogen receptors are

expressed in the skin (Labaree et al., 2001 and 2003). The idea is to increase uptake

locally and prevent systemic circulation and hence the side effects that may result from it.

These locally active estrogens can be used to treat vaginal dyspareunia without the risk

involved with systemic administration. These soft drugs are inactivated by esterases so

that their action is geographically limited to the site of action.

Delivery of 5-FU through the skin enables treatment of actinic keratosis (Dillaha et

al., 1965) and may be useful for psoriarsis (Tsuji and Sugai, 1972) and yet spare the body

from most of its systemic effects. Nicotine, fentanyl, estradiol and nitroglycerine are used

in some transdermal patches available in the market today. Some attractive targets for

transdermal delivery include alcohol cessation agents like naltrexone, testosterone, and

antioxidants like vitamin C and vitamin E. Currently, the annual US market for

transdermal patches is greater than $3 billion dollars; many companies are thus

recognizing the value of transdermal delivery (Prausnitz et al., 2004).

The problems associated with topical delivery include local irritation or allergic

reactions on the skin because of formulation contents and poor penetration of drugs

through the stratum corneal barrier due to poor physicochemical properties of the

molecule.











Approaches to Increase Permeation across the Skin

The three approaches commonly used in increasing transdermal delivery of drugs are.

1. Mechanical or electromechanical methods like ultrasound, iontophoresis and
microneedles.

2. Penetration enhancers and hydration.

3. Prodrugs.

Ultrasound can be used to increase the transport of both low molecular weight

compounds and macromolecules like insulin and interferon. It relies on usage of low

frequency waves which causes disorganization of lipid bilayers and increased

permeability (Mitragotri and Kost, 2004).

Iontophoresis is the use of an electric current applied across the skin to drive drugs

through the epithelium. The flow of electric current increases the permeability of the

skin. The current does not pass through the skin uniformly but transappendageally

through pores or sometimes through lipid channels. The electrical potential provides an

electromotive force that is capable of driving charged molecules through the stratum

corneum (Riviere and Heit, 1997). The formation of HCl and NaOH by the electrolysis of

NaCl leads to a lowering of skin pH and are responsible for the irritation associated with

iontophoresis (Mitragotri et al., 1996).

Microneedles have also been used for transdermal delivery of macromolecules.

Micron sized needles in the patch pierce the skin into 10-15 lm of the upper stratum

corneal layer so that they do not stimulate the nerves found in the lower layers and hence

cause no pain while increasing the permeability of the drug used (Henry et al., 1998).









The second approach to increase permeation is by using penetration enhancers and

hydration. The two distinct mechanisms by which penetration enhancers work are, the

'push' and the 'pull' mechanisms. The 'push' mechanism relies on the use of volatile

components in a formulation to drive a drug into the skin. Evaporation of the volatile

components leads to a supersaturated solution of the drug with thermodyanamic activity

greater than one and results in increased flux through the membrane (Kadir, 1987). The

'pull'mechanism on the other hand increases topical absorption by the use of vehicles

which interact with the skin and decrease the diffusional resistance by disrupting the

barrier, i.e., increase the degree of hydration, leach the lipid components in the stratum

corneal barrier or increases the solubilizing capacity of the skin, so that flux of drug can

increase (Barry, 1987). It is possible to increase the flux of a compound by about 10 fold

by merely altering the vehicle properties before damage to the skin occurs (Sloan, 1992).

Commonly used penetration enhancers include azone, DMSO, propylene glycol and

decylmethyl sulphoxide. Keratolytic agents like salicyclic acid also increase penetration

through the skin but cause damage.

Hydration of skin leads to an increase in elasticity and permeability of the stratum

corneal barrier. Occlusion is the most command way to increase the hydration of the skin

as it prevents loss of moisture from the surface of skin by evaporation. It also leads to an

increase in temperature and humidity on the surface and thereby to increased

permeability of the drug. Topical formulations with fats and oils like glycols, glycerols,

paraffins, waxes, silicones and clay also increase hydration (Block, 2000).

Prodrugs represent yet another way in increasing topical absorption. They are

biologically inactive and labile derivatives of a drug which revert to the active drug









molecule by chemical or enzymatic hydrolysis. In this the case the drug in the form of a

prodrug has better solubility in the skin and hence gets pulled into the skin. An advantage

of prodrugs over penetration enhancers is that prodrugs are a 1:1 molecular combination

of drug and the promoiety compared to penetration enhancers where excess amounts are

used which may cause allergic reactions or local irritation. Prodrugs thus increase

solubility of the drug in the skin while penetration enhancers increase the solubalization

capacity of the skin for a drug molecule. Combination of prodrug with a penetration

enhancer in the same formulation may prove to be more useful (Waranis and Sloan,

1987) but hasn't been fully utilized yet.

Theory of Percutaneous Diffusion

The mechanism of permeation across human skin relies on passive diffusion which

is driven by a difference in the concentration gradient across the membrane. Any solute

diffusing through the skin shows an initial, nonlinear increase in drug concentration

which represents a build up of the drug in barrier region. The emergence of drug from the

barrier region is different from drug to drug because of the time required to saturate the

membranes. This is also true for most controlled release systems like transdermal

patches. This is called a lag-time effect. Once steady state is reached a linear increase of

drug concentration is seen which represents a condition where the exodus of solute from

the dermal side is equal to the mass of material entering the epidermal side (Poulsen,

1971). By simply extrapolating the steady state line to the abscissa it is possible to

determine the time to reach steady state. It also gives an estimate of how much drug

permeates through the transfollicular shunt route. This is very well illustrated by Figure

1-4.














o < 45














TIME (hours)
Figure 1-4 Illustration of a typical flux profile.

The rate of mass transfer across a membrane or flux (J) is proportional to the

concentration gradient expressed across the membrane. Imagine two solution filled

compartments containing different concentrations of some compound (CD and CR) and

separated by a permeable membrane of thickness h (Figure 1-5).The rate at which the

drug diffuses across the membrane from one compartment to the other is described by

Fick's first law. Equation 1-1 shows the relationship in a mathematical form and forms

the basis of Fick's first law (Fick, 1855).

J = (dM/dt) unit area = -D (dC/dx) (1-1)

where dM is the amount in mass or moles of solute passing through the membrane in

time dt, dC/dx is the concentration gradient within the membrane over infinitely small

distances and D is called the diffusion coefficient diffusivityy): its units are area per unit

time (cm2/s). The negative sign indicates that the concentration decreases with distance.






















Figure 1-5 Two compartment diffusion model.

To utilize Fick's law experimentally, the concentration in both compartments (CD

and CR) are maintained constant so as to have a constant concentration gradient (Ci-C2)

across the membrane once equilibrium is established and sink conditions are maintained

i.e., CR--O. The partial differential can be replaced by Ci, C2 and h. The concentration

gradient can further be simplified as

dC/dt = (C1-C2)/h (1-2)

where Ci is concentration of the solute in the donor side of the membrane, C2 is the

concentration of the solute on the receptor side of the membrane and h is the thickness of

the membrane as shown in Figurel-5. Combining (1-1) and (1-2) we get

J = (dM/dt) = -D (Ci C2)/h (1-3)

Both C1 and C2 are difficult to measure being inside the membrane.

However under sink conditions, C1-C2-C1, C1 = SSkin (solubility in the skin), J = JMV

(maximum flux from a saturated solution of drug in a vehicle). To maintain sink

conditions it is necessary that the concentration of drug in the donor compartment doesn't

change with time and hence a suspension in equilibrium with a saturated solution is

generally used for in vitro diffusion experiments and excess drug is used in a transdermal

patch formulation. This type of transport process follows zero order kinetics.


CR
C, Receptor
compartment
(C2 CR)
CD
Donor
compartment
(CD C1)









JMV = D SSkin (1-4)

h

SSkin = Sv. K Skin: V (1-5)

Inserting (1-5) in (1-4)

JMV = (D K Skin: V Sv) (1-6)

h

where Sv is the solubility of solute in the vehicle, JMV/ (Sv) = P:

P = (K Skin: VD) (1.7)

h

P is known as the permeability coefficient and can be determined experimentally. Since

DA/h is constant, permeability coefficient is proportional to vehicle/membrane partition

coefficient of the drug. The more soluble the drug is in the vehicle, the lower the

permeability coefficient for the delivery of the drug from that vehicle (Sloan, 1992).

The partition coefficient between drug in vehicle and in the membrane can be calculated

from theory using equation (1-8).

In K = [(6i -6) 2 Dv2- (6i -_6) 2 s2]Vi (1-8)

RT

where 6i is the solubility parameter of the drug, 6, of the vehicle (8.5 (cal/cm3)1/2) for

IPM isopropyll myristate) and 6, is the solubility parameter of skin (10 (cal/cm3)1/2), Vi is

the molar volume of the drug (cm3/mol), R is the gas constant (1.98 cal/K) and T is the

temperature (305 K) (Sloan et al., 1986; Sherertz et al., 1987; Sloan et al.,1986a). The

solubility parameter of the drug can be determined experimentally or from individual









group contribution methods (Sloan et al., 1986; Sherertz et al., 1987; Sloan et al., 1986a;

Fedors et al., 1974; Martin et al., 1985; Martin et al., 1985a).

Mathematical Modeling of Flux through Human Skin. Derivation of Roberts-Sloan
equation from Fick's law of Diffusion (Roberts and Sloan, 1999).

When the vehicle is water, equation (1-7) which relates permeability P with

partition coefficient between skin and the vehicle can replaced by equation (1-9).

P = (K Skin: AQ D)/h (1-9)

The diffusivity or diffusion coefficient can be estimated from molecular volume through

the following relationship (Cohen and Turnbull, 1959).

D = Doe-z MV (1-10)

The partition coefficient between skin and the vehicle is difficult to measure and thus can

be estimated from the partition coefficient between OCT (octanol) or IPM isopropyll

myristate) and water (AQ) where a lipid like vehicle (OCT or IPM) replaces skin, which

is considered to be lipid-like.

K Skin: AQ= (KOCT: AQ) (1-11)

Here y represents the difference between the partitioning domain of the skin with respect

to the solvent that replaces it, in this case OCT. The closer y is to 1, the closer the solvent

is to being is a good surrogate of stratum corneum lipids, e.g., ether has a y value of 0.53

while OCT has a y value of 0.7. Thus, OCT mimics the skin more closely than ether

does.

By substituting equations (1-10) and (1-11) in equation (1-9) we get equation (1-12)

P= [(KOCT: AQ) Do e-Z MV]/h (1-12)









By collecting the constants, taking the log of both sides and replacing MV (molecular

volume) by MW (molecular weight), the Potts-Guy equation (Potts and Guy, 1992) can

be obtained.

log P = y log KOCT: AQ- z MW +x (1-13)

where x = Do/h

The Roberts-Sloan equation previously known as the transformed Potts-Guy model

can be derived from the Potts-Guy model. The Potts-Guy is useful in predicting

permeability through the skin but its prime limitation is that it correlates permeability

with partition coefficient between a lipid vehicle and polar vehicle and hence is inversely

proportional to solubility of the drug in a polar vehicle like water. This has serious

implications in drug design and misleads medicinal chemists to synthesize more lipid

soluble derivatives in order to optimize topical delivery of a drug. We will talk about the

importance of biphasic solubility on topical delivery in the chapters that follow. A model

for flux (J) instead of permeability (P) is more clinically relevant because it actually tells

us how much solute in moles (amount) is going into the skin compared to permeability.

Since:

JMAQ = (P) (SAQ) (1-14)

Inserting equation (1-14) in equation (1-13) we get

log (J/SAQ) = y log KOCT: AQ z MW + x (1-15)

log JMAQ log SAQ = y log KOCT: AQ z MW + x

log JMAQ log SAQ = y log SOCT y log S AQ z MW + x

log JMAQ = y log SOCT y log SAQ -z MW + log SAQ + X

log JMAQ = x + y log SOCT + (1-y) log SAQ z MW (1-16)









Equation (1-16) is commonly referred as the Roberts-Sloan equation (RS) and in it flux is

proportional to both the lipid and the water solubilities of a drug and inversely

proportional to molecular weight.

If IPM instead of water was used as the vehicle in diffusion cell studies, because

some prodrugs were unstable, a different derivation is required.

Starting at equation (1-6), which was previously derived, but using IPM as the vehicle

and D = Do exp (-z MW) as in equation (1-10) we get

JMIPM =Do exp (-z MW) K Skin: IPM.SIPM

h

Taking the log of both sides and combining constants (x = Do/h) we get

log JMIPM= X + log K Skin: IPM + log SIPM Z MW (1-17)

Since,

K Skin: IPM = K Skin: AQ/ K IPM: AQ (1-18)

And since equation 1-11 relates the partition coefficient between skin and the vehicle to

the partition coefficient between OCT and AQ; where the vehicle is IPM, we can replace

OCT with IPM to give equation (1-19).

K Skin: AQ = (K IPM: AQ) (1-19)

Taking the log of both sides of equation (1-18) and substituting (1-19) for KSkin:AQ we get

equation (1-20)

log KSkin: IPM = y log K IPM: AQ log K IPM:AQ

log KSkin:IPM = y log SIPM y log SAQ log SIPM + log SAQ (1-20)

Substituting equation (1-20) into equation (1-17)

log JMIPM = x + y log SIPM y log SAQ log SIPM + log SAQ + log SIPM z MW









Collecting the terms we arrive at the RS equation.

log JMIPM = x + y log SIPM + (1-y) log SAQ z MW (1-21)

or

log JMV = x + y log SLIPID + (1-y) log SPOLAR z MW (1-22)

Equation 1-22 is the general form of the RS equation.

From equation 1-4

JMV = D SSkin (1-4)

h

Inserting equation 1-10 (D = Do exp (-P MV)) into equation 1-6 we arrive at:

JMV = Do exp (-P MV) SSkin (1-23)

h

Taking the log of both sides and collecting the constants we get:

log JMV = x + log SSkin Z MV (1-24)

where x = D/h and z = P

Correlating equation 1-24 with equation 1-22 (RS) we get

log SSkin = y log SLIPID + (1-y) log SPOLAR (1-25)

Equation 1-25 illustrates that solubility in skin can be modeled by solubility in two

phases: solubility in a lipid phase and solubility in a polar phase. Biphasic solubility thus

becomes an important determinant in optimizing flux through the skin.

The RS equation has been used to predict the topical delivery of homologous series

of prodrugs across hairless mouse skin from their suspensions in isopropyl myristate

(Wasdo and Sloan, 2004) and water in vitro (Sloan et al., 2003) and permeation of

nonsteroidal anti-inflammatory drugs through human skin from mineral oil in vivo










(Wenkers and Lippold, 1999 and Roberts and Sloan, 2001), permeation of solutes,

chemicals and drugs from water in vitro (Flynn, 1990 and Majumdar et al., 2004) and

penetration of sunscreens and antimicrobials in in vivo human skin from PG/water

(Leweke and Lippold, 1995 and Majumdar and Sloan, 2005). In all cases a significant

dependence of flux on water solubility was observed regardless of the vehicle used. Table

1-1 shows the coefficients of x, y, z and r2 of these databases. The RS equation can used

to predict flux of any drug molecule across skin from any vehicle if three

physicochemical parameters SLIPID (solubility in a lipid like vehicle like OCT or IPM),

SPOLAR (solubility in a polar vehicle like water or propylene glycol) and MW are known.

Table 1-1 x, y, z, r2 and Average Residual Errors for Various Databases Fit to RS.
Fit to RS (see text)
Model Database Vehicle n x y z r2 AlogJM
in vivo Wenkers Mineral 10 -1.459 0.722 0.00013 0.93 0.133
Human and oil
Skin Lippold
(1999)
in vitro Sloan and Water 18 -1.497 0.66 0.00469 0.77 0.193
Hairless coworkers
Mouse (2003)
Skin
in vitro Wasdo Isopropyl 61 -0.491 0.52 0.00271 0.91 0.15
Hairless and Myristate
Mouse Sloan
Skin (, 111 i 4
in vivo Flynn Water 103 -2.571 0.56 0.00444 0.9 0.44
Human (1990)
Skin
in vivo Leweke 30% 10 -2.116 0.45 0.00048 0.97 0.11
Human and PG/ water
Skin Lippold
(1995)

Prodrugs

The word prodrug was coined by Adrien Albert to describe compounds that

undergo biotransformation prior to eliciting their pharmacological effects (Albert, 1958).

It is impossible to review prodrugs of all classes; we will therefore cover only the basic









principles involved in prodrug design and their applications in clinical practice (Ettmayer

et al., 2004).

Prodrugs have been primarily designed to increase oral bioavailability, solubility,

enhance chemical stability, prevent premature metabolism, decrease toxicity and improve

taste (Stella, 1985). The primary function of a prodrug is to mask a polar functional group

(-XH) where X can be -OH (phenolic or alcoholic), -COOH, -SH, -NH amidee, imide or

amine) in a transient manner so that once the prodrug is in the target site (which may be a

tissue, cell or membrane) it hydrolyses to release the active drug molecule (Bundgaard,

1991). Since the polar functional group is masked, the tendency of the drug molecule to

form intramolecular hydrogen bonding is also blocked. This leads to improved solubility

properties of the prodrug in both lipid and aqueous phases with respect to the drug

(Bundgaard, 1991). By merely increasing biphasic solubility of drugs it is possible to

improve absorption and permeability across biological membrane barriers like the

enterocyte cells of the GI tract or stratum corneum of skin (Sloan and Wasdo, 2003). An

increase in absorption and permeability results in increased bioavailability. Prodrugs

containing charged promoieties like phosphates, amino acids, hemisuccinates and amines

have often been used in the promoiety to increase the aqueous solubility of drugs which

leads to increased dissolution rates and enhanced oral (Fleisher et al., 1996) and

transdermal absorption of the drug (Sloan and Wasdo, 2003). Masking of a functional

group transiently also may allow drugs to evade P-gp mediated efflux across the GI tract.

(Jain et al., 2004).

To make a hydrolytically labile prodrug it is necessary to attach the drug to a

promoiety which is stable enough to reach the target site but labile enough to release the









drug efficiently. Most prodrugs utilize an ester promoiety because of the presence of

esterases which are largely nonspecific and found in most tissues, biological fluids,

organs and blood etc, and which hydrolyse the prodrug to give the corresponding drug

(Beamount et al., 2003). A schematic representation is shown below (Figure 1-6).

0 ESTERASES

DRUG OR DRUG-COOH+ ROH


0
ESTERASES
DRUG-X R' ESTERASES DRUG-XH + R'COOH


X = N, 0, S; R = ALKYL; R' = OALKYL, N-ALKYL
Figure 1-6 Esterase mediated hydrolysis of prodrugs.

Carbonates of drugs have been made where the esters were too labile. Insertion of

an oxygen atom in the promoiety led to greater stability of the corresponding prodrug in

vivo because of the +1 effect imparted by the oxygen atom which decreases the

electrophilicity of the carbonyl group towards esterases. Similarly a nitrogen atom can be

inserted in the promoiety if a more stable derivative is desired.

Since a prodrug needs to hydrolyse to be effective, the inability of esterases to

efficiently transform penicillin esters to penicillin led to the design of soft alkylated

derivatives which are alkylcarbonyloxymethyl (ACOM) prodrugs. The ACOM promoiety

relies on a 'OCH2' spacer between the drug functional group and the labile ester

functionality. Penicillin esters are sterically hindered towards enzymatic hydrolyses

however insertion of a 'OCH2' spacer made it easier for the esterases to freely access the

ester functionality and hydrolyze it efficiently (Jansen and Russell, 1965).These soft

alkylated derivatives rely on esterase hydrolysis to yield a hydroxymethyl derivative of









the parent drug which is chemically labile and yields the parent molecule and

formaldehyde (Figure 1-7). These types of promoieties rely on both enzymatic and

chemical hydrolyses to release the drug molecule at the target site. In cases where the

ACOM moiety was not sufficiently stable, the alkyloxycarbonyloxymethyl (AOCOM)

promoiety have been used where the ester is replaced by a carbonate functional group.

The use of soft alkylation has been extended to other drugs containing various functional

groups like imides (Bodor and Sloan, 1977; Buur and Bundgaard, 1985 and Taylor and

Sloan, 1998), amines, phenols (Sloan et al., 1983a and 1983b; Bundgaard, et al., 1986

and Seki et al., 1988); alcohols (Beamount et al.), thiols (Sloan, 1983) etc.

0 0 0
ESTERASES -HCHO
DRUG O O R ASES RUG 0 OH -HCHO DRUG-COOH

0
ESTERASES -HCHO
DRUG-X 0 R DRUG-X OH DRUG-XH

X = N, O, S; R = ALKYL or OALKYL
Figure 1-7 Soft alkyl prodrug hydrolysis.

One of the critical issues involving prodrugs is that they should be labile but if they

are too labile they won't reach the target site and their purpose will be lost. Thus it is

important to design derivatives accordingly and use esters or carbonates (ACOMs or

AOCOMs) depending on the problem in hand and fine tune stability to meet design

directives. Sometimes it is necessary to release drugs slowly and in such cases prodrug

derivatives need to be more stable so that the residence time in the body is enhanced. We

will look at some examples of such prodrugs later on.

One of the prime reasons for esters being so widely used as prodrug promoieties is

that they are easy to make and are economical. They release non-toxic side products on









hydrolysis which is an important factor in drug development. Soft alkylated prodrugs

release formaldehyde which is relatively innocuous and biocompatible since it is released

as a byproduct during 0 or N-dealkylation of drugs by CYP 450 catalyzed oxidative

reactions in liver and intestines (Beamount et al., 2003).

Another type of soft alkylating promoiety which has been useful in increasing oral

bioavailability of phenolic drugs like estradiol is 0-imidomethyl saccharin. The oral

bioavailability of estradiol is drastically reduced by sulfation and glucuronidation of the

phenolic functional group which leads to rapid elimination of the drug from the body

before or after it is absorbed. Such premature metabolism can be prevented by transiently

masking the phenolic group with an imidomethyl group such as O-imidomethyl-saccharin

(Figure 1-8). The potency of the drug delivered as a prodrug was increased by about 8

times compared to an equimolar dose of estradiol alone (Patel et al., 1991). The prodrug

has a half life of 100 min under physiological conditions and the mechanism of

hydrolysis is believed to be SN2 (Getz and Sloan, 1993), although others suggest an

addition to the carbonyl group followed by a vinylogous elimination (Iley et al., 1998).

Both mechanisms may be operating. This type of prodrug approach is independent of

enzymatic hydrolysis and can be useful in cases where enzymatic variability becomes an

issue; the ester promoiety is enzymatically too labile or efficient hydrolysis to the active

principle is limited by strict structure specificity of the enzymes as in case of blood

(Beamount et al., 2003).

Although pharmaceutical scientists have often utilized esterases to biotransform a

prodrug to its active parent drug, human alkaline phosphatases are another class of











-OH



O=S-N\/- SN2
S0


0'O
HO

-HCHO


HOI


-OH


Figure 1-8 Hydrolysis pathways for Saccharin based 0-imidomethyl derivative of
estradiol.

enzymes which are found throughout various tissues (Strigbrand and Fishman, 1984) and

which have been used by chemists to dephosphorylate phosphoryloxymethyl prodrugs.

Fosphenytoin (Stella, 1996) is one such drug which is activated by phosphatases to give

hydroxymethyl phenytoin which spontaneously loses formaldehyde to generate phenytoin

(Figure 1-9). Delivery of phenytoin was a problem because of its poor aqueous solubility


S NH









(20-25 [g/mL) and was formulated at pH 12 when given parentally; crystallization of

drug at the injection site was seen. The aqueous solubility was enhanced by using the

phosphoryloxymethyl promoiety by about 4410 times. The water solubility of the

prodrug increased to 142 mg/mL (88.2 mg/mL equivalent of phenytoin).




HO
N HO
0 O
O N N
H PHOSPHATASES
0 N
H

FOSPHENYTOIN

I -HCHO

HN

O N
H


PHENYTOIN
Figure 1-9 Hydrolysis of phosphoryloxymethyl prodrug mediated by phosphatases.

This promoiety has also been used to increase the solubility of amines and alcohols

(Safadi et al., 1993 and Krise et al., 1999). Thus phosphoryloxymethyl is another

example of soft alkylating promoiety. The generic chemical structure of soft alkylating

promoities is shown below. Phosphoryloxymethyl has two X"'R's, i.e.,

X'-P=X"(X"'R')2.










R X"

DRUG-X X' 'X"'R'

X = N, O, S; R = H or ALKYL; X' = N or O; Y= C or P; X" = O; X"' = ALKYL, N or O; R' ALKYLL and H

The following discussion about the use of prodrugs to increase delivery covers some

miscellanenious examples which include the use of a novel enzyme system

(amidoreductases), use of a water soluble polymer (polyethylene glycol) and a

polypeptide (Tat protein).

Amidoximes are bioconverted to amidines by reductases expressed in the kidneys,

liver, brain, lungs and GI tract (Clement, 2002). The double prodrug Ximelagatran relies

on amidoreductases and esterases to yield the active drug melagatran.

H2N H2N
+/H /TOH
NH N


\ [H H 0 N-
H N N H
0 N N
0 0



MELAGATRAN
XIMELAGATRAN


Melagatran is a charged molecule at physiological pH with the carboxylate anion

(acidic pKa 2), amidine (basic pKa 11.5) and secondary amine (basic pKa 7)

functional groups making it very hydrophilic. As a result absorption across the GI tract is

decreased and its oral availability compromised. In the prodrug, the carboxylate ion is

blocked as an ester. Since the ester is electron withdrawing the pKa of the secondary

amine is reduced to 4.5 and it is no longer charged at physiological pH. The amidine is

protected as an amidoxime whose basic pKa was reduced to 5.2 so it is no longer charged









either. Thus, the resultant molecule is neutral at physiological pH, 170 times more

lipophilic based on K values and about 3-6 fold more bioavailable as a result of increased

absorption (Gustafsson et al., 2001 and Clement and Lopian, 2003).

In the prodrugs we have talked about till now, the drug was attached to the labile

promoiety directly or through a linker. In the following example, a drug is conjugated to

the linker (which should be a labile and bifunctional group), through a bridging

functional groups, the linker in turn is attached to a promoiety (which may be something

that increases the solubility of the drug or increases its uptake). This type conjugate is a

new class of prodrugs called tripartate prodrugs. Amino acids, aminoethoxyalcohols,

hydroxybenzylalcohols, aminobenzylalcohols and o-hydroxyphenylpropionic acids have

all been used as bifunctional linkers through which PEGs can be transiently attached to

drugs (Greenwald et al., 1999 and 2000). The active drug molecule is released by

hydrolysis in two steps. An example utilizing hydroxyl-benzylalcohol as the linker and

CO2 as the bridging functional group is shown below for an amine drug like

Daunorubicin (Figure 1-10).These polyethyleneglycol ether (PEGs) prodrugs have been

used to increase the systemic circulation time. Greenwald and coworkers (1996, 2001,

2003) have evaluated a series of PEGylated conjugates of anti cancer drugs like

Campothecan and Taxol with PEGs of various molecular weights. PEG40000-Ala-

Campothecan (Prothecan) is presently in phase II clinical trials for treatment of lung,

pancreatic and gastric cancers. Here the molecule has the aminoacid alanine acting as a

linker between the Campothecan and PEG (Figure 1-11).










0 ESTI
PEG 0 / 0ST


0



HOOH
HO\ OH


ERASES O -D
0 0 NDRUG
H





OH 2+ CO

+


DRUG-NH2
Figure 1-10 Hydrolysis of PEG conjugated to drug using a hydroxyl-benzylalcohol linker
in vivo.


SOH


Figure 1-11 PEG-Ala-Campothecan

These conjugates have higher water solubility than Campothecan which allows

increased dissolution of the drug. Also, since the molecular weight of the conjugates is

close to 45KDa (which is the renal threshold limit), these drugs are retained in the body

longer because of a phenomenon known as 'enhanced permeation retention' (EPR)

(Maeda et al., 1992). These prodrugs need to circulate in the body for longer periods and

release the drug slowly in a controlled manner; they have half lives >10 h compared to

other traditional prodrugs with half-lives of 20 min. These molecules evade glomerular

filteration of kidneys which excretes molecules whose size is 30KDa (Yamaoka et al.,

1994). Thus the drug selectively accumulates in the cancer cells taking advantage of the









leaky tissues and reduced drainage seen in cancerous tissues. This selectively towards

cancerous cells leads to reduced toxicity and better targeting of anti cancer agents.

Drugs have also been conjugated to oligoarginine residues to increase their uptake

across cell membranes and skin. Certain proteins contain subunits like Tat 49-57

(RKKRRQRRR) of HIV-1, that enable the translocation of proteins across the plasma

membrane into the cells (Green and Loevenstein, 1988; Anderson et al., 1993 and

Lindgren et al., 2000). The intact Tat protein has been conjugated to proteins to enhance

their delivery (Kim, 1997 and Nagahara, 1998). The chirality of the arginine residue (D

or L) didn't affect cellular uptake. The Tat protein efficiently crosses membranes of cells

in an energy dependent fashion after endocytosis (Mann and Frankel, 1991; Vives, 2003

and Fuchs and Raines, 2004). There is some evidence for guanidium rich molecules

undergoing receptor mediated endocytosis due their big size i.e. MW >3000. An

alternative mechanism of uptake is believed to be electrostatic interaction between the

positively charged guanidine (pKa ~ 12-13) and the carboxylate ion of the lipid bilayer or

phosphate group of the phospholipids bilayer to form a transient ion pair complex (Figure

1-12) which is less polar than the drug-Arg conjugate (Luedtke et al., 2003 and Rothbarg

et al., 2002). The driving force for the passage through the membrane is voltage potential

across most cell membranes. The positively charged complex formed due to incomplete

ion pairing with anionic cell components moves along the direction of transmembrane

potential intracellularr K levels extracellularlar K+ levels). Uptake is decreased when

membrane potential decreases extracellularr and intracellular K+ levels equal) while it

increases when a peptide antibiotic like valinomycin which selectively shuttles K+ across

the membrane is used in the assay. The complexes dissociate on the inner leaf of the









membrane. Truncation studies and synthesis of a series of analogues of Tat 49-57 revealed

that short chain oligomers (7-9 residues) of arginines are more efficient in translocation

than the entire protein (Wender et al., 2000). Wender and coworkers analyzed a series of

Cyclosporin-Arg7 and Paclitaxel-Args conjugates for uptake across human, mice skins

and various in vitro cell line surrogates of plasma membrane. They found that it is

necessary to have the guanidine moiety; oligolysine, oligohistidine or citruline residues

were not as successful as oligomers of arginine (Mitchell et al., 2000). When the

guanidine residues were alkylated the complex formation was hindered and uptake

diminished. A bidentate ligand like guanidine is able to form stronger ionic complexes

with a phosphate than the regular amine of lysine: as a result uptake is higher for arginine

rich residues than other charged amino acid residues (Rothbard et al., 2005).

H NHI2 -O
O N / /O
N---- 0
H
HN

Figure 1-12 Ionic complexes formed by oligoarginine of Tat with the phosphate groups in
cell membranes.

Too few arginine residues diminishes cell surface adherence while too many positively

charged guanidines lead to reduced escape from the inner leaf of the membrane. The

active drug is released from the conjugate hydrolytically with half lives depending on the

pH sensitive linker being used (Figure 1-13). Cyclosporine- Arg7 conjugates release the

active drug at pH 7.4 and 370C with a half life of 90 min. The mechanism of hydrolysis is

intramolecular nucleophilic attack by the secondary amine on the ester carbonyl

functional group (Rothbard et al., 2000). Similarly in case of Taxol- Args conjugates, the

hydrolysis rates vary depending on the R group attached to the amine from 1 min for R =









H to 107 min for R = Boc. Thus it is possible to control the rates of hydrolysis just by

varying the R group from an electron donating to an electron withdrawing group

(Kirschberg et al., 2003).

0 0
N NHArg7-COOH pH 7.4 N N NNHArg7-COOH


O N OCSA O + CSA

PhPh 0



0 pH 7.4 TAXOL + RN S

S 0 H2NCO-8grA-HN-

RHN NH-Arg,-CONH 0
R = H, Ac, Piv, Boc; CSA Cyclosporin.
Figure 1-13 Chemical hydrolysis of oligoarginine conjugates of cyclosporine and taxol.

Prodrugs for Dermal and Transdermal delivery

Although the previous paradigm (Guy and Hadgraft, 1988; Flynn, 1990) for

increasing dermal delivery focused on increasing KOCT:AQ, most effective prodrug

approaches aimed at improving the delivery of drugs across the skin have relied on

increasing the solubility in a lipid vehicle (SLIPID) like octanol or IPM and the solubility

in a polar vehicle like water (SAQ) of the prodrug over the parent drug. It is believed that

an increase in biphasic solubility of the drug leads to an increase in permeability of drugs

across the stratum corneum (Sloan et al., 1984; Sloan, 1989 and 1992; Sloan and Wasdo,

2003). In a homologous series of lipophilic prodrugs, the more water soluble of the more

lipid soluble member of the series gave the highest flux (Sloan et al., 1984, 1984, 1992,

2003 and 2004). Thus the balance between solubility in lipid and aqueous phases









becomes paramount and flux is better modeled by a combination of these two parameters

rather than K (partition coefficient). Previously it was shown that by merely masking

polar functional groups transiently it is possible to increase biphasic solubility and

thereby flux. While it is easy to see how addition of carbon atoms to the promoiety

conjugated to the drug increases SLIPID, it is difficult to visualize why a simultaneous

increase in SAQ occurs. For example, one may compare caffeine, theophylline and

theobromine to illustrate this increase in SAQ (Windholz et al., 1983). Theobromine has

two intramolecular hydrogen bonding sites; theophylline has one hydrogen bonding site

while caffeine has none. A look at the melting points and SAQ Of these three compounds

reiterates the fundamental idea behind prodrug synthesis. The masking of polar functional

groups leads to decreased intramolecular hydrogen bonding and in turn leads to a

decrease in lattice energy, melting points and increase in biphasic solubilities.

0 0 0

HN N ON N ON N
N N


H


THEOBROMINE THEOPHYLLINE CAFFEINE
mp: 357 270-274 238
Saq: 3 mmol/l 46.55 mmol/l 112.64 mmol/l
Codeine, the ether derivative of morphine, is 40 times more water soluble than

morphine and 2400 times more lipid soluble. Thus masking of a phenolic functional

group increases solubility in both phases.

There are two types of prodrug promoieties that have been used in dermal delivery;

the acyl based approach (N-acyl, O-acyl and S-acyl) and soft alkyl based approach

(ACOM or AOCOM). In the discussion that follows we will look at the importance of









solubilities in optimizing flux across the skin with examples. Consider the table below for

series of 1-alkyloxycarbonyl-5-FU prodrugs and 5-FU with their physicochemical

properties (Table 1-2). Melting points (mp), molecular weight (MW), log solubility in

isopropyl myristate (log SIPM), log solubility in water (log SAQ), log partition coefficients

between IPM and pH 4 buffer (log KIPM: AQ) and log maximum flux of total species

delivered by the prodrug (and 5-FU) through hairless mice skins in vitro from an IPM

donor phase (log JMIPM) (Beall et al., 1993) are given.

Table 1-2 Physicochemical Characterization of 1-Alkyloxycarbonyl esters of 5-FU.
Compound mp MW log SIPM log SAQ log KIPM:AQ log J MIPM
Cl 160 188 0.328 2.05 -1.72 0.42
C2 128 202 1.117 2.24 -1.12 0.77
C3 126 216 1.182 1.63 -0.45 0.36
C4 98 230 1.529 1.37 0.16 0.35
C6 67 258 2.186 0.7 1.48 0.19
C8 98 286 1.561 -0.89 2.46 -0.53
5-FU 284 130 -1.308 1.93 -3.24 -0.62

The melting points of the prodrugs decrease with the addition of each CH2 unit

from Cl to C6 while the melting point of C8 prodrug is higher than the C6 probably

because of van der Waals interaction between the alkyl side chains (Yalkowsky, 1977).

This increase in melting point also leads to a decrease in SIPM. All members of the series

are more lipid soluble than 5-FU. The C6 prodrug derivative is the most lipid soluble of

the series, has the highest K and SIPM. So, if SIPM were the most important determinant,

then its log JMIPM should be the highest instead it is the next to lowest in the series. On the

other hand, the C2 prodrug has a higher lipid solubility than 5-FU (not the highest) and

highest SAQ in the series (1.8 times more water soluble than 5-FU) and gives the highest

JMIPM (25 fold higher than 5-FU) across the skin. Sloan and coworkers (1983, 1984 and

2003) have reported such dependence on biphasic solubility for a series of 6-









mercaptopurine (6MP), ThH and 5-FU prodrugs. It was first observed for 7-ACOM

prodrugs of ThH (Sloan et al., 1982) but not recognized as a new paradigm until later

(Sloan et al., 1984).

There are two schools of thought for optimizing flux across the skin. The first relies

on increasing the lipid solubility without increasing aqueous solubility of the prodrug and

uses increased KOCT: AQ as an indicator of increased lipophicity. Since skin is primarily a

lipophilic barrier it relies on making a prodrug with higher K than the parent drug so that

penetration across the barrier can be enhanced. In this school of thought, any dependence

of flux on aqueous solubility is attributed to the use of a polar vehicle, the nature of

mouse skins (which are more hydrophilic than human skin), in vitro experimental

conditions and metabolic rates of conversion. In in vitro cell experiments, the skin is

abnormally hydrated particularly when water is used as a vehicle. Thus some argue that

the dependence of flux on SAQ could be due to the necessity for increased solubility in the

vehicle. This school of thought also argues that lipid soluble prodrugs undergoing fast

rates of hydrolysis to the more water soluble parent drug bypasses the hydrophilic region

of the skin dermis easily and permeates the skin better. However in case of lipid soluble

prodrugs undergoing slower hydrolysis, the dermis becomes a rate limiting barrier and

the prodrug gets trapped in the dermis, compromising delivery across the skin. Thus

water solubility becomes important only if the designed prodrugs are stable to hydrolysis

during their passage through the skin (Stinchcomb and coworkers, 2002 and 2005).

The second school of thought relies on the importance of biphasic solubility in

order to increase flux. It relies on increasing both lipid and water solubility at the same

time to optimize delivery. It is important to note that flux is independent of metabolic









conversion rates of prodrug to the drug because flux is dependent only on the solubility in

the membrane (Equation 1.4). The observations that flux depends on SAQ and SLIPID holds

true for prodrugs with a half-life of 1-5 min (7-AC-Th, Sloan et al., 2000) to prodrugs

which permeate intact in diffusion cells experiments (1-ACOM-FU, >50% intact prodrug

obtained, Taylor and Sloan, 1998) run on hairless mice skins. The argument against the

dependence of water solubility due to the presence of stagnant water layers in presence of

a polar vehicle or in in vitro conditions when the skin is heavily hydrated comes from

experiments carried out with isopropyl myristate as a vehicle (a non polar vehicle in

which the longer chain prodrugs were more soluble). The same dependence on SAQ was

again observed where IPM was the vehicle, reemphasizing the fact that this dependence

is a result of the inherent properties of the skin. In Vivo human skin (human skin is less

hydrophilic than mouse) experiments using mineral oil also show dependence on water

solubility. Irrespective of the vehicle used, the best performing prodrug of a series from a

vehicle like IPM is also the best performing prodrug from a different vehicle like water.

The best prodrug was the one with the best biphasic solubility. The increase in flux

though varies from vehicle to vehicle depending on the interaction of the skin with the

vehicle. IPM causes more damage than water does; it leaches out the lipids from the

stratum corneum hence compromises the barrier and leads to increased permeability of

prodrugs compared to water (Sloan et al., 2003a). Water solubility is important in

improving flux across the skin whether it is human skin or mouse skin, polar or non polar

vehicle, in vitro or in vivo, and prodrugs which are labile or stable to hydrolysis.

In the 5-FU prodrug series we considered above, the prodrug exhibiting the best

flux had a higher SAQ and SLIPID than 5-FU. It is not always possible to increase SAQ of the









prodrug compared to the parent drug. In such cases, the best performing prodrug is the

one which shows minimum decrease in SAQ with respect to the parent drug, e.g.

methyloxycarbonyl-APAP prodrug shows the highest flux through skin in the

homologous series of alkyloxycarbonyl-APAP prodrugs investigated by Wasdo and

Sloan (Table 1-3). This particular derivative was 6.3 times more lipid soluble and about

3.5 times less water soluble than APAP, yet was the most water soluble prodrug of the

series being investigated.

Table 1-3 Physicochemical Characterization of Alkyloxycarbonyl esters of
Acetaminophen.
Compound mp MW log SIPM log SAQ log KIPM:AQ log J MIPM
Cl 112 209 1.08 1.31 -0.16 0.0
C2 120 223 0.97 0.58 0.32 -0.76
C3 104 237 1.37 0.43 0.9 -0.45
C4 118 251 1.14 -0.43 1.5 -1.01
C6 108 279 1.22 -0.37 2.71 -1.49
APAP 171 151 0.28 2.0 -1.72 -0.29

Similarly in the 7-alkyloxycarbonyl-Th series (Sloan, 2000), C3-Th was most water

soluble prodrug member of the lipid soluble series. This prodrug derivative was 1.3 times

less water soluble than ThH and still gave higher flux than ThH.

Ever since SAQ of a drug was recognized as being important to optimize dermal

delivery, attempts have been made by Sloan and coworkers (Sloan et al., 1984; Sloan et

al., 1988; Saab et al., 1989 and 1990) to incorporate basic amino groups into the

promoiety. The rationale behind introducing a polar functional group like amine into a

promoiety is to increase the water solubility of poorly soluble drugs. Insertion of simple

alkyl groups into the promoiety does increase lipid solubility but increases in water

solubility are modest and are restricted to the shorter alkyl chain members. Mannich

bases (DrugX-CH2-NR2, X = S, N, 0; R = alkyl) of 6MP, 5-FU and ThH were thus









designed to improve SAQ of the prodrugs without decreasing SLIPID compared to the parent

drug and hence to increase flux. Hussain and coworkers (Milosovich et al., 1993 and Jona

et al., 1995) added polarisable amino groups to the alcohol portion of testosterone and

indomethacin ester prodrugs. When the 4-dimethylaminobutyrate hydrochloride ester of

testosterone was examined in vitro using human skin, a 35 fold flux enhancement was

observed (Figure 1-14). Similarly when 2-diethylaminoethyl group was built into the

ester promoiety of indomethacin the SAQ was enhanced compared to the parent drug and

flux through skin increased by about six fold (Figure 1-14).

0
0
0 N(CHCH,C)2
0 ^ ^N(CH,).HC1 MeO







Figure 1-14 Structure of testosterone and indomethacin esters with polarisable side
chains.

Also, attempts have been made by Bonina and coworkers (1995) to increase SAQ

and SLIPID by incorporating short chain polyethylene glycolic ethers into the promoiety.

Thus NSAIDS esters with small PEGs have been evaluated for their flux across human

skin. These polyethers did increase both SAQ and SLIPID, e.g. for the indomethacin esters

addition of a -OCH2CH2 unit increased SAQ by 1.3 fold and SLIPID by 1.02 times and as a

result flux also increased. Although all the derivatives were more lipid soluble than

indomethacin, the prodrug containing n = 5 -OCH2CH2 units, which was 1.77 times more

water soluble and 9 fold more lipid soluble than indomethacin, gave the highest flux,

(Table 1-4).





















PEG-esters of Indomethacin
Prodrug promoieties containing short PEGs can thus increase the biphasic solubility of

lipid soluble drugs with very poor aqueous solubility. It is interesting to note even in this

series of 'ethylene oxy' homologous series it is the more water soluble derivative that

gave the highest flux just as in case of simple alkyl derivatives where a 'CH2'unit is

inserted for 'O'along the series.

Thus, the importance of the balance between SLIPID and SAQ of the prodrugs is

important in optimizing delivery of drug molecules topically.

Table 1-4 Physicochemical Characterization of PEG esters of Indomethacin.
COMPOUNDS SOCT (mmol mL-x 102) SAQ JM
([tmol mL-' x102) ([mol cm-2x 102)
Indomethacin 27.7 22 0.84
n =l1 221.9 6.7 0.4
n= 2 225.8 9.2 0.65
n =3 240.1 17 0.73
n =4 244.3 25 2.83
n =5 251.8 39 3.12









Research Objectives

N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) promoiety has been used to

make prodrugs of 6-mercaptopurine for topical delivery (Siver, 1990). The mechanism of

hydrolysis however wasn't clearly established. The purpose of this research project was

to explore the use of NANAOCAM promoiety as prodrugs of other functional groups like

phenols, carboxylic acids, imides and evaluate its potential use for enhancing the skin

penetration of model phenolic and imide containing drugs.

1. Design, synthesize, and investigate rates of hydrolysis and mechanism of
hydrolysis of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) and N-
aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM) prodrug derivatives of
phenols and carboxylic acid.

2. Synthesis of homologous series of NANAOCAM prodrugs of acetaminophen
(APAP, model phenolic drug) and their physicochemical characterization which
includes: measuring solubilities in isopropyl myristate (IPM) and water, partition
coefficients of prodrugs between IPM and pH 4.0 buffer, investigation of flux of
compounds through hairless mice skins from IPM.

3. Synthesis of homologous series of NANAOCAM prodrugs of theophylline (ThH,
imide containing drug) and their physicochemical characterization which includes:
measuring solubilities in isopropyl myristate (IPM) and water, partition coefficients
of prodrugs between IPM and pH 4.0 buffer, investigation of flux of compounds
through hairless mice skins from IPM.

4. Mathematical modeling of flux

These goals are discussed in three separate chapters. Chapter 2, talks about the

design of NANAOCAM promoiety, synthesis of NANAOCAM-drug derivatives by

alkylation of drug with N-alkyl-N-alkyloxycarbonylaminomethyl chlorides,

determination of rates of hydrolysis in aqueous buffers, its implication on prodrug design

leading to the synthesis and hydrolysis of N-aryl-N-alkyloxycarbonyl-aminomethyl

(NArNAOCAM) prodrugs of phenols and carboxylic acids.









Chapter deals with alkylation of acetaminophen with N-alkyl-N-

alkyloxycarbonylaminomethyl chlorides to synthesize a homologous series of

NANAOCAM prodrugs, evaluation of physicochemical properties and transdermal and

dermal penetration of these prodrugs and prediction of flux of APAP prodrugs using the

RS equation.

Chapter4 deals with alkylation of theophylline with N-alkyl-N-alkyloxycarbonyl-

aminomethyl chlorides to synthesize a homologous series of NANAOCAM prodrugs,

evaluation of physicochemical properties and transdermal and dermal penetration of these

prodrugs and prediction of flux of ThH prodrugs using the RS equation, and all

NANAOCAM prodrugs when fitted to the existing n = 63 database.














CHAPTER 2
DESIGN, SYNTHESIS, HYDROLYSIS OF N-ALKYL-N-ALKYLOXYCARBONYL-
AMINOMETHYL DRUG DERIVATIVES AND ITS IMPLICATIONS ON PRODRUG
DESIGN.

Introduction

Drugs containing polar functional groups pose problems of membrane

permeability, solubility and premature metabolism which limit their oral and dermal

delivery. The prodrug approach, which involves masking these polar functional groups as

labile derivatives which then hydrolyze to the native drug either enzymatically or

chemically, has proved useful in numerous cases (Bundgard, 1991 and Sloan and Wasdo,

2003). In most cases drug functional groups are masked as simple esters. Acyloxymethyl

(ACOM, R'COOCH2-) and alkyloxycarbonyloxymethyl (AOCOM, R'OCOOCH2-)

promoieties have been used to derivatize carboxylic acids in cases where the simple ester

approach wasn't useful because, although simple esters were reasonably stable

chemically so that they could be conveniently formulated, they were not sufficiently

labile enzymatically (Jansen and Russell, 1965; Bundgard et al., 1986; Seki et al., 1988

and Beaumont et al., 2003). Similarly, simple alkylation of phenolic groups with alkyl

halides gives derivatives that are not efficiently reversible in vivo, while ACOM or

AOCOM gives derivatives that are too unstable during the oral absorption process to

protect the phenolic drug from premature metabolism. Replacing the oxygen atom in

OCH2 with nitrogen (N-R, R = alkyl) in R'OCOOCH2- to give a N-alkyl-N-

alkyloxycarbonylaminomethyl (NANAOCAM, R'OCONRCH2-) promoiety could give

medicinal chemists an additional handle and flexibility to improve solubility (better











balance between solubilities in lipid and water) and stability (enzymatic versus chemical)


of prodrugs. The evolution of NANAOCAM promoiety from simple esters to


ACOM/AOCOM to NANAOCAM is shown in Figure 2-1.



DRUG-X R Insert ACOM DRUG CONJUGATE
DRUG-X DRUG-X O R

O 'CH20' Spacer
Insert R- ALKYL




DRUG-X O
R 'CH pacer DRUG-X O olR AOCOM DRUG CONJUGATE
O X O, S, N
ESTER OR CARBONATE-DRUG CONJUGATE
R- ALKYL
Replace 'O' with 'N'

H
DRUG-X ,-N fO R

0

alkylate N

R'

DRUG-X N O



N-ALKYL-N-ALKOXYCARBONYLAMINOMETHYL DRUG CONJUGATE (NANAOCAM)
X O, S, N
R, R' ALKYL
Figure 2-1 Design of NANAOCAM promoiety.


Only one example of the use of a NANAOCAM promoiety has been reported: 6-


mercaptopurine (Siver and Sloan, 1989). The use of a close analogue of NANAOCAM


(R'CONRCH2-) in which the promoiety is an amide instead of a carbamate has been


reported for carboxylic acids (Bundgard et al., 1991; Moreira et al., 1996 and Iley et al.,


1997). Here we extend the use of the NANAOCAM promoiety to other drug functional


groups and investigate the mechanism of chemical hydrolysis and its implications in









prodrug design of these soft alkylated derivatives with the goal of being able to tailor the

promoiety to give the appropriate rates of conversion to the parent drug based on the

route of administration.

In the discussion that follows we will talk about the synthesis ofN-methyl-N-

methyloxycarbonylaminomethyl derivatives of phenols, carboxylic acids and 6-

mercaptopurine (6MP) and N-aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM)

derivatives of phenols and carboxylic acids. We will then investigate the mechanism of

hydrolysis of N-methyl-N-methyloxycarbonylaminomethyl and NArNAOCAM

derivatives of phenols, carboxylic acids and 6MP.

Synthesis of N-methyl-N-methyloxycarbonylaminomethyl and N-aryl-N-methyloxy-
carbonylaminomethyl Prodrugs.

Ten N-methyl-N-methyloxycarbonylaminomethyl and six N-aryl-N-

methyloxycarbonyl aminomethyl derivatives were synthesized (Tables 2-1 and 2-2).

Alkylation of the parent compound with N-methyl-N-methyloxycarbonylaminomethyl

chloride or N-aryl-N-methyloxycarbonylaminomethyl chloride was accomplished in the

presence of a base like triethylamine with CH2Cl2 or DMSO as the solvent. In every case

it was necessary to synthesize the corresponding alkylating agent: N-methyl-N-

alkoxycarbonylaminomethyl chloride or N-aryl-N-methyloxycarbonylaminomethyl

chloride.









Conjugates Synthesized.


Compd X Z R
1 NHCOMe H Me
2 CN H Me
3 CHO H Me
4 H CHO Me
5 COMe H Me
6 COOMe H Me
7 NO2 H Me
8 NO2 H 4'-C6H4-OMe
9 NO2 H 4'-C6H4-COOEt
10 NO2 H C6H5


Table 2-2 N-methyl-N-methyloxycarbonylaminomethyl and NArNAOCAM Conjugates
of Naproxen.


.0 NY CH3

0


Compd R

11 Me

12 C6H5

13 4'-C6H4-OMe

14 4'-C6H4-COOEt


Table


X-









N




0

0 0 N O0
R
R = R' = CH3


0



NOZ N

N N
H


R = R'= CH3


Figure 2-2 Structures of N-methyl-N-methyloxycarbonylaminomethyl prodrugs of
dimethylaminobenzoic acid and 6MP.


CH2=0 +

R


rN +
RN N
R 'R



0

ROJ N Cl
I
R


RNH2


NaOH N

rN N
~~ i


0

O/R'
CH2C12



CH2 Cl2
+ Y-H A*-
TEA


0

\R N Cl
R


0

N Y
R
Y = 6MP,phenol or
carboxylic acid
R, R' = CH3
Compounds 1-7, 11, 15, 16


Figure 2-3 Synthesis of NANAOCAM prodrugs









U 0

2 HN O C1 N O 3
Py TMSC1

CH3OCOC1
(CH2O)n
XX X
0 0

Cl1-1\ N O"CH 3 Naproxen Y1 N '0CH3
or

p-nitrophenol
TEA
X X


X= OCH3, COOC2H,, H.
YH = Naproxen, p-nitrophenol.
Compounds 8-10, 12-14.
Figure 2-4 Synthesis of NArNAOCAM prodrugs

N-Methyl-N-methyloxycarbonylaminomethyl chloride synthesis (Figure 2-3):

The N-methyl-N-methyloxycarbonylaminomethyl chloride was synthesized as

reported by Siver et al., (1990) from 1, 3, 5-trimethylhexahydrotriazine.

(a) 1, 3, 5-Trimethylhexahydrotriazine was synthesized from equimolar equivalents of

aqueous formaldehyde, methyl amine and NaOH according to the protocol originally

developed by Graymore et al., (1932) and modified by Siver et al., (1990). Methyl amine

(0.4 mol, 40% aqueous) was placed in an ice bath and an equivalent of 37% aqueous

formaldehyde was added dropwise over a period of 10 min. The solution was allowed to

equilibrate to room temperature and stirred for one hour, then an equivalent of NaOH was

added and the contents were stirred for 1.5 h more. The solution was extracted with 4 x

50 mL CH2C12, dried over Na2SO4, filtered and concentrated to a clear colorless CH2Cl2

solution containing the hexahydrotriazine derivative. Complete concentration of CH2C12









wasn't carried out as it resulted in some loss of the desired product. For quantification

purposes the CH2C2 'methylene peak'at 65.3 and N-CH2-N peak of hexahydrotriazine

derivative at 63.2 were used: yield = 82% in CH2C2, 1H NMR (400 MHz; CDCl3;

Me4Si):63.2(s, 6H), 62.3(s, 9H).

(b) N-Methyl-N-methyloxycarbonylaminomethyl chlorides were synthesized from 1, 3,

5-trimethylhexahydrotriazine by reacting it with three equivalents of methyl

chloroformate in CH2C2 .To well stirred solution of methylchloroformate in CH2C2

cooled with an icebath was added an equivalent of 1, 3, 5-trimethylhexahydro-triazine

(freshly prepared) in CH2C2 over a period of 10 minutes. The white suspension that was

observed was allowed to equlilibrate to room temperature and stirred overnight. The

suspension was filtered and the filtrate concentrated to oil. The oil contained the desired

product and some of the corresponding bis (N-methyl-N-methyloxycarbonyl-

amino)methane byproduct. The oils were purified by trituration with hexane overnight

followed by ether overnight. The clear solution was decanted leaving the white residue

(bis derivative) behind. The clear solution was then concentrated. The peak at 64.8 due to

the 'CH2 of the bis derivative and peak at 65.3 due to the 'CH2' of N-methyl-N-methyl-

oxycarbonylaminomethyl chloride were used to quantitate the amount of product formed:

yield = 90%, 1H NMR (400 MHz; CDCl3; Me4Si):65.31-5.33 (2s, 2H), 63.73-3.79 (2s,

3H), 62.9-3.0 (2s, 3H).

N-Aryl-N-methyloxycarbonylaminomethyl chloride synthesis (Figure 2-4):

N-Aryl-N-methoxycarbonylaminomethyl chlorides were made from aromatic amines in

two steps. Methylchloroformate was reacted with aromatic amines in the presence of

pyridine and dichloromethane to give N-aryl carbamic acid methyl esters. The

chloromethyl derivative of the carbamic acid derivative was then made by a synthetic









procedure reported by Moreira et al., (1994) for N-methylamides. The N-Methyl

carbamic acid alkyl ester was refluxed with thirteen equivalents of trimethylsilyl chloride

and 1.7 equivants of paraformaldehyde to give the appropriate N-aryl-N-alkoxycarbonyl-

aminomethyl chloride.

(a) N-Aryl carbamic acid methyl ester: To a solution of methylchloroformate (3.5 mmol)

in 15 mL CH2C2 was added dropwise an equivalent of pyridine and aromatic amine. The

reaction mixture was allowed to warm to room temperature and subsequently stirred

overnight. The clear solution was washed with 10 mL brine 3 times, and the organic layer

was dried over Na2SO4 and concentrated to a solid. The solids obtained were

recrystallized from CH2C2: hexane.

N- (Phenyl)carbamic acid methyl ester: yield = 98 %, mp = 44-450C, 1H-NMR (400

MHz; CDCl3; Me4Si): 67.2-7.37(m, 4H), 67.06 (m, 1H), 66.63(s, 1H), 63.76 (s, 3H).

N-(4'-Ethoxycarbonylphenyl)carbamic acid methyl ester: yield = 97 %, mp = 152-1540C,

1H-NMR (400 MHz; CDCl3; Me4Si): 68.0 (d, 2H), 67.45 (d, 2H), 66.9(s, 1H), 64.37 (q,

2H), 63.8 (s, 3H), 61.39 (t, 3H).

N-(4'-Methoxyphenyl)carbamic acid methyl ester: yield = 94 %, mp = 85-860C, 1H-

NMR (400 MHz; CDCl3; Me4Si): 67.27 (d, 2H), 66.85 (d, 2H), 6 3.78(s, 3H), 6 3.75(s,

3H).

(b) N-Aryl-N-methyloxycarbonylaminomethyl chloride: A suspension of N-aryl

carbamic acid alkyl ester (2.5 mmol), 1.7 equivalents of paraformaldehyde and 13

equivalent of trimethylsilyl chloride was refluxed using a CaCl2 drying tube and a water

condenser for 18 h over an oil bath. The suspension was diluted with -10 mL CH2C2 and

filtered to get rid of the unreacted paraformaldehyde. The clear filterate was concentrated









using a rotavapor at 400C under reduced pressure. The yellow oil obtained was triturated

with hexane overnight. The white suspension obtained was filtered and the filtrate was

concentrated to give the desired alkylating agent.

N- (Phenyl)-N-methyloxycarbonylaminomethyl chloride: yield = 75%, 1H NMR (400

MHz; CDCl3; Me4Si): 67.32-7.44 (m, 5H), 65.56(s, 1H), 63.78 (s, 3H).

N- (4'- Ethyloxycarbonylphenyl)-N-methyloxycarbonylaminomethyl chloride: Complete

conversion to product wasn't seen in this case, the crude mixture was thus used in the

next step. The peak at 66.9 due to the 'NH of the N-(4'-ethyloxycarbonylphenyl)

carbamic acid methyl ester and the peak at 65.56 due to the 'CH2' of N-(4'-

ethyloxycarbonylphenyl)-N-methyloxycarbonylaminomethyl chloride were used to

quantify the amount of product formed: yield = 27%, 1H NMR (400 MHz; CDCl3;

Me4Si): 68.1 (d, 2H), 67.5 (d, 2H), 65.56(s, 1H), 64.38 (q, 2H), 63.81 (s, 3H), 61.39 (t,

3H).

N-(4'-methoxyphenyl)-N-methyloxycarbonylaminomethyl chloride: yield = 82%, 1H

NMR (400 MHz; CDCl3; Me4Si): 67.23 (d, 2H), 66.93 (d, 2H), 65.52(s, 1H), 63.82 (s,

3H), 63.76 (s, 3H).

Alkylation of Phenols, 6-Mercaptopurine, Dimethylaminobenzoic acid and
Naproxen with N-methyl-N-methyloxycarbonylaminomethyl chloride or N-aryl-
N-methyloxycarbonylaminomethyl chloride (Figures 2-3 and 2-4).

Typical procedure for phenols: In a round bottom flask was dissolved 1 equivalent of

phenol (-0.01 mol) and 1.1 equivalents triethylamine in 20 mL CH2Cl2. The contents

were stirred for an hour under reflux conditions with a water condenser and oil bath. N-

Methyl-N-alkoxycarbonyl aminomethyl chloride or N-aryl-N-methyloxycarbonyl-

aminomethyl chloride (1.1 equivalents) in 5 mL CH2Cl2 was then added dropwise. An

exothermic reaction occurred and white fumes could be seen. The clear solution or









suspension (depending on the phenol used) was stirred overnight. The reaction was

worked up by filtering the suspension [NEt3 C:, H- NMR(CDCl3): 63.1 (q,2H), 61.5

(t,3H)], diluting the filtrate to 40 mL with CH2C2 and washing it with 3 x 30 mL water.

The CH2C12 solution was dried over Na2SO4 for an hour and filtered. The solution was

concentrated using a rotavapor under vacuum at 400C until solvent free. The resulting

material was purified by recrystallization and, if necessary, column chromatography until

a sharp melting point was obtained, a single spot was seen on TLC and a clean 1H- NMR

was obtained. The particular results for each synthesis are listed below.

1 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and acetaminophen in CH2Cl2. Recrystallization from CH2Cl2: hexane (1:3)

twice gave white crystals: yield = 70%, mp = 86-880C, Rf (0.36, ether). Elemental

analysis (Found: C, 56.81; H, 6.34; N, 11.1. Calc. for C12H16N204 : C, 57.13; H, 6.39; N,

11.1%). UV: Xmax (pH 8.8 buffer)/nm 243.4 (E/LmolEcm10.95 x 10 4). UV: Xmax (pH

7.1 buffer)/nm 240 (E/LmolEcm"1 1.01 x 10 4, 0.09 x 10 4).1H NMR(400 MHz; CDCl3;

Me4Si): 67.6(s,1H), 6 7.39(d,2H), 66.96-6.87(2d,2H), 65.28-5.21(2s,2H), 63.72-

3.7(2s,3H), 6 3.0-2.97(2s,3H), 6 2.0(s,3H).

2 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamineand p-cyanophenol in CH2C2. Recrystallization from ethyl acetate:hexane

(1:2) twice gave white crystals: yield = 55%, mp = 56-580C, Rf (0.17, ethyl

acetate:hexane, 1:4). Elemental analysis (Found: C, 59.54; H, 7.27; N, 9.94. Calc. for

C11H12N203: C, 60.02; H, 7.14; N, 10%). UV: Xmax (pH 8.8 buffer)/nm 245 (E/Lmol"

1cm1 1.26 x 10 4).1H NMR (400 MHz; CDCl3; Me4Si):6 7.6(d, 2H), 6 7.1-6.96(2d, 2H), 6

5.38-5.31(2s, 2H), 6 3.8(s, 3H), 6 3.06-3.0(2s, 3H).









3 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and p-hydroxybenzaldehyde in CH2C12. Purification on a silica gel column

with hexane: acetone (4:1) as the eluent gave a colorless oil: yield = 67%, Rf (0.37, ethyl

acetate:hexane, 1:2). Elemental analysis (Found: C, 59.08; H, 5.86; N, 6.3 Calc. for

ClnH13N04: C, 59.19; H, 5.87; N, 6.27%).UV: Xmax (pH 8.8 buffer)/nm 276.6

(E/L mol 1cm1 1.37 x 10 4).1H NMR(400 MHz; CDCl3; Me4Si): 69.9(s,1H),6 7.83(d,2H),

6 7.1-7.03(2d,2H),65.42-5.35(2s,2H), 6 3.8(s,3H), 6 3.07-3.01(2s,3H).

4 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and salicyldehyde in CH2C2. Recrystallization from acetone gave white

crystals: yield = 87%, mp = 65-670C, Rf(0.76, ether).Elemental analysis (Found: C,

59.06; H, 6.01; N, 6.24 Calc. for CjlH13N04: C, 59.19; H, 5.87; N, 6.27%). UV: Xmax

(pH 8.8 buffer)/nm 315 (E/LmolPcm11.27 x 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 6

10.49(s,1H), 6 7.85(d,1H), 6 7.55(t,1H) 6 7.2(m,2H), 6 5.47-5.38(2s,2H), 63.76(s,3H),

63.08-3.03(2s,3H).

5 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and p-hydroxyacetophenone in CH2C2. Purification on a silica gel column

with hexane: acetone (4:1) as the eluent gave a colorless oil: yield = 82%, Rf (0.75,

ether). Elemental analysis (Found: C, 60.45; H, 5.91; N, 6.22 Calc. for CjlH13N04: C,

60.75; H, 6.37; N, 5.9%). UV: (pH 8.8 buffer)/nm 269.7(E/LmolPlcm-1 1.12 x 10 4).1H

NMR(400 MHz; CDCl3; Me4Si): 67.93(d,2H), 6 7.05-6.94(2d,2H), 6 5.39-5.32(2s,2H), 6

3.8(s,3H), 6 3.05-3.0(2s,3H), 6 2.6(s,3H).

6 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and methyl p-hydroxybenzoate in CH2C2. Purification on a silica gel









column with ethyl acetate: hexane as eluent gave a colorless oil. This oil, after

recrystalization from CH2C2 :hexane (1:2), gave white crystals: yield = 21%, mp = 52-

540C, Rf(0.49, ethyl acetate:hexane,1:4).Elemental analysis (Found: C, 56.98; H, 5.93;

N, 5.49.Calc. for C12H15N05: C, 56.91; H, 5.97; N, 5.53%). UV: Xmax (pH 8.8

buffer)/nm 253 (E/Lmol-1 cm-1 1.49 x 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 6

8.0(d,2H), 6 7.02-6.92(2d,2H), 6 5.37-5.3(2s,2H), 6 3.9(s,3H), 6 3.8(s,3H), 6 3.05-

2.99(2s,3H).

7 was prepared from N-methyl-N-methyloxycarbonylaminomethyl chloride,

triethylamine and p-nitrophenol in CH2C2. Recrystallization from CH2C2 :hexane (1:4)

gave pale yellow crystals: yield = 76%, mp = 77-790C, Rf (0.37,ether: hexane,

1:1).Elemental analysis(Found: C, 49.99; H, 4.94; N, 11.57.Calc. for CloH12N205: C,

50.0; H, 5.04; N, 11.66%). UV: Xmax (pH 8.8 buffer)/nm 310.6 (E/Lmolfcm10.76 x 104).

UV: Xmax (pH 7.1 buffer)/nm 310 (E/Lmolfcm-1 0.75 x 10 4). 1H NMR (400 MHz;

CDCl3; Me4Si): 6 8.21(d, 2H), 6 7.1-6.99(2d, 2H), 6 5.42-5.35(2s, 2H), 6 3.77(s, 3H),6

3.07-3.01(2s, 3H).

8 was prepared from N-(4'-methoxyphenyl)-N-methyloxycarbonylaminomethyl

chloride, triethylamine and p-nitrophenol in CH2C2. Purification on a silica gel column

with ethyl acetate: hexane as eluent gave a colorless oil: yield = 64%, Rf (0.17, ethyl

acetate:hexane, 1:5), UV: Xmax (pH 8.8 buffer)/nm 310 nm (E/Lmol cm-1 1.06 x 10 4).

1H NMR(400 MHz; CDCl3; Me4Si):6 8.2(d,2H), 6 7.16(d,2H), 6 7.05(d,2H), 6

6.89(d,2H), 6 5.64(s,2H), 6 3.81(s,3H), 6 3.73(s,3H).









9 was prepared from N-(4'-ethyloxycarbonylphenyl)-N-methyloxycarbonylaminomethyl

chloride, triethylamine and p-nitrophenol in CH2C2. A white solid residue was seen. This

residue was dissolved in CH2C2 and hexane was added till the solution became turbid

and white crystals were seen. The white crystals were filtered and discarded while the

filterate was reconcentrated to give more white crystals which were filtered. The filterate

was purified on a silica gel column with ethyl acetate: hexane as eluent to give a colorless

oil: yield = 17%, Rf (0.29, ethyl acetate:hexane, 1:3). UV: Xmax (pH 8.8 buffer)/nm 309

(E/Lmolfcm-1 1.03 x 10 4). 1H NMR(400 MHz; CDCl3; Me4Si): 6 8.21(d,2H),

68.07(d,2H), 6 7.37(d,2H), 6 7.05(d,2H), 65.69(s,2H), 6 4.38(q,2H), 63.77(s,3H), 6

1.39(t,3H).

10 was prepared from N-(phenyl)-N-methyloxycarbonylaminomethyl chloride,

triethylamine and p-nitrophenol in CH2C2 Purification on a silica gel column with ethyl

acetate: hexane as eluent gave a colorless oil which, on recrystallization from ether:

petroleum ether (1:2), gave white crystals: yield = 69%, mp = 105-1060C, Rf (0.26, ethyl

acetate: hexane, 1:9). Elemental analysis (Found: C, 59.49; H, 4.63; N, 9.21. Calc. for

C15H14N205: C, 59.6; H, 4.67; N, 9.27%). UV: Xmax (pH 8.8 buffer)/nm 305 nm

(E/Lmolfcm-1 1.19 x 10 4).1H NMR (400 MHz; CDCl3; Me4Si): 6 8.2(d, 2H), 6 7.27-

7.42(m, 5H), 6 7.05(d, 2H), 6 5.67(s, 2H), 6 3.75(s, 3H).

11 was prepared from naproxen (0.01 mol) stirred with triethylamine (O.Olmol) in 50 mL

CH2C2 for an hour. A clear colorless solution was seen. N-Methyl-N-methyloxy-

carbonylaminomethyl chloride (O.Olmol) was added to the reaction mixture and the

contents were stirred overnight. The clear solution was washed 3-times with 10 mL

water. The CH2C2 solution was dried over Na2SO4 for an hour and then evaporated









under reduced pressure to give white crystals: yield = 97%, mp = 100-1010C, Rf (0.49,

ethyl acetate:hexane,1:4). Elemental analysis (Found: C, 65.05; H, 6.45; N, 4.2 Calc. for

Ci8H21N05: C, 65.24; H, 6.39; N, 4.23%). UV: Xmax (pH 7.1 buffer)/nm 271.5 and 245

(E/Lmolfcm-1 0.52 x 10 4, 0.77 x10 4 L/mole.1H NMR(400 MHz;CDCl3;Me4Si):

67.69(t,3H), 67.4(d,lH), 67.11-67.15(m,2H), 6 5.41-5.29(dd,2H), 63.91(s,3H),

63.85(q,1H), 63.7-3.65(2s,3H), 62.89-2.85(2s,3H), 61.57(d,3H).

12 was prepared from naproxen (0.001 mol) stirred with triethylamine (0.001mol) in 50

mL CH2C2 for an hour. A clear colorless solution was seen. N-(Phenyl)-N-methyloxy-

carbonylaminomethyl chloride (0.001mol) was added to the reaction mixture and the

contents were stirred overnight. The clear solution was washed 3-times with 10 mL

water. The CH2C2 solution was dried over Na2SO4 for an hour and then evaporated

under reduced pressure to give a yellow oil. Purification of the oil on a silica gel column

with ethyl acetate: hexane as eluent gave a colorless oil: yield = 60%, Rf (0.17, ethyl

acetate:hexane, 1:5), UV: Xmax (pH 7.1 buffer)/nm 272.8 and 245, (E/Lmolfcm10.35 x

10 4, 0.83 x10 4). 1H NMR(400 MHz;CDCl3;Me4Si): 67.69(t,3H), 67.36-7.39(dd,1H),

67.13-67.17(m,5H), 66.9(d,2H), 6 5.5-5.68(dd,2H), 63.93(s,3H), 63.88(q,lH),

63.65(s,3H), 61.57(d,3H).

13 was prepared from naproxen (0.001 mol) stirred with triethylamine (0.001mol) in 50

mL CH2Cl2 for an hour. A clear colorless solution was seen. N-(4'-Methoxyphenyl)-N-

methyloxycarbonylaminomethyl chloride (0.001mol) was added to the reaction mixture

and the contents stirred overnight. The clear solution was washed 3-times with 10 ml

water. The CH2C2 solution was dried over Na2SO4 for an hour and then evaporated

under reduced pressure to give to give a yellow oil. Purification of the oil on a silica gel









column with ethyl acetate: hexane as eluent gave a colorless oil: yield = 70%, Rf (0.1,

ethyl acetate:hexane, 1:5), UV: kmax (pH 7.1 buffer)/nm 271.5 and 245, (E/Lmolfcm

10.26 x 10 4, 0.91 x10 4 ). 1H NMR(400 MHz;CDCl3;Me4Si):67.69(t,3H), 67.36-

7.39(dd,lH), 67.13-67.17(m,2H), 67.69(t,3H), 67.37(dd,lH), 66.8(d,2H), 66.5(d,2H),6

5.5-5.64(dd,2H), 63.92(s,3H), 63.88(q,lH), 63.68(s,3H), 63.65(s,3H), 61.57(d,3H).

14 was prepared from naproxen (0.001 mol) stirred with triethylamine (0.001mol) in 50

mL CH2C12 for an hour. A clear colorless solution was seen. N-(4'-Ethyloxycarbonyl-

phenyl)-N-methyloxycarbonylaminomethyl chloride (0.001mol) was added to the

reaction mixture and the contents were stirred overnight. The clear solution was washed

3-times with 10 mL water. The CH2Cl2 solution was dried over Na2SO4 for an hour and

then evaporated under reduced pressure to give white crystals. This residue was dissolved

in CH2Cl2 and hexane was added till the solution became turbid and white crystals were

seen. The white crystals were filtered and discarded while the filterate was reconcentrated

to give more white crystals. After purification on a silica gel column with ethyl acetate:

hexane as eluent the filtrate gave a colorless oil: yield = 13%, Rf (0.25, ethyl acetate:

hexane, 1:5), UV: Xmax (pH 7.1 buffer)/nm 270 and 245 (E/Lmolfcm10.25 x 10 4, 0.95

x10 4. UV: Xmax (pH 4 buffer)/nm 245(E/Lmolflcm-10.88 x10 4). UV: Xmax (pH 6

buffer)/nm 245 (E/Lmolfcm-1 0.9 x10 4). UV: Xmax (pH 8.25 buffer)/nm 245 (E/L

mol 1cm1 0.92 x10 4). UV: Xmax (pH 9.2 buffer)/nm 245 (E/LmolPcm10.94 x10 4).

1H NMR(400 MHz;CDCl3;Me4Si): 67.76(d,2H), 67.63-7.71(m,3H),67.34-7.37(dd, 1H),

67.13-7.17(m,2H), 66.98(d,2H),6 5.5-5.7(dd,2H), 64.3(q,2H), 63.94(s,3H), 63.88(q,lH),

63.66(s,3H), 61.57(d,3H), 61.38(t,3H).

15 was prepared from dimethylaminobenzoic acid (0.01 mol) stirred with triethylamine









(O.Olmol) in 50 mL CH2C2 for an hour. To the white suspension that formed was added

N-methyl-N-methyloxycarbonylaminomethyl chloride (0.01 mol) and the contents were

stirred overnight. The clear solution was washed 3-times with 10 mL water. The CH2C2

solution was dried over Na2SO4 for an hour and then evaporated under reduced pressure

to give white crystals: yield = 97%, mp = 100-1010C, Rf (0.49, ethyl acetate: hexane,

1:4), Elemental analysis: (Found: C, 57.73; H, 7.02; N, 10.6. Calc. for C13H18N204: C,

57.64; H, 6.81; N, 10.52 %). UV: Xmax (pH 8.8 buffer)/nm 315 and 287 (E/Lmol-1

cm1 1.41 x 10 4, 1.15 x10 4). 1H NMR(400 MHz;CDCl3;Me4Si): 6 7.9(d,2H), 6

6.6(d,2H), 6 5.58-5.54(2s,2H), 63.76-3.72(2s,3H), 63.05(s,9H).

16 was synthesized using the protocol developed by Siver et al. To 0.01 mol 6MP in 15

mL DMSO was added 1.1 equivalents of N-methyl-N-methyloxycarbonylaminomethyl

chloride. The yellow solution was stirred at room temperature for 1.5 h. Triethyl amine,

2.5 equivalents and 45 mL CHCl3 was added and stirring continued for one more hour.

The reaction mixture was then diluted with 100 mL CH2C2 and washed with 10 ml IN

HC1, 20 ml saturated NaHCO3 solution and 3 x50 mL brine solution. The organic layer

was dried over Na2SO4 and concentrated to give a yellow oil. The oil was triturated with

hexane to give yellow solids which were further recrystallised with CH2C2: hexane (1:5)

to give yellow crystals: yield = 62%, mp = 162-1640C (lit mp = 1630C), Rf= 0.46(10:3,

ether: methanol), Elemental analysis (Found: C, 42.9; H, 4.08; N, 27.78. Calc. for

C9H11N502S: C, 42.68; H, 4.38; N, 27.65 %). UV: Xmax (pH 7.1 buffer)/nm 288.4

(E/Lmolfcm-1 0.71x 10 4). UV: Xmax (pH 8.8 buffer)/nm 310.2 (E/Lmolfcm10.55 x10 4)

.UV: (MeOH)/nm 286 (E/ Lmolflcm 10.41 x 10 4). 1H NMR (400 MHz;CDCl3;Me4Si): 6

8.71(s,1H), 6 8.1-8.37(2s,1H), 6 5.68(s,2H), 63.75-3.85 (2s, 3H), 63.13-3.09(2s,3H).









Hydrolysis Studies.

S6-(N-Methyl-N-methyloxycarbonyl) aminomethyl- 6MP was synthesized by Siver

et al. This derivative reverted to 6MP with a half life of 91 minutes in pH 7.1 buffer at

320 C. An SN1 mechanism of hydrolysis was proposed but not firmly established. We

decided to probe the reactivity of NANAOCAM-phenol conjugates with acetaminophen

(APAP) acting as our model phenolic drug.

Since NANAOCAM-APAP type derivatives were designed as a hydrolytically

labile prodrugs, their rates of hydrolysis in aqueous buffers were investigated. Hydrolysis

of NANAOCAM derivatives of APAP at 320 pH and 7.1 buffer were much slower than

those of 6MP. The rate of hydrolysis of_N-Methyl-N-methoxycarbonylaminomethyl-

APAP (1) at pH 8.8 and 460 C was found to be 60 h. so all rates of hydrolysis were

determined at 46 'C and pH 8.8 buffer S6-(N-Methyl-N-methyloxycarbonyl)

aminomethyl- 6MP (16), resynthesized according to Siver et al. (1990), had a half life of

19 minutes under the same conditions. The anion of APAP (pKa-9.5) is not a good

leaving group and as a result the hydrolysis of its prodrug is slow compared to 6MP

(pKa-7.5). On the other hand, the NANAOCAM derivative of p-nitrophenol (7, Tables 2-

1 and 2-3) had a half life of 22 min at 460C and pH 8.8 buffer. The hydrolysis rate was

higher and t 1/2 lower since the pKa of the leaving group was much lower:7.4. Thus N-

Methyl-N-alkyloxycarbonylaminomethyl derivatives of phenols with an electron

withdrawing group like -NO2 on the ring hydrolyzed faster than those with an electron

releasing group on the ring like -NHCOCH3.

In order to establish the mechanism of hydrolysis and probe the effect of electron

withdrawing groups on hydrolysis rates ofNANAOCAM-phenol conjugates, five more

phenols (2-6, Table 2-1) with an electron withdrawing group on the aromatic ring were









synthesized using the synthetic protocol developed for APAP and rates of hydrolysis

were determined at pH 8.8 and 460 C (Table 2-3). To further establish the effect of pKa

on rates of hydrolysis, the N-Methyl-N-methyloxycarbonylaminomethyl ester of

dimethylaminobenzoic acid (15, Figures 2-1 and 2-3) was also synthesized and its rate of

hydrolysis determined.Thus, rates of hydrolysis were determined where YH = 6MP,

phenol or carboxylic acid and the corresponding anions acted as the leaving group

(Figure 2-5).



-+ OH,
Y OR' Y CH2 OR HO OR'

R R
+
SYH

I-CH2=0


0
H
\N OR'

R
Figure 2-5 Hydrolysis of NANAOCAM-Y in aqueous buffers.

Rates of hydrolysis of NANAOCAM-Y were dependent on the acidity (leaving

group ability) of the parent compound. The more acidic YH was, the faster the rate was.

When YH was cyanophenol with a pKa of 7.95, the half life was 149 minutes. Increasing

the pKa by 0.1 unit as in the case of the methyl paraben derivative, 5 raised the half life to

189 minutes. This sensitivity to small changes in pKa of YH derivative suggests that Y-

was acting as the nucleofuge by either a SN2 or SNI mechanism. The effect of election

withdrawing groups in the para position of the phenol on rates hydrolysis was also









quantified using the Hammett plots between cy substituents versus log K. (Table 2-3).

Plot of log K and sigma (o ) were linear and indicated that rates of hydrolysis were

dependent on the electron withdrawing effect imparted by the substituent at the para

position (Figure 2-6).

Table 2-3 Correlation of Rates of Hydrolysis of NANAOCAM-Y with pKa and Sigma
Values of the Leaving Group (Y).
Compd Y log k (sec-1) t 1/2(min.) pKa o


15 p-Me2N-C6H4COO- -1.30 0.22 5.03
4 o-OHC-C6H40- -3.03 12 6.79
16 6MP -3.22 19 7.5
7 p-02N-C6H40- -3.28 22 7.14 1.25
3 p-OHC-C6H40- -3.81 75 7.66 0.94
2 p-NC-C6H40- -4.11 149 7.95 0.99
5 p-MeOC-C6H40- -4.21 189 8.05 0.82
6 p-MeOOC-C6H40- -4.39 290 8.47 0.74
1 p-MeOCHN-C6H40- -5.49 3600 9.5 0.19

When log k (rate constant) was plotted against the pKa of the leaving group (Y'), a

negative correlation was found with a r2 of 0.98 (Figure 2-7). Rate of hydrolysis were

also independent of the pH of the buffer. When rates were studied in various buffers (pH

4.6, 7.1, 8.8) at 460 C for 7 and log K was plotted against buffer pH a straight line with

zero slope was obtained (Table 2-4, Figure 2-8). The pH rate profile of 14 will be

discussed later.

Table 2-4 Effect of pH of Buffer on Rates of Hydrolysis of 7
pH t1/2 (min) log k
4.6 22.83 -3.29588
7.1 21.83 -3.27655
8.8 22.83 -3.29596







62



y = 2.0288x 5.889
R2 = 0.968


* -N02
-CHO
*-CN
* -COCH3
-COOMe
* -NHCOCH3


Sigma


Figure 2-6 Pseudo-first order rate constants (sec-1) versus a- of parent phenol.
15


y = -0.9325x + 3.4017
R2 = 0.9828


0-4
0

-4


pKa


Figure 2-7 Pseudo-first order rate constants (sec-1) versus acidic pKa of parent.


-2

0 -3

-4

-5

-6


. 16











-3
-3.2 -
-3.4
-3.6
-3.8

0 -4 14
-1 -4.2 -

-4.4
-4.6
-4.8
-5

3.5 5.5 7.5 9.5

pH

Figure 2-8 pH rate profiles of compds 7 and 14

Several mechanisms for base catalysed hydrolysis of NANAOCAM-Y can be

proposed (see above).Figure 2-9A shows an SN2 type of pathway where hydroxide ion

acts as a nucleophile and displaces Y- to give a hydroxymethyl-N-alkylcarbamic acid

alkyl ester. This hemiaminal derivative spontaneously hydrolyzes in water to give

formaldehyde and N-alkylcarbamic acid alkyl ester in the same way that hydroxymethyl

amides do (Johansen et al., 1979 and Bundgard et al., 1980). Similarly the hydroxide

anion can act as a nucleophile and displaces the N-alkylcarbamic acid alkyl ester anion as

in Figure 2-9B. The hydroxymethyl conjugate of the drug, YH, formed as an intermediate

reverts to the parent drug by loss of formaldehyde. This particular mechanism however

can be ruled out because of the lower pKa of YH (-5.2-9.5) compared to the N-

alkylcarbamic acid alkyl ester (-14) making Y- a better leaving group than the N-

alkylcarbamic acid alkyl ester anion.






64



0 -CH2=0O 0

O l N OH 0 N H
R R


OH,
o YH + OH


0 OH

0 N Y


- CH2=O


Y-OH


0 0
OH2 H
O N O N +C
R R
Figure 2-9 SN2 type of hydrolysis of NANAOCAM-Y with Y- or carbamate as the
leaving group.


OH,
Y YH + OH-
+


OH,
20


-CH2=0


0



R


Figure 2-10 SNI type of hydrolysis of NANAOCAM-Y.


-OH


H









A SNI type of pathway is another possibility (Figure 2-10). The lone pair of

electrons on nitrogen can donate its electrons to stabilize an incipient carbocation with Y-

leaving. This carbocation can subsequently react with water to give hydroxymethyl-N-

alkylcarbamic acid alkyl ester which then falls apart to give N-alkylcarbamic acid alkyl

ester. However none of the data plotted in Figures 2-6 and 2-7 provides an insight into

the mechanism of hydrolysis since both SNI and SN2 mediated hydrolysis are dependent

on the leaving group ability of the ionized parent molecule, Y-. However the fact that the

hydrolyses were pH independent strongly favors a SNI mechanism. There is also some

precedent in literature suggesting the mechanism of hydrolysis to be SNl. N-

Alkylamidomethyl esters of carboxylic acid hydrolyze by a SNI mechanism (Moreira et

al., 1994) (Figure 2-11).

0 0 0 0

Ph N 0- R' Ph N -- Ph N OH
R R H2 R
+

R'COO
Figure 2-11 Hydrolysis of N-alkylamidomethylcarboxylic acid esters in aqueous buffers.

Hydrolysis proceeds by donation of electrons from the amide nitrogen resulting in a

carbocation intermediate with the carboxylate group leaving. In the subsequent step, the

carbocation reacts with water to give the hydroxymethylamide. When R' was naproxen

and R was methyl the t 1/2 for hydrolysis of the prodrug was 14 min at pH 7.4 and 320 C,

while when R was -CH2COOEt, t 1/2 for hydrolysis was 2520 min. Thus, introducing an

electron withdrawing group on the amide nitrogen diminishes its ability to donate

electrons and slows down reaction rate, thereby suggesting the mechanism of hydrolysis

to be SNI.










The hydrolysis of 0-Imidomethyl derivatives of phenols has been reported by Getz

et al., (1992). Figure 2-12 above compares the halflives of imidomethyl derivatives of p-

nitrophenol (PNP) with (N-Methyl-N-methoxycarbonyl) aminomethyl-PNP. The

proposed hydrolytic mechanism for the imidomethyl derivatives where saccharin,

phthalimide and succinimide served as the imide, was SN2. Thus, presence of two electron

withdrawing groups on the nitrogen disfavors SNI, (as observed in case of N-alkylamido

methyl esters of carboxylic acids) to the extent that SN2 becomes the major pathway.

t 1/2(min)

0.75(250C) 4.9(250C) 7.43(250C) 22(460C)

NO2 NO, NO2 NO2





0 0 0
O 00

O NO NO OO N-
i o 0
0 0







NO2





OH
Figure 2-12 Hydrolysis of N-imidomethyl derivatives of phenols in aqueous buffers.
Values are shown for tl/2 at the temperature (in parenthesis).









Implications of NANAOCAM-phenol Hydrolysis on Prodrug Design.

NANAOCAM-phenol conjugates are chemically stable and the suggestion that

their mechanism of hydrolysis is SN1 is based on past literature. We were interested in

designing derivatives which would be labile under physiological conditions and which

would illustrate that the mechanism of hydrolysis was SNI. Hence the syntheses of

NANAOCaminoethylidene (ROCO-NR'CH(CH3)), NANAOCaminobenzylidene

(ROCO-NR'CH(Ph)) and NArNAOCAM (ROCO-N(Ph)CH2) promoieties were

examined. NANAOCaminoethylidene and NANAOCaminobenzylidene derivatives of

phenols will stabilize positive charge on the methine carbon leading to a more labile

derivative if hydrolysis follows a SN1 type of pathway and will hinder an SN2 type path

by creating more steric hinderance. Also if the mechanism is SN2, the rate of hydrolysis

should be accelerated by an electron withdrawing group on an N-aryl group where a

positive charge on CH2 in N-CH2-O is increased making the CH2 a better target for

nucleophilic attack. On the other hand, if the mechanism is SN1, the rate of hydrolysis

should be decelerated by an electron withdrawing group on an N-aryl group where a

positive charge on CH2 in N-CH2-O is destabilized. Unfortunately our attempts to

synthesize NANAOCaminoethylidene and NANAOC-aminobenzylidene derivatives of

phenols were unsuccessful. The synthetic protocol used is shown in Figure 2-13. An

aldehyde was reacted with aqueous methyl amine at room temperature to give N-

methylimines which were reacted with methyl chloroformate under nitrogen at -780C to

00C. The major product obtained was the parent aldehyde, N-methyl carbamic acid

methyl ester and 2-3% of the desired alkylating agent (NANAOCaminoethylidene

chloride or NANAOCaminobenzylidene chloride) based on 1H-NMR.

















0o^. Y 0 0
Y 0 N 0Y O N O

X= H, OCH,, COOEt
NANAOaminoethylidene-Phenol NANAOaminobenzylidene-Phenol








x
X= H, OCH,, COOEt
NArNAOCAM-Phenol
Attempts to isolate the alkylating agent by column chromatography led to complete

decomposition of the alkylating agent. Reaction of phenols with the crude reaction

mixture containing the alkylating agent also lead to hydrolysis of the alkylating agent to

the parent aldehyde and N-methyl carbamic acid methyl ester quantitatively.

CHOCOCI
RCHO +CH3NH2 P RCH=NHCH3 RCHO + CH3NHCOOCH3 + RCH -N

major I COOCH3
R = Methyl or Aryl
NANAOC amino ethylidene chloride
or
NANAOC amino benzylidene chloride

minor
Figure 2-13 Attempts at the synthesis of NANAOCaminoethylidene chloride and
NANAOCaminobenzylidene chloride.

However our attempts to make NArNAOCAM conjugates of phenols were

successful. NArNAOCAM chlorides (R'OCONRCH2-, R = aryl, R'= CH3) were

synthesized and used to alkylate p-nitrophenol (Figure 2-3, Table 2-1, 8-10). The half-

lives of hydrolyses clearly illustrate that when an N-alkyl group (Table 2-3, t 1/2 for 7 =

22 min) was replaced by N-aryl (Table 2-5, t 1/2 for 8 and 10 = 400-520 min while t 1/2 for









9 > 24 h) the rates of hydrolyses were slower. An electron donating substituent on the N-

aryl ring like -OCH3 stabilizes the SNI transition state more than an electron withdrawing

group like -COOC2H5 or -H and the half lives are in the order of 9 >10 >8. Thus,

hydrolysis of NArNAOCAM and N-aryl-N-alkyloxycarbonylaminomethyl derivative of

phenols follow a SNI type of mechanism. However, although NANAOCAM-phenols

hydrolyse by a SNI type of pathway, they are chemically too stable to revert to the parent

drug at a sufficient rate to be effective prodrugs based on chemical hydrolysis.

Hydrolyses of NANAOCAM-phenols does occur enzymatically. When 1 was used

in diffusion cell experiments where hairless mouse skin was the membrane, about 23% of

acetaminophen was regenerated from the prodrug during its passage through the skin. We

will talk more about diffusion cell experiments in Chapter 3.

Thus NANAOCAM-phenols represent a novel class of prodrugs which are

sufficiently chemically stable to allow formulation but may be sufficiently enzymatically

labile to revert to the parent drug at a useful rate. Shorter chain NANAOCAM prodrugs

of phenols have both higher lipid and water solubilities compared to ACOM and

AOCOM phenolic conjugates (solubililities shown in Chapter 3). Thus, replacing the

oxygen atom in O-CH2 of ROCOOCH2 with a substituted nitrogen (N-R, R = alkyl)

makes it possible to increase solubility in a membrane which should increase

permeability across a biological barrier such as skin and oral absorption across the GI

tract.









0

02N /N-0 N 0





x


Table 2-5 N-aryl-N-alkyloxycarbonylaminomethyl Derivatives of p-nitrophenol (PNP) a
Compd X log kobsv(sec-1) t 1 (min.)
8 OMe -4.54 400
9 COOEt >24 h
10 H -4.65 519
a Hydrolysis experiments in pH 8.8 and 460C

Implications of NArNAOCAM-carboxylic acid Hydrolysis on Prodrug Design

Besides NANAOCAM derivatives of phenols, NANAOCAM derivatives of

carboxylic acids have also been examined. Carboxylic acids, like phenols, are polar and

being ionized at physiological pH penetrate membranes with difficulty. By transiently

masking the negative charge it has been shown that it is possible to increase the

permeation of carboxylic acids across biological barriers (Bonina et al., 1995 and Rautio

et al., 1999). N-Alkyl-N-alkyloxycarbonylaminomethyl derivatives of carboxylic acids

are chemically too unstable to serve as useful derivatives (compared to phenols which

were chemically stable) because the leaving group has a pKa of -3-5 (compared to 6.8-

9.5), e.g. 15, t 1/2 ~ 6 min at pH 7.1 and 390C. Thus, the goal here was to design

derivatives which were chemically more stable so that they could be easily formulated

but would hydrolyze independent of enzymes. It has been previously shown that 0-

imidomethyl derivatives of phenols like estradiol were enzymatically stable but had a half

life of 100 min in pH 7.4 buffer (Patel et al., 1994 and 1995). This derivative was about 8

times more potent than estradiol alone when given orally. Thus prodrugs whose









hydrolysis is not dependent on enzymes are useful because their hydrolysis isn't limited

by enzymatic variability and strict substrate specificity of some esterases in the blood

which could lead to incomplete hydrolysis to the parent drug (Beamount et al., 2003).

Here, naproxen was chosen as a model carboxylic acid drug for which to prepare

NANAOCAM prodrugs (Table 2-2). The NANAOCAM derivatives of naproxen were

made by alkylating naproxen with NANAOCAM-Cl in presence of triethyl amine in

dichloromethane (Figure 2-3).

11, Table 2-2 had a half life of 2 min at pH 7.1 and 390 C which would make

pharmaceutical formulation difficult. Since the mechanism of hydrolysis of

NANAOCAM esters of carboxylic acids should also be SNI, the NArNAOCAM

promoiety should lead to a chemically more stable and useful prodrug of a carboxylic

acid since the phenol NArNAOCAM derivatives were much more stable. NArNAOCAM

ester derivatives of naproxen (12-14, Table 2-2) were synthesized by alkylating naproxen

with NArNAOCAM-Cl (Figure 2-4) and their rates of hydrolysis determined (Table 2-6).

As expected the substituted N-aryl derivatives increased the half-lives of the hydrolyses

from 2 min to over 150 min. As in the case of phenols the order of rates of hydrolyses

was, -COOEt < -H < -OMe which is consistent with a SNI type of hydrolysis. All three

NArNAOCAM naproxen derivatives represent potentially useful prodrugs which are

reasonably stable but should be sufficiently labile enough to release the drug at an

appropriate rate to express its pharmacological activity. Moreover, since 14 would

eventually release p-aminobenzoic acid, a component of sunscreens, it may be the most

attractive candidate.









x






0\ O N


CHO 0


Table 2-6 Hydrolysis of N-aryl-N-alkyloxycarbonylaminomethyl Derivatives of
Naproxen.b
Compd X log kobs,,.(sec-1). t / (min.)
12 H -4.015 119.62
13 OMe -3.63 49.83
14 COOEt -4.13 156.46
Hydrolysis experiments in pH 7.1 and 390C

The kinetics of decomposition of N-(4'-ethyloxycarbonylphenyl)-N-methyloxy-

carbonylaminomethyl ester of naproxen, 14, was also studied in aqueous buffers at 390 C

over a wide pH range (Figure 2-3).

Table 2-7 Effect of pH of Buffer on Rates of Hydrolysis of 14.
pH tl/2 (min) log k
4 166.76 -4.16
6 156.29 -4.13
7 156.46 -4.13
8.25 152.72 -4.12
9.2 35.45 -3.49

The rates of hydrolysis were independent of the pH of buffers from pH 4.0-8.25 so

the mechanism of hydrolyses along this pH range is believed to be SNI (Moreira et al.,

1996 and Iley et al., 1997). At pH 9.2, a sharp increase in rates of hydrolysis was

observed. This is probably due to a change in the mechanism of hydrolysis from SNI to

addition-elimination where nucleophilic addition occurs on the carbonyl functional group

of the ester followed by elimination of carboxylate ion to form hydroxymethyl-N-methyl










carbamic acid methyl ester (Bundgard et al., 1991). N-Methyl carbamic acid methyl ester

is formed in the subsequent step by the loss of formaldehyde (Figure 2-14). Attempts to

make NArNAOCAM-naproxen derivatives with enhanced water solubility are currently

under investigation. NArNAOCAM-naproxen conjugates are thus prodrugs of carboxylic

acids which unlike ACOM or AOCOM esters are not dependent on enzymatic hydrolysis

and have sufficient chemical stability to be formulated.



/ / H ,--
R N 0 HO N O N 0
H : -CH2=0O



COOEt COOEt COOEt

+

RCOOH
Figure 2-14 Hydrolysis of NArNAOCAM-carboxylicacid conjugates at pH 9.2.














CHAPTER 3
SYNTHESIS AND TOPICAL DELIVERY OF N-ALKYL-N-
ALKYLOXYCARBONYLAMINOMETHYL PRODRUGS OF A MODEL PHENOLIC
DRUG:ACETAMINOPHEN

Topical approaches to masking a phenolic functional group have been limited to

morphine (Drustrup et al., 1991), naltrexone (Stinchcomb et al., 2002; Pillai et al., 2004;

Valiveti et al., 2005; Hammell et al., 2005; Vaddi et al., 2005, Valivetti et al., 2005a),

buprenorphine (Stinchcomb et al., 1996), nalbuphine (Sung et al., 1998) and

acetaminophen (Wasdo and Sloan, 2004). Only three promoieties, alkylcarbonyl (AC),

alkyloxycarbonyl (AOC) and alkylaminocarbonyl (AAC), have been utilized but no soft

alkylated derivatives of phenol have been used for topical delivery. Both AC and AOC

derivatives of phenols rely on esterase catalysed hydrolysis or addition-elimination type

mechanism to revert to the parent drug.The ACOM and AOCOM soft alkyl approach is

presently being investigated in our lab to improve topical delivery of phenols. Insertion of

'N(R')CH2' into the AOC (ROCO-) promoiety gives the NANAOCAM

(ROCONR'CH2-) promoiety which should act as a soft alkyl promoiety of phenols since

it did for 6MP (Siver and Sloan, 1990). It is of interest to see if this insertion improves

the biphasic properties and flux through skin of phenols since addition of heteroatoms

into the promoiety improves aqueous solubility of drugs. In order to test this hypothesis

acetaminophen (APAP) was chosen as the model phenolic drug.

The performance of the prodrug series in diffusion cell experiments will be

compared with that predicted by the Roberts-Sloan (RS) equation. The results will be









added to the Sloan and coworkers database to generate new coefficients for the

parameters in the equation and give a more robust RS equation.

Experimental Procedure

Materials and Methods

Isopropyl myristate (IPM) was obtained from Givaudan Corp (Clifton, NJ).

Theophylline (ThH) was purchased from Sigma Chemical Co. (St. Louis, MO, USA); all

other reagent chemicals were from Aldrich Chemical Co. (Milwaukee, WI, USA). The

water was obtained from a Millipore Milli-Q water ultra filteration system. Ultraviolet

spectra were recorded on a Shimadzu UV-2501 PC spectrophotometer. A radiometer pH

meter 26 was used to determine pH of solutions.The vertical, Franz type diffusion cells

were from Crown Glass (Somerville, NJ, USA) (surface area 4.9cm2, 20 mL receptor

phase volume, 15 mL donor phase volume). The diffusion cells were maintained at 320C

with a Fischer (Pittsburgh, PA, USA) circulating water bath model 25. The female

hairless mice (SKH-hr-1) were from Charles River (Boston, MA, USA). Statistical

analyses were carried out by using SAS 9.0. All animal sacrifices and preparation of

membranes were carried out by Professor Ken Sloan using IACAC approved protocols.

Synthesis of Prodrug Derivatives

Synthesis begins by the alkylation of APAP with N-alkyl-N-alkyloxycarbonyl

aminomethyl chloride (NANAOCAM-C1) in presence of a base like triethylamine and

CH2C12 as the solvent. In every case it was necessary to synthesize the corresponding

alkylating agent, NANAOCAM-C1.









0

N K Cl 0 R 0
CH2O + CH3NH2 NaOH N OR
N N
DCM
R= CH3 and C2H5
Figure 3-1 Synthesis of NANAOCAM-Cl from 1, 3, 5-trialkylhexahydrotriazine.

Synthesis of NANAOCAM-C1 (Figure 3-1)

a) 1, 3, 5-Trimethylhexahydrotriazine was synthesized from equimolar equivalents of

aqueous formaldehyde, methyl amine and NaOH according to the protocol originally

developed by Graymore et al., (1932) and modified by Siver et al., (1990). Methyl amine

(0.4 mol of 40% aqueous) was placed in an ice bath and an equivalent of 37% aqueous

formaldehyde was added dropwise over a period of 10 min. The solution was allowed to

equilibrate to room temperature and stirred for one hour, then an equivalent of NaOH was

added and the contents were stirred for 1.5 h more. The solution was extracted with 4 x

50 mL CH2Cl2 and the collected CH2Cl2 were dried over Na2SO4, filtered and

concentrated to a clear colorless CH2C2 solution containing the the hexahydrotriazine

derivative. Complete evaporation of CH2Cl2 wasn't carried out as it resulted in loss of the

desired product. For quantification purposes the 'CH2' ofCH2C2 at 65.3 and N-CH2-N

peak of hexahydrotriazine derivative at 63.2 were used, yield = 82% in CH2Cl2, 1H NMR

(CDCl3): 62.3 (s, 9H), 63.2 (s, 6H).

Next the 1, 3, 5-trimethylhexahydrotriazine (freshly prepared) in CH2Cl2 was added

to an ice cold solution of 3 equivalent of alkyl chloroformate in CH2C2 over a period of

10 minutes. The white suspension that was observed was allowed to equlilibrate to room

temperature and stirred overnight. The suspension was filtered and the filtrate

concentrated to an oil. The oil contained the desired product and corresponding bis(N-









Alkyl-N-alkyloxycarbonyl)aminomethanes with a 'CH2' peak at 64.8.The oil was

purified by trituration with hexane overnight followed by ether overnight. The clear

solution was decanted leaving the white residue (bis derivative) behind. The clear

solution was then concentrated. The peak at 64.8 due to the 'CH2 of the bis derivative

and peak at 65.3 due to the 'CH2' of N-alkyl-N-alkyloxycarbonylaminomethyl chloride

were used to quantitate the amount of product formed.

N-Methyl-N-methyloxycarbonylaminomethyl chloride: yield = 90%, 1H NMR (CDCl3):

62.9 (s, 3H), 63.75 (s, 3H), 65.3 (s, 2H).

N-Methyl-N-ethyloxyoxycarbonylaminomethyl chloride: yield = 89%, 1H NMR

(CDCl3):61.3 (t, 3H), 62.9 (s, 3H), 64.22 (q, 2H), 65.33 (s, 2H).

N-Methyl-N-propyloxycarbonylaminomethyl chloride, N-methyl-N-butyloxycarbonyl-

aminomethyl chloride, N-ethyl-N-methyloxycarbonylaminomethyl chloride and N-

methyl-N-hexyloxycarbonylaminomethyl chloride were synthesized in an alternate way

via a N-alkyl carbamic acid alkyl ester (Figure 3-2).


RO Cl






3 ROH


0
TEA H
+ R'NH2 RO NH
SR'




+ A TEA
CIS3CO OCCI0 3


(CH2O)n 0

THF RO N/CN I
TMSCI R'


0

RO Cl


R = C3H7, C4H9, CH13
R' = CH3, C2H5
Figure 3-2 Preperation of alkyl chloroformate in situ from alcohol and synthesis of
NANAOCAM-Cl from alkyl amine.









b) N-Alkyl carbamic acid alkyl ester.

To a solution of chloroformate (33 mmol) in 75 mL CH2Cl2 mounted in an ice bath, was

added an equivalent of triethylamine and aqueous alkyl amine. The reaction mixture was

allowed to warm to room temperature and stirred overnight. The clear solution was

washed with 3 x 10 mL brine and the organic layer was dried over Na2SO4 and

concentrated to an oil. This oil was purified by trituration with hexane overnight. The

suspension that resulted was filtered and the filtrate evaporated to a yellow oil.

N-Methyl carbamic acid propyl ester: yield = 60 %, 1H-NMR (CDCl3): 60.97 (t, 3H),

61.7 (m, 2H), 62.9 (d, 3H), 64.06 (t, 2H) ,64.58 (s, 1H).

N-Methyl carbamic acid butyl ester: yield = 49 %, 1H-NMR (CDCl3): 60.92 (t, 3H),

61.38 (m, 2H), 61.6 (t, 2H), 62.8 (d, 3H), 64.06 (t, 2H) ,64.58 (s, 1H).

In the case of N-methyl carbamic acid hexyl ester it was necessary to synthesize the

chloroformate by reacting three molar equivalents of hexanol with an equivalent of

triphosgene and three equivalents of a poorly nucleophilic base, triethylamine (Figure 3-

2). A solution of triphosgene (11 mmol) in 100 mL CH2Cl2 was first prepared and placed

in an ice bath. To this solution was added a mixture of triethylamine (33 mmol) and the

alcohol (33 mmol) in 25 mL CH2Cl2 dropwise over 20 min. The exothermic reaction was

allowed to proceed, the contents were allowed to warm to room temperature and stirred

overnight. To this preformed chloroformate was added methyl amine and triethylamine as

stated above in the synthesis of N-alkyl carbamic acid alkyl esters.

N-Methyl carbamic acid hexyl ester: yield = 59%, 1H NMR (CDCl3): 6 0.89 (t, 3h), 6

1.31 (m, 6H), 6 1.58 (m, 2H), 62.79 (d, 3H), 64.04 (t, 2H) ,64.69(s, 1H).

(c) N-Alkyl-N-alkyloxycarbonylaminomethyl chloride:









A suspension of N-alkyl carbamic acid alkyl ester, 1.7 equivalents of paraformaldehyde

and 13 equivalents of trimethylsilyl chloride were refluxed using a CaCl2 drying tube and

water condenser for 2.5 h over an oil bath. The suspension was diluted with CH2Cl2 and

filtered to get rid of the unreacted paraformaldehyde. The clear filterate was concentrated

with a rotavapor at 400C under reduced pressure. The yellow oil obtained was triturated

with hexane overnight, the white suspension obtained was filtered, and the filtrate was

concentrated to give the desired alkylating agent.

N-Methyl-N-propyloxycarbonylaminomethyl chloride: yield = 85%, 1H NMR (CDCl3):

60.97 (t, 3H), 61.7 (m, 2H), 63.0 (s, 3H), 64.12 (t, 2H), 65.35 (s, 2H).

N-Methyl-N-butyloxycarbonylaminomethyl chloride yield = 82%, 1H NMR (CDCl3):

60.95 (t, 3H), 61.41 (m, 2H), 61.65 (m, 2H), 63.0 (s, 3H), 64.17 (t, 2H), 65.33 (s, 2H).

N-Methyl-N-hexyloxycarbonylaminomethyl chloride: yield = 83%, 1H NMR (CDCl3): 6

0.97 (t, 3H), 6 1.3 (m, 6H), 6 1.6 (m, 2H), 63.02 (s, 3H), 64.15 (t, 2H), 65.33 (s, 2H).

Synthesis ofNANAOCAM-APAP prodrugs (Table 3-1): Briefly a suspension of

APAP (0.Olmol) and triethylamine (0.011 mol) in 25 mL dichloromethane was stirred

under reflux conditions for an hour followed by the addition of the alkylating agent,

NANAOCAM-Cl (0.01 Imol). The contents were stirred overnight and subsequently

diluted with 50 mL dichloromethane and washed with water (3 x 10 mL). The

dichloromethane layer was, dried over Na2SO4 and concentrated at 400C over a rotary

evaporator. The yellow oil obtained was then purified by column chromatography using

ethyl acetate: hexane as eluent.









Table 3-1. NANAOCAM Prodrugs of APAP.
0

0 N O, R





NHCOCH3

Compound N-R' O-R

1 CH3 CH3
17 CH3 C2H5
18 CH3 C3H7
19 CH3 C4H9
20 CH3 C6H13


1 was prepared in 70 % yield from N-methyl-N-methyloxycarbonylaminomethyl

chloride, triethylaminie and acetaminophen in CH2C2 after recrystallization of the oil

obtained using CH2C2: hexane 1:3: mp = 86-880C, Rf (0.36,ether), 1H NMR(CDCl3):

67.6(s,1H), 6 7.39(d,2H), 66.96-6.87(2d,2H), 65.28-5.21(2s,2H), 63.72-3.7(2s,3H), 6 3.0-

2.97(2s,3H), 6 2.0(s,3H). Anal calcd for C12H16N204 : C, 57.13; H, 6.39; N, 11.1. Found:

C, 56.81; H, 6.34; N, 11.

17 was prepared in 65% yield from N-Methyl-N-ethyloxycarbonyl aminomethyl chloride,

triethylamine and acetaminophen in CH2C2 after trituration with hexane overnight to

give yellow crystals which were recrystallized from ethyl acetate:hexane (1:3) to give

white crystals: mp = 75-770C, Rf (0.6, Et20), 1H NMR(CDCl3): 6 7.38(d,2H),

67.12(s,1H), 6 6.96(dd,2H), 65.3(s,2H), 64.15(q,2H), 6 3.0(s,3H), 6 2.15(s,3H),

61.25(3H,t). Anal calcd for C13H18N204 : C, 58.64; H, 6.81; N, 10.52. Found: C, 58.53;

H, 6.93; N, 10.47.









18 was prepared in 76% yield from N-Methyl-N-propyloxycarbonyl aminomethyl

chloride, triethylamine and acetaminophen in CH2C2 after silica gel column

chromatography in ethyl acetate:hexane (3:2) followed by trituration in hexane overnight

to give pale white crystals. These crystals were further recrystallized from ethyl

acetate:hexane (3:2) to give white crystals: mp = 58-590C, Rf (0.2, ethyl acetate:hexane

3:2), H NMR(CDCl3): 6 7.38(d,2H), 67.14(s,1H), 6.96(dd,2H), 65.3(s,2H), 64.05(t,2H),

6 3.0(s,3H), 6 2.15(s,3H), 61.65(2H,m) 60.91(3H,t). Anal calcd for C14H20N204: C,

60.01; H, 5.45; N, 12.73. Found: C, 60.1; H, 5.35; N, 12.58.

19 was prepared in 66 % yield from N-Methyl-N-butyloxycarbonyl aminomethyl

chloride, triethylamine and acetaminophen in CH2C2 to give a colorless oil which was

purified after silica gel column chromatography in ethylacetate:hexane (3:2) followed by

trituration in hexane overnight to give a colorless oil: Rf= 0.13(3:7, Ethyl acetate:

hexane), H NMR(CDCl3): 6 7.38(d,2H), 67.14(s,lH), 6.96(dd,2H), 65.3(s,2H),

64.05(t,2H), 6 3.0(s,3H), 6 2.15(s,3H), 61.65(2H,m), 61.4(2H,m), 60.91(3H,t). Anal calcd

for C15H23N204 : C, 61.21; H, 7.53; N, 9.52. Found: C, 61.16; H, 7.65; N, 9.24.

20 was prepared in 63 % yield from N-methyl-N-hexyloxycarbonylaminomethyl

chloride, triethylamine and acetaminophen in CH2C2 to give a colorless oil which was

purified after silica gel column chromatography in ethyl acetate:hexane (4:1) followed by

trituration in hexane overnight to give a colorless oil: Rf (0.36, 7:3, ethyl acetate :

hexane), 1H NMR(CDCl3): 6 7.38(d,2H), 67.29(s,1H), 66.95-6.89(2d,2H), 65.29-

5.23(2s,2H), 64.11-4.07(m,2H), 6 3.02-2.98(2s,3H), 6 2.15(s,3H), 61.63(2H,m),

61.3(6H,m), 60.89(3H,m). Anal calcd for C17H27N204 : C, 62.33; H, 8.13; N, 8.69.

Found: C, 61.96; H, 8.14; N, 8.36.









Determination of Solubilities and Partition Coefficients

Molar absorbtivities were determined in triplicate for each member of the series in

acetonitrile (ACN) and pH 7.1 phosphate buffer at the maximum absorption wavelength.

The molar absorbtivities were calculated using Beer's law (E = A/c). The solubilities of

the prodrugs in isopropyl myristate (IPM) were determined in triplicate by stirring

suspensions of the compound in 3 mL IPM with a magnetic stirrer for 24 h at room

temperature (23 1C) (Martin and coworkers, 1985 and Beall et al., 1994). The test

tubes containing the suspensions were sealed and thermally insulated from the stirrer.

After stirring, the suspensions were filtered through a 0.45 [tm nylon membrane filter. An

aliquot (-0.1-0.3 mL) was withdrawn from the clear filtrate of saturated solutions and

diluted to 10 mL in a volumetric flask with ACN. The samples were then analyzed by

UV spectroscopy using absorbances determined at 240 nm for APAP prodrugs. The

solubility in IPM was calculated from the following relationship (equation 3-1):

SIPM = (A/s) (Dilution factor) (3-1)

Dilution factor = (Vfinaialiquot) (3-2)

where A is the absorbance of the sample at 240 nm, s is the molar absortivity of the

sample at 240 nm in ACN and Valiquot is the volume of the saturated filterate aliquot and

Vfinal is the final diluted sample volume. In the case of prodrug derivatives which were

oils, direct solubility measurements were not possible. Thus partition coefficients

between IPM and pH 4.0 buffers were used to estimate SIPM.

Solubilities in water (SAQ) were determined by stirring suspensions in deionized

water for 1 h to limit the extent of hydrolysis of the prodrugs. The samples were filtered

through nylon filters diluted with ACN and analyzed by UV spectroscopy. SAQ was

determined using the following equation:









SAQ = (A/s) (Dilution factor) (3-3)

Determination of SAQ of compounds which were oils was carried out by stirring the

compound in deionized water for 1 h and ensuring that a biphasic solution was present at

all times. The test tubes containing the biphasic solution were centrifuged for 2 minutes;

an aliquot (-0.1-0.3 mL) was withdrawn from the water layer and diluted to 10 mL with

ACN in a volumetric flask. The samples were then analyzed by UV spectroscopy as

above.

For determination of partition coefficients between IPM and pH 4.0 buffer (KIPM:

4.0) for compounds which were solids at room temperature, a measured volume (-0.5 mL-

1 mL) of the filtered saturated IPM solutions from the lipid solubility experiments were

mixed with a measured volume of pH 4.0 acetate buffer (-1-5 mL) in a 10 mL test tube

(Beall et al., 1993). The test tube was capped and vigorously shaken for 10 seconds and

subsequently centrifuged for 2 min to allow the clear separation of two phases. An

aliquot (-0.3 mL) was withdrawn from the IPM layer and diluted to 10 mL with ACN in

a volumetric flask and analyzed by UV spectroscopy. The KIPM: 4.0 was calculated using

the following relationship:

KIPM: 4.0 = (V4.0/VIPM) x AF/ (Al-AF) (3-4)

where V4.0 is the volume of pH 4.0 buffer used, VIPM is the volume of IPM used, AI is the

initial absorbance of the saturated IPM solution before partitioning and AF is the

absorbance of the compound remaining after partitioning. The pH 4.0 buffer solubility

was estimated from KIPM: 4.0 using the following equation:

S4.0 = SIPM / KIPM: 4.0 (3-5)









Determination of partition coefficients between IPM and water (KIPM: AQ) for

compounds which were oils at room temperature was carried out by using a measured

volume (-0.5 mL 1.0 mL) of saturated solution used for determination of SAQ placed in

a 10 mL test tube and a measured volume (-1-10 mL) of IPM. The test tubes were

centrifuged; an aliquot was taken from the water layer and diluted with ACN to 10 mL in

a volumetric flask. Samples were subsequently analyzed by UV spectroscopy. KIPM: AQ

and SIPM were calculated using the following equations:

KIPM: AQ = (V4.0/VIPM) X (AI-AF)/AF (3-6)

SIPM = KIPM: AQ x SAQ (3-7)

Solubility ratios (SR) were calculated from the ratio of SIPM / SAQ. The methylene Rt

values were calculated using equation 3-8:

x7 = (log SR n+m log SR n)/m (3-8)

where n is the number of methylene units in the promoiety of one prodrug (the lowest

member of the homologous series) and m is the number of additional units in the

promoiety in the higher member of the homologous series. Similarly the methylene 7R

values (Leo et al., 1971 and Hansch and Leo, 1979) using K values are also reported.

t = (log K n+m log K n)/m (3-9)

Determination of Flux through Hairless Mice Skins (Beall et al., 1994)

The mice were rendered unconscious using CO2 and sacrificed by cervical

dislocation. Full thickness skins were removed by dissection; the pieces were scraped to

remove excess fat, cut into proper sizes and placed dermal side down on the diffusion

cells. A Franz diffusion cell consists of two compartments; donor compartment and a

receptor compartment. The receptor compartment has a side arm which can be used to

sample the compartment. The skins were held in place using rubber rings, and the two